<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF
  xmlns:owl="http://www.w3.org/2002/07/owl#"
  xmlns:ddiem="http://ddiem.phenomebrowser.net/"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
  xmlns:obo="http://purl.obolibrary.org/obo/"
  xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d89716ba-72e2-438f-a421-19b2b27951b6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08e198b2-811c-443b-81f4-b5f03a5a4eec">
        <rdfs:label>Hyperglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003074</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003074</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe509ce9-81d3-4c8d-85f2-f30a2e25cfad">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c59e88f-d346-4fd7-8cea-91599f65ba85"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd769ffd-f890-47dd-a883-ff28a825257a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>Hypertriglycridemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246650">
        <rdfs:label>LIPASE DEFICIENCY, COMBINED</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/246650</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1085</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/743a0196-eaf3-469d-b0f8-9aba8ef1f782"/>
        <ddiem:iembaseAccessionNumber>1085</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0003304>W464X</obo:RO_0003304>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000352">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000352</ddiem:url>
        <dc:identifier>ECO:0000352</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/33bc7e1a-c38a-4f6d-a1b6-1afe4d19c4a6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef880a2d-b78d-4152-aeeb-59c149620929"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b3123d7-360a-48a4-8d1f-cf439fb07d47">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/57041edf-5b1a-4aa9-9c3a-8e01812a611c"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/616d4ba5-d93a-4a1d-980d-1861f1142dd7">
    <ddiem:ecNumber>2.3.1.43</ddiem:ecNumber>
    <ddiem:uniprotId>P04180</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/39eb0793-945c-4ee2-ab80-6c11d4941eb9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3931</dc:identifier>
        <rdfs:label>LCAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00650</ddiem:keggEntryId>
    <rdfs:label>lecithin-cholesterol acyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/92abb799-feec-4142-b3cd-7b67ce190caa">
    <ddiem:ecNumber>3.1.1.13</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/36002e46-77cb-4c04-87bc-fad314b77b8e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3988</dc:identifier>
        <rdfs:label>LIPA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lysosomal acid lipase</rdfs:label>
    <ddiem:keggEntryId>K01052</ddiem:keggEntryId>
    <ddiem:uniprotId>P38571</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21742686-2b0d-4b74-937b-dde9e2bdf41b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/87961b08-722c-4642-8d38-aec9cda90fdb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/462f4ffe-d9a1-43b5-b9ff-c2d232f7cf8e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9046addd-c582-4a31-ac8d-33e1d963d4e2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eb13706f-6664-4d58-a882-8068ac6717e7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26f3d96e-38a4-47f5-979a-95dd91f902bf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/15c290ba-ca52-4db2-8f0e-e61f4e278029"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/384b4562-0cd7-4e11-8b2c-3672b1de7767">
        <dc:identifier>HP:0012823*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Slow recovery</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012823</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/535000">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LEBER OPTIC ATROPHY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/402</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/535000</dc:identifier>
        <ddiem:iembaseAccessionNumber>402</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c1652b3-7331-419d-9b75-7bebb3f2c8e4"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e723bc4-abc6-4596-8ff1-1a3965fa7456">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd769ffd-f890-47dd-a883-ff28a825257a"/>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/33bc7e1a-c38a-4f6d-a1b6-1afe4d19c4a6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8b3123d7-360a-48a4-8d1f-cf439fb07d47"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/693048de-e7f7-46e7-a638-19b800a1807f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9e0193f8-513c-42f4-b8d3-ad3468cc220b">
        <rdfs:label>SLC39A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55630</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14710</ddiem:keggEntryId>
    <rdfs:label>zinc/iron-regulated transporter-like protein</rdfs:label>
    <ddiem:uniprotId>Q6P5W5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6bd14f02-2a3a-4af8-8a16-ea79e1ca5efc">
    <ddiem:uniprotId>Q13472</ddiem:uniprotId>
    <ddiem:keggEntryId>K03165</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1ede508c-c8b5-4ebd-8003-ace4f229554a">
        <rdfs:label>TOP3A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7156</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>5.6.2.1</ddiem:ecNumber>
    <rdfs:label>DNA topoisomerase 3-alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ccef388a-2720-4fad-b71c-da11bc790666">
    <ddiem:ecNumber>3.5.4.6</ddiem:ecNumber>
    <ddiem:uniprotId>P23109</ddiem:uniprotId>
    <rdfs:label>AMP deaminase</rdfs:label>
    <ddiem:keggEntryId>K01490</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/129a0a9e-27aa-4e9d-9a4a-321afb9a6040">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/270</dc:identifier>
        <rdfs:label>AMPD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c7b20b1b-963f-4569-89e6-55693ab35778">
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/04dc1b76-9b6e-49a5-af50-1f023539c7fe">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1188</dc:identifier>
        <rdfs:label>CLCNKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14426</ddiem:keggEntryId>
    <rdfs:label>sodium chloride co-transporter/ chloride channel called ClC-Kb</rdfs:label>
    <ddiem:uniprotId>P55017</ddiem:uniprotId>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/57de54ef-84ae-429b-b64d-7634344e261d">
        <rdfs:label>SLC12A3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6559</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac855fd6-1373-4f40-be26-c56758c6a311">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d48e21fb-fac0-4d4f-8fdf-640573fa23a0">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:label>Mental impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4f3cacc-4e2d-496b-be7a-3153ffaa73c7">
        <rdfs:label>Difficulty walking</rdfs:label>
        <dc:identifier>HP:0002355</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002355</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f11e9a37-9c02-44cf-8b43-be0a8d2015bb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e6635e94-c0bd-4358-86a8-60c163050ab6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2873525</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24e75afb-f86a-4bc2-a429-ba36fa3f9af8">
        <rdfs:label>Elevated total plasma homocysteine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0002160</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277400">
        <ddiem:iembaseAccessionNumber>90</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d106b8c9-b251-4e05-934c-995318f859e2"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/90</ddiem:iembaseUrl>
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/277400</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c913cb3-bf03-461b-908c-180cf55425de">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
        <dc:identifier>HP:0000712</dc:identifier>
        <rdfs:label>Emotional lability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a06daf69-d7a3-41de-a859-b97529496071">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000649</ddiem:url>
        <dc:identifier>HP:0000649</dc:identifier>
        <rdfs:label>Abnormal visual evoked potentials</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd31abbc-ba65-4d6e-8d48-61299b00e5f0">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>Psychiatric disturbances</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a53e94da-e15d-42a4-9bf5-6e542b08c26d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b7e5437e-b5f4-4fe5-81d5-786aee58a283"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530304</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf2abc2e-89b6-4e5e-9d25-3c3c0bc0f4da">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006958</ddiem:url>
        <dc:identifier>HP:0006958</dc:identifier>
        <rdfs:label>Abnormal brain stem auditory evoked potentials</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/301c1ff6-86ff-4cba-97f7-20d597ed093e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11503bbf-250e-4d10-9d8b-cba1c2304c95">
        <rdfs:label>Dementia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <dc:identifier>HP:0000726</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c92a615-a2d3-4f72-90cb-653ede48cf6c">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>High urine methylmalonic acid level</rdfs:label>
        <dc:identifier>HP:0012120</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611209">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/344</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/611209</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aec325c2-6b10-4ab5-9574-148100eb099b">
        <rdfs:label>COG1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9382</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G</rdfs:label>
    <ddiem:iembaseAccessionNumber>344</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/01a0654f-e353-4733-af09-601586832442">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d25b5d52-4979-424f-97ba-750bf314cbf2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21c2d4b9-052f-44cd-ba97-b8595d0624f7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2464ef8e-6401-4dc2-a288-040f84f55cd1">
        <rdfs:label>Elevated hepatic transaminases</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1dc72fe7-f705-441b-819a-71af064e2d22">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2250d47e-f993-419a-b0da-31818b524446"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/306000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/492</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4a1f8dde-2920-417c-a7af-12276acc8c60"/>
        <dc:identifier>https://www.omim.org/entry/306000</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXa1; GSD9A1</rdfs:label>
        <ddiem:iembaseAccessionNumber>492</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/418ef44f-59c0-444f-8e5e-1ff917b07041">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/006340d1-713a-4add-9146-42ba4a1c2434">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dcdf5bd9-0ca7-49e6-82ae-235132a37d3d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15fbc68d-b8fa-4389-8113-2e23df2c223b">
        <rdfs:label>hypoglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7fd0fecd-8a92-4bcb-af70-8e65c2c73b31">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d34f268-062f-4d53-b879-4e0b1bfff743"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606762">
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/606762</dc:identifier>
        <ddiem:iembaseAccessionNumber>567</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/567</ddiem:iembaseUrl>
        <rdfs:comment>Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d840f6f9-121b-4019-b4bf-a43067fa1c60"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/438c0ed5-138c-4d1d-b0e3-e6dc6519a07c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/71717604-13cf-459f-99e3-f5732516d7b3"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/86f0fdf5-0b34-4345-8274-ea216fe2a3aa">
    <ddiem:uniprotId>Q8WZA1</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K09666</ddiem:keggEntryId>
    <rdfs:label>Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0782cf8c-bb7a-4af1-b0d7-e77bff88ef15">
        <rdfs:label>POMGNT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55624</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/73b064e3-53dc-4224-bd8b-164411a34659">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d603f945-aeef-479d-b2df-46d023fc1077">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3028</dc:identifier>
        <rdfs:label>HSD17B10</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08683</ddiem:keggEntryId>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase type II</rdfs:label>
    <ddiem:uniprotId>Q99714</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.35; 1.1.1.51; 1.1.1.178</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d044d1e4-7198-406b-94a5-75988d6ba00c">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfeeb237-c3fa-4a01-bd1b-217c0fad121b">
        <rdfs:label>Verruciform plaques(verruciform xanthomas)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031517*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f191ea2-b8be-46ac-bd6e-f70037a5a9a7">
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Itchy skin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/308050">
        <rdfs:label>CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS</rdfs:label>
        <ddiem:iembaseAccessionNumber>194</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/00609be1-7016-4170-8461-f1aaae11c819"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/194</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/308050</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82ee7077-0312-44a6-902e-b095e79f250f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/05eb566e-5f9c-42be-978d-207a5c895a60"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60ffed6a-7b69-4c80-91b0-cc3b96238851">
        <dc:identifier>HP:0007431</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007431</ddiem:url>
        <rdfs:label>Ichthyosiform erythroderma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/69f563a0-3577-4ca5-ac5d-fb1eeb0177a3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d1368145-f552-4445-aa4e-a5fed0c6a3b7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b83d5b6-c186-45ad-acc8-154a08f3ea35">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:label>Scaling Skin</rdfs:label>
        <dc:identifier>HP:0040189</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fbe740f-d7ba-4f04-be2a-17c7ce87d16d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>VX‐like lesions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29341259</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b37ec182-9fec-485b-ad8d-12c89f91cbc5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Erythema</rdfs:label>
        <dc:identifier>HP:0010783</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f4ac1c8b-c7ae-412c-b72f-8260b5208416">
    <rdfs:label>beta-alanine-alpha-ketoglutarate transaminase.</rdfs:label>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3b9dba3c-58af-4423-8bc2-8c9218b6e57d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/93183</dc:identifier>
        <rdfs:label>PIGM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2f459251-3ec9-4cce-b9d3-66b27a9c2697">
    <ddiem:keggEntryId>K01876</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/64f4eb4b-3b96-4524-a524-b1d75512b7e2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55157</dc:identifier>
        <rdfs:label>DARS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>mitochondrial aspartyl-tRNA synthetase</rdfs:label>
    <ddiem:uniprotId>Q6PI48</ddiem:uniprotId>
    <ddiem:ecNumber>6.1.1.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b4e01884-ad05-4b49-8bcb-a77901485408">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/14cd9cdf-09ca-4198-b50c-8b6ab27aa610">
        <rdfs:label>ABHD5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51099</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8WTS1</ddiem:uniprotId>
    <ddiem:keggEntryId>K13699</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.51</ddiem:ecNumber>
    <rdfs:label>adipose triglyceride lipase (ATGL)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/23398243-d444-400e-9453-4f8be04ae2de">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232220">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/485</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ib; GSD1B</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/232220</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c1b0cbba-a690-4868-871b-5e670170d0ac"/>
        <ddiem:iembaseAccessionNumber>485</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d60ea006-22f9-4900-b4af-ab310e343416">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003162</ddiem:url>
        <dc:identifier>HP:0003162</dc:identifier>
        <rdfs:label>Fasting hypoglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9773883e-12b9-4d2f-9b06-1ef3f6a1fec4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance,Poor sleep qaulity</rdfs:label>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007121</ddiem:url>
        <dc:identifier>ECO:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b0aa1c2f-597f-44a4-b5a3-296405b0a47c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7ff27b74-1aaa-43ba-9d0e-dfae23834546"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8938747b-f028-46b9-8b0e-057a6a48f528">
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <rdfs:label>Low quality of life(Constitutional symptoms)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ca2bedce-fc81-4716-9c8a-a24cbcb05faa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a9b5eb2-9d98-43b2-af4c-2edba7e3e2fc">
        <rdfs:label>hypertriglycernemia</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/131f6cb2-8d13-41be-b95d-4485ac53fc80">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c34967cc-8819-4516-9ca2-8b762b01c815"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f8771284-0cb6-43be-a7d9-d829e9ffe76b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8cbadad2-c029-4568-ac0b-048119eb9aa2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00214604</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617347">
        <dc:identifier>https://www.omim.org/entry/617347</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/507</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c48c7f15-16df-4596-9301-890ea683977b"/>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE III</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>507</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b494e503-73b0-4572-b199-3f530eb6aedc">
    <ddiem:keggEntryId>K01556</ddiem:keggEntryId>
    <rdfs:label>kynureninase</rdfs:label>
    <ddiem:ecNumber>3.7.1.3</ddiem:ecNumber>
    <ddiem:uniprotId>Q16719</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7a32e566-a25b-4769-8fa3-59980360b99e">
        <rdfs:label>KYNU</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8942</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d0040910-8f2a-4227-9e84-d1c6f75c90c3">
    <rdfs:label>quinoid dihydropteridine reductase</rdfs:label>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2c57b2a5-6ade-4a0c-b706-cedc208fa5df">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5860</dc:identifier>
        <rdfs:label>QDPR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613724">
    <rdfs:label>LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN</rdfs:label>
    <ddiem:iembaseAccessionNumber>1114</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/613724</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/080375ed-7ef9-4f3a-85e0-bd9b5432ff28">
        <rdfs:label>SCP2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6342</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1114</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1840303f-a751-4818-91eb-b085a3cce21b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Oxidative stress</rdfs:label>
        <dc:identifier>HP:0025464</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4867f14-c14e-45d9-842a-a4b9e8375753">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>Behavioural abnormalites</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0de52245-d225-449c-bcae-fcf59bba042c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21c503c7-1815-4367-9962-5dbe89bc0ef5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12ac27d4-90eb-4cde-9546-d9729fd8e8c2">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001328</ddiem:url>
        <rdfs:label>Learning impairment</rdfs:label>
        <dc:identifier>HP:0001328</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7921b44c-c5ac-49b6-87bc-979510175e9e">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>Memory impairment</rdfs:label>
        <dc:identifier>HP:0002354</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cc9771c-dfb5-482e-a5f8-4beb4bebe666">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>cognitive imapirment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b2c7b03d-c9c8-4e65-a722-cc4fc1f89ddf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8ebb9344-9c61-4d6c-bf2b-8331882d6136"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246900">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89793ab0-57b2-4d74-87f9-2b007d6ca98a"/>
        <dc:identifier>https://www.omim.org/entry/246900</dc:identifier>
        <rdfs:label>DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15938133</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/64a890de-fe15-4e36-8b50-4d7c28c09af4">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a17bc22c-f47e-495a-a0ec-bf749b0c81bd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1644</dc:identifier>
        <rdfs:label>DDC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01593</ddiem:keggEntryId>
    <rdfs:label>Aromatic-L-amino-acid decarboxylase</rdfs:label>
    <ddiem:ecNumber>4.1.1.28</ddiem:ecNumber>
    <ddiem:uniprotId>P20711</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8b89b0a7-7700-4821-bf57-3028fca96291">
    <ddiem:uniprotId>Q8NCH0</ddiem:uniprotId>
    <ddiem:ecNumber>2.8.2.35</ddiem:ecNumber>
    <rdfs:label>Dermatan-4-sulfotransferase-1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fe0dbe90-9564-4566-a06e-2603c20077bd">
        <rdfs:label>CHST14</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/113189</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08105</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8907b1ac-260c-4792-9391-cf39b6c4bc67">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40c70283-f926-4d0f-81dc-32ca59139b01">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/51004fec-5e13-4c0e-88b7-5d7dfe230564"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/274270">
        <dc:identifier>https://www.omim.org/entry/274270</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1a34c414-f563-4db4-8fe7-667ebc917768"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/159</ddiem:iembaseUrl>
        <rdfs:label>DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>159</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0">
        <rdfs:label>seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42cc703e-c02d-43ca-9e33-9b94536acae0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/905c6bce-556d-4cfd-91d5-2f6b3258caf4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222748">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/268</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/222748</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/42980054-6ac5-45d3-a4ae-53880ab7597a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1807</dc:identifier>
        <rdfs:label>DPYS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD</rdfs:label>
    <ddiem:iembaseAccessionNumber>268</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4d626cbc-8502-4e8d-81e2-f884e710c0f6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6565b404-fd04-4ef7-a606-5358e8e6734d">
        <rdfs:label>Low quality of life (Constitutional symptoms)*</rdfs:label>
        <dc:identifier>HP:0002123</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbe890a3-fe2c-4989-aa4f-9e2ca2c754b6">
        <dc:identifier>HP:0002180</dc:identifier>
        <rdfs:label>Myoclonus</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66ba728c-bb25-40f2-855b-ea26c278656f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac6d2d8a-b6db-4c37-a6ef-aca962fc4b1a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/545000">
        <dc:identifier>https://www.omim.org/entry/545000</dc:identifier>
        <rdfs:label>MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/27c0dbb8-f980-49b9-a28b-cd8bf27602b8"/>
        <ddiem:iembaseAccessionNumber>400</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/400</ddiem:iembaseUrl>
        <rdfs:comment>Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28686997</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/98df1883-1660-4fb7-8d41-750ecee8cdef"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/24fe6a16-16f1-4f1a-b722-eb9856e444b5">
    <ddiem:uniprotId>P35520</ddiem:uniprotId>
    <ddiem:ecNumber>4.2.1.22</ddiem:ecNumber>
    <ddiem:keggEntryId>K01697</ddiem:keggEntryId>
    <rdfs:label>cystathionine beta-synthase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c93516e9-010d-4d9f-a769-bb7ba02b2ee1">
        <rdfs:label>CBS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/875</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/80c9b5c0-21af-4412-940a-f77fdfd1d1a5">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b0aa1c2f-597f-44a4-b5a3-296405b0a47c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d60ea006-22f9-4900-b4af-ab310e343416"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3072a53-ac45-45c6-83f0-3fe3d728bed7">
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance,Poor sleep quality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232200">
        <ddiem:iembaseAccessionNumber>484</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/484</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/232200</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ia; GSD1A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aa518431-a65e-4d96-a784-999421b2bde8"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8938747b-f028-46b9-8b0e-057a6a48f528"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/35ba0c86-8ec6-4b1b-9b35-b003aed40f3e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/338dacd5-05fb-4bc7-ba19-99e311b4d2cf">
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>developmental delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5386146a-2730-4a4e-8ea4-4bb02d1b6c80">
        <rdfs:label>High plasma long-chain acylcarnitines</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0045045</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0030095-caa1-4aa7-9bef-d8cfd5e66af7">
        <rdfs:label>Hypocarnitinemia</rdfs:label>
        <dc:identifier>HP:0003234</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/212138">
        <ddiem:iembaseAccessionNumber>229</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/212138</dc:identifier>
        <rdfs:label>CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/229</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d5fc7f42-73ef-4009-8a72-c38da07b2e91"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4f0415b3-9909-44f9-979d-67456199b5cc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c0a6fc88-c3fa-4d4f-8ec9-a91b039f9a56"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17508264</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a5422aa8-2d55-42b1-9c35-8ac3a4d1ef3e">
    <ddiem:ecNumber>3.2.1.24</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bfde057e-008c-49ae-ad2b-31d121b63d1d">
        <rdfs:label>MAN2B1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4125</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O00754</ddiem:uniprotId>
    <rdfs:label>Alpha-mannosidase</rdfs:label>
    <ddiem:keggEntryId>K12311</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615042">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/604</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dc2b7e51-04f6-44cb-9ede-d03c886c0505">
        <rdfs:label>DPM2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8818</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/615042</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U</rdfs:label>
    <ddiem:iembaseAccessionNumber>604</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/de4bfe7d-4eee-41cc-af31-94af3040a382">
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005542">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005542</ddiem:url>
        <dc:identifier>ECO:0005542</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07f368e3-ffb6-4e99-bce4-f82ca4a1d3e7">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006785</ddiem:url>
        <rdfs:label>Muscle dystrophy</rdfs:label>
        <dc:identifier>HP:0006785</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613153">
        <dc:identifier>https://www.omim.org/entry/613153</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>645</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dd67c847-a456-4ea9-8519-e2f6118413cb"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/645</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/da7dc67b-2e19-4f43-b7ea-1de6f4150296">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a1e8d12a-f395-454e-a530-04457eb21852"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/052a9b84-aa45-4e56-8297-efc0689218e6">
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bb6bfbb2-7cfa-4c3c-a668-27b779339c3e">
        <rdfs:label>SLC35C1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55343</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GDP-fucose transporter 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a71acb71-ffed-4701-8b8b-d84e8ddc4775">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8c8d8e4-443e-4055-9063-4402e045e971">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004337</ddiem:url>
        <rdfs:label>Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*</rdfs:label>
        <dc:identifier>HP:0004337*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b52338dd-94e9-4c3d-b514-e08b80f71881">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>lethargy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001254</ddiem:url>
        <dc:identifier>HP:0001254</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f3d143e-271b-45fc-911a-5855a25121f0">
        <rdfs:label>anorexia</rdfs:label>
        <dc:identifier>HP:0002039</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/765e11e8-deaa-450e-b5b8-c23954ba102f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9d9d8730-f5db-44c6-be4f-0f05f4afcbb0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4216e31-4d7a-49da-9c01-1ce09c7971e7">
        <dc:identifier>HP:0001987</dc:identifier>
        <rdfs:label>hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdfs:comment>It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6572e0d5-cf04-445b-9806-6bd9dade75bf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
        <dc:identifier>HP:0011966</dc:identifier>
        <rdfs:label>Elevated plasma citrulline level</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6aef4bb8-5567-4b44-a3bf-edbbeb69c3a7">
        <rdfs:label>Poor growth</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/234a1a61-f558-4ae3-bc72-ed55c27c8d05">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a57643e-2ed3-445b-8ec1-87af8404ca75"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e488a7c-ff62-4cb6-9cc7-42eebb23022d">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Elevated serum pancreatic secretory trypsin inhibitor</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d448309d-54ff-44fc-9b61-66d1a4fde126">
        <dc:identifier>HP:0012378</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:label>fatigue</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603471">
        <rdfs:comment>Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4b0619c8-8b80-45ba-afc3-9b68957785a5"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/18</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>18</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/603471</dc:identifier>
        <rdfs:label>CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1707de59-c46d-4295-9760-ab671a88fb66">
    <ddiem:keggEntryId>K09539</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96DA6</ddiem:uniprotId>
    <rdfs:label>DnaJ heat shock protein family (Hsp40) member C19</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/68eb49b2-1a90-4362-86e4-bd18d6b85fca">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/131118</dc:identifier>
        <rdfs:label>DNAJC19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fff97693-5c8a-4645-826d-24d162392f57">
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608896">
        <dc:identifier>https://www.omim.org/entry/608896</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/62ab49dd-d395-42a1-8479-98a52cd66569"/>
        <rdfs:label>SARCOGLYCAN, GAMMA; SGCG</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/83346d22-5b82-4332-b72d-0accc48d6d3e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/92c14f1b-1165-4cdf-b13e-1e3145abfc97"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15252120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2880b2e6-5754-4925-89c2-5f59bc82cca7">
    <ddiem:ecNumber>4.4.1.1</ddiem:ecNumber>
    <ddiem:uniprotId>P32929</ddiem:uniprotId>
    <ddiem:keggEntryId>K01758</ddiem:keggEntryId>
    <rdfs:label>cystathionine gamma-lyase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9a31b920-cc23-4bfa-9b5f-24a916acc23c">
        <rdfs:label>CTH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1491</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8e3bed6-9d50-498b-98de-61d5685c9d9c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29246599</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f11e9a37-9c02-44cf-8b43-be0a8d2015bb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05c5c6f1-3fcf-479a-add3-c6666626204a">
        <rdfs:label>High plasma homocysteine level(Abnormal homocysteine level)*</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0010919</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603174">
        <rdfs:label>HOMOCYSTEINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6555c4ea-7367-4031-a014-333ccf23068d"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/603174</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f17dc0c-fc55-497a-a367-f0acdf57d5d0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/488b4f8a-bb56-4982-8364-aa8298c07ddb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee69fbef-4f21-47b9-87c5-043d0af63a4e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87961b08-722c-4642-8d38-aec9cda90fdb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6bc0404e-c22d-4e21-ba86-3a4069f43a2f">
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <rdfs:label>DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE</rdfs:label>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c88947aa-0766-4304-b49f-2fac99c0fe39">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6718</dc:identifier>
        <rdfs:label>AKR1D1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3960bc6e-fcb5-42fd-9144-ec064f01f43e">
    <ddiem:uniprotId>Q9Y259</ddiem:uniprotId>
    <ddiem:keggEntryId>K14156</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.32; 2.7.1.82</ddiem:ecNumber>
    <rdfs:label>Choline/ethanolamine kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9a500002-117b-4ddd-adc2-2148af735ea1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1120</dc:identifier>
        <rdfs:label>CHKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/66dc3f07-7ba2-44c8-acb3-f87f726e94dc">
    <ddiem:keggEntryId>K13624</ddiem:keggEntryId>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <rdfs:label>Ferroxidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/32e4d2c8-b362-4d73-ad02-b69998945327">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1356</dc:identifier>
        <rdfs:label>CP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P00450</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b60061e4-d741-4d2c-8451-91fe96e2be6c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f11e9a37-9c02-44cf-8b43-be0a8d2015bb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc8025e5-2f54-458b-841a-e104df6e2c37">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Abnormality of homocysteine metabolism</rdfs:label>
        <dc:identifier>HP:0010919</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0184233f-63b9-4972-8b21-f59725d0e186">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>low muscle tone</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <dc:identifier>HP:0001290</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ba4b0ba7-0654-4cd1-a6df-644af85ccee6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1c895f2d-25f6-491f-8604-210077362172"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/89f4cef5-3041-4890-a21f-d26fbeee6ce1">
    <rdfs:label>Protein O-mannosyl-transferase 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c84998fd-a1f8-4421-8fb7-d589e87f05f6">
        <rdfs:label>POMT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/29954</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
    <ddiem:uniprotId>Q9UKY4</ddiem:uniprotId>
    <ddiem:keggEntryId>K00728</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/75bd6cb9-a8c9-4f78-addb-6a6aa5f8b8e7">
    <ddiem:uniprotId>Q9Y223</ddiem:uniprotId>
    <rdfs:label>glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b43c8bbf-3a50-4741-8b8e-fe76f9acb197">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10020</dc:identifier>
        <rdfs:label>GNE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.183; 2.7.1.60</ddiem:ecNumber>
    <ddiem:keggEntryId>K12409</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2087a795-d4d2-4694-a88d-5695c63ad3b2">
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <rdfs:label>methylenetetrahydrofolate reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6555c4ea-7367-4031-a014-333ccf23068d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4524</dc:identifier>
        <rdfs:label>MTHFR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bb195487-70c7-48c3-8f50-5c02ae268a95">
    <ddiem:keggEntryId>K13511</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/14f46567-2484-478a-9b49-fa0447d05534">
        <rdfs:label>TAZ</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6901</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tafazzin ( Protein)</rdfs:label>
    <ddiem:uniprotId>Q16635</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a133ecf1-8ebf-4a53-af7c-c0dd3109d0f2">
    <ddiem:uniprotId>P21953</ddiem:uniprotId>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00167</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f1aac431-4d69-45c9-8007-a7c90df8489a">
        <rdfs:label>BCKDHB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/594</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit beta, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2b062194-85cb-4870-b98c-ca2e9e06552b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa43463b-192e-4340-aeb2-49401bfdf29f">
        <rdfs:label>social interaction defect</rdfs:label>
        <dc:identifier>HP:0000735</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4bb6646c-64f8-4457-a379-fba640c179e4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a5307c5b-f236-4b60-930f-ee46854b9b11"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28b456aa-eb6f-4e97-8764-49a4718478b0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:label>lack eye-eye contact</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/280eb90a-c548-4bd2-aa9c-d12e2ec019ee">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001433</dc:identifier>
        <rdfs:label>Hepatosplenomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/19d207b9-f6fa-4fd2-af26-d56a6281799e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc8d0c48-cdee-486a-81cc-fd0089f5063d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b6d257d-76cc-4564-a009-0b3fc1ebf9d2">
        <rdfs:label>episodic behavioral abnormalities</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222700">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/51</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>51</ddiem:iembaseAccessionNumber>
        <rdfs:comment>General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c1cad92a-0df8-4623-a30c-24bcd18d762f"/>
        <rdfs:label>LYSINURIC PROTEIN INTOLERANCE; LPI</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/222700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/78d99393-eb35-4e5c-b2e1-e950d3095df9">
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89793ab0-57b2-4d74-87f9-2b007d6ca98a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1738</dc:identifier>
        <rdfs:label>DLD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <rdfs:label>dihydrolipoamide dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600627">
    <dc:identifier>https://www.omim.org/entry/600627</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9d2c1d82-620d-49e8-9e00-bfa1ffde8715">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6999</dc:identifier>
        <rdfs:label>TDO2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>HYPERTRYPTOPHANEMIA; HYPTRP</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/618</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>618</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/92810bca-db47-43bd-994c-65a9c55e1814">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89609e9a-eb95-4fc3-a8fd-7bc51d6374ee">
        <dc:identifier>HP:0002664</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neoplastic growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002664</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26170630</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18381602</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b7b480e-92e2-4068-a835-36fc626f33d7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/900001f7-3034-4510-9109-22c9ab8b116a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03234e09-ed6a-4647-9f02-72d32caea53f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99c34140-404b-4958-aa67-518946d40205"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162300">
        <rdfs:label>MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9dc56779-7126-4bb0-abf6-5b83fce2d8db"/>
        <dc:identifier>https://www.omim.org/entry/162300</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/83c3a9d5-84ec-4b6c-85a1-ef013ea20989">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f4439a1c-79a9-4dfa-a07c-c02c066ca61b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/383</dc:identifier>
        <rdfs:label>ARG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P05089</ddiem:uniprotId>
    <ddiem:ecNumber>3.5.3.1</ddiem:ecNumber>
    <rdfs:label>Arginase</rdfs:label>
    <ddiem:keggEntryId>K01476</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3055c716-cc7c-4819-8f43-9c9c6ad7124e">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610131">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>942</ddiem:iembaseAccessionNumber>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/488a8f67-c486-4da7-8aaf-692d9714b43a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/942</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/610131</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/676077e2-dffb-4e14-9351-f1af0c3345f3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b79391b9-196c-447b-b0fa-1a62ccad2a0e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23248042</dc:provenance>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6164a5ef-dbf5-4cbe-b8d1-72efb3c40bb1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0d6a2991-b608-4451-9da6-b6677e3f9d8a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6dade404-f397-43a9-8145-12de61e23a18">
        <rdfs:label>Mitochondrial epilepsy(Epilepsy)*</rdfs:label>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66ba728c-bb25-40f2-855b-ea26c278656f"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3b8e4881-908e-46b5-bfcb-acd7bc007a7c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/396d104d-4d36-47d6-a038-9ddd097586f2">
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19285442</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246700">
        <dc:identifier>https://www.omim.org/entry/246700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CHYLOMICRON RETENTION DISEASE; CMRD</rdfs:label>
        <ddiem:iembaseAccessionNumber>1083</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1083</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5968fcd2-3929-4240-ba71-59930910fbe4"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/494647e7-6fb9-4d4d-92ca-5b06695e10cf">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012638</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012638</ddiem:url>
        <rdfs:label>Muscular abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/124aa044-4056-4ac4-8a44-cfb04e243187"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cae040dd-7492-4cac-8cb7-1c2c9bb064fa">
        <rdfs:label>Minor visual abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000505</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000505</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/da43e5a3-939d-43e6-9afa-dc08821ae030">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a3ce599-ebd7-4907-a98c-53055e1abcd8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/74c236af-24ab-41c6-b002-8d9ae35bce39">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/53d0fd74-95f3-4d7c-bff1-ebe717e507bc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c42e229c-47fc-4f4a-83d3-6549f17cf7dd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26917598</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602473">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8ae49822-9664-422c-94fd-4a6ece7674bb"/>
        <rdfs:label>ENCEPHALOPATHY, ETHYLMALONIC; EE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602473</dc:identifier>
        <ddiem:iembaseAccessionNumber>172</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/172</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a6ef9c68-d0f3-4d0f-aacf-b7c4b994bb25">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/333e73a4-0bc8-4d2f-a482-17d48595acbf">
        <rdfs:label>Abnormal EEG</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/540000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7e3139fa-55b5-4fbf-aae3-3b57510ef838"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cec7412b-3fa9-4f67-9445-0cd8f878b80f"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/49d8daf6-2845-4e1a-b8dd-daf2423eb382"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c8b998bb-477e-4812-9612-a2f20625cf8c"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/27c0dbb8-f980-49b9-a28b-cd8bf27602b8"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9cad528d-f87c-4dac-95bd-1023642693d8"/>
        <ddiem:iembaseAccessionNumber>399</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/399</ddiem:iembaseUrl>
        <rdfs:comment>MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/063b005e-3ab9-49f0-b247-215819d856a3"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/87c79233-3453-4453-9cb3-d225cad8651e"/>
        <rdfs:label>MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6e67320b-65bc-4c39-8dc1-72a844a0a474"/>
        <dc:identifier>https://www.omim.org/entry/540000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/60a752e5-d980-4dc9-bce5-c54dc0e47e62"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/0022510X89901123</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26f3d96e-38a4-47f5-979a-95dd91f902bf"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a2476aff-f4e2-464b-8202-c58bf5397981">
    <ddiem:uniprotId>P53680</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fc3f499e-142b-487e-9b2d-2f784f3001ce">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1175</dc:identifier>
        <rdfs:label>AP2S1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K11827</ddiem:keggEntryId>
    <rdfs:label>adaptor protein-2 σ-subunit</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162350">
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B</rdfs:label>
    <ddiem:iembaseAccessionNumber>309</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3e811f28-cbe2-4789-a3ef-53a68669ac52">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80331</dc:identifier>
        <rdfs:label>DNAJC5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/309</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/162350</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe3e80f6-3ff0-4956-ba62-1b9b99b69738">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1691971-0ed3-4f73-bd0e-bef7d49f58e3">
        <rdfs:label>Dystonia</rdfs:label>
        <dc:identifier>HP:0001332</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300322">
        <ddiem:iembaseAccessionNumber>145</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/300322</dc:identifier>
        <rdfs:label>LESCH-NYHAN SYNDROME; LNS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/145</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/238b8521-1afc-4ad2-8ca6-bbd356320f51"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cdeba2d-427a-4187-bbfd-ea073ffc31bf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002072</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Chorea</rdfs:label>
        <dc:identifier>HP:0002072</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa865077-9eaf-4f02-ba68-c41c72145650"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/54c1d61a-6285-4496-875b-d82db036f16b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a05c495-c683-4080-8b50-03d8faf829b5"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616479">
    <dc:identifier>https://www.omim.org/entry/616479</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3e9bf89f-aee7-415f-8fdd-daedc167a182">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/246243</dc:identifier>
        <rdfs:label>RNASEH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/73fbf759-d485-4c44-a89d-e564b768dd85">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b4792a2e-65f2-472a-b442-4d74ba4b527d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6218</dc:identifier>
        <rdfs:label>RPS17</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02974</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/49b586db-015a-4deb-880e-42b1d390e1a6">
        <rdfs:label>RPL5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6125</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02947</ddiem:keggEntryId>
    <ddiem:keggEntryId>K09182</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/65cc861d-c9f9-4adf-88f6-70122a09ebfd">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/and</dc:identifier>
        <rdfs:label>and</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P62854</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cdbb7c8d-74df-4fc8-b72d-9181d4ec69ff">
        <rdfs:label>RPS24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6229</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02993</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02966</ddiem:keggEntryId>
    <ddiem:uniprotId>P62913</ddiem:uniprotId>
    <ddiem:uniprotId>P08708</ddiem:uniprotId>
    <ddiem:uniprotId>P15976</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e49b752c-8070-405d-8d20-022eea534877">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6201</dc:identifier>
        <rdfs:label>RPS7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dbfbf4d0-56d0-4d17-bf2a-1d4768ecee51">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6204</dc:identifier>
        <rdfs:label>RPS10</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02917</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/997247b1-12ef-4e70-b192-3c47d30ec9b4">
        <rdfs:label>RPL11</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6135</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eb09844a-439b-4909-bd5a-edfc7bf20d16">
        <rdfs:label>RPS26</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6231</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02962</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5f0b27ab-2ba4-4522-b2dc-4b18bb1c5741">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6223</dc:identifier>
        <rdfs:label>RPS19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P62081</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/53ad2080-0be4-482a-b7aa-490f3e5b16ff">
        <rdfs:label>RPL35A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0f779234-87c3-48ef-b1c4-8d766cc635cd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2623</dc:identifier>
        <rdfs:label>GATA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02932</ddiem:keggEntryId>
    <ddiem:uniprotId>P18077</ddiem:uniprotId>
    <ddiem:uniprotId>P62847</ddiem:uniprotId>
    <ddiem:keggEntryId>K02868</ddiem:keggEntryId>
    <rdfs:label>40S ribosomal protein S19</rdfs:label>
    <ddiem:keggEntryId>K02976</ddiem:keggEntryId>
    <ddiem:uniprotId>P39019</ddiem:uniprotId>
    <ddiem:uniprotId>P46777</ddiem:uniprotId>
    <ddiem:uniprotId>P46783</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2814fbef-b91c-4eb9-becf-31195fca6a12">
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <rdfs:label>Fukutin-related protein</rdfs:label>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dd67c847-a456-4ea9-8519-e2f6118413cb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79147</dc:identifier>
        <rdfs:label>FKRP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000014">
    <rdfs:label xml:lang="en">surgical or physical treatment procedure</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure to mitigate the immediate or future effects of the presence of a genetically defective protein which involves physical conditioning or anatomical modification.[PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:30+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/77b1d5df-c53f-4828-b206-9a0dd5af7c2c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/27c0dbb8-f980-49b9-a28b-cd8bf27602b8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>MT-TK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Beta-1,4-glucuronyltransferase 1</rdfs:label>
    <ddiem:uniprotId>O43505</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a9c93d28-8c0d-420c-888d-19fc07e5dc31">
        <rdfs:label>B4GAT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11041</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K21032</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f553b4fb-0488-4de7-960a-cec029bbb829">
    <rdfs:label>acid ceramidase</rdfs:label>
    <ddiem:ecNumber>3.5.1.23; 3.5.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K12348</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13510</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6221b727-dad1-4017-8032-ed99832ecf9f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/427</dc:identifier>
        <rdfs:label>ASAH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e7e5324-4f6a-471a-b3ac-52f5305fe726">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b2a250f4-93fb-4476-9b29-1754ba11daaa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231680">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/98251691-b8b7-4a7e-bb9b-704433a30ff2"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/234cc3fe-5efc-46c5-b237-4ab7d18e283a"/>
        <dc:identifier>https://www.omim.org/entry/231680</dc:identifier>
        <ddiem:iembaseAccessionNumber>1257</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1257</ddiem:iembaseUrl>
        <rdfs:label>MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b1c60511-ac28-4309-b93a-7a44f778ef17"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2775502c-5918-4232-9556-82a13fc1a40a">
        <dc:identifier>HP:0003234*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <rdfs:label>Secondary Carnitine deficiency( Carnitine deficiency)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2947cd6e-d2a3-490c-b083-1a5dcc231e08">
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>High serum creatine kinase</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b07909e-8b29-4fe6-ba0f-e3a3f345a96f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:label>Muscle weakness</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/509febd3-7fba-4d67-8d9d-b2a42276be1d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9b3cf7d3-56e4-4c8b-ad05-a16efa8f9035">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/213cd643-7fa5-414e-a68a-350580181a20"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/105650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/997247b1-12ef-4e70-b192-3c47d30ec9b4"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cdbb7c8d-74df-4fc8-b72d-9181d4ec69ff"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/53ad2080-0be4-482a-b7aa-490f3e5b16ff"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dbfbf4d0-56d0-4d17-bf2a-1d4768ecee51"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e49b752c-8070-405d-8d20-022eea534877"/>
        <dc:identifier>https://www.omim.org/entry/105650</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5f0b27ab-2ba4-4522-b2dc-4b18bb1c5741"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b4792a2e-65f2-472a-b442-4d74ba4b527d"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/49b586db-015a-4deb-880e-42b1d390e1a6"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eb09844a-439b-4909-bd5a-edfc7bf20d16"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/65cc861d-c9f9-4adf-88f6-70122a09ebfd"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0f779234-87c3-48ef-b1c4-8d766cc635cd"/>
        <rdfs:label>DIAMOND-BLACKFAN ANEMIA 1; DBA1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/feace97a-22c1-4fe3-8d87-777a5adbc8ad">
        <rdfs:label>low Hb level</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs12185-016-2044-9</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/02931f50-0c6f-40bc-9619-662b63aca346">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0923db47-b553-4296-a3ab-24ccffd17487"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a683308-75d8-4fff-ab72-71e528ba95c2">
    <rdfs:label>glutathione synthetase</rdfs:label>
    <ddiem:ecNumber>6.3.2.3</ddiem:ecNumber>
    <ddiem:uniprotId>P48637</ddiem:uniprotId>
    <ddiem:keggEntryId>K21456</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/39f15644-b578-40c2-9141-32b5f97f2328">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2937</dc:identifier>
        <rdfs:label>GSS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614128">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/916</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/456f9c0f-0fc3-4dbe-a38d-46652758721c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3939</dc:identifier>
        <rdfs:label>LDHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/39a81e67-aaed-4fd8-8423-a1717e74fbfc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3945</dc:identifier>
        <rdfs:label>LDHB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>916</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/614128</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c09a6349-0eef-48f4-b783-403caaa6de35">
    <ddiem:uniprotId>P54259</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/24e32e6f-e411-4916-98a8-335583111802">
        <rdfs:label>ATN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1822</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05626</ddiem:keggEntryId>
    <rdfs:label>atrophin 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5eeed81-f481-447b-a4c5-556a33357a8f">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/010abe84-4958-4559-9ba0-c5effa11b2e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ae6cf2f5-0f58-40f8-b87d-2c698e715497"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4b0ba7-0654-4cd1-a6df-644af85ccee6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a03983e0-7352-4efa-9213-ffd618a6df18">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261630">
        <dc:identifier>https://www.omim.org/entry/261630</dc:identifier>
        <ddiem:iembaseAccessionNumber>5</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/5</ddiem:iembaseUrl>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2c57b2a5-6ade-4a0c-b706-cedc208fa5df"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d82799d0-d54f-46fc-8c88-621e89f8b674">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>high plasma phenylalanine level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ffab47f-b1b3-4f47-8b76-7794f6534a8c">
        <rdfs:label>High serum  prolactin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040086</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040086</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eeb09cac-d55d-4b2e-ba2f-2a0d9113dd08">
        <rdfs:label>abnormal blood Phe levels</rdfs:label>
        <dc:identifier>HP:0010893</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010893</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0df7e23-0dea-49d2-bdf4-037a2ab35888">
    <ddiem:uniprotId>Q8NBK3</ddiem:uniprotId>
    <ddiem:keggEntryId>K13444</ddiem:keggEntryId>
    <rdfs:label>Formylglycine-generating enzyme</rdfs:label>
    <ddiem:ecNumber>1.8.3.7</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/837535b1-39a5-4acc-9f7e-864666ca7262">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/285362</dc:identifier>
        <rdfs:label>SUMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7a3eadea-dd45-4dd9-acda-0d2d8ad64eef">
    <ddiem:keggEntryId>K00626</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fd474b3b-a38a-499b-a7ce-7c0e7b13c910">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/38</dc:identifier>
        <rdfs:label>ACAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P24752</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.9</ddiem:ecNumber>
    <rdfs:label>Acetyl-CoA C-acetyltransferase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/799f91f9-fd0c-46a7-8d1b-b06fb03ca569">
    <ddiem:uniprotId>P43005</ddiem:uniprotId>
    <rdfs:label>solute carrier family 1 member 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f330cea9-c6c6-470f-8b85-691192d89320">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6505</dc:identifier>
        <rdfs:label>SLC1A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05612</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b355befd-a4d8-4ec4-be08-691aa423de33">
    <rdfs:label>Steroid 17-alpha-hydroxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ae9020de-6d73-4dcd-88bd-c9afbfc4ecab">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1586</dc:identifier>
        <rdfs:label>CYP17A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00512</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.14.19; 1.14.14.32</ddiem:ecNumber>
    <ddiem:uniprotId>P05093</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8ed74544-dade-4951-add4-51cd560b7d88">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e39503c1-d187-444f-8de6-fe3606f9e5b3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ISPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>D-ribitol-5-phosphate cytidylyltransferase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/65d1e103-8efe-46d1-9603-d1f2965ed597">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cf9e2f7-5eaa-4518-b7ff-b02a2e164008">
        <rdfs:label>Sleep disturbance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232400">
        <rdfs:label>GLYCOGEN STORAGE DISEASE III; GSD3</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/487</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>487</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/62cb75b1-c5a1-436c-9ec8-1f17c1ecd968"/>
        <dc:identifier>https://www.omim.org/entry/232400</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b0aa1c2f-597f-44a4-b5a3-296405b0a47c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d60ea006-22f9-4900-b4af-ab310e343416"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6733a83-e4ec-493d-96d0-1a519f06f6d5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54c1d61a-6285-4496-875b-d82db036f16b"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/010abe84-4958-4559-9ba0-c5effa11b2e5"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72728d3c-630c-4785-a724-e7906fa2eddc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e3a74729-5b00-484d-bd92-5cc718096e50"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d82799d0-d54f-46fc-8c88-621e89f8b674"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ed8f116e-ac94-4105-85a0-2a3011c42924">
    <rdfs:label>arginine:glycine amidinotransferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4ff25e12-546a-4efc-85c8-2a95e0d9d5c6">
        <rdfs:label>GATM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2628</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00613</ddiem:keggEntryId>
    <ddiem:ecNumber>2.1.4.1</ddiem:ecNumber>
    <ddiem:uniprotId>P50440</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/12ab2323-9835-43dd-b335-256d9001d87c">
    <ddiem:ecNumber>2.4.1.-; 2.4.2.26</ddiem:ecNumber>
    <ddiem:keggEntryId>K07605</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/144823ee-1d3a-4acd-829f-852a1cbbfecb">
        <rdfs:label>KRT5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3852</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8NBL1</ddiem:uniprotId>
    <ddiem:keggEntryId>K13667</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e977e5a9-b644-48a0-83e3-03fd897476c1">
        <rdfs:label>POGLUT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56983</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>keratin 5/protein O-glucosyltransferase</rdfs:label>
    <ddiem:uniprotId>P13647</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b795ee5a-3b79-4b98-9d57-aadec48a635d">
    <rdfs:comment>Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c92a615-a2d3-4f72-90cb-653ede48cf6c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9788703e-c97f-4424-a31d-fc05ed8a3f03">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <rdfs:label>decreased glomerular filtration rate</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0012213</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210590</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d15deb6f-38b6-4e1f-9997-9701298b850f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <dc:identifier>HP:0011025</dc:identifier>
        <rdfs:label>Fatigue</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a53e94da-e15d-42a4-9bf5-6e542b08c26d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9262c430-0d2e-44da-bd03-cf3f051292f5">
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:label>Haemolysis</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59829092-4608-4c0f-9ea7-80764167fd12">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0002395</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002395</ddiem:url>
        <rdfs:label>Lower limb hyperreflexia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24e75afb-f86a-4bc2-a429-ba36fa3f9af8"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fef7129e-c3bb-495d-a3b3-060b068aec86">
        <dc:identifier>HP:0012211</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:label>Impaired renal function</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8c6210e-3d6c-401d-80f2-9e4e6223467e">
        <dc:identifier>HP:0031258</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031258</ddiem:url>
        <rdfs:label>Delirium</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4564bd3b-979f-474e-9998-dbfd773b4a22">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001257</dc:identifier>
        <rdfs:label>Spasticity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210589</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4b0ba7-0654-4cd1-a6df-644af85ccee6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/165ce715-75de-4509-a340-2b2d1651d411">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Anorexia</rdfs:label>
        <dc:identifier>HP:0002039</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f11e9a37-9c02-44cf-8b43-be0a8d2015bb"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f1893504-a50b-4231-9ff8-68b0113a00a3">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da7dc67b-2e19-4f43-b7ea-1de6f4150296"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07f368e3-ffb6-4e99-bce4-f82ca4a1d3e7"/>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236670">
        <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/236670</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cae73afc-fe20-4f34-831b-d408e40d55d9"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aedb75d9-0007-4e60-b57d-696bb215b51b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/218800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/70e21725-088a-4672-9be2-2850fe9ac9fb"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/218800</dc:identifier>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE I</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/db9e8854-310a-4f73-b270-0c2d201c3f26">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc26e1e8-946d-4c3b-9dbe-5cb2f5cd8841"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0b1aae4-2a10-4af7-8011-f6497d19fb5a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:label>Study was suspended based on Sponsor Decision.</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/429efccf-c4f5-4526-9ae4-14614d6ac5d9">
    <rdfs:label>Fructose-1,6-bisphosphatase 1</rdfs:label>
    <ddiem:uniprotId>P09467</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/864ad736-e067-48c0-9ed4-45464f827683">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2203</dc:identifier>
        <rdfs:label>FBP1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.11</ddiem:ecNumber>
    <ddiem:keggEntryId>K03841</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f7d2db52-be79-4453-8cef-08c715a51fae">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d7df0109-8376-429c-88cc-149e0617e638">
        <rdfs:label>NPC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10577</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13443</ddiem:keggEntryId>
    <rdfs:label>NPC2 protein</rdfs:label>
    <ddiem:uniprotId>P61916</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612933">
    <rdfs:label>GLYCOGEN STORAGE DISEASE XI; GSD11</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612933</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/456f9c0f-0fc3-4dbe-a38d-46652758721c"/>
    <ddiem:iembaseAccessionNumber>499</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/499</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d700a379-bc0d-4da3-a73a-e6b1a76ab3e7">
    <ddiem:uniprotId>O00462</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.25</ddiem:ecNumber>
    <rdfs:label>Beta-mannosidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e26e4ad6-70bf-49ec-a379-d860bd259661">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4126</dc:identifier>
        <rdfs:label>MANBA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01192</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d1ff9a64-d7f5-41dd-8487-3f47bc9ef55a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03028e0c-f932-4d26-a08f-52e21abf5e53">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/57ac0e4c-3bd9-4367-8b96-e6509c4cfdbf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d6df4f3-6864-4a49-9cf2-b56ae9a6ac7f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/092096ab-ad8e-4bc5-b65f-91b913051445"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4f3cacc-4e2d-496b-be7a-3153ffaa73c7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615156">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615156</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/946</ddiem:iembaseUrl>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6</rdfs:label>
        <ddiem:iembaseAccessionNumber>946</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/67d8eab3-6451-47aa-9bc1-d1d44a40dceb"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2398798a-f78f-4d3d-a5e6-ad303fcd17c0">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/627c2f6e-e686-473e-a12c-fceeaa186a51">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4976</dc:identifier>
        <rdfs:label>OPA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>mitochondrial dynamin like GTPase</rdfs:label>
    <ddiem:ecNumber>3.6.5.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K17079</ddiem:keggEntryId>
    <ddiem:uniprotId>O60313</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/257d5a56-0a27-430e-b5f5-dcfa87cb83a4">
    <ddiem:keggEntryId>K00542</ddiem:keggEntryId>
    <ddiem:ecNumber>2.1.1.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a072b5bc-510d-49d9-bb3c-d31793ed464d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2593</dc:identifier>
        <rdfs:label>GAMT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q14353</ddiem:uniprotId>
    <rdfs:label>guanidinoacetate methyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4aa5d104-6e0b-4d43-aace-812b05aa3760">
    <ddiem:ecNumber>4.2.1.18; 4.2.1.56</ddiem:ecNumber>
    <ddiem:keggEntryId>K05607</ddiem:keggEntryId>
    <rdfs:label>Methylglutaconyl-CoA hydratase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/df8571b4-0c01-4d33-ab1c-6d214bf08545">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/549</dc:identifier>
        <rdfs:label>AUH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13825</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/39ff3458-a404-4e9d-8cc6-23fad57333e1">
    <rdfs:label>ferrochelatase</rdfs:label>
    <ddiem:uniprotId>P22830</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/241f2074-4370-468c-9c0d-30d442ae3d00">
        <rdfs:label>FECH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2235</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01772</ddiem:keggEntryId>
    <ddiem:ecNumber>4.99.1.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/53b892d5-a5c7-4896-bd2c-35c7b93c4b6a">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/200100">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/371</ddiem:iembaseUrl>
        <rdfs:label>ABETALIPOPROTEINEMIA; ABL</rdfs:label>
        <rdfs:comment>The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/55a149b2-645b-40c9-9414-6a2616b2ebed"/>
        <ddiem:iembaseAccessionNumber>371</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/200100</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b4ec6ec-b385-4c9d-ba04-e8b9acbff1c2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Disease progression (Progressive)</rdfs:label>
        <dc:identifier>HP:0003676</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb1e4da4-0265-44ed-9835-43790517afff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8c451e6c-9bc6-402b-a77b-d8e87b2c622a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f0415b3-9909-44f9-979d-67456199b5cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da43e5a3-939d-43e6-9afa-dc08821ae030"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d67c41b-22e7-4f22-9069-f8901f795625">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0128be07-0f09-49f8-aa48-9b39536d16aa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a03983e0-7352-4efa-9213-ffd618a6df18"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8f7b6a53-243a-4059-aef4-ab49ac11aa55">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231670">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/14a57dcf-8fb4-4231-a3ca-617cc67229ae"/>
        <dc:identifier>https://www.omim.org/entry/231670</dc:identifier>
        <ddiem:iembaseAccessionNumber>163</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/163</ddiem:iembaseUrl>
        <rdfs:label>GLUTARIC ACIDEMIA I; GA1</rdfs:label>
        <rdfs:comment>It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef7dcd2d-b04f-4a6c-be09-d95926e14705">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3db0de1f-88f2-49cb-99c8-d2bd2b9ef8fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20923787</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21f2a0f7-1c0a-41ca-afe5-060a689f7d83">
        <dc:identifier>HP:0003530</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003530</ddiem:url>
        <rdfs:label>Glutaric acidemia</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/487b328e-bb8b-4c96-a7ef-c601b2d2536b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8bb7c67f-0057-4a3a-80e3-4e7394c6cd95"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/234a1a61-f558-4ae3-bc72-ed55c27c8d05"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>The combination was accompanied by Low L-lysine diet</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e8f8bf4c-fe02-4ae2-a3b8-d8a772306155">
    <ddiem:keggEntryId>K00869</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c5921f5e-e89e-4091-af27-e5b21f4200d1">
        <rdfs:label>MVK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4598</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>mevalonate kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
    <ddiem:uniprotId>Q03426</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c0cd6bd1-96c3-45ca-8e25-f3ac9f112230">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a9260e7e-181c-4cb9-a8ff-f1f7afc8a20e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5476</dc:identifier>
        <rdfs:label>CTSA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase</rdfs:label>
    <ddiem:ecNumber>3.4.16.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K13289</ddiem:keggEntryId>
    <ddiem:uniprotId>P10619</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0ed01e3-5f7b-451c-9c85-f304d335287b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/154e2e37-2081-4625-9a0d-96d64520e32d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7369</dc:identifier>
        <rdfs:label>UMOD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18274</ddiem:keggEntryId>
    <rdfs:label>uromodulin</rdfs:label>
    <ddiem:uniprotId>P07911</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215140">
    <rdfs:label>GREENBERG DYSPLASIA; GRBGD</rdfs:label>
    <ddiem:iembaseAccessionNumber>197</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3544c7d2-7d5a-47fa-985d-1b969ed53687">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3930</dc:identifier>
        <rdfs:label>LBR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/215140</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/197</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/856ff4e4-f9b3-444a-ad09-f8fa09ab0f3a">
    <ddiem:uniprotId>Q16836</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b393fbe1-867a-4b16-88aa-aaddf4dcf486">
        <rdfs:label>HADH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3033</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3-hydroxylacyl-CoA dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.1.1.35</ddiem:ecNumber>
    <ddiem:keggEntryId>K00022</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215720">
    <rdfs:label>CITRULLINE TRANSPORT DEFECT</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/215720</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5968fcd2-3929-4240-ba71-59930910fbe4">
        <rdfs:label>SAR1B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51128</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4b9dfeac-fe99-4dd6-9d1b-7b9ec8af51b3">
    <rdfs:label>Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b04911e1-a4e6-49a2-b2a7-5d667f2591dd">
        <rdfs:label>MT-CYB</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CYB</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c998df8-5622-4e9e-a368-79d833d778fb">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO3</dc:identifier>
        <rdfs:label>MT-CO3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ab11b4c3-998e-4f4f-a132-9c5ce9f7518c">
        <rdfs:label>MT-CO1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4bff209f-2572-499e-b298-0d1167906dd0">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c32d1534-f897-41d0-b90c-f5933a4b9c67">
        <rdfs:label>CPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1373</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P31327</ddiem:uniprotId>
    <ddiem:keggEntryId>K01948</ddiem:keggEntryId>
    <ddiem:ecNumber>6.3.4.16</ddiem:ecNumber>
    <rdfs:label>Carbamoyl-phosphate synthase (ammonia</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0147b518-322c-49bc-9758-cc764d4c35e2">
    <rdfs:label>hemojuvelin/hepcidin</rdfs:label>
    <ddiem:keggEntryId>K23106</ddiem:keggEntryId>
    <ddiem:uniprotId>Q6ZVN8</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cef41258-25bd-45ff-8ee5-824b7a656ef0">
        <rdfs:label>HAMP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/57817</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K23100</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4ca1e314-7546-47b7-81ef-765a3621bcb4">
        <rdfs:label>HJV</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148738</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P81172</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615249">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12</rdfs:label>
    <ddiem:iembaseAccessionNumber>1122</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615249</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1122</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a082a54-f516-466a-875d-28846ab2de24">
        <rdfs:label>POMK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84197</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9907aa71-619e-439d-a2cf-8dc95a4b5d71">
    <ddiem:uniprotId>P35575</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aa518431-a65e-4d96-a784-999421b2bde8">
        <rdfs:label>G6PC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2538</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.9</ddiem:ecNumber>
    <rdfs:label>Glucose 6-phophatase</rdfs:label>
    <ddiem:keggEntryId>K01084</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a98fbec8-d5d0-4d88-9aab-1401f0b420c0">
    <rdfs:label>Ribonucleoside-diphosphate reductase subunit M2 B</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/27b8a290-fbf6-41f8-aa6b-9d3ccea3d4eb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50484</dc:identifier>
        <rdfs:label>RRM2B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.17.4.1</ddiem:ecNumber>
    <ddiem:uniprotId>Q7LG56</ddiem:uniprotId>
    <ddiem:keggEntryId>K10808</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/af20f042-0dbf-4083-aafb-949f5a9b873a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2775502c-5918-4232-9556-82a13fc1a40a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b0cbf6b-09c3-412b-b3d0-9c08c4833887">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <dc:identifier>HP:0002015</dc:identifier>
        <rdfs:label>Dysphagia</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26236614</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4f3cacc-4e2d-496b-be7a-3153ffaa73c7"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/565b82c4-dfa5-4a7e-8871-d1c1a35be3af">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e800e0ef-28d8-4414-83fc-82cff27926a5">
        <rdfs:label>Elevated urine 5-oxoproline</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266130">
        <ddiem:iembaseAccessionNumber>512</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/266130</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2156448a-9a49-420d-ab59-dfec8fa46250"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/512</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87961b08-722c-4642-8d38-aec9cda90fdb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9046addd-c582-4a31-ac8d-33e1d963d4e2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/291c1c0d-1ec7-4b50-b00f-eade29b012f2">
        <dc:identifier>HP:0008315</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008315</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Decreased blood free carnitine</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/19c8dc2d-3194-4eb2-9f63-4ce04024cbfb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/54678609-9f3f-4bb7-b33a-badc911fbfd0"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/17bb112c-b0ef-4dfe-9ce6-ceef7052f7cd">
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/31d998d3-0996-42b0-a947-548d3304762d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2395</dc:identifier>
        <rdfs:label>FXN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K19054</ddiem:keggEntryId>
    <rdfs:label>Frataxin, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q16595</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3b73f40a-8fc6-4602-a077-3994accaa3fb">
    <ddiem:uniprotId>P20933</ddiem:uniprotId>
    <ddiem:keggEntryId>K01444</ddiem:keggEntryId>
    <rdfs:label>N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase</rdfs:label>
    <ddiem:ecNumber>3.5.1.26</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e1f64ba4-9b02-4f2b-a256-c871201d828b">
        <rdfs:label>AGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248510">
    <dc:identifier>https://www.omim.org/entry/248510</dc:identifier>
    <rdfs:label>MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e26e4ad6-70bf-49ec-a379-d860bd259661"/>
    <ddiem:iembaseAccessionNumber>261</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/261</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab7a3c8c-5218-4e20-a380-3b2ab94533df">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/271245">
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c4db02f4-ce26-4ca9-8fcc-8646732922ed"/>
        <rdfs:comment>Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/271245</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/944</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>944</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>Seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/901ab7a1-3bc4-43d4-838d-57a26ee4df82">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b2f6605-4177-4f9e-85ee-c7a604bc99ff"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9b5b77f7-9d1b-48aa-a13e-6616959c5dad">
    <ddiem:uniprotId>P07949</ddiem:uniprotId>
    <ddiem:keggEntryId>K05126</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.10.1</ddiem:ecNumber>
    <rdfs:label>Proto-oncogene tyrosine-protein kinase receptor Ret</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9dc56779-7126-4bb0-abf6-5b83fce2d8db">
        <rdfs:label>RET</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5979</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/76cc2545-ab49-446c-a108-bbbd52f573b3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/370d70b9-60ac-495c-b144-f2b019a2ea98">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>The study was terminated</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <dc:identifier>HP:0001942</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a3ef1281-9a00-46e2-8d22-b8fab8378462">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f8fcfec-7c46-4df4-9d71-d3b3dad9b82d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/100435b6-f035-4fff-ace7-6021f7cb8105">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c402ee46-4c10-4445-af8c-a16d764509c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261515">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/274</ddiem:iembaseUrl>
        <rdfs:comment>No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261515</dc:identifier>
        <rdfs:label>D-BIFUNCTIONAL PROTEIN DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d74a235c-1c5d-42e5-be3d-824e465f3062"/>
        <ddiem:iembaseAccessionNumber>274</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/899cb993-10bb-4aec-a3bd-8a84b0a17f7b">
    <rdfs:label>hepatic lipase</rdfs:label>
    <ddiem:ecNumber>3.1.1.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6ef00ad1-d9a6-4738-9b90-d19d625098ff">
        <rdfs:label>LIPC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3990</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P11150</ddiem:uniprotId>
    <ddiem:keggEntryId>K22283</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615287">
    <ddiem:iembaseAccessionNumber>1124</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1124</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a9c93d28-8c0d-420c-888d-19fc07e5dc31"/>
    <dc:identifier>https://www.omim.org/entry/615287</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/770cca47-4728-4826-86d2-8eb6d212ca2d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b99da675-4944-4686-a865-2044e7e6d93f">
        <rdfs:label>CPT1B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1375</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q92523</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <rdfs:label>carnitine O-palmitoyltransferase 1, muscle isoform</rdfs:label>
    <ddiem:keggEntryId>K19523</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ddc8d4c2-5b2c-47e5-8b34-e2819289e02e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/82c03500-0cae-4e34-997f-4fe92db305a0">
        <rdfs:label>ADCK3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Atypical kinase COQ8A, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/84695a12-9ebe-478f-aba6-8b10d213548f">
    <rdfs:label>insulin like growth factor 1</rdfs:label>
    <ddiem:uniprotId>P05019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1c4b447f-fe0f-4aa6-916f-5ac0b321d8de">
        <rdfs:label>IGF1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3479</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05459</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5eb0b014-366f-49d0-aa65-e973258486f8">
    <ddiem:keggEntryId>K08171</ddiem:keggEntryId>
    <ddiem:uniprotId>O43826</ddiem:uniprotId>
    <rdfs:label>Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c1b0cbba-a690-4868-871b-5e670170d0ac">
        <rdfs:label>SLC37A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2542</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/413c41a1-f6d7-42e9-9c85-5f6ce67b6569">
    <ddiem:keggEntryId>K12309</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b91ef82b-6f42-49e4-8ce1-4856f8ed9f85">
        <rdfs:label>GLB1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2720</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>beta-galactosidase</rdfs:label>
    <ddiem:ecNumber>3.2.1.23</ddiem:ecNumber>
    <ddiem:uniprotId>P16278</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cde44332-4b68-4865-b5b2-b7dd6993c209">
    <ddiem:keggEntryId>K00871</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.11.19</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9143fd32-0479-44c6-bb13-cb21305cff3c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5261</dc:identifier>
        <rdfs:label>PHKG2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphorylase b kinase gamma catalytic chain, liver/testis isoform</rdfs:label>
    <ddiem:uniprotId>P15735</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611722">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4ec8fccb-2a3c-4155-bec9-ff4f9a186750">
        <rdfs:label>PSAP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5660</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/611722</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/292</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>292</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5403e8d-928b-4de3-aff5-31ad053a3d35">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4b0ba7-0654-4cd1-a6df-644af85ccee6"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f11e9a37-9c02-44cf-8b43-be0a8d2015bb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a53e94da-e15d-42a4-9bf5-6e542b08c26d"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18848477</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24e75afb-f86a-4bc2-a429-ba36fa3f9af8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c92a615-a2d3-4f72-90cb-653ede48cf6c"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81346c3e-bb13-4d8f-aa7c-987d6ad6ba80">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/100435b6-f035-4fff-ace7-6021f7cb8105"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/baf82bcb-897a-49e7-847c-60c073471f15">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>Abnormal liver function tests</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8707100</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/326fb3fa-d048-4674-9658-407253f77e8f">
        <rdfs:label>Liver biopsy abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3ef1281-9a00-46e2-8d22-b8fab8378462"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/296a1cce-2a5a-4f72-9b84-fd7ebe6bdafb">
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>Abnormal bilirubin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235555">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c88947aa-0766-4304-b49f-2fac99c0fe39"/>
        <dc:identifier>https://www.omim.org/entry/235555</dc:identifier>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3bcb720b-fd99-42a3-a4d1-ea8a5801ea34">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6e67320b-65bc-4c39-8dc1-72a844a0a474">
        <rdfs:label>MT-TS1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/985c0580-1073-4ef1-84d9-df3d370bfb78">
        <rdfs:label>MT-TE</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TE</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/27c0dbb8-f980-49b9-a28b-cd8bf27602b8"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/60a752e5-d980-4dc9-bce5-c54dc0e47e62">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND1</dc:identifier>
        <rdfs:label>MT-ND1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7e3139fa-55b5-4fbf-aae3-3b57510ef838">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND5</dc:identifier>
        <rdfs:label>MT-ND5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/49d8daf6-2845-4e1a-b8dd-daf2423eb382">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TQ</dc:identifier>
        <rdfs:label>MT-TQ</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cec7412b-3fa9-4f67-9445-0cd8f878b80f">
        <rdfs:label>MT-TH</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TH</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c8b998bb-477e-4812-9612-a2f20625cf8c">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MTTC</dc:identifier>
        <rdfs:label>MTTC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9cad528d-f87c-4dac-95bd-1023642693d8">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND6</dc:identifier>
        <rdfs:label>MT-ND6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/063b005e-3ab9-49f0-b247-215819d856a3">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TL1</dc:identifier>
        <rdfs:label>MT-TL1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/87c79233-3453-4453-9cb3-d225cad8651e">
        <rdfs:label>MT-TS2</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS2</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/81728096-eba1-429f-a6aa-7c64547d0660">
    <rdfs:label>Fumarate hydratase, mitochondrial</rdfs:label>
    <ddiem:ecNumber>4.2.1.2</ddiem:ecNumber>
    <ddiem:uniprotId>P07954</ddiem:uniprotId>
    <ddiem:keggEntryId>K01679</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/21b2bb6e-e685-453c-be55-686caf9b28be">
        <rdfs:label>FH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2271</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614202">
    <dc:identifier>https://www.omim.org/entry/614202</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5bae4794-e359-4352-9163-89e8c417e461">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11253</dc:identifier>
        <rdfs:label>MAN1B1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/611</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15</rdfs:label>
    <ddiem:iembaseAccessionNumber>611</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/87a8a024-2c60-4fa0-a668-dc03194e918b">
    <rdfs:label>GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase</rdfs:label>
    <ddiem:ecNumber>2.4.99.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/23b60be1-7e62-4a31-b5ed-a83c9629da31">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8869</dc:identifier>
        <rdfs:label>ST3GAL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UNP4</ddiem:uniprotId>
    <ddiem:keggEntryId>K03370</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/01fc29e8-7a42-47c2-bc24-f20ca40b3e16">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/151be5f7-feb3-406a-b7c1-8a240a66e45d">
        <rdfs:label>Osteoporosis</rdfs:label>
        <dc:identifier>HP:0000939</dc:identifier>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d67c41b-22e7-4f22-9069-f8901f795625"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/56daa269-79df-4970-a0a5-7a4f5f97d9a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d02ee231-7521-4727-a574-2ed0b6537466"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e0813014-e6d6-474e-85b3-6afd1fa34df5">
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
    <rdfs:label>Phospholipase A(2)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ae8e22c9-edd7-4d39-a519-14870f47ed86">
        <rdfs:label>PLA2G6</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8398</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/739d65b3-2409-4df2-9627-6445d2f0cebe">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a03b3dbd-4410-4fe2-98e2-45aadc7bc4c7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>Developmental delay</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/243500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/56</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ae95f944-9973-4305-935a-0d7eccbee237"/>
        <dc:identifier>https://www.omim.org/entry/243500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ISOVALERIC ACIDEMIA; IVA</rdfs:label>
        <ddiem:iembaseAccessionNumber>56</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bdefc79-a7a1-4007-a535-8db57f12c7db">
        <rdfs:label>Metabolic stress</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <dc:identifier>HP:0001942</dc:identifier>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069539</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20807522</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15624372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8804338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17299485</dc:provenance>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16602101</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff67e84a-5086-41c0-85ff-0419c5cba5cb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High toxic acyl-CoA level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e463ef9a-d5bb-4185-805d-5c4b1d0ae868">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001942</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:label>Metabolic acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7e66c71a-7374-45d1-baf3-c15de90914f1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02f1c411-cf4d-4752-8d7a-6e706c0b85d1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21290185</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f5b5dfe-092d-4591-9f0d-d0a8f6145549">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High 3-hydroxyisovaleric acid level (C5)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccebd768-d208-4cd4-9f27-a2ddc9708e12">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"abnormal Na+,K+-ATPase activity"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/271cfbf7-abe0-41ff-a52a-0e151b84e771">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/488b4f8a-bb56-4982-8364-aa8298c07ddb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ce1dc87-d303-420a-a88e-c349887388bf">
        <rdfs:label>Megaloblastic anemia</rdfs:label>
        <dc:identifier>HP:0001889</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5301410</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229100">
        <ddiem:iembaseAccessionNumber>47</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/229100</dc:identifier>
        <rdfs:comment>The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/47</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2b46ac74-8ffb-48e4-a656-558c11ea5e78"/>
        <rdfs:label>GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7ac110ac-3f86-4941-9781-8901e2d5f01f">
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8e2dc30d-37e3-47fc-8df8-ad10df602a21">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94cf7d76-41b4-4946-bcbe-3b2366300907"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93651caf-7d41-4249-bd4e-ff34b8e6a110">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:label>Study is still recruiting</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/30bc38ae-fe59-44f4-a5b0-780827997989">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91eecaec-90e2-402e-8ba5-085529ab6618">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
        <rdfs:label>Delayed receptive language</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0010863</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08ade565-e136-435b-94fd-9efecffe4e94">
        <rdfs:label>Neurological impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fb2ca183-815b-4e46-9791-80170dd281d7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55d16a8e-a807-43a3-b876-43a3875fc313"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/010abe84-4958-4559-9ba0-c5effa11b2e5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95a3161d-8e66-44f7-8b86-1918985138bb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperphenylalaninemia</rdfs:label>
        <dc:identifier>HP:0004923</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a03b3dbd-4410-4fe2-98e2-45aadc7bc4c7"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eaa749d3-0274-4866-b455-b38fc391bf84">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc831033-aae4-4699-89c5-403ecdce600c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/73b1c4ce-867e-4866-9fce-f7d97bf842ec">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/396d104d-4d36-47d6-a038-9ddd097586f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eaa749d3-0274-4866-b455-b38fc391bf84"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/010abe84-4958-4559-9ba0-c5effa11b2e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3af44e7e-dfcf-4dce-ad64-c3c4e7d1ae3b">
        <rdfs:label>Elevated blood phenylalanine concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2dabf38d-e110-49a4-ba86-8152a8db464f">
        <dc:identifier>HP:0012535</dc:identifier>
        <rdfs:label>Abnormality of neurotransmitter metabolism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614643">
    <ddiem:iembaseAccessionNumber>641</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e39503c1-d187-444f-8de6-fe3606f9e5b3"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/641</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/614643</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/947cc444-d0b3-4afc-ac1d-1265a1f21781">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40c70283-f926-4d0f-81dc-32ca59139b01"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/983620da-647e-4bef-8f93-59acb546ac43">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b8682971-e50f-4a86-92af-c9db09824987"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18060820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/271e1384-eeb5-47e2-89e0-489bcf8a6643">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001285</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Spastic tetraparesis</rdfs:label>
        <dc:identifier>HP:0001285</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acac7d13-b71a-49a7-9328-20d28ae4d560">
        <rdfs:label>Epilepsy</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f6427916-d04b-4914-990a-0b8662ccfe04">
    <ddiem:keggEntryId>K09658</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/dc2b7e51-04f6-44cb-9ede-d03c886c0505"/>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 2</rdfs:label>
    <ddiem:uniprotId>O94777</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9dbbad43-fe17-4f61-b12f-da84b766e734">
    <ddiem:keggEntryId>K23555</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96S06</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/743a0196-eaf3-469d-b0f8-9aba8ef1f782">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64788</dc:identifier>
        <rdfs:label>LMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lipase maturation factor 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4855c883-8204-4de2-afff-b12eeb4a337d">
    <rdfs:label>Ribitol-5-phosphate xylosyltransferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6456ed39-60d5-4f99-bd6a-7f6532db893c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10329</dc:identifier>
        <rdfs:label>RXYLT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K21052</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9Y2B1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_epigenetic_manipulation">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by epigenetic manipulation</rdfs:label>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115 xml:lang="en">Modulation of the level or specificity of expression of a genetically defective gene through modification of an epigenetic mark or process using chemical, biological or genetic means.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/462074b6-678d-47fd-af77-0de905d96083">
    <rdfs:label>GTP cyclohydrolase 1</rdfs:label>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bb3721c7-e100-4eb3-82a0-5a09841510ed">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2643</dc:identifier>
        <rdfs:label>GCH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/006e47ba-cc02-426a-8be3-bdb7ef34111c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/983620da-647e-4bef-8f93-59acb546ac43"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66ba728c-bb25-40f2-855b-ea26c278656f"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613839">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d80eb962-dd0d-4dc6-ac0e-9080423a45c5"/>
        <dc:identifier>https://www.omim.org/entry/613839</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93dc92e9-7f93-4c80-9038-55658b2e920f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>seizure</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/51ebb6ae-9b60-42bc-8160-7040e5cdbd85">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4bcbfadf-16dd-4f29-b2a9-a16a37311c14">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8029</dc:identifier>
        <rdfs:label>CUBN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14616</ddiem:keggEntryId>
    <ddiem:uniprotId>O60494</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b2c60bbc-d256-4d3c-b733-2b54d38ee601">
        <rdfs:label>AMN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/81693</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cubilin/amnion associated transmembrane protein</rdfs:label>
    <ddiem:keggEntryId>K18259</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9BXJ7</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e7dc55f8-9500-4e63-8705-724064e0b232">
    <rdfs:label>ATM serine/threonine kinase</rdfs:label>
    <ddiem:uniprotId>Q13315</ddiem:uniprotId>
    <ddiem:keggEntryId>K04728</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4562bac0-537c-40fb-902f-2c1470a16042">
        <rdfs:label>ATM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/472</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.11.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9ba3236-8026-44b7-94b8-ef05bb91020a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/291c1c0d-1ec7-4b50-b00f-eade29b012f2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/334b6661-4a81-48a6-8c93-fdb7f04c8f9a">
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>Hypoglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87961b08-722c-4642-8d38-aec9cda90fdb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e800e0ef-28d8-4414-83fc-82cff27926a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e463ef9a-d5bb-4185-805d-5c4b1d0ae868"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c8dc2d-3194-4eb2-9f63-4ce04024cbfb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9046addd-c582-4a31-ac8d-33e1d963d4e2"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5f7581c5-e52f-484c-89a2-dbec0ec8f5fe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69ddb981-89fd-4009-b8b4-0385122298f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222730">
    <dc:identifier>https://www.omim.org/entry/222730</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f330cea9-c6c6-470f-8b85-691192d89320"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/49</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>49</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>DICARBOXYLIC AMINOACIDURIA; DCBXA</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ef5be88d-e609-49df-89c9-9ca1ab43f4e5">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.7</ddiem:ecNumber>
    <rdfs:label>Carnitine acetyltransferase</rdfs:label>
    <ddiem:uniprotId>P43155</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0f2bf92d-33c6-42d2-9ac0-d3522b64a5b5">
        <rdfs:label>CRAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1384</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/100a5001-ce1e-4010-a03a-ba02ee6bfd78">
    <ddiem:keggEntryId>K01279</ddiem:keggEntryId>
    <ddiem:ecNumber>3.4.14.9</ddiem:ecNumber>
    <rdfs:label>TRIPEPTIDYL PEPTIDASE I</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/30b9a252-10a0-4124-bd60-0e65670066c0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1200</dc:identifier>
        <rdfs:label>TPP1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O14773</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f96f3b18-9d13-474b-ace7-7a8bcb1efd4a">
    <ddiem:ecNumber>1.5.1.8; 1.5.1.9</ddiem:ecNumber>
    <ddiem:keggEntryId>K14157</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4432578f-b895-436f-8ceb-cdec72322f82">
        <rdfs:label>AASS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10157</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase</rdfs:label>
    <ddiem:uniprotId>Q9UDR5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/da0f33bf-f4e3-4128-84a6-d1c8b7096327">
    <rdfs:label>Fukutin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b0185df9-7ec6-4b06-9aec-b281b49dc3d8">
        <rdfs:label>FKTN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a48e84e5-51fd-4060-b6b2-9d192c06feff">
    <ddiem:keggEntryId>K01099</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.3.36; 3.1.3.56; 3.1.3.86</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/767d8e63-348a-439c-99e3-8f5c68a0b666">
        <rdfs:label>OCRL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4952</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q01968</ddiem:uniprotId>
    <rdfs:label>inositol polyphosphate 5-phosphatase OCRL-1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/87550b19-5bce-4200-a1c2-3b16c272bd3b">
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <rdfs:label>mitochondrial ribosomal protein L44</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/abf9b520-fb37-46a8-b136-17596cdcae86">
        <rdfs:label>MRPL44</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/65080</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c7ab3c08-8af0-4cf6-8254-c4400f492766">
    <ddiem:keggEntryId>K14425</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13621</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/34c89dc8-7477-4f74-ba96-61c6475b2ef0">
        <rdfs:label>SLC12A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6557</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Solute carrier family 12 member 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/865a77fb-19d7-4f3c-b84f-8a244b09799c">
    <ddiem:uniprotId>P11168</ddiem:uniprotId>
    <ddiem:keggEntryId>K07593</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ccc115ba-589b-4989-bc38-a5811a8f8be4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6514</dc:identifier>
        <rdfs:label>SLC2A2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Solute carrier family 2, facilitated glucose transporter member 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/99acb551-2513-4085-8051-015c1264b768">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46f21f88-d4a4-4c5a-9795-fe8c92d0a58e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9b68aa05-0eed-4129-acbd-10ed44da11da"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8fa9c06-7894-4ec4-ac4a-8fa0a32a832e">
        <rdfs:label>brain atrophy</rdfs:label>
        <dc:identifier>HP:0012444</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012444</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/30b9a252-10a0-4124-bd60-0e65670066c0"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/306</ddiem:iembaseUrl>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/204500</dc:identifier>
        <ddiem:iembaseAccessionNumber>306</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0001565">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0001565</ddiem:url>
        <dc:identifier>ECO:0001565</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ecebbe86-2957-4d8f-a1e5-d4b36c163073">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9046addd-c582-4a31-ac8d-33e1d963d4e2"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68f1454e-4e15-4233-ba3b-0b290eb199ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cd76293d-a0d3-49f1-ac98-01eeaefed550"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/325dcf44-b7b6-4046-97fb-27a1ec6113e6">
    <rdfs:label>Mitochondrially encoded tRNA lysine</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/27c0dbb8-f980-49b9-a28b-cd8bf27602b8"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239510">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/49b5ac44-5bdd-4200-8daa-2d531e6e3739">
        <rdfs:label>ALDH4A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8659</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/239510</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPERPROLINEMIA, TYPE II; HYRPRO2</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/38</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>38</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c45504d6-e51a-41fc-8775-96453429e55d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/24579575-9738-45f9-82b6-ba9dd1c4b57c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7c1aa3d1-05a1-4d6f-b299-916795533248"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/174fc494-ed06-4bbc-b084-fd441213246f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ccdf40c9-437c-48bb-a167-2245c2beec1a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608747">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1c4b447f-fe0f-4aa6-916f-5ac0b321d8de"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/608747</dc:identifier>
        <rdfs:label>INSULIN-LIKE GROWTH FACTOR I DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f9955fc-5971-4eb9-bbee-e38c21c1c84b">
        <rdfs:label>Short stature</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/00d3a03e-4323-42c9-b3b0-f77399fc951d">
    <rdfs:label>L-2-hydroxyglutarate dehydrogenase.</rdfs:label>
    <ddiem:ecNumber>1.1.99.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K00109</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9P8</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fa24c0af-030e-4a53-9dc3-b39119f47aec">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79944</dc:identifier>
        <rdfs:label>L2HGDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5404cb65-d540-4f10-810b-2a693350bf1d">
    <ddiem:keggEntryId>K00728</ddiem:keggEntryId>
    <rdfs:label>protein O-mannosyltransferase 1</rdfs:label>
    <ddiem:uniprotId>Q9Y6A1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cae73afc-fe20-4f34-831b-d408e40d55d9">
        <rdfs:label>POMT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10585</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2259bafb-8e2d-4e0d-b799-996cc0350f00">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/238700">
        <rdfs:label>HYPERLYSINEMIA, TYPE I</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4432578f-b895-436f-8ceb-cdec72322f82"/>
        <dc:identifier>https://www.omim.org/entry/238700</dc:identifier>
        <rdfs:comment>Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in our patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42cc703e-c02d-43ca-9e33-9b94536acae0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f3fd80e-449d-4c25-8675-36389a2e22be">
        <dc:identifier>HP:0010818</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Generalized tonic convulsions</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010818</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40c70283-f926-4d0f-81dc-32ca59139b01"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e726f790-9889-42b4-86f1-9a2aba2b8ade">
    <ddiem:uniprotId>O43766</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f7f2fbd6-0215-4ef6-9eb2-cca1a8cbfd9a">
        <rdfs:label>LIAS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11019</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.8.1.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K03644</ddiem:keggEntryId>
    <rdfs:label>lipoic acid synthetase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616538">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/616538</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d9a5de27-60e4-49c7-a69a-d3edc18afc7b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1605</dc:identifier>
        <rdfs:label>DAG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/33d00f1a-5bbb-4853-848d-060dd8073cd4">
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28087478</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9238b3bd-c306-4de4-bdc0-b6815ef0a424">
        <dc:identifier>HP:0000793</dc:identifier>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000793</ddiem:url>
        <rdfs:label>membranoproliferative glomerulonephritis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9870afa7-3c0e-4f24-a0fa-0d5265cbfbb2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4bff6752-89bd-4fa8-bd07-3ef2579c794f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1d5e2336-a347-460e-b381-51cd392d43f3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a2e0c5d1-3370-4e73-8949-0ec8797173cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612932">
    <rdfs:label>GLYCOGEN STORAGE DISEASE XIII; GSD13</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/326bd4bc-c556-4b62-96da-7f5e2603faa9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2027</dc:identifier>
        <rdfs:label>ENO3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/612932</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/501</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>501</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a46a41d5-6762-45c4-9fb9-21469cd9b999">
    <ddiem:uniprotId>P06280</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.22</ddiem:ecNumber>
    <ddiem:keggEntryId>K01189</ddiem:keggEntryId>
    <rdfs:label>alpha-galactosidase A</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b0eef80b-5d7c-4b16-ac23-76e6368ca683">
        <rdfs:label>GLA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2717</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615041">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>640</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/615041</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/640</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6456ed39-60d5-4f99-bd6a-7f6532db893c"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac42465e-9a8d-4b81-894a-900dc763c444">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256730">
        <ddiem:iembaseAccessionNumber>305</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/305</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f40ff08a-55e4-4666-903d-0bf6e7908693"/>
        <dc:identifier>https://www.omim.org/entry/256730</dc:identifier>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/97aaa65a-3f9a-407c-9710-a4fb03b0a19f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99a23473-56d0-4ce6-ba16-87500d4af4b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d05f52d0-4cde-450e-94c2-a9129d1f3f03">
        <dc:identifier>HP:0004372</dc:identifier>
        <rdfs:label>Defected alertness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004372</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997880</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0de52245-d225-449c-bcae-fcf59bba042c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd4dc823-d14b-4339-97c5-d67c463a1f6e">
        <dc:identifier>HP:0000737</dc:identifier>
        <rdfs:label>irritability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a4e5128-b4ca-44a9-ae84-65281479e748">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Isoelectric electroencephalogram</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5071605f-a928-4a12-9ff1-78f53457b703">
        <rdfs:label>granular osmiophilic deposits (GROD)</rdfs:label>
        <dc:identifier>HP:0003657</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003657</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/74224bf6-0d40-4f76-82b2-a2cc241c0be7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30ebc749-d19a-4207-83eb-66da1bf9202f">
        <rdfs:label>High resting plasma lactate concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003288</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003288</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17080429</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d3900744-4943-49e9-8155-95730c2e2cf8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b3f65ca-a732-4358-a273-1f287d414f7e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb49d6cf-bb02-4e5d-9d07-cef6e79b2224">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:label>Ankle weakness progression(Disease progression)*</rdfs:label>
        <dc:identifier>HP:0003287</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8c01622c-e83a-4a24-b632-2f0b9b60a408">
    <ddiem:ecNumber>4.1.1.37</ddiem:ecNumber>
    <ddiem:keggEntryId>K01599</ddiem:keggEntryId>
    <rdfs:label>uroporphyrinogen decarboxylase</rdfs:label>
    <ddiem:uniprotId>P06132</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3900e827-1f82-466f-b8eb-a0b334883dff">
        <rdfs:label>UROD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7389</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/15b70619-7e08-4fce-ab2f-497e3d229c48">
    <ddiem:keggEntryId>K18592</ddiem:keggEntryId>
    <ddiem:uniprotId>P19440</ddiem:uniprotId>
    <rdfs:label>Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d107f3f7-47d2-4fcc-9652-33fdd65114e5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2678</dc:identifier>
        <rdfs:label>GGT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.4.19.13; 2.3.2.2; 3.4.19.14</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/203e2bc3-c621-4e09-bc9b-ce17af88b148">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2049ed65-0418-453a-9225-8c2b2e74bd1e">
        <rdfs:label>PGM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5236</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01835</ddiem:keggEntryId>
    <rdfs:label>Phosphoglucomutase-1</rdfs:label>
    <ddiem:uniprotId>P36871</ddiem:uniprotId>
    <ddiem:ecNumber>5.4.2.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/41016bde-01d0-47b0-8e78-f879e6e707e3">
    <rdfs:label>malonyl-CoA decarboxylase</rdfs:label>
    <ddiem:uniprotId>O95822</ddiem:uniprotId>
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/789562f1-0458-4a1c-914b-777d1c649c36">
        <rdfs:label>MLYCD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23417</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01578</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a79a2fcf-3838-442f-af35-7afb3ae6c59e">
    <ddiem:ecNumber>2.7.1.113</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3c046327-0cd6-4a12-8650-f1a1fa5cbd90">
        <rdfs:label>DGUOK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1716</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Deoxyguanosine kinase, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00904</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16854</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/378bdb1f-08ec-4730-95db-152207c6b94a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6be377e-fb7c-49f3-8954-fac433baa08e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Psychomotor retardation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025356</ddiem:url>
        <dc:identifier>HP:0025356</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0618bb32-35fc-4298-b052-b0d99980f84a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cognitive impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0eb01b4-e787-4698-81cf-fe073da695ac">
        <rdfs:label>Functional motor deficit</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <dc:identifier>HP:0004302</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916321</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af93b8ae-59b9-4bfc-b615-35f8c60e2e2e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <rdfs:label>Elevated plasma acylcarnitine levels</rdfs:label>
        <dc:identifier>HP:0045045</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa3f82d0-7543-4ae4-8102-16b04ff4a6a9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002028</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <rdfs:label>Chronic mucoid diarrhea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/761de381-13d9-42b9-89c9-60ce0aeb53f9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000967</ddiem:url>
        <dc:identifier>HP:0000967</dc:identifier>
        <rdfs:label>Petechiae</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5516a0ad-d2b5-4bb4-9b53-95477bb5ebdc">
    <ddiem:uniprotId>Q9UJS0</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4b0619c8-8b80-45ba-afc3-9b68957785a5">
        <rdfs:label>SLC25A13</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K15105</ddiem:keggEntryId>
    <rdfs:label>citrin ( protein)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b3305158-7bbd-4c66-bf7b-edfa28a6e5ad">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/49b5ac44-5bdd-4200-8daa-2d531e6e3739"/>
    <rdfs:label>Δ1-pyrroline 5-carboxylate dehydrogenase</rdfs:label>
    <ddiem:uniprotId>P30038</ddiem:uniprotId>
    <ddiem:keggEntryId>K00294</ddiem:keggEntryId>
    <ddiem:ecNumber>1.2.1.88</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c4d44410-6b46-41fd-bf37-83f7bbefef63">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c4db02f4-ce26-4ca9-8fcc-8646732922ed">
        <rdfs:label>TWNK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56652</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <rdfs:label>Twinkle protein, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f42dac27-7e38-4c14-8500-1de53094c0b1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/676d3812-e2b8-46f4-82cd-a11c384a5d67">
        <rdfs:label>DBT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P11182</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.168</ddiem:ecNumber>
    <rdfs:label>Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K09699</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614830">
    <dc:identifier>https://www.omim.org/entry/614830</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1120</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e99326ba-3b20-4ca7-992a-b5dc2b121f7b">
        <rdfs:label>POMGNT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84892</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1120</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c0d4f81a-d3b3-478d-8a3e-a77879438594">
    <ddiem:uniprotId>Q9BZV2</ddiem:uniprotId>
    <rdfs:label>thiamine transporter</rdfs:label>
    <ddiem:keggEntryId>K14610</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/83096072-0304-4c9f-9bd1-365dd07bf7de">
        <rdfs:label>SLC19A3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80704</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d5d6897a-2317-4790-9048-3d71f1666fd7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2bcc0495-93fc-4e68-a89e-7838141e72cf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/215</dc:identifier>
        <rdfs:label>ABCD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>7.6.2.4</ddiem:ecNumber>
    <ddiem:uniprotId>P33897</ddiem:uniprotId>
    <rdfs:label>adrenoleukodystrophy protein</rdfs:label>
    <ddiem:keggEntryId>K05675</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/476e3d01-1da7-4c66-8299-7b33c7b282f1">
    <rdfs:label>GPI mannosyltransferase 1</rdfs:label>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3b9dba3c-58af-4423-8bc2-8c9218b6e57d"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fece8e92-2357-41df-9fd7-1b67530ac6bb">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3544c7d2-7d5a-47fa-985d-1b969ed53687"/>
    <ddiem:keggEntryId>K19532</ddiem:keggEntryId>
    <ddiem:uniprotId>Q14739</ddiem:uniprotId>
    <rdfs:label>lamin B receptor</rdfs:label>
    <ddiem:ecNumber>1.3.1.70</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ea1ae976-c234-463d-b67d-a66fa72a4802">
    <rdfs:label>battenin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3de8ff71-9a1f-4c0d-8d07-b3dcde812eee">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1201</dc:identifier>
        <rdfs:label>CLN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12389</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13286</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300868">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/300868</dc:identifier>
    <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2</rdfs:label>
    <rdfs:comment>Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216</rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/50060d00-4d39-4fd7-a0a7-e0ce03002b47">
        <rdfs:label>PIGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5277</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e093bef7-335f-4536-aa4f-9c2cf3af8435">
    <ddiem:keggEntryId>K01204</ddiem:keggEntryId>
    <rdfs:label>alpha-N-acetylgalactosaminidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6a8fd555-cdc1-4f9e-921b-5ae176ce3025">
        <rdfs:label>NAGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4668</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.49</ddiem:ecNumber>
    <ddiem:uniprotId>P17050</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f4c76ed0-da2b-45c8-b0c0-4468ed5fdc8e">
    <rdfs:label>isovaleryl-CoA dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00253</ddiem:keggEntryId>
    <ddiem:ecNumber>1.3.8.4</ddiem:ecNumber>
    <ddiem:uniprotId>P26440</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ae95f944-9973-4305-935a-0d7eccbee237">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3712</dc:identifier>
        <rdfs:label>IVD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5cd916d1-9cf2-4b49-b364-1904f0b9726c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8701a715-6567-4ec5-9f62-aa275ae960dc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/340024</dc:identifier>
        <rdfs:label>SLC6A19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2ff16de-d88d-4661-9436-743862407b95">
        <rdfs:label>SLC36A2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/153201</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <ddiem:uniprotId>Q495M3</ddiem:uniprotId>
    <ddiem:keggEntryId>K14209</ddiem:keggEntryId>
    <rdfs:label>solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19</rdfs:label>
    <ddiem:keggEntryId>K05048</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/56315906-74e4-487f-9a25-3520e16ea2ee">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54716</dc:identifier>
        <rdfs:label>SLC6A20</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9NP91</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d8126851-eaf8-4a8e-827d-b470411880a5">
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <rdfs:label>tissue-nonspecific alkaline phosphatase (TNSALP)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/32182380-a2be-4223-860c-38f61a119062">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/249</dc:identifier>
        <rdfs:label>ALPL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/252500">
    <ddiem:iembaseAccessionNumber>299</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUCOLIPIDOSIS II ALPHA/BETA</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/299</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/78d38e44-0b80-4055-a449-6a813450a5be">
        <rdfs:label>GNPTAB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79158</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/252500</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/906039ef-3acc-49d4-b742-bd455247b04a">
    <rdfs:label>DNA replication ATP-dependent helicase/nuclease DNA2</rdfs:label>
    <ddiem:keggEntryId>K10742</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/67d8eab3-6451-47aa-9bc1-d1d44a40dceb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1763</dc:identifier>
        <rdfs:label>DNA2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P51530</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.-.-; 3.6.4.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ce1f4ac7-d5a9-4a2c-81ef-2c153fe26832">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea1c71cd-9146-4f9c-b40a-e2125ff8e001">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>stenotic coronary atherosclerosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001677</ddiem:url>
        <dc:identifier>HP:0001677</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cb2be8e-537c-484e-8d27-daff05a2601d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000991</ddiem:url>
        <dc:identifier>HP:0000991</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>xanthomas</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68442f21-ea90-43e5-9f50-bfaab706f2ca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/18a6bc70-9e55-4571-8f41-1436c8708fd5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26ea6467-c631-49bb-85ed-3e5779580e0e">
        <rdfs:label>angina pectoris</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001681</ddiem:url>
        <dc:identifier>HP:0001681</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2fba4826-3f52-431c-9a08-f2752f86735e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/77c8a7bc-fe4c-41ab-889c-5dac9e884e0b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bdca0b32-558f-4cce-8063-514ee7f12213">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8548fedc-af0b-4e16-8b5c-bf0c08df5ffd">
        <rdfs:label>chlorpropamide-induced hypoglycaemia (Hypoglycemia)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001943*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42cc703e-c02d-43ca-9e33-9b94536acae0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5a40abd0-42ff-4130-9631-9ff64a330549">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/73a32f2b-8fe7-46c5-bb22-713f58ab73ba"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125700">
        <dc:identifier>https://www.omim.org/entry/125700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9a138cac-2536-42d4-9e9d-26b25143b068"/>
        <rdfs:label>DIABETES INSIPIDUS, NEUROHYPOPHYSEAL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/434571d8-9644-4142-a999-1c917cdba5b5">
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Polyuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <rdfs:comment>This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac3c4a8f-9cdd-447b-9c53-7d6949733865">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17ade3ee-d1d1-4c6b-81e2-f75e1c02a66d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a3e1f5d5-fa49-4b40-b147-0009650d4139"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28283348</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37072294-14df-4e7f-bf99-ff38ee95072b">
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:label>Watery Diarrhea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dad0b1c-6029-4e5d-8bce-fefc190ce08a">
        <rdfs:label>Dehydration</rdfs:label>
        <dc:identifier>HP:0001944</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001944</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606824">
        <rdfs:comment>Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187</rdfs:comment>
        <ddiem:iembaseAccessionNumber>482</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9b5c8d49-d4a1-4766-a7df-d08da3ed70b1"/>
        <dc:identifier>https://www.omim.org/entry/606824</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/482</ddiem:iembaseUrl>
        <rdfs:label>GLUCOSE/GALACTOSE MALABSORPTION; GGM</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1dc72fe7-f705-441b-819a-71af064e2d22"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10404446</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20486940</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9cc2cf8-9443-4912-ad07-fdad2f64f794">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f7cf24a4-1e73-4e42-81d8-2e565fa5c339">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8143ff86-7a7d-49d2-9939-fedd95a708b6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e3f64ab3-3fe6-4571-ac7f-7ba7da2fb6f0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/506869ce-6735-4a2d-8e7d-4407bc25d642"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162000">
        <rdfs:label>HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1</rdfs:label>
        <ddiem:iembaseAccessionNumber>1405</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/154e2e37-2081-4625-9a0d-96d64520e32d"/>
        <dc:identifier>https://www.omim.org/entry/162000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1405</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc3298b2-7af2-47c1-9319-2a74dee8c02e">
        <rdfs:label>Hyperurecemia</rdfs:label>
        <dc:identifier>done</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0cc795e-13a9-49ea-b528-e203cee9a2e2">
    <rdfs:label>biotinidase</rdfs:label>
    <ddiem:keggEntryId>K01435</ddiem:keggEntryId>
    <ddiem:uniprotId>P43251</ddiem:uniprotId>
    <ddiem:ecNumber>3.5.1.12</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7d52c3cb-7967-4a65-8590-d555a1463a9f">
        <rdfs:label>BTD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/686</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d16bf711-8049-42e4-99e8-315ab58cd103">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f84cffa0-b61e-4ebd-bf13-1acfc40c3cfe">
        <rdfs:label>Nephropathy</rdfs:label>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <dc:identifier>HP:0000112</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007764">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007764</ddiem:url>
        <dc:identifier>ECO:0007764</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/81d489ea-ae3a-4867-bea3-8f63da521d9a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/75aed908-eabe-43b2-b01d-2cc012f72b2b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43cd9b0d-2b07-469c-aa26-3ffc8b9f227d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b919094f-0c8c-44fc-aa5e-393d99e38604"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/279fc6a3-2b6a-4d73-a0fa-2875059ff161">
    <ddiem:uniprotId>P13866</ddiem:uniprotId>
    <ddiem:keggEntryId>K14158</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9b5c8d49-d4a1-4766-a7df-d08da3ed70b1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6523</dc:identifier>
        <rdfs:label>SLC5A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>sodium/glucose cotransporter protein called SGLT1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9efb6f07-35fd-4ee6-92da-00b9f8b4b5bd">
    <ddiem:keggEntryId>K01230</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5bae4794-e359-4352-9163-89e8c417e461"/>
    <ddiem:ecNumber>3.2.1.113</ddiem:ecNumber>
    <ddiem:uniprotId>Q9UKM7</ddiem:uniprotId>
    <rdfs:label>mannosidase alpha class 1B member 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1d30900a-2f6d-4e5c-ab95-8f5bf396ac51">
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <rdfs:label>system B(0) neutral amino acid transporter 1 (B0AT1)</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8701a715-6567-4ec5-9f62-aa275ae960dc"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/24eb8dc7-79fc-4849-8c37-881295c089b9">
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <rdfs:label>GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase</rdfs:label>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bb33917a-72c1-45f8-bab6-18478ea88778">
        <rdfs:label>SPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6697</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <ddiem:ecNumber>1.1.1.153</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/bb3721c7-e100-4eb3-82a0-5a09841510ed"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a234286b-e8ab-42e1-83cd-6d5d0fa43b5c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7054</dc:identifier>
        <rdfs:label>TH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00072</ddiem:keggEntryId>
    <ddiem:uniprotId>P35270</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f0c407c-950e-48a7-8356-08ea644a592d">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610768">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ad2fa533-2fe0-42db-8b3d-b2d607dabc70"/>
        <ddiem:iembaseAccessionNumber>342</ddiem:iembaseAccessionNumber>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/342</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/610768</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c6c6292d-89d5-414c-bb7a-1c87f78ca878">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ae9df943-3a2c-408c-a10f-3e55ca622782"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0c7ef80d-9872-4a36-b414-81965a9b9fd7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20e89f6e-3af1-4fbd-af94-d73b700b0ccc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e12fa5cd-9a92-4ffc-ae84-a48912728b62">
    <ddiem:uniprotId>Q04656</ddiem:uniprotId>
    <rdfs:label>Copper-transporting ATPase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/037ef9e7-a5b0-4120-a9aa-93e4cacc7f43">
        <rdfs:label>ATP7A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/538</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>7.2.2.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K17686</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2c473d63-b18f-4c79-a564-19d91fd3c363">
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/abf9b520-fb37-46a8-b136-17596cdcae86"/>
    <rdfs:label>MITOCHONDRIAL RIBOSOMAL PROTEIN L44</rdfs:label>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dfcaf2a2-354d-447e-9f03-d9adda48e01a">
    <rdfs:label>apolipoprotein B-48 + apolipoprotein B-100</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/01299a9d-cf13-44eb-8fa0-269f6166c7c6">
        <rdfs:label>APOB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/338</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14462</ddiem:keggEntryId>
    <ddiem:uniprotId>P04114</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:IAO_0000115>modification of the amount or stability of a transcript or the efficiency of translation of a transcript in order to reduce or increase the expression of a  genetically abnormal protein.</obo:IAO_0000115>
    <obo:IAO_0000115>any procedure designed to suppress or mitigate the effects of a recessive genetic change in an abnormal protein by modification of its transcription or translation, excluding those strategies which involve epigenetic modification or modification of the germline or somatic genome sequence. For example an abnormal Vmax of reaction, alteration of KM, failure to respond to positive  feedback, acquisition of neofunction.</obo:IAO_0000115>
    <dc:date>3.10.19</dc:date>
    <rdfs:label>activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification</rdfs:label>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d833e132-d3b1-4ede-91fe-7ca3f0a0bb1d">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3e9bf89f-aee7-415f-8fdd-daedc167a182"/>
    <rdfs:label>Ribonuclease H1</rdfs:label>
    <ddiem:keggEntryId>K03469</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.26.4</ddiem:ecNumber>
    <ddiem:uniprotId>O60930</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/30b9e1f2-60dd-4e59-8009-3a2e749cef29">
    <ddiem:keggEntryId>K17725</ddiem:keggEntryId>
    <rdfs:label>persulfide dioxygenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8ae49822-9664-422c-94fd-4a6ece7674bb">
        <rdfs:label>ETHE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23474</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O95571</ddiem:uniprotId>
    <ddiem:ecNumber>1.13.11.18</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/afdc606e-5896-474f-8fc1-716d60d1c632">
    <ddiem:ecNumber>3.1.2.22</ddiem:ecNumber>
    <ddiem:uniprotId>P50897</ddiem:uniprotId>
    <rdfs:label>PALMITOYL-PROTEIN THIOESTERASE</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f40ff08a-55e4-4666-903d-0bf6e7908693">
        <rdfs:label>PPT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5538</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01074</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/daa38788-0bef-4281-8cee-a3c05e68c4d4">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d25b5d52-4979-424f-97ba-750bf314cbf2"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/334b6661-4a81-48a6-8c93-fdb7f04c8f9a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1dc72fe7-f705-441b-819a-71af064e2d22"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606812">
    <ddiem:iembaseAccessionNumber>174</ddiem:iembaseAccessionNumber>
    <rdfs:label>FUMARASE DEFICIENCY; FMRD</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/21b2bb6e-e685-453c-be55-686caf9b28be"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/174</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/606812</dc:identifier>
    <rdfs:comment>The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812</rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ee5e3707-4639-4ce4-b833-47cc7531f45c">
    <ddiem:ecNumber>3.1.11.7; 3.1.12.2</ddiem:ecNumber>
    <ddiem:uniprotId>Q7Z2E3</ddiem:uniprotId>
    <rdfs:label>Aprataxin</rdfs:label>
    <ddiem:keggEntryId>K10863</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/12a5dd89-3af3-4fc0-b220-5c92e4aa45e5">
        <rdfs:label>APTX</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54840</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8cea9a7d-5ba6-447c-95cc-35ae96c07271">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a5ac47d4-f42d-4f4b-a1bd-a312b56f9941">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3fc74b16-9757-4b3d-b4fe-3f02bf113f35"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/691fbe9d-ccf5-45d2-bb04-9bac8ab7404d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <rdfs:label>Increased plasma iron concentration(Increased serum iron)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003452</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604250">
        <ddiem:iembaseAccessionNumber>582</ddiem:iembaseAccessionNumber>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 3; HFE3</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/604250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/582</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3956412c-2db3-4dc2-919a-d269c4aea4fd"/>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/24f34c35-a895-4601-be12-49f10bb8afc3">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3120dca5-a013-4e1c-8c8d-1bedbe9e1a5c">
        <rdfs:label>ANKH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56172</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9HCJ1</ddiem:uniprotId>
    <ddiem:keggEntryId>K22734</ddiem:keggEntryId>
    <rdfs:label>Progressive ankylosis protein homolog</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2bd4107d-a836-43f4-94a9-048e9a5b6e65">
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <rdfs:label>Aldo-keto reductase family 1 member D1</rdfs:label>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c88947aa-0766-4304-b49f-2fac99c0fe39"/>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/56fdb9a7-258b-4a88-b848-726faf540c04">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c8dc2d-3194-4eb2-9f63-4ce04024cbfb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612073">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/503</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/612073</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2d686505-691c-413f-9614-420718c65321"/>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5</rdfs:label>
        <ddiem:iembaseAccessionNumber>503</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/45fb7c91-ae46-4915-8fad-afa38d8eeff7">
    <ddiem:uniprotId>Q7L5A8</ddiem:uniprotId>
    <ddiem:keggEntryId>K19703</ddiem:keggEntryId>
    <rdfs:label>fatty acid 2-hydroxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/db3d865d-5c85-422d-967f-445bd0a4e461">
        <rdfs:label>FA2H</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79152</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.18.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4f04dd5-4ab2-4e2d-a160-d27f6556a859">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14d20edc-032a-4808-93c8-23aba1c64fc9">
        <rdfs:label>Abnormal lymphocyte counts</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040088</ddiem:url>
        <dc:identifier>HP:0040088</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/813b7572-ea75-4d2b-a2a8-a61870e51b3d">
        <rdfs:label>Abnormal serum fast ORAC(oxygen reduced absorbance capacity)</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3900744-4943-49e9-8155-95730c2e2cf8"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208900">
        <rdfs:label>ATAXIA-TELANGIECTASIA; AT</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4562bac0-537c-40fb-902f-2c1470a16042"/>
        <dc:identifier>https://www.omim.org/entry/208900</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4cbbc885-d9da-4a64-84e7-a69ea36ba2a4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/552c6b43-1ca7-4b4b-8833-aac9b1f9aee6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/07d69d09-ca80-49fd-a9dc-eade42390f27">
    <ddiem:uniprotId>Q99707</ddiem:uniprotId>
    <ddiem:ecNumber>2.1.1.13</ddiem:ecNumber>
    <rdfs:label>Methionine synthase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0c81a8b7-e3a0-4b52-83ab-1d96674b26c8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4548</dc:identifier>
        <rdfs:label>MTR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00548</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/702ad67e-6620-4819-8a62-1e1629c38990">
    <ddiem:uniprotId>P49638</ddiem:uniprotId>
    <rdfs:label>α-tocopherol transfer protein</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8dbd6624-313c-4dfb-8ed0-83ecb96420f6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7274</dc:identifier>
        <rdfs:label>TTPA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/34a7d127-b397-4a59-a560-eb18f72f796f">
    <rdfs:label>Dystroglycan</rdfs:label>
    <ddiem:uniprotId>Q14118</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d9a5de27-60e4-49c7-a69a-d3edc18afc7b"/>
    <ddiem:keggEntryId>K06265</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a14b1e15-0f33-464a-8871-c4ba10c9f4bd">
    <rdfs:label>fukutin-related protein (FKRP)</rdfs:label>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/dd67c847-a456-4ea9-8519-e2f6118413cb"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/62b55532-28a9-4198-9e64-c0add88bbc9c">
    <ddiem:keggEntryId>K11538</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UKU7</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.8.-</ddiem:ecNumber>
    <rdfs:label>isobutyryl-CoA dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8f30a9f0-ed26-47dc-90aa-149c31c810a0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27034</dc:identifier>
        <rdfs:label>ACAD8</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b222ccbb-36a5-4532-8dc6-bdaf50f0d383">
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/487b328e-bb8b-4c96-a7ef-c601b2d2536b"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335963</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e463ef9a-d5bb-4185-805d-5c4b1d0ae868"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2775502c-5918-4232-9556-82a13fc1a40a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ab959336-4ff3-4517-aedb-40d0cfa07163">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/73bf8348-437e-49c0-bb08-26e548629cbb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26790a3a-3426-44a6-83eb-28e897143864">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Disease progression</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9763e986-bf98-4d4d-ad53-e60255454863">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1a34c414-f563-4db4-8fe7-667ebc917768">
        <rdfs:label>DPYD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1806</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q12882</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
    <rdfs:label>dihydropyrimidine dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00207</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f441e1e9-7cef-47cf-ac39-3bc1235b9c08">
    <ddiem:keggEntryId>K00451</ddiem:keggEntryId>
    <ddiem:uniprotId>Q93099</ddiem:uniprotId>
    <ddiem:ecNumber>1.13.11.5</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2749c6a2-6b4b-476b-a8d0-0e74f1613927">
        <rdfs:label>HGD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3081</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Homogentisate 1,2-dioxygenase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d74ec72b-5e43-4c4a-bc38-6356337b475f">
    <ddiem:ecNumber>3.2.1.45; 2.4.1.-; 3.2.1.104</ddiem:ecNumber>
    <rdfs:label>beta-glucocerebrosidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8d84618c-2ff1-4a3c-8aee-e89eefc6d4c2">
        <rdfs:label>GBA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01201</ddiem:keggEntryId>
    <ddiem:uniprotId>P04062</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5db77db1-6ffc-4e12-b1b6-aa7ae90abc6e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da7dc67b-2e19-4f43-b7ea-1de6f4150296"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613154">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1125</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/613154</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d6cb128d-20dd-4981-b430-d7c8e550916a"/>
        <ddiem:iembaseAccessionNumber>1125</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07f368e3-ffb6-4e99-bce4-f82ca4a1d3e7"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b9bb30c7-c925-4e53-81c6-3df2102db682">
    <ddiem:keggEntryId>K15100</ddiem:keggEntryId>
    <ddiem:uniprotId>P53007</ddiem:uniprotId>
    <rdfs:label>Tricarboxylate transport protein, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/96325b78-f9f3-4fc0-bad0-7470dd401745">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6576</dc:identifier>
        <rdfs:label>SLC25A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605637">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f6bb1f8c-b076-4ce9-909b-eb6765f9b1e0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4620</dc:identifier>
        <rdfs:label>MYH2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/605637</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2f6a00b6-50ad-44c1-a31a-e2ad7cb245ab">
    <ddiem:uniprotId>P12235</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/26fae327-b7cd-416c-a6d8-fdfdf607a6b3">
        <rdfs:label>SLC25A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/291</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ADP/ATP translocase 1</rdfs:label>
    <ddiem:keggEntryId>K05863</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/701b146e-a70b-40fa-aadf-cb165e72265b">
    <ddiem:keggEntryId>K01719</ddiem:keggEntryId>
    <rdfs:label>uroporphyrinogen III synthase</rdfs:label>
    <ddiem:ecNumber>4.2.1.75</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0fabd277-755e-46bc-b0b5-8c2c1c2012a7">
        <rdfs:label>UROS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7390</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P10746</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8fa6084c-2099-41bd-b622-79cfdea139ee">
    <rdfs:label>fukutin</rdfs:label>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b0185df9-7ec6-4b06-9aec-b281b49dc3d8"/>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9813cd44-3ca3-4212-a522-3324bf9a1343">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef7dcd2d-b04f-4a6c-be09-d95926e14705"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e877f1bd-75d6-4ca2-888f-20ea519a94c7">
        <rdfs:label>hypercholesterolemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0003124</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a44f9fc7-ff53-4ce4-b9a9-750f949cebc0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c7533576-9582-4e6f-8f7b-d7963a33aaaa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/99b74142-8439-4d9f-b2d4-3b95edd98ca0">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/234cc3fe-5efc-46c5-b237-4ab7d18e283a">
        <rdfs:label>ETFA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2108</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P13804</ddiem:uniprotId>
    <rdfs:label>electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00311</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/98251691-b8b7-4a7e-bb9b-704433a30ff2">
        <rdfs:label>ETFDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2110</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16134</ddiem:uniprotId>
    <ddiem:keggEntryId>K03522</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b1c60511-ac28-4309-b93a-7a44f778ef17">
        <rdfs:label>ETFB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2109</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03521</ddiem:keggEntryId>
    <ddiem:uniprotId>P38117</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.5.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3dbb8a77-8404-4f41-b063-b30702495d40">
    <ddiem:uniprotId>Q9Y4U1</ddiem:uniprotId>
    <ddiem:keggEntryId>K14618</ddiem:keggEntryId>
    <ddiem:ecNumber>1.16.1.-</ddiem:ecNumber>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type C protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d106b8c9-b251-4e05-934c-995318f859e2">
        <rdfs:label>MMACHC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/25974</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/70e9aefb-72e0-4071-a576-1b96be767614">
    <rdfs:label>lamins ( Lamins A and C)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9b8c5763-b3c1-419c-a4bb-ccf47a282d08">
        <rdfs:label>LMNA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4000</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12641</ddiem:keggEntryId>
    <ddiem:uniprotId>P02545</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/60ae5b1b-eacf-4b05-8325-9f782af1b226">
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <rdfs:label>3-beta-hydroxy-delta-5-C27 steroid oxidoreductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a547561a-25ca-4d4a-962c-5856d48f5bde">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80270</dc:identifier>
        <rdfs:label>HSD3B7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e276d62e-8489-4140-8f30-68cc4c6714e4">
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <rdfs:label>Tyrosine hydroxylase</rdfs:label>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a234286b-e8ab-42e1-83cd-6d5d0fa43b5c"/>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/550500">
    <rdfs:label>MYOGLOBINURIA, RECURRENT</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4c998df8-5622-4e9e-a368-79d833d778fb"/>
    <dc:identifier>https://www.omim.org/entry/550500</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0c916260-43cf-4d19-a65a-b064ec4d105c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/70e21725-088a-4672-9be2-2850fe9ac9fb">
        <rdfs:label>UGT1A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54658</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <rdfs:label>uridine diphosphate–glucuronyl transferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7e21e0bd-112a-47eb-86ce-89727fb17ecc">
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <rdfs:label>iduronidase, alpha-L</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0b8c1fd4-df81-44b5-a497-03cfc2225b81">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3425</dc:identifier>
        <rdfs:label>IDUA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ef61f47a-6efa-46c3-acc5-574e386aa7ed">
    <rdfs:label>hypoxanthine phosphoribosyltransferase 1</rdfs:label>
    <ddiem:keggEntryId>K00760</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.8</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/238b8521-1afc-4ad2-8ca6-bbd356320f51">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3251</dc:identifier>
        <rdfs:label>HPRT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P00492</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/45ae94e9-6731-4109-b806-bfa1d0622c10">
    <ddiem:uniprotId>Q9UPQ8</ddiem:uniprotId>
    <rdfs:label>dolichol kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ad2fa533-2fe0-42db-8b3d-b2d607dabc70">
        <rdfs:label>DOLK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/22845</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00902</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.108</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/de879026-9f80-4a33-9724-bc681ebf1c62">
    <ddiem:ecNumber>4.2.1.96</ddiem:ecNumber>
    <ddiem:keggEntryId>K01724</ddiem:keggEntryId>
    <ddiem:uniprotId>P61457</ddiem:uniprotId>
    <rdfs:label>pterin-4 alpha-carbinolamine dehydratase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/14d0357e-a06d-49f1-b54e-9dbb0f976147">
        <rdfs:label>PCBD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5092</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0a14e13c-3594-446d-9377-2e7a74fe4f89">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5968fcd2-3929-4240-ba71-59930910fbe4"/>
    <rdfs:label>Sar1b protein</rdfs:label>
    <ddiem:keggEntryId>K07953</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9Y6B6</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/64f04ac7-a9c4-4e71-bd63-7ea1b7d01f45">
    <ddiem:keggEntryId>K00819</ddiem:keggEntryId>
    <rdfs:label>ornithine aminotransferase</rdfs:label>
    <ddiem:uniprotId>P04181</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3b03411a-ff41-4513-8e3b-59463dfa310a">
        <rdfs:label>OAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4942</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.6.1.13</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cf936331-be9b-443c-af0a-2bc11b6b5e71">
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e66c71a-7374-45d1-baf3-c15de90914f1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5af1e6f0-0f8d-44ef-94e2-34fc3144cbc2">
        <rdfs:label>Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939 *</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/BF00710419</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12ec49c0-855b-443b-b86b-87b795b7cf2d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <rdfs:label>Acute metabolic crisis ( Metabolism abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939 *</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/210200">
        <rdfs:label>3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/126abe19-fe24-46c5-9d87-be6ec9359f42"/>
        <dc:identifier>https://www.omim.org/entry/210200</dc:identifier>
        <ddiem:iembaseAccessionNumber>1284</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/93f5afe5-de9d-47b2-82ff-b5a1ce455963"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1284</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ac7f8df5-f013-4bfc-bf39-96c236af2a5d">
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/60a752e5-d980-4dc9-bce5-c54dc0e47e62"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bf4a4376-4928-446c-8de1-0fa3f7afaf1e">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND4L</dc:identifier>
        <rdfs:label>MT-ND4L</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9cad528d-f87c-4dac-95bd-1023642693d8"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3efe11c9-ec34-4bc5-b931-00fce2698dd5">
    <rdfs:label>85/88 kDa calcium-independent phospholipase A2</rdfs:label>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ae8e22c9-edd7-4d39-a519-14870f47ed86"/>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9db9de58-57a4-43e7-a8f1-24ceb13e16ce">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/410bed4b-d403-4ac7-8867-94c19af796e2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2645</dc:identifier>
        <rdfs:label>GCK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glucokinase-4</rdfs:label>
    <ddiem:keggEntryId>K12407</ddiem:keggEntryId>
    <ddiem:uniprotId>P35557</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f64db06c-f61a-4341-802b-c29a9a5a011a">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89a8cec7-01f9-4c7c-9ed8-7004e633c7d4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>PTPS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/87c8221d-c402-4d22-8257-8fb1c23f8784">
    <ddiem:uniprotId>P22307</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/080375ed-7ef9-4f3a-85e0-bd9b5432ff28"/>
    <rdfs:label>sterol carrier protein 2</rdfs:label>
    <ddiem:keggEntryId>K08764</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.176</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7ecf2cc8-995f-492d-9ea6-68603dabbc34">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bdd82c59-3050-4e57-b63a-244dffdd84a9">
        <rdfs:label>PNPO</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55163</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.4.3.5</ddiem:ecNumber>
    <rdfs:label>Pyridoxamine 5'-phosphate oxidase</rdfs:label>
    <ddiem:uniprotId>Q9NVS9</ddiem:uniprotId>
    <ddiem:keggEntryId>K00275</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c3ec41af-8e31-42c0-95cb-2c1992b87f06">
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <rdfs:label>cytochrome c oxidase assembly factor</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8e73758c-2d95-469d-8b0b-c36fd2dd6e4d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/728294</dc:identifier>
        <rdfs:label>D2HGDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a526efa5-24b3-4af1-a187-3eb71bcd9745">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8bd86f50-3250-47f1-ac26-0a0a9d5656e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21c18d11-e70b-4dcc-8357-747d1814a2af"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236792">
        <ddiem:iembaseAccessionNumber>165</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/236792</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fa24c0af-030e-4a53-9dc3-b39119f47aec"/>
        <rdfs:label>L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/165</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08ade565-e136-435b-94fd-9efecffe4e94"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26208971</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f1a0ccfb-e291-4f11-8325-a2ea2a690c66">
    <rdfs:label>Dihydropteridine reductase</rdfs:label>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2c57b2a5-6ade-4a0c-b706-cedc208fa5df"/>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bbbc29ae-e1a6-4963-bb2a-424d4e54e93a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d6cb128d-20dd-4981-b430-d7c8e550916a">
        <rdfs:label>LARGE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>LARGE xylosyl- and glucuronyltransferase 1</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/272200">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>301</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/837535b1-39a5-4acc-9f7e-864666ca7262"/>
    <dc:identifier>https://www.omim.org/entry/272200</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/301</ddiem:iembaseUrl>
    <rdfs:label>MULTIPLE SULFATASE DEFICIENCY; MSD</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/278fc6d4-79ba-4ae7-9cc1-6b065908a4fe">
    <ddiem:uniprotId>Q9UNF1</ddiem:uniprotId>
    <rdfs:label>Melanoma-associated antigen D2</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9dc638ba-576e-4430-a8fe-e7746dfa3e6a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10916</dc:identifier>
        <rdfs:label>MAGED2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f20ab0f8-98dc-40c6-8bb8-3ce8e90e1359">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/63e9be0f-b90e-4269-bfb8-2c74071ab7cb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/846</dc:identifier>
        <rdfs:label>CASR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P41180</ddiem:uniprotId>
    <rdfs:label>calcium-sensing receptor</rdfs:label>
    <ddiem:keggEntryId>K04612</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/011f9ae5-e3cd-4ed5-ad93-8ae9a944c02a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4a1f8dde-2920-417c-a7af-12276acc8c60">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5256</dc:identifier>
        <rdfs:label>PHKA2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P46019</ddiem:uniprotId>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <rdfs:label>Phosphorylase b kinase regulatory subunit alpha, liver isoform</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/72e7787c-84b9-4f0e-b225-b04cf588674b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6b7b9a4c-5731-4c1e-b43f-6ec2042ec5d6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1075</dc:identifier>
        <rdfs:label>CTSC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01275</ddiem:keggEntryId>
    <ddiem:uniprotId>P53634</ddiem:uniprotId>
    <rdfs:label>cathepsin C</rdfs:label>
    <ddiem:ecNumber>3.4.14.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/45a822a0-d8c0-48ea-9f6e-f2e04c024ae8">
    <ddiem:keggEntryId>K01464</ddiem:keggEntryId>
    <rdfs:label>dihydropyrimidinase</rdfs:label>
    <ddiem:ecNumber>3.5.2.2</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/42980054-6ac5-45d3-a4ae-53880ab7597a"/>
    <ddiem:uniprotId>Q14117</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/975be2fc-2959-4eab-972f-cfded917e3af">
    <ddiem:keggEntryId>K11529</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a140ea5a-bca6-41ef-80d2-2cd23448237f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/132158</dc:identifier>
        <rdfs:label>GLYCTK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.31</ddiem:ecNumber>
    <ddiem:uniprotId>Q8IVS8</ddiem:uniprotId>
    <rdfs:label>d-glycerate kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6c898e7f-5829-4bdb-a9ee-9285811be0e2">
    <ddiem:ecNumber>2.-.-.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K05285</ddiem:keggEntryId>
    <rdfs:label>GPI ethanolamine phosphate transferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/64a3cccb-66f9-47d2-9a18-303da28bd4ac">
        <rdfs:label>PIGN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23556</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O95427</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e7042db1-f0fc-4378-b309-a262a2ff2b67">
    <ddiem:uniprotId>P06737</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dd2cdcc7-3960-4f32-8746-1f863b401fe4">
        <rdfs:label>PYGL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5836</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glycogen phosphorylase, liver form</rdfs:label>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/84e1d106-ad68-4d0c-8d32-85af77440402">
    <rdfs:label>aldolase, fructose-bisphosphate A</rdfs:label>
    <ddiem:ecNumber>4.1.2.13</ddiem:ecNumber>
    <ddiem:uniprotId>P04075</ddiem:uniprotId>
    <ddiem:keggEntryId>K01623</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/107cd3f5-fc78-4d74-a615-9d03ac1e1786">
        <rdfs:label>ALDOA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/226</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8cfe8b96-bbb0-4fb5-bdc9-378b921d2163">
    <ddiem:uniprotId>P54840</ddiem:uniprotId>
    <ddiem:keggEntryId>K00693</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b25a3484-5220-45a9-9691-641f595d10db">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2998</dc:identifier>
        <rdfs:label>GYS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glycogen synthase 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a4280fa8-82aa-41b7-9534-418e9802bf3a">
    <ddiem:uniprotId>Q8WTW3</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/aec325c2-6b10-4ab5-9574-148100eb099b"/>
    <rdfs:label>component of oligomeric golgi complex 1</rdfs:label>
    <ddiem:keggEntryId>K20288</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ce6c3a0e-bb6c-494f-ba34-6304ddc5cd22">
    <rdfs:label>CLN6, transmembrane ER protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/11749cac-dc3e-4068-bf22-2febbd4a1a23">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54982</dc:identifier>
        <rdfs:label>CLN6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9NWW5</ddiem:uniprotId>
    <ddiem:keggEntryId>K12359</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54445a1c-bf7b-4634-b5e0-46dbb5c8c85c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f799ee8-a478-44c9-bc90-612cdecf51dd">
        <rdfs:label>High erythrocyte turnover(Abnormality of erythrocytes)*</rdfs:label>
        <dc:identifier>HP:0001877*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9046addd-c582-4a31-ac8d-33e1d963d4e2"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0de52245-d225-449c-bcae-fcf59bba042c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/26615295-0d5b-4588-b8d7-bfc9d9da83f3">
    <ddiem:uniprotId>Q30201</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Hereditary hemochromatosis protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6630951e-cec2-457a-9bbd-412650641604">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3077</dc:identifier>
        <rdfs:label>HFE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/44e677b9-5bf9-494e-9610-ee0cf212041a">
    <rdfs:label>ATP-dependent 6-phosphofructokinase, muscle type</rdfs:label>
    <ddiem:keggEntryId>K00850</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2b13025-aeb2-4d19-b7e1-335fc819e756">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5213</dc:identifier>
        <rdfs:label>PFKM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P08237</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cf65881d-787b-42c5-8836-ad141b8fbec6">
    <ddiem:uniprotId>Q9P2R7</ddiem:uniprotId>
    <rdfs:label>Succinyl-CoA synthetase ( beta subunit)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2d686505-691c-413f-9614-420718c65321">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8803</dc:identifier>
        <rdfs:label>SUCLA2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01900</ddiem:keggEntryId>
    <ddiem:ecNumber>6.2.1.5</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4087e999-37fa-4b9c-95d3-b6dce8d1ac03">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f16bbf46-0981-43bf-8e51-ba2fb92e8ddf">
        <rdfs:label>DPM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8813</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O60762</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.83</ddiem:ecNumber>
    <rdfs:label>dolichol-P-mannose synthase 1</rdfs:label>
    <ddiem:keggEntryId>K00721</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/677a13d1-9ea6-4445-ac0b-439435532823">
    <ddiem:uniprotId>P50416</ddiem:uniprotId>
    <ddiem:keggEntryId>K08765</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <rdfs:label>carnitine palmitoyltransferase 1A</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7d81da2f-4ed6-4e6f-856a-9faa30ebd99c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1374</dc:identifier>
        <rdfs:label>CPT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0c373c8c-8e53-4995-984a-d63088ac921a">
    <ddiem:uniprotId>P20807</ddiem:uniprotId>
    <rdfs:label>calpain 3</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ff86e590-2864-4f9f-b19f-be1fd4f731fe">
        <rdfs:label>CAPN3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/825</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.4.22.54</ddiem:ecNumber>
    <ddiem:keggEntryId>K08573</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/af70da01-e6c3-4249-9000-6121c04ff76d">
    <ddiem:uniprotId>Q8IWY9</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/048efba9-1008-40ff-be21-bdcd0abe59be">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/146059</dc:identifier>
        <rdfs:label>CDAN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>codanin 1</rdfs:label>
    <ddiem:keggEntryId>K19531</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ff0c2d11-5686-4c7d-9dd1-828c49d79aae">
    <ddiem:uniprotId>Q8WZ55</ddiem:uniprotId>
    <rdfs:label>barttin</rdfs:label>
    <ddiem:keggEntryId>K19331</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1079702a-a144-4da5-b533-922e78a4910b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7809</dc:identifier>
        <rdfs:label>BSND</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2de7b33b-3795-4faf-9253-3910562c4990">
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/00dace53-b78b-45e5-9b17-48727d09a210">
        <rdfs:label>POLG</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5428</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <rdfs:label>DNA polymerase subunit gamma-1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/34ed9d54-fc7d-4532-9177-9e6ce931aa8c">
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ad08ad5-a381-4ba8-bcfb-3799f285fe36">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e928333b-209a-4d72-a049-12baa4fd3e51"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/257220">
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C1; NPC1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/303</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/257220</dc:identifier>
        <ddiem:iembaseAccessionNumber>303</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d2f5995f-24d6-47b1-8236-91db6782bfb1"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736622</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52a1376d-08cb-4c04-a2d0-71d41754afeb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c71e83c1-f30d-46af-9e5f-86a3136d643e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd7175be-f025-4e3f-9673-ad07e410ae70">
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/328358cc-01a6-423a-a744-fd03045f280f">
    <ddiem:uniprotId>Q8NAT1</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e99326ba-3b20-4ca7-992a-b5dc2b121f7b"/>
    <rdfs:label>Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2</rdfs:label>
    <ddiem:keggEntryId>K18207</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.312</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/77650823-88be-42ed-a9da-65018e80492a">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/feace97a-22c1-4fe3-8d87-777a5adbc8ad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02931f50-0c6f-40bc-9619-662b63aca346"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/93165bd0-7267-4574-a548-abeecd612c17">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/41e30bba-60cd-4e49-b848-e2a13f7a6a36"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7ad5ffea-5c06-4abd-b4f9-f11d55f72943">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e683de2e-5d55-4e8c-af92-9c46bac98b77">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ffa61f77-9d83-4105-89e1-14d080f57115"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/234a1a61-f558-4ae3-bc72-ed55c27c8d05"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207900">
        <ddiem:iembaseAccessionNumber>15</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/15</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/207900</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ARGININOSUCCINIC ACIDURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b6abc536-8276-4a60-836a-d1e66b18d096"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d1ec00d-fe63-46dd-97b8-1541001b8050">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:label>Hyperammonemia</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001987</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00345605</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5a60f252-6ee7-41ca-87cf-818ab6eca9d7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d0d4d5d6-b1f2-4696-a618-161460a1fc84">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3030</dc:identifier>
        <rdfs:label>HADHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P40939</ddiem:uniprotId>
    <ddiem:keggEntryId>K07515</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.-; 4.2.1.17; 1.1.1.211</ddiem:ecNumber>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/05643028-3297-4602-a21b-5d7be8604263">
    <ddiem:keggEntryId>K00552</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/da36c1f7-09b8-4104-ad9d-000cf941da8e">
        <rdfs:label>GNMT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.1.20</ddiem:ecNumber>
    <rdfs:label>glycine N-methyltransferase</rdfs:label>
    <ddiem:uniprotId>Q14749</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8a2358f0-1127-42e9-a100-e717bcf4fad1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5c3b8002-6f22-44a9-8fab-5aec77a28aee">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5255</dc:identifier>
        <rdfs:label>PHKA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>alpha subunit of muscle phosphorylase kinase</rdfs:label>
    <ddiem:uniprotId>P46020</ddiem:uniprotId>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb1bd924-f88f-4809-a9cb-edb10cc2e288">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/396d104d-4d36-47d6-a038-9ddd097586f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26f3d96e-38a4-47f5-979a-95dd91f902bf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b3692b2-cced-4be0-932f-763b34546c97">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <dc:identifier>HP:0002401</dc:identifier>
        <rdfs:label>Stroke-like attacks</rdfs:label>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b664cf91-8944-4d65-97e4-51c7c48059e2">
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Abnormal EEG (focal epileptiform activity)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7996bb8b-9bc3-4cf4-9a31-1151707b6ffc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030890</ddiem:url>
        <rdfs:label>Hyperintensity of cerebral white matter on MRI</rdfs:label>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <dc:identifier>HP:0030890</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11382201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a562663d-05be-46fb-a7ea-9872a2690f1a">
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c4db02f4-ce26-4ca9-8fcc-8646732922ed"/>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <rdfs:label>twinkle mtDNA helicase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c13f5b51-383a-42d0-8bcf-eab99aa111f6">
    <rdfs:label>apolipoprotein E</rdfs:label>
    <ddiem:uniprotId>P02649</ddiem:uniprotId>
    <ddiem:keggEntryId>K04524</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c48c7f15-16df-4596-9301-890ea683977b">
        <rdfs:label>APOE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/348</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609308">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cae73afc-fe20-4f34-831b-d408e40d55d9"/>
    <dc:identifier>https://www.omim.org/entry/609308</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1</rdfs:label>
    <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b0e0307d-a967-4ee7-8708-fa117502308d">
    <ddiem:ecNumber>2.4.1.18</ddiem:ecNumber>
    <rdfs:label>Limit dextrin alpha-1,6-maltotetraose-hydrolase</rdfs:label>
    <ddiem:keggEntryId>K00700</ddiem:keggEntryId>
    <ddiem:uniprotId>Q04446</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7bae13fa-12bc-456e-9e43-1752da353b9a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2632</dc:identifier>
        <rdfs:label>GBE1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ec1269fd-b339-4481-9578-12778e9d1846">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3c1652b3-7331-419d-9b75-7bebb3f2c8e4">
        <rdfs:label>MT-ND4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 4</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b529d0af-682e-4710-aabd-9b77080b29a6">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3e54f8c5-4c4c-4e0e-a0da-8ab051da8112">
        <rdfs:label>PIGT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51604</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q969N2</ddiem:uniprotId>
    <rdfs:label>GPI transamidase component PIG-T</rdfs:label>
    <ddiem:keggEntryId>K05292</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e93129b6-73f5-4de9-8ed4-9fe44c2e3056">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/326bd4bc-c556-4b62-96da-7f5e2603faa9"/>
    <ddiem:keggEntryId>K01689</ddiem:keggEntryId>
    <ddiem:uniprotId>P13929</ddiem:uniprotId>
    <rdfs:label>enolase 3</rdfs:label>
    <ddiem:ecNumber>4.2.1.11</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f2fc6fc0-84dc-419d-a20d-cfb2994252da">
    <ddiem:ecNumber>2.7.1.30</ddiem:ecNumber>
    <rdfs:label>Glycerol kinase</rdfs:label>
    <ddiem:keggEntryId>K00864</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7177bb06-2aa0-4c92-a26b-58c86f95ba40">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2710</dc:identifier>
        <rdfs:label>GK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P32189</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b1aa456f-5c4b-4226-8f2e-cc5c0ff43918">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/488a8f67-c486-4da7-8aaf-692d9714b43a">
        <rdfs:label>POLG2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UHN1</ddiem:uniprotId>
    <rdfs:label>DNA polymerase subunit gamma-2, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K02333</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/54694a50-075e-48b0-9836-0fc28f1b7c89">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4ec8fccb-2a3c-4155-bec9-ff4f9a186750"/>
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <rdfs:label>prosaposin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7416ab4e-7734-40b4-81df-0cafc3b980bf">
    <rdfs:label>alpha-1-antitrypsin (major plasma serine protease inhibitor)</rdfs:label>
    <ddiem:uniprotId>P01009</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f22da568-30e8-47fe-af1a-878f2b1d908e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5265</dc:identifier>
        <rdfs:label>SERPINA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K03984</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/23f6325b-4c5b-45fa-af05-a9a927be7268">
    <ddiem:uniprotId>Q15392</ddiem:uniprotId>
    <ddiem:keggEntryId>K09828</ddiem:keggEntryId>
    <rdfs:label>3-beta-hydroxysterol delta-24-reductase</rdfs:label>
    <ddiem:ecNumber>1.3.1.72</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6bc05c72-dac9-40ef-9a45-d23a1ef3bf13">
        <rdfs:label>DHCR24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1718</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/92319e5d-334d-4c83-bfa6-921fb505cd84">
    <ddiem:uniprotId>Q14693</ddiem:uniprotId>
    <rdfs:label>Phosphatidate phosphatase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/36f71f72-b6c2-46bd-b734-b88ff49b9e2a">
        <rdfs:label>LPIN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K15728</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.3.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/43977ae3-9503-4b67-8e27-f25f487b132e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/47c14578-abfb-4942-809c-0f142e302865">
        <rdfs:label>GALT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>beta-1,4-galactosyl transferase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ff472ef4-6a64-4a58-ab13-9fdb44434eff">
    <ddiem:ecNumber>2.1.2.5; 4.3.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>O95954</ddiem:uniprotId>
    <rdfs:label>formiminotransferase cyclodeaminase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2b46ac74-8ffb-48e4-a656-558c11ea5e78">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10841</dc:identifier>
        <rdfs:label>FTCD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13990</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f2f74a02-5ab5-40a2-9c90-95a6ef9293ce">
    <rdfs:label>transferrin</rdfs:label>
    <ddiem:keggEntryId>K14736</ddiem:keggEntryId>
    <ddiem:uniprotId>P02787</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/84e5beca-fdee-46a4-a9d4-6b6a971627ad">
        <rdfs:label>TF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7018</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3b7c3db5-25e5-4a82-b16f-8dadbd1bf40f">
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/776eec99-ff94-4e22-8948-7e59352f3fc8">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Abnormal hemoglobin level</rdfs:label>
        <dc:identifier>HP:0025546</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025546</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a8d9aba-0afa-467b-a837-176f856c7a71">
        <dc:identifier>HP:0025065</dc:identifier>
        <rdfs:label>Abnormal MCV level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025065</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/488b4f8a-bb56-4982-8364-aa8298c07ddb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a53e94da-e15d-42a4-9bf5-6e542b08c26d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/541cc893-0f82-4cd1-900d-d8364318aab7">
    <ddiem:uniprotId>Q96RQ3</ddiem:uniprotId>
    <ddiem:keggEntryId>K01969</ddiem:keggEntryId>
    <ddiem:keggEntryId>K01968</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/126abe19-fe24-46c5-9d87-be6ec9359f42">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56922</dc:identifier>
        <rdfs:label>MCCC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/93f5afe5-de9d-47b2-82ff-b5a1ce455963">
        <rdfs:label>MCCC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64087</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>6.4.1.4</ddiem:ecNumber>
    <rdfs:label>3 Methylcrotonyl-CoA carboxylase</rdfs:label>
    <ddiem:uniprotId>Q9HCC0</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0720123f-621a-4eb2-bbf3-02bd86a6e882">
    <rdfs:label>Hydroxymethylbilane synthase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/809cdea5-90bd-4edc-bb76-32deba3ff8f9">
        <rdfs:label>HMBS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3145</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01749</ddiem:keggEntryId>
    <ddiem:ecNumber>2.5.1.61</ddiem:ecNumber>
    <ddiem:uniprotId>P08397</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fd337664-0538-4fe8-b6ac-84000405bd0d">
    <rdfs:label>17β-hydroxysteroid dehydrogenase type 4</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d74a235c-1c5d-42e5-be3d-824e465f3062">
        <rdfs:label>HSD17B4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3295</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P51659</ddiem:uniprotId>
    <ddiem:keggEntryId>K12405</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.n12; 4.2.1.107; 4.2.1.119</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4d1a0ef5-bebe-416a-99ce-d2935bd14436">
    <ddiem:uniprotId>O43272</ddiem:uniprotId>
    <rdfs:label>proline dehydrogenase 1</rdfs:label>
    <ddiem:keggEntryId>K00318</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.5.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e725d631-8ac8-4d17-9925-a70da0cceda3">
        <rdfs:label>PRODH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5625</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/08688c09-b766-42c4-9bb4-68264399f658">
    <ddiem:ecNumber>1.1.1.170</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/00609be1-7016-4170-8461-f1aaae11c819">
        <rdfs:label>NSDHL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50814</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q15738</ddiem:uniprotId>
    <ddiem:keggEntryId>K07748</ddiem:keggEntryId>
    <rdfs:label>NAD(P) dependent steroid dehydrogenase-like</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7a07ec34-249a-45b5-a3f8-ba47531bfce9">
    <ddiem:keggEntryId>K09478</ddiem:keggEntryId>
    <rdfs:label>3-hydroxy-2-methylbutyryl-CoA dehydrogenase</rdfs:label>
    <ddiem:uniprotId>P45954</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.8.5</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/263ada67-f2bc-4e79-b7d9-d9badcd7a61f">
        <rdfs:label>ACADSB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/36</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/creator"/>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/date"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/870dd2f4-f35f-4fa2-855e-7101dee749b9">
    <ddiem:uniprotId>Q9H3Z4</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3e811f28-cbe2-4789-a3ef-53a68669ac52"/>
    <ddiem:keggEntryId>K09525</ddiem:keggEntryId>
    <rdfs:label>DnaJ homolog subfamily C member 5(cysteine string PROTEIN)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000016">
    <rdfs:label xml:lang="en">functional complementation or a defective protein by stimulation</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that stimulates a component of the pathway or network in which a genetically defective defective protein is found, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:09:20+00:00</dc:date>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/61b93e98-8253-4671-b323-c13ec7a63540">
    <rdfs:label>lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme</rdfs:label>
    <ddiem:keggEntryId>K00016</ddiem:keggEntryId>
    <ddiem:uniprotId>P00338</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.27</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/456f9c0f-0fc3-4dbe-a38d-46652758721c"/>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/39a81e67-aaed-4fd8-8423-a1717e74fbfc"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3005c09e-c7f2-4388-bd1f-08a06359a014">
    <ddiem:ecNumber>2.6.1.19; 2.6.1.22</ddiem:ecNumber>
    <ddiem:keggEntryId>K13524</ddiem:keggEntryId>
    <ddiem:uniprotId>P80404</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ff9bd34f-9a2b-46c9-b404-9d61b23fa34f">
        <rdfs:label>ABAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/18</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GABA-transaminase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18f20c6a-9ebf-4443-9c2b-4fa330ad430f">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b07909e-8b29-4fe6-ba0f-e3a3f345a96f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3229565</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e66c71a-7374-45d1-baf3-c15de90914f1"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/514df51f-6c81-4cfc-99ad-fa1bce52ec49">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28288174</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6a32b018-99ab-4d2d-bae1-d16c40936add">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea489b4e-c464-4c5e-b2ea-85999ff6106a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f9955fc-5971-4eb9-bbee-e38c21c1c84b"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607364">
        <dc:identifier>https://www.omim.org/entry/607364</dc:identifier>
        <rdfs:label>BARTTER SYNDROME, TYPE 3; BARTS3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/04dc1b76-9b6e-49a5-af50-1f023539c7fe"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27918a38-5398-4b52-9250-e62f8de8bb21">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/201f602c-aa20-45f6-9b34-af41f441f76e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c1a2d404-b82b-4ce1-88f0-e0e490ca39e3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea886e7b-56da-4144-90c5-5fe5f0db4b5e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e481d940-8b39-4992-9955-84c33ee3435f">
    <rdfs:label>sarcoglycan gamma</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/62ab49dd-d395-42a1-8479-98a52cd66569">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6445</dc:identifier>
        <rdfs:label>SGCG</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13326</ddiem:uniprotId>
    <ddiem:keggEntryId>K12564</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2ca43ecb-e609-43ae-9128-b7728d47afc4">
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/89793ab0-57b2-4d74-87f9-2b007d6ca98a"/>
    <rdfs:label>Dihydrolipoyl dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b6db8a19-76ed-47d0-a466-7477dc127475">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8a082a54-f516-466a-875d-28846ab2de24"/>
    <ddiem:uniprotId>Q9H5K3</ddiem:uniprotId>
    <ddiem:keggEntryId>K17547</ddiem:keggEntryId>
    <rdfs:label>Protein O-mannose kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.183</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4e5ba538-4409-464b-b7e0-e7738411334f">
    <ddiem:uniprotId>P09172</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/08f1703c-eae8-4070-9a2a-8884b114834a">
        <rdfs:label>DBH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1621</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dopamine beta (β)-hydroxylase</rdfs:label>
    <ddiem:keggEntryId>K00503</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.17.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a1aa79ad-a8ba-4f35-9003-9a43f76d7fe0">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4461613d-26ac-4053-8910-4b1c8e59299b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/116519</dc:identifier>
        <rdfs:label>APOA5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
    <rdfs:label>apolipoprotein A5</rdfs:label>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/be2fb002-122d-463a-b31f-8a37e56ffdab">
    <ddiem:keggEntryId>K00140</ddiem:keggEntryId>
    <ddiem:ecNumber>1.2.1.18; 1.2.1.27</ddiem:ecNumber>
    <ddiem:uniprotId>Q02252</ddiem:uniprotId>
    <rdfs:label>3-hydroxyisobutyrate dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6df95112-2478-4e0e-bacc-04b45c64ab04">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4329</dc:identifier>
        <rdfs:label>ALDH6A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7c84f6d6-ba99-410f-905b-e66b8136bb2d">
    <ddiem:uniprotId>O43772</ddiem:uniprotId>
    <rdfs:label>carnitine-acylcarnitine translocase</rdfs:label>
    <ddiem:keggEntryId>K15109</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d5fc7f42-73ef-4009-8a72-c38da07b2e91">
        <rdfs:label>SLC25A20</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/788</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ff29c2a3-ccd8-4fb2-ae41-3c56cf97cd03">
    <ddiem:keggEntryId>K12565</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f3c0c70f-97aa-40a3-becf-6019d88a3528">
        <rdfs:label>SGCA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6442</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16586</ddiem:uniprotId>
    <rdfs:label>sarcoglycan alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a6ca925d-c8d1-4c45-8d07-0fb87843da7d">
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <rdfs:label>guanosine 5'-diphosphate (GDP)-fucose transporter</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/bb6bfbb2-7cfa-4c3c-a668-27b779339c3e"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e630c96f-7bbd-4ab0-a13d-829d931cb7ad">
    <ddiem:uniprotId>P00813</ddiem:uniprotId>
    <rdfs:label>Adenosine deaminase</rdfs:label>
    <ddiem:ecNumber>3.5.4.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K01488</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fb722ecc-3c64-40cd-a1b6-ce36c1731adc">
        <rdfs:label>ADA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/100</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d3d133c2-4ca3-4af9-a9a2-49bbbece57ec">
    <rdfs:label>Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)</rdfs:label>
    <ddiem:keggEntryId>K01196</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/62cb75b1-c5a1-436c-9ec8-1f17c1ecd968">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/178</dc:identifier>
        <rdfs:label>AGL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P35573</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.25; 3.2.1.33</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f0195940-2d38-4303-ab3c-5d1c303b63b2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba4521c3-51da-4121-81f2-1b0d5915e0bb">
        <rdfs:label>APRT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/353</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Adenine phosphoribosyltransferase</rdfs:label>
    <ddiem:ecNumber>2.4.2.7</ddiem:ecNumber>
    <ddiem:uniprotId>P07741</ddiem:uniprotId>
    <ddiem:keggEntryId>K00759</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612937">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2b961f6-acb9-4a95-b57e-634c9318cf59">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54344</dc:identifier>
        <rdfs:label>DPM3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612937</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>387</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/387</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/90d91b20-b689-45d9-bb66-7f32801c1d21">
    <ddiem:uniprotId>P00374</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K00287</ddiem:keggEntryId>
    <rdfs:label>Dihydrofolate reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d80eb962-dd0d-4dc6-ac0e-9080423a45c5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1719</dc:identifier>
        <rdfs:label>DHFR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b16f9fe9-f4de-46b4-bcf2-8448e595b678">
    <rdfs:label>argininosuccinate lyase</rdfs:label>
    <ddiem:uniprotId>P04424</ddiem:uniprotId>
    <ddiem:ecNumber>4.3.2.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b6abc536-8276-4a60-836a-d1e66b18d096">
        <rdfs:label>ASL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/435</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01755</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba1bcbb7-ed36-4199-9975-7e24386f84c5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602485">
        <ddiem:iembaseAccessionNumber>1289</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/410bed4b-d403-4ac7-8867-94c19af796e2"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1289</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602485</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0003304>W99L</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/334b6661-4a81-48a6-8c93-fdb7f04c8f9a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/033bc881-e7d2-45ef-85f7-cf902d5c8144">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d57b3b9f-bd3c-41b4-9ede-ebc83635bab8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/006340d1-713a-4add-9146-42ba4a1c2434"/>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aaa9ea98-c5b4-42b0-a6b9-b8d13fecb3b7">
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <rdfs:label>alpha-L-iduronidase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0b8c1fd4-df81-44b5-a497-03cfc2225b81"/>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7697a43e-0402-426d-8057-1daeac68a19f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff279d44-3012-4245-b9bc-190557833a02">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Elevated Hepatic transaminases</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1dc72fe7-f705-441b-819a-71af064e2d22"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232700">
        <dc:identifier>https://www.omim.org/entry/232700</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/490</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE VI; GSD6</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>490</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dd2cdcc7-3960-4f32-8746-1f863b401fe4"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d25b5d52-4979-424f-97ba-750bf314cbf2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b698178c-3bd0-4865-a223-510dfcd24319">
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4ec8fccb-2a3c-4155-bec9-ff4f9a186750"/>
    <rdfs:label>Prosaposin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/259ea9dc-1739-450e-a0fe-ba83a0205337">
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/70e21725-088a-4672-9be2-2850fe9ac9fb"/>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <rdfs:label>UDP glucuronosyltransferase family 1 member A1</rdfs:label>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5abb025e-9dff-4b0c-87b6-ef23a260a34b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/505fe7c9-fc9a-4ed8-a04b-e24c4bdd9ff9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79783</dc:identifier>
        <rdfs:label>SUGCT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18703</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9HAC7</ddiem:uniprotId>
    <rdfs:label>succinate-hydroxymethylglutarate coA-transferase</rdfs:label>
    <ddiem:ecNumber>2.8.3.13</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7d1c5dcf-54f6-41c4-8e6a-38728b542083">
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6555c4ea-7367-4031-a014-333ccf23068d"/>
    <rdfs:label>Methylenetetrahydrofolate reductase</rdfs:label>
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9a836a30-329e-4dde-8de6-6c230c83ba54">
    <rdfs:label>3-beta-hydroxysteroid-delta-5-desaturase</rdfs:label>
    <ddiem:keggEntryId>K00227</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a5f455f9-8dc8-4f43-aaae-864db7968c31">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6309</dc:identifier>
        <rdfs:label>SC5D</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O75845</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.19.20</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/28dc8618-98c5-4408-9716-7a3527b2fab9">
    <ddiem:uniprotId>P00439</ddiem:uniprotId>
    <rdfs:label>PHENYLALANINE HYDROXYLASE</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d139edfa-125e-488e-bddf-438c1ace9444">
        <rdfs:label>PAH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5053</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00500</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.16.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616896">
    <dc:identifier>https://www.omim.org/entry/616896</dc:identifier>
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/627c2f6e-e686-473e-a12c-fceeaa186a51"/>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611881">
    <ddiem:iembaseAccessionNumber>500</ddiem:iembaseAccessionNumber>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XII; GSD12</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/500</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/611881</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/107cd3f5-fc78-4d74-a615-9d03ac1e1786"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b13f6542-4466-44ea-835c-bf52034c1fac">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3956412c-2db3-4dc2-919a-d269c4aea4fd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7036</dc:identifier>
        <rdfs:label>TFR2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>transferrin receptor 2</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UP52</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0c7d6d46-67c6-4782-a056-435c9214fcdf">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16857760</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611283">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/135</ddiem:iembaseUrl>
        <rdfs:label>ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD</rdfs:label>
        <ddiem:iembaseAccessionNumber>135</ddiem:iembaseAccessionNumber>
        <rdfs:comment>It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8f30a9f0-ed26-47dc-90aa-149c31c810a0"/>
        <dc:identifier>https://www.omim.org/entry/611283</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2b49132-6488-42f4-b9fe-0ac7366c373c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <dc:identifier>HP:0001507</dc:identifier>
        <rdfs:label>Growth abnormality</rdfs:label>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/55e94832-571b-4475-9aea-947b74f60c3f">
    <ddiem:keggEntryId>K04995</ddiem:keggEntryId>
    <ddiem:uniprotId>P48048</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/95bd3945-376d-474a-a473-244df4b4d7bf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3758</dc:identifier>
        <rdfs:label>KCNJ1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ATP-sensitive inward rectifier potassium channel 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/88d28f51-f016-4253-acb9-b0eed21d8b37">
    <ddiem:uniprotId>Q3T906</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/78d38e44-0b80-4055-a449-6a813450a5be"/>
    <ddiem:ecNumber>2.7.8.17</ddiem:ecNumber>
    <rdfs:label>(α) &amp;(β)GlcNAc-1-phosphotransferas</rdfs:label>
    <ddiem:keggEntryId>K08239</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cf893d97-5335-4762-86ce-19ecc8f44d3a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d840f6f9-121b-4019-b4bf-a43067fa1c60">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2746</dc:identifier>
        <rdfs:label>GLUD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P00367</ddiem:uniprotId>
    <ddiem:ecNumber>1.4.1.3</ddiem:ecNumber>
    <ddiem:keggEntryId>K00261</ddiem:keggEntryId>
    <rdfs:label>Glutamate dehydrogenase, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/35debb92-ed78-423b-8b7e-2c9dbf7dc8f9">
    <rdfs:label>solute carrier family 17 member 5</rdfs:label>
    <ddiem:keggEntryId>K12301</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9NRA2</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2445f697-eec9-4fff-848a-44629c65ba06">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/26503</dc:identifier>
        <rdfs:label>SLC17A5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/40b66ec2-2c6d-467d-a828-771da92c340c">
    <ddiem:keggEntryId>K00166</ddiem:keggEntryId>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <ddiem:uniprotId>P12694</ddiem:uniprotId>
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d41e520c-8d6e-439c-88d7-0a8444963e0b">
        <rdfs:label>BCKDHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/77eb63ac-2733-4fbc-aa43-4a9e875156f5">
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <rdfs:label>Chloride channel protein ClC-Kb</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/04dc1b76-9b6e-49a5-af50-1f023539c7fe"/>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b0477a67-35b2-435d-a129-3b18e28ed9e7">
    <ddiem:uniprotId>Q02318</ddiem:uniprotId>
    <ddiem:keggEntryId>K00488</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.15.15</ddiem:ecNumber>
    <rdfs:label>Cholestanetriol 26-monooxygenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b2bdd40d-6b44-4e8f-a573-088490178fa4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1593</dc:identifier>
        <rdfs:label>CYP27A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0a422b00-d0e3-47e5-80a4-00c2bc74a806">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/80a4a40c-a8ce-4181-819d-bbe0309b2e45">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1244</dc:identifier>
        <rdfs:label>ABCC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05666</ddiem:keggEntryId>
    <ddiem:uniprotId>Q92887</ddiem:uniprotId>
    <ddiem:ecNumber>7.6.2.2</ddiem:ecNumber>
    <rdfs:label>Multidrug resistance protein-2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/440ba12d-59a6-49b4-96c4-95879cd27499">
    <ddiem:ecNumber>2.7.1.21</ddiem:ecNumber>
    <ddiem:uniprotId>O00142</ddiem:uniprotId>
    <ddiem:keggEntryId>K00857</ddiem:keggEntryId>
    <rdfs:label>Thymidine kinase 2, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/43932e7d-9a44-4650-9eeb-5c4db9354704">
        <rdfs:label>TK2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7084</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c34c1201-6c0f-4eb4-a3a6-13afb3d69b9b">
    <ddiem:uniprotId>O60931</ddiem:uniprotId>
    <ddiem:keggEntryId>K12386</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ebb0f727-b587-481a-a075-d124564c9831">
        <rdfs:label>CTNS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1497</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cystinosin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8fe2a2e0-694e-41bd-9388-e6e664d84be6">
    <rdfs:label>leucine-rich pentatricopeptide repeat-containing protein</rdfs:label>
    <ddiem:keggEntryId>K17964</ddiem:keggEntryId>
    <ddiem:uniprotId>P42704</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/06153792-4b74-48fe-9323-ddd06c321ccc">
        <rdfs:label>LRPPRC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10128</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/72aeccff-1d67-4506-aac3-c896de1c4397">
    <ddiem:keggEntryId>K09659</ddiem:keggEntryId>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 3</rdfs:label>
    <ddiem:uniprotId>Q9P2X0</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e2b961f6-acb9-4a95-b57e-634c9318cf59"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/242600">
    <rdfs:label>IMINOGLYCINURIA</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/798</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8701a715-6567-4ec5-9f62-aa275ae960dc"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/56315906-74e4-487f-9a25-3520e16ea2ee"/>
    <dc:identifier>https://www.omim.org/entry/242600</dc:identifier>
    <ddiem:iembaseAccessionNumber>798</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/19083008-7bf6-40b4-9d48-77071fa55b0d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d349738a-8804-4023-be1c-8909f9497c33">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6833</dc:identifier>
        <rdfs:label>ABCC8</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ATP binding cassette subfamily C member 8</rdfs:label>
    <ddiem:uniprotId>Q09428</ddiem:uniprotId>
    <ddiem:keggEntryId>K05032</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8a8bc717-6174-4902-8158-1bb73f8dc101">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7a7c96dd-d2cf-44ad-819c-ca0c50844862">
        <rdfs:label>MMADHC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27249</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type D protein, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q9H3L0</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/procedure_to_mitigate_dominant_effects_of_a_genetically_abnormal_protein">
    <obo:IAO_0000115>a procedure to suppress or mitigate the effects of a dominant alteration in a genetically abnormal protein by reducing or suppressing  transcription or translation of the abnormal protein gene or rna, or destabilising or otherwise inhibiting an abnormally increased activity or neoactivity of the abnormal protein.</obo:IAO_0000115>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <dc:date>4.10.19</dc:date>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e9cd456d-c053-4048-b3ea-36e20ec197da">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c2da5b56-c237-437e-82dd-b4e2450c0119">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6513</dc:identifier>
        <rdfs:label>SLC2A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07299</ddiem:keggEntryId>
    <rdfs:label>glucose transporter protein type 1 (GLUT1)</rdfs:label>
    <ddiem:uniprotId>P11166</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/50e05ff6-98c9-48ad-8ec5-50176f246888">
    <ddiem:uniprotId>P51570</ddiem:uniprotId>
    <rdfs:label>galactokinase 1</rdfs:label>
    <ddiem:ecNumber>2.7.1.6</ddiem:ecNumber>
    <ddiem:keggEntryId>K00849</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0b102994-c333-4d51-ad40-64bd2328854c">
        <rdfs:label>GALK1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2584</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3539b46a-d6a4-43c3-83ec-c2ecc6a4bcbf">
    <ddiem:keggEntryId>K10352</ddiem:keggEntryId>
    <rdfs:label>myosin heavy chain 2</rdfs:label>
    <ddiem:uniprotId>Q9UKX2</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f6bb1f8c-b076-4ce9-909b-eb6765f9b1e0"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4e44ca4d-431a-4e76-8415-33ea8120cdf4">
    <rdfs:label>a-L-fucosidase</rdfs:label>
    <ddiem:keggEntryId>K01206</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.51</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/25b6ec43-4cde-4f04-bde1-f2f0649b43c6">
        <rdfs:label>FUCA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2517</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04066</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b8eaf6fd-f6e4-461b-a723-eb19cdde8043">
    <ddiem:ecNumber>2.4.1.313</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/774dd6ca-1f70-471a-8b5a-4f6e55e3a3ed">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148789</dc:identifier>
        <rdfs:label>B3GALNT2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8NCR0</ddiem:uniprotId>
    <rdfs:label>UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2</rdfs:label>
    <ddiem:keggEntryId>K09654</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7969da5e-1a54-4928-8f27-4d59eab3539b">
    <ddiem:uniprotId>Q92947</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.8.6</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/14a57dcf-8fb4-4231-a3ca-617cc67229ae">
        <rdfs:label>GCDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2639</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00252</ddiem:keggEntryId>
    <rdfs:label>glutaryl-CoA dehydrogenase, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2b8e679f-295b-4c53-8e5d-f6687628a791">
    <rdfs:label>Phospholipid-transporting ATPase ABCA1</rdfs:label>
    <ddiem:keggEntryId>K05641</ddiem:keggEntryId>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
    <ddiem:uniprotId>O95477</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8d1dc40a-6273-43d1-bfde-9b69bce5a8af">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/19</dc:identifier>
        <rdfs:label>ABCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7cfce819-88aa-4a95-828d-c6ec6a893832">
    <rdfs:label>HMG-CoA lyase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/656c5966-c6cc-4034-a0ee-63c9d2e88ee9">
        <rdfs:label>HMGCL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3155</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.3.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K01640</ddiem:keggEntryId>
    <ddiem:uniprotId>P35914</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5e18e1d2-7147-4f12-9c7b-9c38da64e209">
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <rdfs:label>Alkaline phosphatase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/32182380-a2be-4223-860c-38f61a119062"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/352e590a-974f-43fa-8a66-53c626da5248">
    <rdfs:label>Mannose-6-phosphate isomerase</rdfs:label>
    <ddiem:uniprotId>P34949</ddiem:uniprotId>
    <ddiem:keggEntryId>K01809</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/554bdbcc-d8dc-4ee3-8e42-6d53f76b9a9d">
        <rdfs:label>MPI</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4351</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>5.3.1.8</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/36d51711-d3e3-4bde-a135-ba5c6d9d50e8">
    <ddiem:keggEntryId>K13649</ddiem:keggEntryId>
    <ddiem:uniprotId>P15328</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1b444430-2ae5-4edb-bee1-7ae52d8f7be2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2348</dc:identifier>
        <rdfs:label>FOLR1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Folate receptor alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ce7b1e62-fb9a-4545-b579-1c00c31464df">
    <ddiem:uniprotId>P32754</ddiem:uniprotId>
    <ddiem:ecNumber>1.13.11.27</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6f9d6060-ffff-49a0-9aff-2d7cac6101df">
        <rdfs:label>HPD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3242</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>4-hydroxyphenylpyruvate dioxygenase</rdfs:label>
    <ddiem:keggEntryId>K00457</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aaefcc9f-a059-4e5e-840d-a6229dca75ea">
    <ddiem:keggEntryId>K19480</ddiem:keggEntryId>
    <rdfs:label>anoctamin 5</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1e93208f-b805-45a7-b916-baa7975d7899">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/203859</dc:identifier>
        <rdfs:label>ANO5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q75V66</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f983233e-8fcd-4b25-a6f7-3caf204407e0">
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
    <rdfs:label>3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE</rdfs:label>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a547561a-25ca-4d4a-962c-5856d48f5bde"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7e067c97-d9f5-4d8c-ba5f-5b84577c688f">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/4461613d-26ac-4053-8910-4b1c8e59299b"/>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <rdfs:label>Apolipoprotein A-V</rdfs:label>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/57b36b5d-3552-4b69-8b97-e51b229463b2">
    <ddiem:keggEntryId>K00789</ddiem:keggEntryId>
    <ddiem:uniprotId>Q00266</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ab4e16cf-cbe4-4f63-8f91-57a5abf7810a">
        <rdfs:label>MAT1A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4143</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.5.1.6</ddiem:ecNumber>
    <rdfs:label>S-adenosylmethionine synthase isoform type-1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b6597210-f92c-4fdd-8998-4938891d1e15">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6acf3d17-a024-4398-8929-7fe2ed727e8e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>GIF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>gastric intrinsic factor</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c8097ae3-3728-4d19-bd74-dcfc386a49fa">
    <rdfs:label>guanine nucleotide-binding protein (Gα11)</rdfs:label>
    <ddiem:keggEntryId>K04635</ddiem:keggEntryId>
    <ddiem:uniprotId>P29992</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d73402a5-a661-43ee-ab46-d0c6de58565a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2767</dc:identifier>
        <rdfs:label>GNA11</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3306e9eb-c417-4243-beeb-61a4e6d4b988">
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8e73758c-2d95-469d-8b0b-c36fd2dd6e4d"/>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <rdfs:label>D-2-hydroxyglutarate dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0810d5e1-5e17-424f-8fde-88662027c4e9">
    <rdfs:label>Phosphorylase b kinase regulatory subunit beta</rdfs:label>
    <ddiem:uniprotId>Q93100</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/44a62397-5fe5-4c00-a6b2-fbba26670891">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5257</dc:identifier>
        <rdfs:label>PHKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d4a07b0a-825d-419d-acad-a29df245dfb2">
    <ddiem:keggEntryId>K05242</ddiem:keggEntryId>
    <rdfs:label>Hormone ( Arginine vasopressin)</rdfs:label>
    <ddiem:uniprotId>P01185</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9a138cac-2536-42d4-9e9d-26b25143b068">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/551</dc:identifier>
        <rdfs:label>AVP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/179850">
    <dc:identifier>https://www.omim.org/entry/179850</dc:identifier>
    <rdfs:label>DOWLING-DEGOS DISEASE 1; DDD1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e977e5a9-b644-48a0-83e3-03fd897476c1"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0b293576-42ac-42a1-9d5d-5658050f31f9">
    <rdfs:label>Y+L amino acid transporter 1</rdfs:label>
    <ddiem:uniprotId>Q9UM01</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c1cad92a-0df8-4623-a30c-24bcd18d762f">
        <rdfs:label>SLC7A7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9056</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13867</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230200">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>474</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/230200</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0b102994-c333-4d51-ad40-64bd2328854c"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/474</ddiem:iembaseUrl>
    <rdfs:label>GALACTOKINASE DEFICIENCY</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608799">
    <ddiem:iembaseAccessionNumber>336</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/336</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/608799</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f16bbf46-0981-43bf-8e51-ba2fb92e8ddf"/>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d1fc0c9d-433e-4a58-a0b6-59e06331ca03">
    <rdfs:label>Phosphatidylinositol N-acetylglucosaminyltransferase subunit A</rdfs:label>
    <ddiem:uniprotId>P37287</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/50060d00-4d39-4fd7-a0a7-e0ce03002b47"/>
    <ddiem:keggEntryId>K03857</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.198</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3dbf68b5-08c5-4bbd-99f7-ae833b01cffe">
    <ddiem:keggEntryId>K00948</ddiem:keggEntryId>
    <rdfs:label>Ribose-phosphate diphosphokinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e0dbfb80-6c70-44e4-b7bf-086e8e3957bd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5631</dc:identifier>
        <rdfs:label>PRPS1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P60891</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.6.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/62dbd08f-aeb3-4977-b9d7-8b82a0dc6fba">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/327fe6b2-6c85-4e45-a2ca-8ff094d8df8c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8291</dc:identifier>
        <rdfs:label>DYSF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dysferlin</rdfs:label>
    <ddiem:uniprotId>O75923</ddiem:uniprotId>
    <ddiem:keggEntryId>K18261</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d42ef666-30bc-48ac-9fe1-70acc2ad293f">
    <rdfs:label>NPC intracellular cholesterol transporter 1</rdfs:label>
    <ddiem:uniprotId>O15118</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d2f5995f-24d6-47b1-8236-91db6782bfb1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4864</dc:identifier>
        <rdfs:label>NPC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12385</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611307">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/611307</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1e93208f-b805-45a7-b916-baa7975d7899"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/da9957f0-13c7-473d-b35d-f9de5b28bbc2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7e2e7307-a3a6-4005-a577-31d7f6383407">
        <rdfs:label>PYGM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5837</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <ddiem:uniprotId>P11217</ddiem:uniprotId>
    <rdfs:label>Glycogen phosphorylase, Muscle form</rdfs:label>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b9496bfa-419f-48a8-8886-0e1f94bb6b97">
    <ddiem:ecNumber>1.16.1.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K00597</ddiem:keggEntryId>
    <rdfs:label>Methionine synthase reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ad873cfc-4504-45d6-b73f-1d633d5ba146">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4552</dc:identifier>
        <rdfs:label>MTRR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UBK8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bf11d296-5ecf-48ee-a5a0-b0377ba3d4df">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2156448a-9a49-420d-ab59-dfec8fa46250">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2752</dc:identifier>
        <rdfs:label>GLUL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P15104</ddiem:uniprotId>
    <rdfs:label>Glutamine synthetase</rdfs:label>
    <ddiem:keggEntryId>K01915</ddiem:keggEntryId>
    <ddiem:ecNumber>6.3.1.2; 2.3.1.225</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/815e15d9-526d-4f88-9191-a581f34c4e86">
    <ddiem:uniprotId>Q9Y276</ddiem:uniprotId>
    <rdfs:label>ubiquinol-cytochrome c reductase complex chaperone</rdfs:label>
    <ddiem:keggEntryId>K08900</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/46a724ac-023a-435f-b6f8-2214139913a2">
        <rdfs:label>BCS1L</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/617</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b76850fe-80b7-4dbb-9ccb-6877692a3e63">
    <ddiem:keggEntryId>K14463</ddiem:keggEntryId>
    <rdfs:label>microsomal triglyceride transfer protein</rdfs:label>
    <ddiem:uniprotId>P55157</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/55a149b2-645b-40c9-9414-6a2616b2ebed">
        <rdfs:label>MTTP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4547</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aa66c023-e150-4dea-a64a-90bb27d2b3ce">
    <rdfs:label>extracellular matrix protein 1</rdfs:label>
    <ddiem:uniprotId>Q16610</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d6e3b98e-a7f5-418f-9f85-6174b0fc8576">
        <rdfs:label>ECM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1893</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:Ontology rdf:about="http://purl.obolibrary.org/obo/">
    <owl:imports rdf:resource="https://raw.githubusercontent.com/OGMS/ogms/v2019-04-30/src/ontology/ogms.owl"/>
  </owl:Ontology>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ccc32f43-5d39-45e7-9b08-bab51516f3ec">
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <rdfs:label>DNA polymerase subunit gamma-2</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/00dace53-b78b-45e5-9b17-48727d09a210"/>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000115"/>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_genome_editing">
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by genome editing</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115 xml:lang="en">Modulation of the activity or stability of a genetically defective gene through direct modification of one or both endogenous alleles of the gene, using genome editing techniques such as CRISPR/Cas</obo:IAO_0000115>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f64c29ba-30c7-474b-b27a-2e2ad8a0970b">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9d2c1d82-620d-49e8-9e00-bfa1ffde8715"/>
    <ddiem:uniprotId>P48775</ddiem:uniprotId>
    <ddiem:ecNumber>1.13.11.11</ddiem:ecNumber>
    <rdfs:label>tryptophan 2,3-dioxygenase</rdfs:label>
    <ddiem:keggEntryId>K00453</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f49a3a1a-3b53-4777-a0c7-bdb9707949f3">
    <dc:identifier>DB00159</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00159</ddiem:url>
    <rdfs:label>Icosapent</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b431d121-9774-49c7-8be5-dbc4def8ecc3">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd769ffd-f890-47dd-a883-ff28a825257a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfaca255-b768-41ba-b14b-47928f08109e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5afcfa-4bc1-4c74-afea-b6ada175c895"/>
        <rdfs:comment>Poor compliance to the treatment was noticed</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/33bc7e1a-c38a-4f6d-a1b6-1afe4d19c4a6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/047567d0-5bda-44c4-adff-efe264d274b4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8be47966-1bac-4db2-9c3d-cf7233b5370a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e3ce9c6-96a3-4e98-a8af-f97f89c40c71">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
        <dc:identifier>HP:0003198</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19891905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a5a60b4-79e1-4ab6-8d99-ad04c6c121a9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0200125</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
        <rdfs:label>Mitochondrial respiratory chain defects</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/530000">
        <ddiem:iembaseAccessionNumber>398</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/398</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4ec8fccb-2a3c-4155-bec9-ff4f9a186750"/>
        <rdfs:label>KEARNS-SAYRE SYNDROME; KSS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/530000</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37ca99dd-4927-4b2d-bbdf-b8aebd404967">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010444</ddiem:url>
    <rdfs:label>pulmonary regurgitation</rdfs:label>
    <dc:identifier>HP:0010444</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f0670b81-a688-43f6-8f4e-a5348037d5eb">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf856a0f-c374-4ebf-a3bc-60e7331a0779">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00734</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7cb34be1-8c51-40e9-a09e-82606365fa37"/>
        <rdfs:label>Risperidone</rdfs:label>
        <dc:identifier>DB00734</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aeb89235-5ed0-438a-ba09-8396dcf286e0"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1710cb8c-c69c-403e-96da-cd88af6a1416">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002333</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0002333</dc:identifier>
    <rdfs:label>Abnormal neuromotor function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f8ff6c6-0ad3-4dcf-9c7a-7df1f8021f77">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7438ce79-c9e3-4155-bd3a-62990050e475">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040063</ddiem:url>
        <dc:identifier>HP:0040063</dc:identifier>
        <rdfs:label>Decreased adipose tissue</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23543666</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03234e09-ed6a-4647-9f02-72d32caea53f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38a203bf-ab58-4ad5-9697-77b6f3a39517">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002653</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0002653</dc:identifier>
        <rdfs:label>Bone pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53b6b2db-5980-4cad-ba3d-6a1c519310bd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low quality of life ( Constitutional symptom)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01ca16d7-8265-4391-8cc7-c828b9ce70f7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:label>disease control rate(  Rapid disease progression)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6922939d-ae18-44a0-b90f-a1901c8a8111">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short Progression-free survival</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22665903</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00514046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20371662</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22025146</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cfff282-1c7e-434d-a7a2-9ebc4c85a5cb">
        <rdfs:label>Elevated calcitonin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003528</ddiem:url>
        <dc:identifier>HP:0003528</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c21a9104-91ce-4d87-af53-ea38a97f3c75">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Objective response rate (ORR)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>M918T</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/742fea86-e860-40c7-94ef-0ea4c1c833bf">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003199</ddiem:url>
        <rdfs:label>Low skeletal muscle mass</rdfs:label>
        <dc:identifier>HP:0003199</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27650489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23766359</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9ec2b24-604f-4569-a702-cb87bab6703c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012531</dc:identifier>
        <rdfs:label>Pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c54ad1d-9801-4908-b240-fb9b7ab7dd69">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031029</ddiem:url>
        <rdfs:label>Increased plasma CEA</rdfs:label>
        <dc:identifier>HP:0031029</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bd5fea8-0474-4aac-bd8f-7c65cc66539d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001824</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Weight loss</rdfs:label>
        <dc:identifier>HP:0001824</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e511aab5-2354-416f-b713-ce1725c48bdf">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06039f73-b3d7-48b5-93d5-6b00b8bb8d67">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031375</ddiem:url>
        <rdfs:label>Refractory Arthritis</rdfs:label>
        <dc:identifier>HP:0031375</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22658375</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19289295</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/212d8a7c-7362-4f81-964e-232081f0d116">
        <rdfs:label>Recurrent repisode of flares (Recurrent)*</rdfs:label>
        <dc:identifier>HP:0025303</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025303</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22341584</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7413b36-70b7-43f9-ab63-d4269033def2">
        <dc:identifier>HP:0001369</dc:identifier>
        <rdfs:label>Arthritis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118600">
        <rdfs:label>CHONDROCALCINOSIS 2; CCAL2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/118600</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3120dca5-a013-4e1c-8c8d-1bedbe9e1a5c"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c84c4ab8-d2ee-4af5-a0fd-36192f4e3035">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4cc70fa-629a-43c6-8f50-8f103139579e"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1d6ae3a2-74ca-4b53-9a9b-81f5af923800"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a280745f-2cfc-4571-ab55-0a9b7e720b11">
        <rdfs:label>Synovitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100769</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100769</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59b54556-33c6-457d-a4d7-16bffeff71dd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4b0ba7-0654-4cd1-a6df-644af85ccee6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a9091dc-a37f-4e24-b74d-c07a44ae5ef6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012335</ddiem:url>
        <rdfs:label>abnormal folate homeostasis in the CNS</rdfs:label>
        <dc:identifier>HP:0012335</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe76e298-2237-4c72-bbef-65b65ff96504">
        <dc:identifier>HP:0012446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>depletion of cerebral folate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/233910">
        <ddiem:iembaseAccessionNumber>3</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/3</ddiem:iembaseUrl>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb3721c7-e100-4eb3-82a0-5a09841510ed"/>
        <dc:identifier>https://www.omim.org/entry/233910</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21c18d11-e70b-4dcc-8357-747d1814a2af">
    <dc:identifier>DB03147</dc:identifier>
    <rdfs:label>Flavin adenine dinucleotide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03147</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2fda526e-814e-4afe-97de-0181ee678b14">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7705cf09-ef71-4d71-821f-02567e2be87f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b249562c-530a-4dd4-8d59-c1c777dfd069"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
        <dc:provenance>https://n.neurology.org/content/70/13/1051</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e6a3394-2968-4fce-9964-01d85cf8d21b"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08ade565-e136-435b-94fd-9efecffe4e94"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18362286</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/087fd8a8-711c-4ff0-b94c-2577485a933c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8bd86f50-3250-47f1-ac26-0a0a9d5656e5"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c6c963b-2bff-4545-80fa-19976d8995cd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08860</ddiem:url>
    <rdfs:label>Pitavastatin</rdfs:label>
    <dc:identifier>DB08860</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/679b1b60-2f1b-4cc9-8260-0b98ad6cbabc">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e2787bb-2d69-4fe8-bfc8-7621bfa87b56"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
        <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99400896-2303-4d11-a1a8-334d0fe79dd6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/12eec389-bb30-4a74-88b5-f8d71c41c2c1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1a0effa-2dc5-4dfb-b323-d49a5165f72a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal walking distance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c678c229-1955-4830-bb11-cd4df3ff1d80">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012514</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012514</ddiem:url>
        <rdfs:label>Lower limb pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1acbe2ec-fbe2-497c-96ea-713b531c85ad">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011023</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011023</dc:identifier>
        <rdfs:label>Abnormal prostaglandin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16803637</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10574582</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b07909e-8b29-4fe6-ba0f-e3a3f345a96f"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/561</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/32182380-a2be-4223-860c-38f61a119062"/>
        <ddiem:iembaseAccessionNumber>561</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOPHOSPHATASIA, INFANTILE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/241500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f17dd4f4-1a56-444b-8704-8e92c9daa6ba">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a26b6774-041f-4886-b801-26108936435c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8938747b-f028-46b9-8b0e-057a6a48f528"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/901044b3-3627-4005-8e45-796a464963f3">
    <rdfs:label>progressive leukodystrophy</rdfs:label>
    <dc:identifier>HP:0002415</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83badaeb-1c5c-4a4d-8075-8cc91f2d0b70">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Acidemia</rdfs:label>
    <dc:identifier>HP:0001941</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b4958bde-45b3-498e-a7c4-e2d36c7c5e9e">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23772144</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/63ac8e86-ebed-4dc1-846b-c25d35c43e3a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e3377d0e-77f3-4d17-8663-6be82deb2a36"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a130ba5-9c52-47d8-a6b8-e65e969b3c22">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected ClC-Kb expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0003304>W610X</obo:RO_0003304>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4bff6752-89bd-4fa8-bd07-3ef2579c794f">
    <rdfs:label>Prednisolone</rdfs:label>
    <dc:identifier>DB00860</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/741bc2ee-75a2-4b5a-b139-7d5dd9e9a7a7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
        <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9870afa7-3c0e-4f24-a0fa-0d5265cbfbb2"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0750ccbc-b2a8-4b58-a000-aaa003d79ff6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/921733</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/328323dd-97c5-4fdd-a03a-4c7cc7bea68d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/33230b8b-a5a7-45e6-a1de-044fec419155"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c2db1c3-de24-41e0-9113-6d9938f02d12"/>
        <obo:RO_0003304>compound V377I and I126T mutations</obo:RO_0003304>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/56513bf6-6130-4ae0-b5e5-7a470380f7c8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9870afa7-3c0e-4f24-a0fa-0d5265cbfbb2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18839211</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/71d03073-07b6-481d-8f6f-e2be1dbf90e4">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b07909e-8b29-4fe6-ba0f-e3a3f345a96f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1592654-e867-4f54-a297-6f6c7245dbea"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/287077a0-645c-4c1e-804c-ed361a97a4d2"/>
        <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607155"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28931339</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/868344ce-660a-4774-b6b3-11e17672736f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334834</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07f368e3-ffb6-4e99-bce4-f82ca4a1d3e7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4f3cacc-4e2d-496b-be7a-3153ffaa73c7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9870afa7-3c0e-4f24-a0fa-0d5265cbfbb2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23817215</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25048216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28480302</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67cc6fe4-a599-4eb7-aed2-dacf0341e63e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28107841</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17446099</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00860</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9e4b5c19-9b0e-4e44-842a-b29588ed9b82">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10055238-a111-4f80-8bcd-a044f42bd247">
        <rdfs:label>Abnormal aPTT level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003645</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24499211</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28617415</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c56d7b9-7b61-4fa2-ad17-9dfe0a1ec215">
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>abnormal aspartate transaminase</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14c86b0d-582b-498e-9913-87e36646b71f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001976</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
        <rdfs:label>Abnormal Antithrombin-III levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff6ad3d5-7ef4-436b-886a-7de76c6343f2">
        <rdfs:label>Abnormal AST level (Abnormal liver enzymes)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c170faa2-65c3-433f-9d72-fd27bc405d2f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
        <rdfs:label>abnormal activated partial thromboplastin time</rdfs:label>
        <dc:identifier>HP:0003645</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1b7a3f3-b9a1-43d3-ac82-38bcae1e4bd1">
        <rdfs:label>abnormal Antithrombin-III levels</rdfs:label>
        <dc:identifier>HP:0001976</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84432cf3-b7ca-4ba5-be63-2602dc7d1add">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"abnormal alanine transaminase,"</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9278b8f4-56d1-4826-a3de-1cf2c8573d10">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>Abnormal ALT level(Abnormal liver enzymes)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614921">
        <dc:identifier>https://www.omim.org/entry/614921</dc:identifier>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/600</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>600</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2049ed65-0418-453a-9225-8c2b2e74bd1e"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c12a627-e822-4099-affe-497aa1e72345">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal nucleotide sugars</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d3635cd1-3b91-412b-9c97-5603c1165159">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/935c1f4c-9aa0-4ec9-9714-563835f634c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab64781c-b21a-4d9e-9116-a602c8c5a8e3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e547bea8-dcae-4614-8715-acde4386ab30">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:label>Abnormal liver function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3ef1281-9a00-46e2-8d22-b8fab8378462"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/218e4b21-bec7-48e1-9a48-8095940ce512">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hepatomegaly</rdfs:label>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/466140af-74f4-4cec-9794-4e78f6dd5933">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal liver function</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28697823</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42aab52a-c496-446b-bc78-3278c6faba65">
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>Hepatomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a3735385-5c90-4da4-8a2a-242b6f50e72f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28895280</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3be4f51b-47ad-482c-831b-07977a9d3143">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Decreased hemoglobin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45481ba3-00d4-486e-b32b-a94255df9c61">
        <rdfs:label>High ferritin level</rdfs:label>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2c23ba08-b860-441f-a62c-659007c2c1e6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d11c0c4d-2578-4982-87d8-1298f95304ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/209300">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/206</ddiem:iembaseUrl>
        <rdfs:label>ATRANSFERRINEMIA</rdfs:label>
        <ddiem:iembaseAccessionNumber>206</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/209300</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/84e5beca-fdee-46a4-a9d4-6b6a971627ad"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <rdfs:comment>Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. "Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aae06e95-846b-45e0-b376-f0c4d77d437d">
    <rdfs:label>Voluntary movement abnormalities(Abnormality of movement)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <dc:identifier>HP:0100022*</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e6a3394-2968-4fce-9964-01d85cf8d21b">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040144</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
    <rdfs:label>L-2-hydroxyglutaric aciduria</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/74c351c6-099e-4925-b48e-d2eacbedfca1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94e0ed61-4a09-42b0-a052-4505bc92ec8b">
        <rdfs:label>Purkinji cells apoptosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0000880</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0000880</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f03f9ea-bc04-4d9b-af38-4d79ef3c6f31">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21f44098-1558-4390-835d-eaa247572634">
        <rdfs:label>Neuronal vacuolation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b7d2292-97f4-4407-aa11-368718547d65">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0013438</dc:identifier>
        <rdfs:label>Hypomyelination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013438</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37bec66f-1abc-4437-b6e1-915457bdf9c5">
        <rdfs:label>Microgliosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3f25c65-0c59-46b8-a4a6-910bd0cab252">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
        <rdfs:label>High level of fucosyl-linked oligosaccharide accumulation</rdfs:label>
        <dc:identifier>HP:0100614</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/310e680e-17c6-4a3f-9452-b8f593646283">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42c04718-12ea-449a-abeb-50a20cc0b7e9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59381b9c-e7d1-450f-bcfb-945ed84ebb9a">
        <rdfs:label>Astrocytosis in cerebral cortex</rdfs:label>
        <dc:identifier>HP:0002446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002446</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18b5e2a5-13fe-443b-ae9b-4e70066b6579">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal neurololgical function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21575633</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d59889c-27c3-46e0-8754-7ce882f1a664">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <dc:identifier>HP:0004356*</dc:identifier>
        <rdfs:label>Lysosomal expansion in neurons of deep cortex</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230000">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/230000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/259</ddiem:iembaseUrl>
        <rdfs:label>FUCOSIDOSIS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/25b6ec43-4cde-4f04-bde1-f2f0649b43c6"/>
        <ddiem:iembaseAccessionNumber>259</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03acc2e2-b512-47ab-abb2-dd6949a1a3f4">
        <rdfs:label>Pyramidal neuron loss</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002062</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002062*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/065bf5ed-2064-4e66-98c5-519cc1c6282d">
        <dc:identifier>HP:0100709</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100709</ddiem:url>
        <rdfs:label>Oligodendrocyte loss</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d80c04b-36cf-47b9-a72d-099a2418d77d">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003354</ddiem:url>
        <rdfs:label>Astrocytosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0003354</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fbc44c09-5b70-46e9-8521-0ed03c0837d8">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9b3cf7d3-56e4-4c8b-ad05-a16efa8f9035"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d93a17e-4cf8-465a-a037-a4f5c452a539">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012410</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012410</dc:identifier>
        <rdfs:label>Pure red bllod cell aplasia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2d108acb-5861-4639-a0bb-fcf5c145d8e9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97f97345-0388-4f8a-a86e-69ba4487dc7a"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f1903f8-f9e1-430b-91c9-aa3166a91eb7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001367</ddiem:url>
    <dc:identifier>HP:0001367</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Joint disesae</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0e72615c-5d73-4b6f-ba7c-f3f04ce4a0a7">
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea496222-f361-44cc-aa1a-c4cbef1276b1">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <dc:identifier>HP:0002630</dc:identifier>
        <rdfs:label>Malabsorption of lipid-soluble vitamins (Fat malabsorption)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d67c41b-22e7-4f22-9069-f8901f795625"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/184b9ff4-161b-4554-933e-f33f0aeb55c1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00053</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb7375f4-601c-41fb-8513-ea7ab0efaaf9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0596d554-20c9-4f30-b83c-59dcfe5ae886"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58c9f06f-ece8-4cbf-a31e-e28cb096b106"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c007aac0-f158-4798-8bc1-67e29bea54be"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18d11b93-cb35-4d4a-ad35-2fc2f66f3b0b"/>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c968b70-5bbc-4983-930e-0119a1c5a8ea"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3a535919-b7ad-4dca-bfb6-d9ae4407216e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42aab52a-c496-446b-bc78-3278c6faba65"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee96c974-592a-400f-b348-701e34bb0cb7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT02770625</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00053</dc:identifier>
    <rdfs:label>Imiglucerase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbc26a2d-3d02-4d2c-98ca-7bc81e81cfd4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>atypical psychomotor development</rdfs:label>
    <dc:identifier>HP:0001263*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/925e129a-69f0-4cff-b92c-b63cf2c61533">
    <dc:identifier>S01EC</dc:identifier>
    <rdfs:label>Carbonic anhydrase inhibitors</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/82c47514-475e-4a3d-b462-5b47e8cdc98d">
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8d157187-611f-4162-9ed1-548d7d7f0f6e"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0eded305-f65b-44e1-814f-a90eb2223998"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dd800350-7a11-4d8a-93d8-06bee5bc4c6e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01EC</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a005e20-e819-4769-a8cc-dee51746e2de">
    <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
    <dc:identifier>HP:0003233</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:label>Decreased plasma HDL-c levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0fd09e75-b756-4bba-b4e4-3408e2f1d2d2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8019978b-9d11-4f06-ae45-bbf16809ec40">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ab0b594-0336-49bd-92cf-df1cea291a8c"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ba03807-4438-4c2e-8d29-5c26e666f2ff"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10f49877-1012-4b56-b226-81e3a5eaa8de"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d1903b5d-3a9c-4a7c-8e78-c69fa98596b8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/302060">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/59</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/14f46567-2484-478a-9b49-fa0447d05534"/>
        <rdfs:label>BARTH SYNDROME; BTHS</rdfs:label>
        <ddiem:iembaseAccessionNumber>59</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/302060</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ff05de5-e492-40a3-8c41-3cb6e4b3306a">
        <dc:identifier>HP:0001635</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:label>Heart failure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13a831a7-4594-4cdd-8101-3ba601dab22a">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>neurologic deficits</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb6e4275-647c-4d9d-b4e9-1d38d9ed7d73">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2c61cf0-77f4-4ffb-b7da-3c61c47d4327">
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <rdfs:label>Dermatitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/201100">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9e0193f8-513c-42f4-b8d3-ad3468cc220b"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/202</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>202</ddiem:iembaseAccessionNumber>
        <rdfs:label>ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/201100</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/375935</dc:provenance>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1322eb23-0dbe-486f-b67b-bb40bb965c41">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca10883d-d6bf-43a1-afb8-53a1d0d74373"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30669644</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ef2ce195-7d13-4a57-84ec-e5c4edf44b0c">
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fc0895c-cc0e-4511-ad80-441489b5a827">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>Splenomegaly</rdfs:label>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230800">
        <rdfs:label>GAUCHER DISEASE, TYPE I</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230800</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/288</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8d84618c-2ff1-4a3c-8aee-e89eefc6d4c2"/>
        <ddiem:iembaseAccessionNumber>288</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c968b70-5bbc-4983-930e-0119a1c5a8ea">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:label>thrombocytopenia</rdfs:label>
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22916340</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb8b9af0-de32-4dee-b6fc-2ed062233afd">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>low bone marrow fat fraction value</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27839981</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/060f88fd-e269-40b5-94a9-6da06806127c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1dde6c80-7a90-4241-b9ed-4c28c6b08fa0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42aab52a-c496-446b-bc78-3278c6faba65"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03021941</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/806eca2e-05f9-4bc0-98de-d01c7dc64b1a">
        <rdfs:label>anaemia</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3619e842-2242-42b9-ae94-3d42062cf945">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025547</ddiem:url>
        <dc:identifier>HP:0025547</dc:identifier>
        <rdfs:label>low mean hemoglobin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29388611</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28131618</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01422187</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a27ff32e-347f-4abb-b5ff-ceeab02faa6a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
    <rdfs:label>somnolence</rdfs:label>
    <dc:identifier>HP:0002360</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab44e824-ad62-4810-9439-fc9e6a27b908">
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <rdfs:label>high plasma RAAS activity</rdfs:label>
    <dc:identifier>HP:0000847*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000847</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/76f2cd70-2954-4989-ad8f-1bcfe01e71d4">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9df5f717-c16f-4c10-9cc7-f0c8108d1c3a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/43e592ef-1c4f-49f9-882e-95dae9884a62"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17e4f501-0dde-4d86-8eec-f71b201c8ea0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/04a3bf9c-60dc-45ab-bea4-53f2077a8bd8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53727e42-b864-452a-bb50-3cdcd5b3bff4">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>NO revealed clinical benefit</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004450</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300100">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/280</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/300100</dc:identifier>
        <rdfs:label>ADRENOLEUKODYSTROPHY; ALD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2bcc0495-93fc-4e68-a89e-7838141e72cf"/>
        <ddiem:iembaseAccessionNumber>280</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/daf5dba6-ab76-4899-b05f-c5ecfc7c3b9b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23323877</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/144650">
        <dc:identifier>https://www.omim.org/entry/144650</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1086</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4461613d-26ac-4053-8910-4b1c8e59299b"/>
        <ddiem:iembaseAccessionNumber>1086</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE V</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8771284-0cb6-43be-a7d9-d829e9ffe76b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b9f05af-d412-453c-b18f-2baf7a1fa90c">
        <rdfs:label>High total cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003124</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c33e3708-1198-4aee-9618-bcbd610cf5ee">
        <rdfs:label>High Apoliporprotein B level(Abnormal abpolipoprotein level)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <dc:identifier>HP:0025201*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00473655</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e2787bb-2d69-4fe8-bfc8-7621bfa87b56">
        <rdfs:label>hypertriglyceridemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00007121">
        <dc:identifier>ECO:00007121</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00007121</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99bb7f34-f369-4de4-9740-ff303136f75f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High LDL level</rdfs:label>
        <dc:identifier>HP:0003141</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/db3bac08-c0ad-41ee-ae38-a5b75c764dd8">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fd10946-1343-48a6-9d29-c156af9d2b49">
        <rdfs:label>glomerular damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000095</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0000095*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f61b401d-9504-4f60-845d-0d418c4ad130">
        <rdfs:label>Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0010918*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9758713</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/192e4b03-578a-46b1-ab72-d940b271edd0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>development of extra-renal pathologies ( Progressive disorder)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a211a502-2c81-42f7-99b4-a104f945de37">
        <rdfs:label>Delayed growth</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/97aaa65a-3f9a-407c-9710-a4fb03b0a19f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/428bd512-a1b2-4d39-9fd6-7ab510cf8872">
        <rdfs:label>cystine accumulation in muscle parenchyma</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003358</ddiem:url>
        <dc:identifier>HP:0003358</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4855682f-e390-4480-8830-afb4e6a8b1d4">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>shorter life expectancy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/725cd630-6d36-494d-9307-c4468298008c">
        <rdfs:label>Reduction of WBC cystine levels</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001803</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2cdac22-d11d-4e0c-9055-d810afe322ce">
        <dc:identifier>HP:0000821</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
        <rdfs:label>hypothyroidism</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8d43919-b641-4c1a-9d49-31822b313478">
        <dc:identifier>HP:0000613</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Photophobia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eeeb66f8-f903-446a-90cd-b89c580f3009">
        <rdfs:label>renal function declines</rdfs:label>
        <dc:identifier>HP:0012622</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d747426-1dbc-4f28-a4d2-16c2a6bb6da1">
        <dc:identifier>HP:0000531</dc:identifier>
        <rdfs:label>corneal crystals</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000531</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219800">
        <dc:identifier>https://www.omim.org/entry/219800</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <rdfs:label>CYSTINOSIS, NEPHROPATHIC; CTNS</rdfs:label>
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ebb0f727-b587-481a-a075-d124564c9831"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23416144</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/525ac712-f8c0-4dc5-9b3c-291070daba26">
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Kidney disease progression ( Progressive disorder)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2eb7f245-ae15-436a-84ac-d9afa5a22c79">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f194769a-ca33-46bc-b41d-a2892ecfb1aa">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22386973</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3287f1f-e5c0-4585-ba5c-1144012bcb80"/>
        <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602360"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00b63c8f-0a41-432c-8e93-7bd5590a11df"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f4d804f3-35db-4b08-96a9-4e3095bfe98c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23770102</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9511275c-2da8-4476-aef1-14e317a09ae2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a22c6df3-d7d7-4891-b994-58e908697c6e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20682460</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ddc8301-39b6-495d-bd92-671bd769cc63"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/09fe99c8-adf4-49c9-924f-67c404fb40e2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8276f584-b8f9-4ed5-a7d6-85d25a24d482"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8278ac64-df9a-495f-b076-78bb1de0e6e0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c9fc23e-421f-4970-a54d-15edc9bc2144"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc4235b3-07bd-4065-b959-92596d7eb98c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/52c143c1-5b06-4377-b6c3-981d6867a5cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20625172</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/66137ccd-7515-4251-9533-3cb54c6c6f38">
        <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe3d213-7f57-40fe-b527-eb5ee95ca47e"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d1485e2-3605-44f0-8f82-149371c09649"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Phosphocreatine</rdfs:label>
    <dc:identifier>DB13191</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13191</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dd6d5c30-02b4-484d-830e-30e47c4acb79">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3aa51c93-bb3f-4781-bcf9-f966870c547e">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01205</ddiem:url>
        <dc:identifier>DB01205</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac0f9a96-305d-4fa8-b627-d2722b22c69b"/>
        <rdfs:label>Flumazenil</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28b419e5-4ed4-4305-9570-1bb54e9481fc">
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
    <dc:identifier>HP:0002401</dc:identifier>
    <rdfs:label>Stroke-like episodes</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/45e955eb-1792-4af9-9f30-02ee490c6151">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00936</ddiem:url>
    <dc:identifier>DB00936</dc:identifier>
    <rdfs:label>Salicylic acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dd62a22c-7c0e-4021-8693-3f5b2815ca2e">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b7e484e-749c-4b01-9395-62dc3548331f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/edf8fc13-bba5-4e0a-8fb1-34316117286f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78d8575f-e6f6-48ca-945c-cae48d47b073"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ceab7b2f-47c0-4bef-b8bb-5b56f752f8aa">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220110">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/937</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>937</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/220110</dc:identifier>
        <rdfs:label>MITOCHONDRIAL COMPLEX IV DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8e73758c-2d95-469d-8b0b-c36fd2dd6e4d"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/676077e2-dffb-4e14-9351-f1af0c3345f3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/de7d98c9-99c8-4943-bacc-7d468cd43f0a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44ee1005-890b-428d-a10f-967d0766540a">
        <dc:identifier>HP:0001714</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001714</ddiem:url>
        <rdfs:label>ventricular hypertrophy</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbe2f48d-3848-4c8c-b390-32df14d8b124">
        <dc:identifier>HP:0004356</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30170069</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/290d545b-0ef3-4e6d-bf51-f7c38383f789">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0001640</dc:identifier>
        <rdfs:label>cardiac dilation, Heart enlargment, cardimegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8700879</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6c33f0a9-a4c0-45a9-a66d-afbcc938d7cf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/88ab34e5-744f-4f68-a839-0fdeb75e6347"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607014">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/607014</dc:identifier>
        <rdfs:label>HURLER SYNDROME</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0b8c1fd4-df81-44b5-a497-03cfc2225b81"/>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bb49ec6-f0c2-4b38-9ae5-aeffe9186b70">
        <dc:identifier>HP:0030872</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030872</ddiem:url>
        <rdfs:label>Left ventricle dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82dd2de6-9590-4da7-bb09-7920bcc43cf0">
        <dc:identifier>HP:0006670*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>left ventricularc contractility abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7232993d-8f17-4d38-903e-e6f2bb789774">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb97c7ef-67f4-449c-947c-6c494dae3d7a">
        <rdfs:label>premature differentiation of erythroid cells</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012130</ddiem:url>
        <dc:identifier>HP:0012130*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02931f50-0c6f-40bc-9619-662b63aca346"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/836aa435-19b1-458e-8222-6c0dcdabe6c4">
        <rdfs:label>Pathological apoptosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/133284cc-0711-40af-acac-2413f640b2cc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025034</ddiem:url>
        <dc:identifier>HP:0025034*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>erythroid progenitor depletion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs12185-016-2044-9</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/780ea4a4-836f-4fa9-afc2-e922eed9cda3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>low hb level</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa882250-96bf-482e-9c73-4c3eeddbdc83">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:label>low quality of ife</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d586f4c-4404-49bc-bad5-811db942e84f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/908e4390-317e-4e74-8d1d-bb38345cbe29">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1455e95-814b-4f38-b695-419c193d2975"/>
        <rdfs:label>Beneprotein</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3bd95a65-e948-48bf-9620-803f73b0fb0f">
    <rdfs:label>Microhematuria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002907</ddiem:url>
    <dc:identifier>HP:0002907</dc:identifier>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2f3abba6-53df-4d5c-a86d-3b81178c1ac7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c7ef80d-9872-4a36-b414-81965a9b9fd7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602579">
    <ddiem:iembaseAccessionNumber>322</ddiem:iembaseAccessionNumber>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/602579</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/322</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/554bdbcc-d8dc-4ee3-8e42-6d53f76b9a9d"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8136b13d-6db4-4065-b224-d545e8290752">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21744491</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601776">
        <rdfs:label>EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1</rdfs:label>
        <ddiem:iembaseAccessionNumber>1130</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1130</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fe0dbe90-9564-4566-a06e-2603c20077bd"/>
        <dc:identifier>https://www.omim.org/entry/601776</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/577c212c-538c-4314-a084-d9900395d701">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1f0db5f8-1cad-4afb-9823-70181cca07e1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1817f18-80ab-4a5a-bf73-b968e903fd04">
        <dc:identifier>HP:0002019</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002019</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>constipation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f060b54f-c986-45d9-8772-bc0415bc58de">
    <rdfs:label>low energetic state of heart(Abnormality of cardiovascular system physiology)*</rdfs:label>
    <dc:identifier>HP:0011025*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/67e8ee54-a513-4c65-9de8-38978344bf7f">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/08d46567-2359-4f92-8506-2f1b12c12ef1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d426369d-6e0e-485a-8c39-520b5b95aa42"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cb473cd-e11e-4220-bb06-6edf52595c92">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <dc:identifier>HP:0003077*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High liver triglyceride level(hyperlipidemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151660">
        <dc:identifier>https://www.omim.org/entry/151660</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9b8c5763-b3c1-419c-a4bb-ccf47a282d08"/>
        <rdfs:comment>Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/</rdfs:comment>
        <rdfs:label>LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02430077</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2d65786-1e62-4afa-b922-4ecaf2cbf7d0">
        <rdfs:label>Hepatic steatosis</rdfs:label>
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606785">
    <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE II</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/70e21725-088a-4672-9be2-2850fe9ac9fb"/>
    <rdfs:comment>Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/606785</dc:identifier>
    <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/metabolic_disease_treatment">
    <obo:IAO_0000115 xml:lang="en">a treatment strategy or plan which the clinician beleives will cure or ameliorate a disease caused by a deleterious genetic variation in a patient, affecting their metabolism. It may modify some or all of its signs or symptoms, or alter the prognosis and course of the disease, either by severity, timecourse or phenotypic quality.</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:creator xml:lang="en">https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:label xml:lang="en">metabolic disease treatment</rdfs:label>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa09411f-e9ad-4936-9560-61cd6f250c84">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9d7adddd-2f09-4caa-bf43-b84628b11912">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad20502c-211b-4489-95e3-d245aa5a2f29"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af5ba1da-196e-45e4-af77-84eaa2659c21">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>neurological abnormalities</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69d3cb0e-eeea-493a-ab92-ba4fdc24fef4">
        <rdfs:label>Abnormal Adipose tissue tocopherol level.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/84095002-127a-46b0-98b1-16104c97bb90">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602398">
        <dc:identifier>https://www.omim.org/entry/602398</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6bc05c72-dac9-40ef-9a45-d23a1ef3bf13"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DESMOSTEROLOSIS</rdfs:label>
        <ddiem:iembaseAccessionNumber>195</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/195</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6703020-99a0-4dda-800a-d938b3e43349">
        <rdfs:label>High desmosterol levels (Abnormality of cholesterol metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <dc:identifier>HP:0003107*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69f563a0-3577-4ca5-ac5d-fb1eeb0177a3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/225b0779-2d61-4d88-b3d3-55e9fb8b5e06">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0838ad0-4388-4159-85c2-eb9f57ecedc0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
        <dc:identifier>HP:0010535</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Sleep apnea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37ca99dd-4927-4b2d-bbdf-b8aebd404967"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/581b0309-f205-4325-9ad8-026256a7cc46">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002877</ddiem:url>
        <rdfs:label>Nocturnal hypopnea</rdfs:label>
        <dc:identifier>HP:0002877</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bda89eaf-7a0f-489f-9b21-ec38ace4ce96">
        <rdfs:label>impaired Visual acuity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4eeb4d3c-a6b5-40b1-9b5b-73ef7204484e">
        <dc:identifier>HP:0005180</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
        <rdfs:label>tricuspid regurgitation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/280eb90a-c548-4bd2-aa9c-d12e2ec019ee"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5f694a2-f3de-4cec-b0b1-5fcb05bf124c">
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:label>pitting edema</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/227105f2-5ca7-4730-b907-c15183f7f7dd">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>brain MRI abnormalities</rdfs:label>
        <dc:identifier>HP:0002500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89acaeac-b28e-4cf7-957d-df22f8370003">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <rdfs:label>white matter abnormalities</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0002500</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19748810</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36007384-1955-4cee-8a32-ea2c227bce27">
        <rdfs:label>Abnormal apnea–hypopnea index</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41353df4-b005-403c-b730-5028eaebee93">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>low exercise endurance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1de3ef0-c31f-446d-abad-7dc878a49943">
        <dc:identifier>HP:0000613</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>photophobia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/001d2136-b2e6-4503-b41f-77b32ca823e8">
        <dc:identifier>HP:0012763</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>dyspnea at rest</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012763</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0eaa22d-0cdd-44a0-873a-96c735c5f587">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011729</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0011729</dc:identifier>
        <rdfs:label>Abnormality of joint mobility</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2550835d-89a9-483d-bd53-5e25ae8d2819">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0002189</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002189</ddiem:url>
        <rdfs:label>Daytime somnolence</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cd288e2-6dd4-49fa-966c-03c1399e506e">
        <dc:identifier>HP:0003541</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003541</ddiem:url>
        <rdfs:label>Urinary glycosaminoglycan excretion</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ffdf848-cc90-4fef-be67-e9795baa632f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ede27c3e-0424-48b9-b09f-21864d5df0af"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607014"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d43f2b6-9180-43a0-81a7-90fc78d54327">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>low quality of sleep</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0a10f42-fc97-4d63-936f-594c9ea2e6ac">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002119</ddiem:url>
        <dc:identifier>HP:0002119</dc:identifier>
        <rdfs:label>brain ventricular dilatation</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11172140</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a96f0df5-11b6-4b4a-b19b-d7303ab4b4ec">
        <rdfs:label>conjunctival irritation</rdfs:label>
        <dc:identifier>HP:0030953</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030953</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a936c969-5b8b-4677-b847-fddeed1408b4">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/32eec264-5189-4b23-a635-0efe36323f65">
        <rdfs:label>CORTICOSTEROIDS FOR SYSTEMIC USE</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a46eb64e-3549-4415-9277-cde43a393917"/>
        <dc:identifier>H02</dc:identifier>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=H02</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f0cc4bd-254d-4f8a-b72d-175167253f5f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040084</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
    <rdfs:label>Abnormal circulating renin</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dec8b089-abc7-4413-b65a-cc6fdbdfba48">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A06AA</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08cd11fe-41fd-4f79-bd22-63f200aa1114">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c30587ef-0d72-442e-8b50-7a5632334a26"/>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25178b7f-2610-41d8-9f29-03cc7cb20d6d"/>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a81963ff-a25b-4ef5-9ae6-fa93ae6360c7"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28636073</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e052f281-ed0b-4396-8cd6-fd0ab5139ced"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e80ec72-78d9-4cd7-adff-3f59f3e052d8"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label> Softeners, emollients</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/913fca9a-2e33-4493-9022-9d6f2503804c">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c30587ef-0d72-442e-8b50-7a5632334a26"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f359034-d240-4753-8a38-b3cc7e447802"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21981352</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/476e55b2-afb5-4171-86b0-a476c5435b9a"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ec2c82f-ce75-410d-93d5-3883dd1f9d45"/>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25178b7f-2610-41d8-9f29-03cc7cb20d6d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/637f1a84-cd1f-4356-b17a-5237166bb398"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28979034</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71841b8e-c568-44d5-a869-c2503acfab13"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b37ec182-9fec-485b-ad8d-12c89f91cbc5"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>A06AA</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ed44de4f-cea1-4307-a151-2d0ba8d0305b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad9dd243-05b1-4b07-823c-d680307fee89">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b8a56f47-f142-44c9-a573-3f86427a647b"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB03766</ddiem:url>
        <dc:identifier>DB03766</dc:identifier>
        <rdfs:label>Propanoic acid</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245900">
    <ddiem:iembaseAccessionNumber>380</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/245900</dc:identifier>
    <rdfs:label>LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/39eb0793-945c-4ee2-ab80-6c11d4941eb9"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/380</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0658f2a0-b589-4152-a4fb-5c35c71429fc">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acc95b70-a2f0-4208-b7e8-afb999a60269">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002020</ddiem:url>
        <dc:identifier>HP:0002020</dc:identifier>
        <rdfs:label>Acid regurgitation</rdfs:label>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11c39f5e-8af4-4346-953c-40e515baedc0">
        <dc:identifier>HP:0410019</dc:identifier>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>Epigastric pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0410019</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/520000">
        <rdfs:label>DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/985c0580-1073-4ef1-84d9-df3d370bfb78"/>
        <ddiem:iembaseAccessionNumber>409</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/063b005e-3ab9-49f0-b247-215819d856a3"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/409</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/27c0dbb8-f980-49b9-a28b-cd8bf27602b8"/>
        <dc:identifier>https://www.omim.org/entry/520000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6f77b744-855b-4e4a-9880-c42099808367">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/35b45750-2ed4-4c8a-9e39-5e485588603c"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/43613542-7133-4f07-8df9-3f52c99335f3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b77c6287-2a13-4c13-8ba1-faa70985fd7f">
        <dc:identifier>HP:0005952</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:label>Low pulmonary function</rdfs:label>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/082cfcc7-692d-43d7-b6c8-f7bb77492b35">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/664953e9-af75-48bc-8726-5b4a32305124"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9afb226d-56f3-4ca4-aa85-f599b4b5fd58">
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006517</ddiem:url>
        <dc:identifier>HP:0006517</dc:identifier>
        <rdfs:label>Pulmonary Alveolar Proteinosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d0f3f330-8114-42f3-a693-151eacfc8eaf">
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613077">
        <dc:identifier>https://www.omim.org/entry/613077</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/27b8a290-fbf6-41f8-aa6b-9d3ccea3d4eb"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29f58ace-9e5c-4cd5-a9d7-225d9afc2d2e">
    <rdfs:label>Myalgia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
    <dc:identifier>HP:0003326</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c176db2a-b65b-4852-87ce-f0bde51aad1e">
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2fc4d99-3de6-4984-8c3b-769ad27b15b0">
        <rdfs:label>Poor fine motor skills</rdfs:label>
        <dc:identifier>HP:0007010</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9afce81f-3d1a-4e8c-ad37-3af89235e98d">
        <dc:identifier>HP:0001336</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <rdfs:label>myoclonuic Jerk</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/947a9760-a2d0-4749-a67a-d235a6f09052">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0012477</dc:identifier>
        <rdfs:label>Voice tremor</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012477</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c6c6292d-89d5-414c-bb7a-1c87f78ca878"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26232052</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f69d6a34-9036-47de-96a1-55100a14f6b5">
        <rdfs:label>Poor intelligibility</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001249</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607330">
    <ddiem:iembaseAccessionNumber>196</ddiem:iembaseAccessionNumber>
    <rdfs:label>LATHOSTEROLOSIS</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/607330</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a5f455f9-8dc8-4f43-aaae-864db7968c31"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/196</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89812241-82c4-4bda-98a6-5e76a715a0a2">
    <rdfs:label>Low total RBC folate level</rdfs:label>
    <dc:identifier>HP:0040087</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7ff59a8-abb9-45b9-ab15-5178c0e3745f">
    <rdfs:label>High serum pyridoxal 5'-phosphate</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253260">
    <ddiem:iembaseAccessionNumber>93</ddiem:iembaseAccessionNumber>
    <rdfs:label>BIOTINIDASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/93</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7d52c3cb-7967-4a65-8590-d555a1463a9f"/>
    <dc:identifier>https://www.omim.org/entry/253260</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ff6e5e9d-4fd1-427e-bfb7-caee0ed94fb5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766179</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d48bee5-66b1-4df4-a25f-77d2815321fa">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Bacterial glutric acid production</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de78ed5b-005e-4c3b-9019-a0475a80ae99">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002013</ddiem:url>
        <dc:identifier>HP:0002013</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Cyclic vomiting (Vomiting)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231690">
        <rdfs:label>GLUTARIC ACIDURIA III; GA3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/505fe7c9-fc9a-4ed8-a04b-e24c4bdd9ff9"/>
        <dc:identifier>https://www.omim.org/entry/231690</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>537</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/537</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/16747996-08f2-4ae1-8c71-08399633830b">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3bd95a65-e948-48bf-9620-803f73b0fb0f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f34d3026-eedd-446e-a2a7-37dff939eaf5">
        <rdfs:label>Microalbuminura</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012594</ddiem:url>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:identifier>HP:0012594</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fd204c20-824d-4e4d-a681-e7691fa8f0a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f58ca36-5264-46eb-9102-9db6bfcee0d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/147f6533-1afd-4aed-a059-1b432c41f86c">
        <rdfs:label>Thrombotic microangiopathy</rdfs:label>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99082cbf-1c71-460e-8990-f7c5bf667520">
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>Anemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f21aa42-405f-4f79-9298-88572999b642">
        <rdfs:label>Thrombocytopenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001873</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250940">
        <dc:identifier>https://www.omim.org/entry/250940</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/30</ddiem:iembaseUrl>
        <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG</rdfs:label>
        <ddiem:iembaseAccessionNumber>30</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0c81a8b7-e3a0-4b52-83ab-1d96674b26c8"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f573d87b-f907-4ddb-bf62-c0cfa09c2c7b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/80787394-37ac-4037-b4bf-0382063aacd6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/222da882-988e-43a8-8ef9-fc51b4693900"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232600">
        <ddiem:iembaseAccessionNumber>489</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/232600</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7e2e7307-a3a6-4005-a577-31d7f6383407"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/489</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE V; GSD5</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba887d54-d562-439c-8ebf-ab828fc0128e">
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:label>exercise intolerance</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/83dc4150-136b-47cb-8e0d-6e0908dd53fb">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2d65786-1e62-4afa-b922-4ecaf2cbf7d0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03508687</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/71928157-df81-4396-ad29-c9aa6aa1d7da">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1001f21f-dc2b-4445-a1d2-fee306bf9a12"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>Hypertriglyceridemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1824982a-b31b-4281-a7af-33d6ab85c41d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609286">
        <dc:identifier>https://www.omim.org/entry/609286</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c4db02f4-ce26-4ca9-8fcc-8646732922ed"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c8e9e07-22d4-44e3-b77f-7caa6cfb24c5">
        <dc:identifier>HP:0001332</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Parkinsonism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/84a408d4-668a-4fbb-a3c1-59aee1603e7c">
    <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfb1cdcc-f994-43b5-bd75-faaa0cea1447">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b0990825-ce94-4864-8aa0-4e72fec215af"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7edc789-d3a0-4fd3-a82c-97c11627605b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <rdfs:label>Delayed motor development</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001270</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/abddf098-a793-4e93-a312-1ba879330696">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c382fbd-4998-47be-b8a1-081b4c974f69">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Low AGA activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fc45998-1f3c-41e8-b415-75b58b766348">
        <rdfs:label>Unstable AGA enzyme</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0003304>T122K</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fb6d751-490a-46ba-978e-8764fdab651e">
        <rdfs:label>Abnormal AGA processing</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208400">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/258</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>258</ddiem:iembaseAccessionNumber>
        <rdfs:comment>As by 2016 Banning et al. mentioned "Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years</rdfs:comment>
        <rdfs:label>ASPARTYLGLUCOSAMINURIA; AGU</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e1f64ba4-9b02-4f2b-a256-c871201d828b"/>
        <dc:identifier>https://www.omim.org/entry/208400</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44e24ccf-ee32-4858-a9b0-fe97a469c973">
        <rdfs:label>Misfolded AGA</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f11e9a37-9c02-44cf-8b43-be0a8d2015bb"/>
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e50edfe1-379d-43af-96ad-fc38e0b05e71">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64a1a374-6d10-42d2-abbd-21beb9c22b70">
        <rdfs:label>Postural tremor</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002174</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002174</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022510X16303495</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf53bf1f-30d0-4e05-99cd-c0a2643e5f3d">
        <rdfs:label>Bradykinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002067</ddiem:url>
        <dc:identifier>HP:0002067</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f69271b-96ea-4fcf-8791-a7250e67a1e7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <dc:identifier>HP:0001300</dc:identifier>
        <rdfs:label>parkinsonian symptoms</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1691971-0ed3-4f73-bd0e-bef7d49f58e3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aff36f26-1292-4278-ad5e-8274f25ee290">
        <rdfs:label>Kinetic tremor</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030186</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030186</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/74b9b86b-d7d2-4000-bd9b-4da2d0931366">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a4ae640c-b06c-4029-8cd1-f3b3c9383a2b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0e566ad3-7527-4183-9ab9-21ccd32a521f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/269920">
        <rdfs:label>INFANTILE SIALIC ACID STORAGE DISEASE; ISSD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2445f697-eec9-4fff-848a-44629c65ba06"/>
        <ddiem:iembaseAccessionNumber>267</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/269920</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/267</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0523eb32-f854-4004-bb26-2be192203b23">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8fa90139-889a-4b47-a02e-e925f8f87048"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a90c116e-7714-423c-904b-426bd90bb6f1">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef8cea65-913b-4840-b880-749ffbc9318d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ace068c8-eca0-4862-98bf-9d942e90f9e4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b234fa27-4ab5-4d71-9b9d-be8aea771691">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4e4f5fd2-5e4c-4208-902a-0191abcc3233"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/54678609-9f3f-4bb7-b33a-badc911fbfd0">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2821f8bc-93b2-4309-933b-3f40199d3334">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c8dc2d-3194-4eb2-9f63-4ce04024cbfb"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00152</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1355f504-c6f5-4a3a-ac4b-48759feac418">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/59131206-1a57-45a5-a8a2-b613fa00d8cb"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c8dc2d-3194-4eb2-9f63-4ce04024cbfb"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a815c185-42ae-4d95-abc2-d9fba34819c0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c8dc2d-3194-4eb2-9f63-4ce04024cbfb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5712406-b651-41d7-9eba-4e4b0417f6fe"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7df9fa37-5d3c-4946-9c1b-197ec6241f98">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a5ee1ca-99bf-46e1-8ee8-1a211fed86c9"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c8dc2d-3194-4eb2-9f63-4ce04024cbfb"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK220444</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1ec89296-3d52-4471-bed1-5095f2127554">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/777bb2b0-b626-48c8-96be-6c7c6895c676"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6304e1e1-8f67-46c1-924c-e3bb8b175687"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31061755</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b6c7201-cf67-4902-b22d-09168d9b255a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/018a9910-dcdd-4448-aea3-c90ee09687bd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27749535</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1691971-0ed3-4f73-bd0e-bef7d49f58e3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/849f8577-045f-4843-bf30-8613a3ebd056"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607483"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c8dc2d-3194-4eb2-9f63-4ce04024cbfb"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00152</dc:identifier>
    <rdfs:label>Thiamine</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a07b603-7aa8-42db-a318-d597ce0b656d">
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236795">
        <rdfs:label>3-HYDROXYISOBUTYRIC ACIDURIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236795</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6df95112-2478-4e0e-bacc-04b45c64ab04"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b65154cd-07a6-4112-a2c2-26f4bf9781db">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <dc:identifier>HP:0001941</dc:identifier>
        <rdfs:label>acidemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>http://eknygos.lsmuni.lt/springer/365/81-92.pdf</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aeed8480-af8d-4818-a221-af1bc77d0565">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01219</ddiem:url>
    <rdfs:label>Dantrolene</rdfs:label>
    <dc:identifier>DB01219</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd0777d6-e534-4ae3-8a6e-6ed6aa83369b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c69b6fb-da21-486c-918f-2ac50c189397"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5c60ce28-6cf1-456f-8d49-a14640207547"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7705cf09-ef71-4d71-821f-02567e2be87f"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/758e5331-1851-400d-aba8-0d52415d272e">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8857440c-7bf5-4609-8472-17312a6704b9">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77eb1f3a-c389-4bb0-ad7e-0923fb9ea65f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07400f16-4667-4233-872e-acc32860997a"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Taurine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d9734741-4a7b-4982-97e4-f003eb272f5a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27023909</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fcf74aa4-1530-436c-ab50-a8a6e53e73a8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs00726-017-2462-x</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07400f16-4667-4233-872e-acc32860997a"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01956</ddiem:url>
    <dc:identifier>DB01956</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa785027-3063-4132-a0d6-87b8d0a3a21d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8c5a4324-cec2-4ca9-ad9b-c22ca2ebedd9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b58a00e0-7502-4b2d-95c9-2688df47a7da"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59159003-efc0-448b-a221-a6141cd2c247">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/32bcc737-44fd-4297-9554-cde531ebec14"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a8aaa7a-c9db-4200-8e18-a4e2d734e023">
        <dc:identifier>HP:0000713</dc:identifier>
        <rdfs:label>Agitation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000713</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46d2dfe3-57bd-461a-a293-11531b761696">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Aggressive behavior</rdfs:label>
        <dc:identifier>HP:0000718</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cf87205-402c-432e-bcac-c6f06afe1940">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
        <dc:identifier>HP:0000718</dc:identifier>
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <rdfs:label>Complex partial seizure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdd0a7b7-39b3-4686-af6b-d08b12e33f70">
        <rdfs:label>Generalized convulsion</rdfs:label>
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <dc:identifier>HP:0000718</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cd06fc7c-2e4b-4f58-88fc-5b8adfb9b7ff">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a51a5b34-b91f-4325-b61a-ef1f346afe34">
        <dc:identifier>HP:0003119*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>high non-HDL-C (Abnormality of lipid metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef7dcd2d-b04f-4a6c-be09-d95926e14705"/>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1d66ab7-adb0-48e2-aff2-21417234c18b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e5482320-6aa9-474b-ab45-5c533f1580a7">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f30827c9-7ac5-4b67-956e-00e8e82c4b35"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd20e54d-1bf7-4235-b7cd-108b88fc2a52"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/260e414a-a52f-4774-9fc3-654ccbec52cb"/>
        <dc:identifier>DB00909</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00909</ddiem:url>
        <rdfs:label>Zonisamide</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4247578a-2b31-497d-9fe1-4bd80f04f2a7">
    <rdfs:label>working spatial memory impairment*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002354</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9fceb068-ba0f-432f-a660-15b5fe71d437">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/334b6661-4a81-48a6-8c93-fdb7f04c8f9a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3f04971-64ad-43e4-b397-0c7c7f4c528b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cdd1ed46-f8ec-4962-a35b-d4e37d5530c2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f09338c7-611b-46ce-9252-ea52e7361d4c">
    <rdfs:label>Chloral hydrate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ed6a7b13-172f-42b1-b3be-7f656c743c5e">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb23a033-3822-4336-a31a-12fd0178a6e5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ab959336-4ff3-4517-aedb-40d0cfa07163"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1691971-0ed3-4f73-bd0e-bef7d49f58e3"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77309851-b999-4e2e-9277-d540468e8fc2"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8881997</dc:provenance>
        <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01563</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01563</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd3ab056-38f2-482a-9e04-54bf48789c5b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/84a1e733-2f6f-447d-a8bb-f86034f0a833">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0671d13b-592d-4795-92b0-dd66de06f330"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea091722-bd8a-4cfc-bfbe-556d457f31a4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003800</ddiem:url>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <dc:identifier>HP:0003800</dc:identifier>
        <rdfs:label>Muscle abnormality related to mitochondrial dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03432871</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9545778-548b-432b-a207-76ae9b607196">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12141411</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eee0e6b6-361b-42bc-97d2-d8757085684a">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Refractory hypokalemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da1b1ec4-96f5-4340-830a-dcf73a14d31e">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004319</ddiem:url>
        <rdfs:label>Abnormally reduced levels of aldosterone</rdfs:label>
        <dc:identifier>HP:0004319</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0085253816306020</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/205bfa1e-cb2f-4a30-aed0-2cc294ff026f">
        <rdfs:label>Abnormal serum renin level</rdfs:label>
        <dc:identifier>HP:0040084</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/57de54ef-84ae-429b-b64d-7634344e261d"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/889</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>889</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/04dc1b76-9b6e-49a5-af50-1f023539c7fe"/>
        <rdfs:label>GITELMAN SYNDROME; GTLMNS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/263800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8beece2d-f883-442b-a3ae-1b1f4e6ec619">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7893271d-a01f-4f73-a5d2-55721471203e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8d34d61e-2ca2-4227-bafb-1716031b86ae">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0003304>R219K</obo:RO_0003304>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e7892b2-aeaa-4e1f-ac4f-6f8ae3407816">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low HDL cholesterol concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9cc6d6f-6fa8-457b-ae5d-525b2c60c9e4">
        <dc:identifier>HP:0003233</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>hypoalphalipoproteinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecdeafe6-0152-4f88-8762-4b3dd6285dff">
        <dc:identifier>HP:0003141</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased low-density lipoprotein cholesterol concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT00458055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604091">
        <dc:identifier>https://www.omim.org/entry/604091</dc:identifier>
        <ddiem:iembaseAccessionNumber>379</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8d1dc40a-6273-43d1-bfde-9b69bce5a8af"/>
        <rdfs:label>HYPOALPHALIPOPROTEINEMIA, PRIMARY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/379</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131f6cb2-8d13-41be-b95d-4485ac53fc80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24854628</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f69c0b72-cf76-4666-86a9-daf4c9472ceb">
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261640">
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89a8cec7-01f9-4c7c-9ed8-7004e633c7d4"/>
        <ddiem:iembaseAccessionNumber>4</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/4</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261640</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb2ca183-815b-4e46-9791-80170dd281d7"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65ebab3f-be36-43b0-a7f6-bfc107d870b1">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal serum folate</rdfs:label>
        <dc:identifier>HP:0040087</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f73dbb7e-c50b-4f0a-b980-f6c2bb70feee">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19cc165b-bc2d-410c-af0e-e99f49312e78">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Disease progression (Rapidly progressive)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0003678*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f659c79-720e-46f4-b093-41db71177f32">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000707*</dc:identifier>
        <rdfs:label>Unstable neurological function (Abnormality of the nervous system)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c3c9f2bd-2f0f-4070-ab7f-0bc6200b6e0c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/83a51cd9-b823-4b18-965a-1d496121a0fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d71f9e9-fbd1-4923-a475-4a31ca4c27d8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010909</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Elevated blood arginine levels( Abnorality in arginie metabolism)*</rdfs:label>
        <dc:identifier>HP:0010909*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03378531</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26358771</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207800">
        <rdfs:label>ARGININEMIA</rdfs:label>
        <ddiem:iembaseAccessionNumber>16</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/16</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/207800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f4439a1c-79a9-4dfa-a07c-c02c066ca61b"/>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/33402a6e-1a43-4505-800a-c6687ff36859">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7a77af3b-a1be-4b74-8e9a-b2fb0c4c88eb">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/341955</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791288</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac93228f-a4cd-4dcf-849b-8f4881bc4f01"/>
        <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bb443dc-c9a1-4a47-9858-b8d6f176b41a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd6c50dd-915a-4fd5-9ad4-e1a3ba0c0969"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06755</ddiem:url>
    <rdfs:label>Beta carotene</rdfs:label>
    <dc:identifier>DB06755</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/661b4198-289a-4668-8d69-cb00c611db56">
    <dc:identifier>DB12537</dc:identifier>
    <rdfs:label>Benzodiazepine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd0777d6-e534-4ae3-8a6e-6ed6aa83369b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12537</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/20f15606-5c05-4ada-a683-d9e1bd06e351">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/676077e2-dffb-4e14-9351-f1af0c3345f3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
    <rdfs:comment>The drug is occasionally effective especially when started early in status epilepticus.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c248a5c-0ca7-4f77-a5f3-287c416ead24">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000819</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
    <rdfs:label>Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/49f729cc-0749-420b-a741-e1c45021f106">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b733de1b-e102-4516-ab28-1539789e2758">
        <rdfs:label>abnormal fasting glucose</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013277</ddiem:url>
        <dc:identifier>MP:0013277</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d140159d-dc00-4d3c-8693-78faff00eee8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040217</ddiem:url>
        <dc:identifier>HP:0040217</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high  HbA1c levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b873b4da-b7ab-46b7-a42f-c6735eafbbb3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d3ecf923-0d3d-453f-ab43-164f152179e4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/06d21628-d4fd-4d93-be7a-435600733ad4">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f773df7-1cc2-40b9-b255-5565dedd7116">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:label>Study was Terminated (Interim analysis demonstrated the treatment was not effective)</rdfs:label>
        <dc:identifier>HP:0000992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01550705</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/177000">
        <ddiem:iembaseAccessionNumber>107</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/107</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/177000</dc:identifier>
        <rdfs:label>PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/241f2074-4370-468c-9c0d-30d442ae3d00"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22cfc964-4d56-4633-89eb-b0c8f736644c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4639114-18ba-4d55-9b88-40477ce44812"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/62fc3b50-15de-4767-bf69-fdda802d35f9">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c437b67a-752a-4e29-b3cf-18c25a1d2048">
        <rdfs:label>Tricusped incompetence</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005180</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/650080bc-f589-4d8b-a300-5f8e583603cb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
        <rdfs:label>Low ejection fraction</rdfs:label>
        <dc:identifier>HP:0012664</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/09fadcb7-13ea-4113-9121-88e823b4ddea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/24d11bb4-dd80-4e72-9af2-74a5e1e52193"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7e31f02-079c-48b1-9b63-9f4625117777">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001653</ddiem:url>
        <rdfs:label>Mitral incomptence</rdfs:label>
        <dc:identifier>HP:0001653</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c04ef1ef-eb2e-429a-9e63-2eb0d822fc75">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b39c7d1b-51f6-4eae-8ec5-10bf5b44838f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b946393a-202e-47cc-ba91-40f5344d0537"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608158">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CoQ-RESPONSIVE OXPHOS DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608158</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/70e21725-088a-4672-9be2-2850fe9ac9fb"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4216e31-4d7a-49da-9c01-1ce09c7971e7"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ace9b493-14b8-4a7f-95fa-fe40c5f53168">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a7d3b484-0f9e-406b-818b-d3d27abf7dca">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/efe0f2aa-bd21-44e1-9651-252ba4aebe3b"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb5333f7-506c-467d-9c78-5729a713f3d6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>A11</dc:identifier>
    <rdfs:label>VITAMINS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1411e574-7daa-4af3-adb9-1d26e9e42459">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cace90f-632e-4ad2-af5a-7097505df6b8">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>boost residual AADC activity with a cofactor excess</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fc926f6d-1742-4d6f-8d84-e3eba110d255">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4d7dec9c-337a-49a0-90d5-5a6868d32bfe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608643">
        <rdfs:label>AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a17bc22c-f47e-495a-a0ec-bf749b0c81bd"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/100</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>100</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/608643</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/48ebff14-4388-4607-8598-c0a0bd142e37">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b4e4480-87c3-492d-a7ed-d89d68c0e7f2">
        <rdfs:label>Rapid progression in body fat mass( Abnormality of adipose tissue* )</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009124</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0009124*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4b594f5-4b80-405c-b6e0-1f86b01642dd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cc67426f-4fc5-42fd-b403-387b7bcc658b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151800">
        <rdfs:label>LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/151800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/27c0dbb8-f980-49b9-a28b-cd8bf27602b8"/>
        <rdfs:comment>The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26790a3a-3426-44a6-83eb-28e897143864"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2897261</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b3ac6d0-6c35-421e-a56a-7994457ac3c3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased intraabdominal fat</rdfs:label>
        <dc:identifier>HP:0008993</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008993</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce351f77-3b29-4f98-a9bc-37d7e438c8b0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002181</ddiem:url>
    <dc:identifier>HP:0002181</dc:identifier>
    <rdfs:label>Brain oedema</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/05a0086b-a39d-4da9-98e7-8b74d8712215">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/28</ddiem:iembaseUrl>
        <rdfs:label>CYSTATHIONINURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9a31b920-cc23-4bfa-9b5f-24a916acc23c"/>
        <rdfs:comment>Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897</rdfs:comment>
        <ddiem:iembaseAccessionNumber>28</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/219500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/20584029</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54f7ab03-e2df-4a9f-aeaf-4d51c344b078">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003153</ddiem:url>
        <rdfs:label>Cystathioninuria</rdfs:label>
        <dc:identifier>HP:0003153</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/417288</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94802ea5-4b53-4e4b-9621-658bcc9fa618">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>EEG abnormality</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f106f5c7-4475-47ae-ace6-297114719c56">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
        <dc:identifier>HP:0001337</dc:identifier>
        <rdfs:label>Tremor</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf217edf-cdcc-4b1a-8914-eec0f23e2ff6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
        <dc:identifier>HP:0007010</dc:identifier>
        <rdfs:label>Impaired fine motor skillls</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa70ff2a-49ce-4a4e-b2bf-03f7b6fe38b2">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:label>High total homocysteine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d3bded0b-d256-4a9b-8764-8f233eb2e399">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2c7b03d-c9c8-4e65-a722-cc4fc1f89ddf"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9811fb78-29ba-43d3-92e4-1f6d5f219c8f">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001931</dc:identifier>
        <rdfs:label>hypochromic anemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8187613</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a948d558-4a17-41cf-ae97-29aa5a972d90">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89a1dbac-d9db-4e8d-8315-50362f18aa9f">
        <rdfs:label>Clonic contractions</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610090">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bdd82c59-3050-4e57-b63a-244dffdd84a9"/>
        <dc:identifier>https://www.omim.org/entry/610090</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/76</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>76</ddiem:iembaseAccessionNumber>
        <rdfs:label>PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0003304>R229W</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02850c69-15c8-445e-97be-54855e3f4813">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>Lip-smacking automatisms(Epilepsy)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b37f33e-58f9-4e24-bce2-d7e586c65675">
    <dc:identifier>HP:0004396</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <rdfs:label>Poor appetite</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c482cb1-22f9-4db5-a34e-ac302092922f">
    <rdfs:label>hyperuricemia</rdfs:label>
    <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
    <dc:identifier>HP:0002149</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/83cc5294-624e-41a2-9b9e-a3262cdb783d">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02930655</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5bd5253c-2789-4819-83be-13628d578a6f">
        <rdfs:label>High Gb3(globotriaosylceramide) accumulation.</rdfs:label>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28088251</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b0eef80b-5d7c-4b16-ac23-76e6368ca683"/>
        <rdfs:label>FABRY DISEASE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/301500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/296</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>296</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03737214</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/70560a50-d2b7-41d9-9f94-341dbbdc2d1a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/14bd7029-0cbd-46ef-ba4b-9c7bea76000a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29982630</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03425539</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b2c282f0-7725-4143-904f-a4fcfb8571d4">
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/740a7023-61ad-4d20-af46-992194b1687c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3ecc3fdf-82a3-46a7-8a3e-756ec2866e29"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c91023a3-bfc2-46fe-ae3d-26dd44924b2d">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>Low mean hemoglobin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d16e6ff-5ec9-4071-9138-a605221ae310">
    <dc:identifier>HP:0008344</dc:identifier>
    <rdfs:comment>Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.</rdfs:comment>
    <rdfs:label>Branched-chain amino acid accumulation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/926fef4f-4ec0-4116-a558-1a6540c7fa59">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208920">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/12a5dd89-3af3-4fc0-b220-5c92e4aa45e5"/>
        <rdfs:label>ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/208920</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28277561</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c10db7c-8ca7-4425-b85f-97deb690265c">
        <rdfs:label>lack of strenght</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
        <dc:identifier>HP:0003750</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3069a73-d8d3-4ce3-b6a5-6495c5b2ce43">
    <rdfs:label>elevated liver iron concentration</rdfs:label>
    <dc:identifier>HP:0040134</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040134</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c0dbbf5-fa56-4380-ae4b-f2d72bad2eb8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3efaa0dc-c68a-4f61-9053-35f84df1360b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9fbc310d-1671-4216-976c-0a727578c9be"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b952cd1a-5a8e-4130-afc2-ffce823c5518">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001433</dc:identifier>
        <rdfs:label>hepatosplenomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205</dc:provenance>
    <dc:provenance>https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c41f7267-e0f7-4ed4-8773-e48e748fc0c4">
        <rdfs:label>Abnormal immune function</rdfs:label>
        <dc:identifier>HP:0010978</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/102700">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fb722ecc-3c64-40cd-a1b6-ce36c1731adc"/>
        <dc:identifier>https://www.omim.org/entry/102700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/142</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>142</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da8af273-9110-449d-8703-401c630083de">
        <dc:identifier>HP:0004325</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Low weight</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32010829-4b87-4a8b-a678-cc35b7e2412f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001888</ddiem:url>
        <dc:identifier>HP:0001888</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>lymphopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7547c554-cc2f-4cb5-b773-82a0833d58f1">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002960</dc:identifier>
        <rdfs:label>Thyroid antibodies (autoimmunity)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002960</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e319ca43-4a04-406f-abc2-50556bf0221c">
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:label>dermatitis</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bcffc36-8f71-4fd1-936f-20ea204d9e50">
        <dc:identifier>HP:0001879</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001879</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal eosinophil counts</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://adisinsight.springer.com/trials/700243447</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a587bd4-6e54-4620-819a-a299c98f8f12">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <rdfs:label>Hemolysis</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001878</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c2affe3-f67d-4f40-b7e2-2a25a4d04edb">
        <rdfs:label>Elevated liver enzyme levels</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa865077-9eaf-4f02-ba68-c41c72145650">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a346d3d9-aaaa-4f26-95d7-701390b92d47">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258450"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c8e9e07-22d4-44e3-b77f-7caa6cfb24c5"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0f3f330-8114-42f3-a693-151eacfc8eaf"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6944c4c-9aff-4bf2-b901-3f14a90776ac">
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617069"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e122c7dc-689d-49e1-a910-3f78fae0dc59">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e48c0ef-ef8d-4458-89a1-072b3d07abe4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/157640"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24943079</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c8e9e07-22d4-44e3-b77f-7caa6cfb24c5"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30941926</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f106f5c7-4475-47ae-ace6-297114719c56"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d1a55ef-6f84-4d03-a743-63512788e253"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30838265</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ab49dff-ad2e-4f07-9a4f-ccb1ef637b64"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf53bf1f-30d0-4e05-99cd-c0a2643e5f3d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f63cc1fe-8fcf-47a0-9f3a-f9c3a3153139"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1824982a-b31b-4281-a7af-33d6ab85c41d"/>
    <rdfs:label>Levodopa</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/710a49af-3726-4803-9e06-170c359e4960">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7705cf09-ef71-4d71-821f-02567e2be87f"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/adc0abef-4fae-4067-acfc-2971a76182d9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617070"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2ecb9285-74c3-4cd9-a069-11183fd2116a">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609283"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5b29b2c2-1989-4344-a363-d0e6b51574aa">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
        <rdfs:comment>The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/180a9576-bb7e-41b4-9f7a-00618d1aaef6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0eb01b4-e787-4698-81cf-fe073da695ac"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
        <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2dd11df7-af0f-4e6d-a1c1-38f3f7904d05">
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25660576</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f84d6a38-d67b-447d-9daa-517159d50702"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01235</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45090e76-920c-4401-8822-f4623f98129d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>Abstract</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607483"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7705cf09-ef71-4d71-821f-02567e2be87f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01235</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2b4b8a5c-e76b-4ecc-8bb3-fed1a8c10256">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16908750</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1691971-0ed3-4f73-bd0e-bef7d49f58e3"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/170a7be9-04e3-4672-b84b-1dd3e9f90c79"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd69de66-aaf9-47e3-8d85-54f327007677"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9886460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c8e9e07-22d4-44e3-b77f-7caa6cfb24c5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d15deb6f-38b6-4e1f-9997-9701298b850f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f3c36e11-64fa-4869-96cd-4a6f9a363522">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/618098"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/650a8b06-38a6-47bc-8e71-db2b107cf0b5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dabf38d-e110-49a4-ba86-8152a8db464f"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ad550cd-e601-49c6-a1d4-701af184ef25"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe7d6914-d155-4dda-82e3-26bbb7986779"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia " LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3be7c341-4782-4283-a0ef-68eb7d3e9405">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12391354</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7705cf09-ef71-4d71-821f-02567e2be87f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b1fa480-7c9f-401d-8a83-0cacbbea237f">
    <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <rdfs:label>Abnormal blood Phenylalanine levels</rdfs:label>
    <dc:identifier>HP:0004923</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/923532a0-4c2d-491d-b095-37d3326e9c9d">
    <dc:identifier>HP:0000952</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000952</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>Jaundice</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66d768bc-3899-4bf0-9dec-1fe58d6e8da8">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9035c99e-dfa9-46cf-91b0-07e92b3a0646">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01109</ddiem:url>
        <rdfs:label>Heparin</rdfs:label>
        <dc:identifier>DB01109</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e5b7ef2-243c-4552-8bb9-978150c7101e"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80d72dbc-8013-4960-82cd-d0ac7a366c59">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f240a42b-04ed-4b3f-8989-9d579454afff">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f11e9a37-9c02-44cf-8b43-be0a8d2015bb"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ebc8ac9f-1335-4689-a0e7-1afc4fc2e16e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916316</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a53e94da-e15d-42a4-9bf5-6e542b08c26d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87581fac-db17-4ef5-bfe2-26b940cd6d20"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b05134df-ff75-4503-a55c-5f19b9076e67"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>5-methyltetrahydrofolic acid</rdfs:label>
    <dc:identifier>DB04789</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04789</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97fad832-944b-4f76-9921-69d21a4f50a7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal fasting triglycerides</rdfs:label>
    <dc:identifier>HP:0002155*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f34dc074-8341-4da6-998e-fd685fb86a2d">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/713a11d7-179f-40ce-94ee-367c3aa92000">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0003304>"c.84−322A&gt;T, c.163 + 695_163 + 751del57, or c.164−712A&gt;T"</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5db1a34-1a50-4510-9ef8-c7e2ba649228"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/605b5870-24b5-49e8-b116-1f36795713f3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21542064</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Antisense morpholino oligonucleotides (AMOs)</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/530c25ba-8e41-4837-860f-78aa26080fa6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbb384d1-9b3e-4e8e-88c8-3b1313402e64">
        <dc:identifier>HP:0045010</dc:identifier>
        <rdfs:label>Abnormality of peripheral nerves</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045010</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00840112</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231530">
        <ddiem:iembaseAccessionNumber>236</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/231530</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/236</ddiem:iembaseUrl>
        <rdfs:label>3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b393fbe1-867a-4b16-88aa-aaddf4dcf486"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7c9130a-cd05-4eac-9b3f-ae69465f0f06">
        <dc:identifier>HP:0009830</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neuropathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/354665e3-ec16-4be4-884e-4a5accf9eefc">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a5790da9-514b-400b-93b3-3a223e76ba7c">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29395598</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/73c3bd63-7956-4388-a436-5fe57f4c6f33"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ed148c7-0062-4530-86a4-2e5bc3923f75"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb3f8598-5f6d-4433-9a02-db4f7a993f03"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00869</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00869</ddiem:url>
    <rdfs:label>Dorzolamide</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe3970d4-ca2e-49df-bf20-da83bac44bee">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d1ec00d-fe63-46dd-97b8-1541001b8050"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19d207b9-f6fa-4fd2-af26-d56a6281799e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2c9f493f-ba6c-4be8-94b8-c89b133bba78">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f7581c5-e52f-484c-89a2-dbec0ec8f5fe"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09e26eb0-7114-47f5-a087-4d153ed09eea">
        <dc:identifier>HP:0100786</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
        <rdfs:label>Hypersomnia</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/923532a0-4c2d-491d-b095-37d3326e9c9d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19c8dc2d-3194-4eb2-9f63-4ce04024cbfb"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6cd68142-6b8c-4c6e-99ee-ca4a3b6900ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/51e74382-b33a-4ee3-b09f-e926b79dda48"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80f6b2d4-007a-4961-9f80-879789299121">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Carnitine deficiency</rdfs:label>
        <dc:identifier>HP:0003234</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c620b734-6eb7-4cc8-8462-c031696e20fe">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:label>Hypotonia</rdfs:label>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fa7f43d-6691-429f-b62b-75b88fce95c9">
    <rdfs:label>abnormal glucocerebroside level</rdfs:label>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003656</ddiem:url>
    <dc:identifier>HP:0003656</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e70f994-27c9-4e4d-a986-2bd0beab0cb0">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253601">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/253601</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/327fe6b2-6c85-4e45-a2ca-8ff094d8df8c"/>
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02579239</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://musculardystrophynews.com/resolaris-atyr1940</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1592654-e867-4f54-a297-6f6c7245dbea">
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>Abnormal muscle function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/07aba7f1-1bc0-42ea-a38d-5f278980be4a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9c0abdc8-54a2-4c9c-a2f2-6bca4546ab77"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/87181041-8b19-4f5b-924b-866a8620e1dc">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15e4c981-d915-4f89-9a39-a4ab125b9905">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000100</ddiem:url>
        <dc:identifier>HP:0000100</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>glomerular proteinuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14690254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/899e2f47-9424-4fe5-8593-50c02f330ea3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/087c929d-e223-4849-ad29-fa854cc76e7e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/221e1eb6-a9b5-455a-a1c0-0c7b6a081ecd">
        <rdfs:label>Albuminuria</rdfs:label>
        <dc:identifier>HP:0012592</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012592</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c84814e-2432-4850-88ea-db6bafa7cdf5">
    <dc:identifier>HP:0001939*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>Hepatic Biochemical abnormalities (Laboratory abnormality)*</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb048a6e-7f4a-4e2a-929b-f2c7a6fe54eb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66ba728c-bb25-40f2-855b-ea26c278656f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/05bbedef-c68f-404e-abed-7ac65add4c22">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19cc165b-bc2d-410c-af0e-e99f49312e78"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00107783</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/07621479-228d-435d-a301-13b7e4ba5143">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1954b0ac-2125-486a-bdf6-fd1241548bb3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fae1fa08-5c90-4b24-b958-7dda5ecd5aba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030764</ddiem:url>
        <rdfs:label>ochronosis</rdfs:label>
        <dc:identifier>HP:0030764</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26891864</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203500">
        <rdfs:label>ALKAPTONURIA; AKU</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/23</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2749c6a2-6b4b-476b-a8d0-0e74f1613927"/>
        <ddiem:iembaseAccessionNumber>23</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/203500</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f1903f8-f9e1-430b-91c9-aa3166a91eb7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae058a08-c2a4-45eb-96dc-56fc95ddcac1">
        <rdfs:label>High circulating HGA (homogentisic acid)level</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/35f94696-5960-469d-8da2-b6c54fc3ecec">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b9e75a2-6dec-4521-8e62-6049e6a9734e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d96b39e4-978e-492f-a2aa-8c6a7ecb5d72"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c815a0a6-9e2b-4ee6-bdd4-c68fb13e89ba">
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <rdfs:label>Hypokalemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/202110">
        <rdfs:label>ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>125</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/202110</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ae9020de-6d73-4dcd-88bd-c9afbfc4ecab"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/125</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b09e8356-feb4-4c4c-9ed9-5e4808c44dfc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bone mass loss</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c303b716-bd7c-44e5-a362-7a7629eb4068">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040085</ddiem:url>
        <rdfs:label>Abnormal plasma aldosterone</rdfs:label>
        <dc:identifier>HP:0040085</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/baa5bc29-097a-4f7f-9bd7-b4056e03d8d4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypertension</rdfs:label>
        <dc:identifier>HP:0000822</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f0cc4bd-254d-4f8a-b72d-175167253f5f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5182b3d3-d161-4891-a2af-829e1b717080">
    <rdfs:label>abnormal motor development</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
    <dc:identifier>HP:0001270</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab22f209-2c7d-4ca2-b877-8f18119c110b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03514420</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ecd73e7f-8f9c-435b-8b5f-198dc4e5dedc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dcfb37cb-d346-46da-a4ec-ee32dd1bdf2e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56dbf746-71e2-4e8c-8c71-c2f2eb09ae1e">
        <rdfs:label>high fasting triglycerides</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf7cbaec-f52e-4751-ab3f-b56a2a9a5740">
    <rdfs:label>Lack of emotional expressions</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030213</ddiem:url>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <dc:identifier>HP:0030213</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/36230340-83f2-409c-af8f-a505d7454a35">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88cf1e1b-908d-4b38-b0f0-325a006f3910">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
        <dc:identifier>HP:0011031*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>iron overload(Abnormality of iron homeostasis)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17124037</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2c7b03d-c9c8-4e65-a722-cc4fc1f89ddf"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602390">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/581</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602390</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4ca1e314-7546-47b7-81ef-765a3621bcb4"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cef41258-25bd-45ff-8ee5-824b7a656ef0"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 2A; HFE2A</rdfs:label>
        <ddiem:iembaseAccessionNumber>581</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cc9d3eb-f131-41aa-91e8-31cc0640fe8d">
    <rdfs:label>High serum  bilirubin concentration</rdfs:label>
    <dc:identifier>HP:0002904</dc:identifier>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/87d9fae8-8dd8-4fd5-a0f4-ba16cff8c354">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28935503</dc:provenance>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3619e842-2242-42b9-ae94-3d42062cf945"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231005">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GAUCHER DISEASE, TYPE IIIC</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8d84618c-2ff1-4a3c-8aee-e89eefc6d4c2"/>
        <dc:identifier>https://www.omim.org/entry/231005</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c968b70-5bbc-4983-930e-0119a1c5a8ea"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0003304>CYP2D6</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2fa7f43d-6691-429f-b62b-75b88fce95c9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/740a7023-61ad-4d20-af46-992194b1687c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30264864</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/280eb90a-c548-4bd2-aa9c-d12e2ec019ee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29680197</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cba92a08-d51f-4df4-bbb5-3082dc781462">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7af4598-a392-4fbb-a3ac-92810586605c">
        <rdfs:label>Fat malabsorption</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/81f97e19-18c2-4605-a66c-b048e474f27d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/29c5b4b8-21b3-4761-a894-74e857e66700"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2596948</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b90f14f1-0f9d-4c19-8d78-fc314266505c">
    <dc:identifier>HP:0000817</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <rdfs:label>defect in eye contect</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9e269da9-3962-41c0-aef3-f4a00b2628a2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1d077bc-5b83-4cd6-a7c9-e66e41dcdde1">
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"No remarkable clinical improvement was observed and therefore, treatment was discontinued"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890588</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/321b231f-f343-4dc2-a059-6d139812133a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40c70283-f926-4d0f-81dc-32ca59139b01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615181">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1121</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1121</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615181</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/774dd6ca-1f70-471a-8b5a-4f6e55e3a3ed"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac68cac4-e406-4e85-ac7b-1c7baa6d3abb">
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9046addd-c582-4a31-ac8d-33e1d963d4e2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/310a7f40-db1e-436a-8be8-aa92d97ae0b7">
        <rdfs:label>oxidative stress</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aeda1843-ddb1-41cb-b2f1-e7f39a2437f2">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/41501593-2696-4c57-ac5e-f7a8c80c44a3">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21393975</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19aa756d-5b56-432f-8256-6811b5817130"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f095d250-f471-402a-b16d-db8821fbe28e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c229c5a2-4af7-4983-99a8-9d44a982820c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f43dd3e-ced0-46c0-ae59-85c028feaef8"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ec2c82f-ce75-410d-93d5-3883dd1f9d45"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01015)</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01015)</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1ca0642c-65fe-4a74-b063-d1ab25ff2b91">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87961b08-722c-4642-8d38-aec9cda90fdb"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99082cbf-1c71-460e-8990-f7c5bf667520"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bf8619da-7c0a-4693-b916-6eea3d25a40c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3c69ada4-8ee7-41c5-ba96-d8a94c719d02"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/085c2464-f549-41f4-910b-718913aa87ae">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <dc:identifier>HP:0001263</dc:identifier>
    <rdfs:label>Developmetal delay</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ea1818b-f3e0-41a4-b222-8ec9e7552f0a">
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
    <rdfs:label>Rimmed vacuoles</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003805</ddiem:url>
    <dc:identifier>HP:0003805</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fefccdac-036c-4aad-ad96-e6c25d60446f">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d39d14a-8da0-4ad7-92fd-a79fd4fea28e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <dc:identifier>HP:0045082</dc:identifier>
        <rdfs:label>Low lean body mass</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10770174</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/174fc494-ed06-4bbc-b084-fd441213246f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65542f39-1939-4b25-959d-d0a6df27f95b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
        <rdfs:label>Insulin resistance</rdfs:label>
        <dc:identifier>HP:0000855</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of "increlex " supply.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12fbb925-4b64-4abc-89a1-4e170eb4aed6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <rdfs:label>Abnormal linear growth (Decreased linear growth ,Abnormal body height)*</rdfs:label>
        <dc:identifier>HP:0000002</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6d0c224-d3a0-43af-b4c3-c96874f85ece">
        <dc:identifier>HP:0040215</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040215</ddiem:url>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <rdfs:label>Abnormal circulating insulin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0191401d-1943-4610-8981-115113817ef0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031034</ddiem:url>
        <dc:identifier>HP:0031034</dc:identifier>
        <rdfs:label>Abnormal circulating IGFBP level</rdfs:label>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3eb6f54e-fc97-452a-bc0d-5773a3bfea68">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008189</ddiem:url>
        <dc:identifier>HP:0008189</dc:identifier>
        <rdfs:label>low insulin senstivity</rdfs:label>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7376a1ec-0206-44d6-a27a-d91e2759a425">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:label>Low height velocity</rdfs:label>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <dc:identifier>HP:0004322</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4c961ea-da06-4d23-8621-78683f9edc05">
        <rdfs:label>Decreased body mass index</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <dc:identifier>HP:0045082</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d68314ac-d018-4283-8618-ddded2696cab">
        <dc:identifier>HP:0025521</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025521</ddiem:url>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <rdfs:label>Abnormal Body fat composition</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10323388</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92d02e21-aa2a-4d03-9333-410ff48e8e55">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0032367</ddiem:url>
        <dc:identifier>HP:0032367</dc:identifier>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <rdfs:label>Abnormal circulating GH level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b83246bb-8f17-4e47-9e4f-70b9f3d6a878">
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e547bea8-dcae-4614-8715-acde4386ab30"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/278000">
        <dc:identifier>https://www.omim.org/entry/278000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/302</ddiem:iembaseUrl>
        <rdfs:label>LYSOSOMAL ACID LIPASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>302</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/36002e46-77cb-4c04-87bc-fad314b77b8e"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4c49daa0-d8fa-484f-b63d-f8331d6bf23b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da3da51e-fe71-4ff9-b3cd-919ac2de0761"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99ba6e96-be29-4a5d-b98d-36043b4604b5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dyslipidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261600">
    <rdfs:label>PHENYLKETONURIA; PKU</rdfs:label>
    <rdfs:comment>Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d139edfa-125e-488e-bddf-438c1ace9444"/>
    <ddiem:iembaseAccessionNumber>1</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/261600</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/226e1adc-7f31-42af-996b-2f807da94587">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601678">
        <dc:identifier>https://www.omim.org/entry/601678</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/34c89dc8-7477-4f74-ba96-61c6475b2ef0"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27918a38-5398-4b52-9250-e62f8de8bb21"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6a32b018-99ab-4d2d-bae1-d16c40936add"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da477659-1364-473b-b18d-41190cdd5085">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>electrolyte disturbances</rdfs:label>
        <dc:identifier>HP:0003111</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003111</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/200ad486-10bb-42a1-868c-708c42a6b386">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10f49877-1012-4b56-b226-81e3a5eaa8de"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3dfb6e43-b532-44e9-b8df-f6f3065cad18">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High CSF guanidinoacetate levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c924500a-b941-4daf-bbfe-54edd7cec2b8">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c815a0a6-9e2b-4ee6-bdd4-c68fb13e89ba"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0433baae-48a3-4248-8b26-e61c8326e1e0">
        <dc:identifier>HP:0003566</dc:identifier>
        <rdfs:label>Elevated prostaglandin E2</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003566</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef63b1c0-40ee-41c6-bc30-49e359b8ffc1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/57dcb855-2b70-453f-ae37-6d34cb1c8ba2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af25a0a8-2a6a-44b3-bcf9-bbd2aee55ef3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High calcium excretion in urine</rdfs:label>
        <dc:identifier>HP:0002150</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7991dd77-d27c-4918-a27a-6f3d836350cb">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d6df4f3-6864-4a49-9cf2-b56ae9a6ac7f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba887d54-d562-439c-8ebf-ab828fc0128e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <dc:provenance>https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66f17444-16ba-4113-8cf3-9ee36bf20693">
    <dc:identifier>HP:0011042</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011042</ddiem:url>
    <rdfs:label>Abnormality of potassium homeostasis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/df632b91-9862-400b-a71b-94357212cf24">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e3ce9c6-96a3-4e98-a8af-f97f89c40c71"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba887d54-d562-439c-8ebf-ab828fc0128e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/906b6b67-2b7b-4487-aa52-b012b42ebf72">
        <dc:identifier>HP:0003200</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>Mitochondrial proliferation in the muscle</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33162769-4298-4b8d-9531-af50f5f5c559">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:label>Lactic acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1017b322-be22-4ef2-82d6-573ce5455c64">
        <dc:identifier>HP:0003546</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003546</ddiem:url>
        <rdfs:label>Exercise intolerance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62189108-4c04-4c9b-ad4d-d5dbef663633">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
    <dc:identifier>HP:0100529</dc:identifier>
    <rdfs:label>Abnormality of phosphate homeostasis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1dddedbf-19fb-4213-99bb-9670b1ff50d1">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1bc86550-6c8c-45be-b501-444db9985da9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/040e9c4d-3fe6-4f13-85cd-9917b95cdac7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e16f343-1deb-471c-98c3-d30b29cced18">
        <rdfs:label>hypokalemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.nejm.org/doi/full/10.1056/NEJM197807132990214</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602522">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602522</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1079702a-a144-4da5-b533-922e78a4910b"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9806fd37-4b2c-4760-b1ba-219e83d03d0c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd3582cc-97e9-4d5d-8b45-ddfc12e2eac2">
        <rdfs:label>Skin papules</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
        <dc:identifier>HP:0200034</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8ec2c82f-ce75-410d-93d5-3883dd1f9d45">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bcbe2b99-136c-4d8c-bebc-8849697ed432"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5a9aa2f-f401-454e-b833-a22607ae9745">
        <rdfs:label>Skin lesion</rdfs:label>
        <dc:identifier>HP:0011122</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011122</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24748909</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a14971bb-80a8-4c5f-8be4-1c66a479fc69">
        <dc:identifier>HP:0001072</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001072</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elbow skin thickening</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28681064</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d423cd6-6750-4f45-b0c3-547aaa3e338a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
        <rdfs:label>Mucosal lesions</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0200034</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23259080</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18808438</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df3a2cd6-81b0-472c-84d7-0b8b41c21da0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000962</ddiem:url>
        <dc:identifier>HP:0000962</dc:identifier>
        <rdfs:label>hyperkeratosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44a6219b-74e7-4d7a-b2c8-0259860d5da0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hoarseness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001609</ddiem:url>
        <dc:identifier>HP:0001609</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e15a74e8-77a1-47b4-8eb2-e2ffacfa1ad3">
        <dc:identifier>HP:0012500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012500</ddiem:url>
        <rdfs:label>verrucous lesions</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/247100">
        <rdfs:label>LIPOID PROTEINOSIS OF URBACH AND WIETHE</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d6e3b98e-a7f5-418f-9f85-6174b0fc8576"/>
        <dc:identifier>https://www.omim.org/entry/247100</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28720532</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/98f5a9a0-1ca3-4f81-8ce0-7ef6b51d6a26">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14169454</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17334708</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236800">
        <rdfs:label>HYDROXYKYNURENINURIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7a32e566-a25b-4769-8fa3-59980360b99e"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2019216/pdf/archdisch01582-0040.pdf</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e319ca43-4a04-406f-abc2-50556bf0221c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfbeb8f9-411a-427c-9e6f-3463feca702d">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:label>diarrhoea</rdfs:label>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63332306-8f4f-4a2e-b509-f3b07e1dbad8">
        <dc:identifier>HP:0000726</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <rdfs:label>dementia</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a48e2ea-b4b4-4935-8f9a-5f1940e8590e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f2970c3b-0e99-4125-90e5-2af43fd55728"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9adef28d-3df3-49ea-9bd6-ab6c3a5bca76">
    <dc:identifier>HP:0002180</dc:identifier>
    <rdfs:label>Neuromuscular degeneration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75e2f30a-baa6-49b4-bf12-bcd751ed1ca7">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>High blood ammonia levels</rdfs:label>
    <dc:identifier>HP:0001987</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b1cc5f1d-04dc-4739-9cdc-474889cb0fdc">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a03983e0-7352-4efa-9213-ffd618a6df18"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8b7a562-51f7-4dd0-9f13-6629d76e62dd">
        <rdfs:label>Normocytic anemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001897</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001897</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22219566</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26040326</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9b30696-aae6-419d-9f44-6ddf03f0dd96">
        <rdfs:label>Abnormal methylmalonic acid level.</rdfs:label>
        <dc:identifier>HP:0012120</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b24cdcf1-0885-4aa2-9af0-295d5f390a19">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040126</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low level of serum B12</rdfs:label>
        <dc:identifier>HP:0040126</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24222293</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51f37eb8-c480-4082-8501-6ce913a4f7d5">
        <rdfs:label>Hyperpigmentation</rdfs:label>
        <dc:identifier>HP:0000953</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000953</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f1283d9e-bcea-43ee-9a95-111eb639f753">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/93611818-145d-424e-bd73-b74469a02618"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29572946</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27942180</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/335e2fb2-d78f-4127-9bec-fab9b8c8fcc5">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001889</dc:identifier>
        <rdfs:label>Megalobalstic anaemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23364648</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d1ec00d-fe63-46dd-97b8-1541001b8050"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c255c403-ab85-4cd9-8314-ee9e902adc72">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Increased liver enzyme activities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18768530</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26958680</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261100">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4bcbfadf-16dd-4f29-b2a9-a16a37311c14"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/83</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b2c60bbc-d256-4d3c-b733-2b54d38ee601"/>
        <ddiem:iembaseAccessionNumber>83</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/261100</dc:identifier>
        <rdfs:label>MEGALOBLASTIC ANEMIA 1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14593474</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da588ead-0424-4da0-a6c7-00dca2fa8e50">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002756</ddiem:url>
    <rdfs:label>stress fractures(Pathologic fracture)*</rdfs:label>
    <dc:identifier>HP:0002756*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7909105d-5301-414d-8868-2f4ab5efd53a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/324a2bb9-a318-4e19-a857-4cc1e7a786ef">
        <rdfs:label>Renal tubular acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001947</ddiem:url>
        <dc:identifier>HP:0001947</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/227810">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ccc115ba-589b-4989-bc38-a5811a8f8be4"/>
        <rdfs:label>FANCONI-BICKEL SYNDROME; FBS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/227810</dc:identifier>
        <ddiem:iembaseAccessionNumber>481</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/481</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f7581c5-e52f-484c-89a2-dbec0ec8f5fe"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d7b7406-d67a-46cf-9906-1832f0b95a20">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:label>Abnormality of metabolism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/48177d94-d3e3-40b1-927c-1c025b88246b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4564bd3b-979f-474e-9998-dbfd773b4a22"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7705cf09-ef71-4d71-821f-02567e2be87f">
        <dc:identifier>HP:0001332</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:label>dystonia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ab959336-4ff3-4517-aedb-40d0cfa07163"/>
    <dc:provenance>https://emedicine.medscape.com/article/942055-treatment</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cb38fb38-cce2-41fa-9c58-da137f24db73">
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8b3123d7-360a-48a4-8d1f-cf439fb07d47"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9493705</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e7892b2-aeaa-4e1f-ac4f-6f8ae3407816"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44a4e2fe-c3de-42b3-9906-d8e948b5af7c">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4216e31-4d7a-49da-9c01-1ce09c7971e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26865117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e683de2e-5d55-4e8c-af92-9c46bac98b77"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603358">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/208</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/603358</dc:identifier>
    <rdfs:label>GRACILE SYNDROME</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>208</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/46a724ac-023a-435f-b6f8-2214139913a2"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b20d2032-88df-43c8-989d-84ab22855911">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/835b9b70-742c-4248-ab3d-3e21690ad988">
        <rdfs:label>MorningHypoglycemia (Hypoglycemia)*</rdfs:label>
        <rdfs:comment>Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012051</ddiem:url>
        <dc:identifier>HP:0012051</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240600">
        <rdfs:label>GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A</rdfs:label>
        <rdfs:comment>GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>497</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/240600</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/497</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b25a3484-5220-45a9-9691-641f595d10db"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d25b5d52-4979-424f-97ba-750bf314cbf2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7899a335-be11-4ec0-a3c4-bcb7df781008">
        <rdfs:label>Ketosis</rdfs:label>
        <dc:identifier>HP:0001946</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acbbc2cc-7bca-4944-b0d7-a90ee6b323a4">
    <dc:identifier>HP:0012212</dc:identifier>
    <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012212</ddiem:url>
    <rdfs:label>Glomerular hyperfilteration (Abnormal glomerular filtration rate)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b6e6b72d-5c2b-43c5-bb16-edd8237f90e1">
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/249866bc-1f9a-41c1-8aa5-eb8380eb114a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55c84033-7af0-4536-ab1d-959de1029e72"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309000">
        <ddiem:iembaseAccessionNumber>1061</ddiem:iembaseAccessionNumber>
        <rdfs:label>LOWE OCULOCEREBRORENAL SYNDROME; OCRL</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1061</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/767d8e63-348a-439c-99e3-8f5c68a0b666"/>
        <dc:identifier>https://www.omim.org/entry/309000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e16619e4-094a-4e2b-9821-ac38cb51742e">
        <dc:identifier>HP:0004918</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004918</ddiem:url>
        <rdfs:label>Metabolic acidosis (Hyperchloremic metabolic acidosis)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c815a0a6-9e2b-4ee6-bdd4-c68fb13e89ba"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a78425e9-6824-49aa-9952-78a5ab0908b4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24873726-ae88-40da-a171-752293433d82">
        <rdfs:label>cognitive deficits</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01681940</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db2c2973-d953-4897-a240-b78e1af162b6">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>High NFL (neurofilament light signature ) in CSF</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d676e176-24c3-49c5-96c7-288ca3105143">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Elevated Tau-p level in CSF</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609458">
        <rdfs:label>MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/609458</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bfde057e-008c-49ae-ad2b-31d121b63d1d"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60505e7c-66c9-41fa-9589-ec318e0cc2ae">
        <dc:identifier>HP:0030878*</dc:identifier>
        <rdfs:label>Low FVC%</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030878</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/921670be-9fb2-4adf-8d76-6c7965350513">
        <rdfs:label>High CSF MAN2-oligosaccharides</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82a574cc-56c8-48fd-bb03-a29cce75e2d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5eaf7e8b-cdb3-4852-95b2-a6f197efb99f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1093831-5f62-48ea-9b26-f1c187c34d1c">
        <rdfs:label>Elevated GFAP(Glial fibrillary acidic protein) level in CSF</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/607fc8ca-5920-474a-976e-fceff3a5261b">
        <rdfs:label>Reduced pulmonary function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/69c1e634-ccf9-44c9-8182-07a576fb14bb">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db9e8854-310a-4f73-b270-0c2d201c3f26"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cc9d3eb-f131-41aa-91e8-31cc0640fe8d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/994905b2-8b95-4390-ac4e-5d2a11fdfecd">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99ba6e96-be29-4a5d-b98d-36043b4604b5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e547bea8-dcae-4614-8715-acde4386ab30"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/02aa72cf-ad1a-48f8-975e-bf54c10fd78f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a1d3af4-e466-43c5-933d-0f733b2ce2ba"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82ee7077-0312-44a6-902e-b095e79f250f"/>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1801793</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c7df8813-36c4-4b7b-8e7a-4a952d72b5c6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc622bf1-30e1-416a-9f4e-0a5d0455c587">
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:label>Pruritus</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3ef1281-9a00-46e2-8d22-b8fab8378462"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a68fa1fe-78d0-4bf4-a877-8aabf06efbed">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0012029</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012029</ddiem:url>
        <rdfs:label>Abnormal urinary steroids levels(Abnormality of urine hormone level)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3acd50e7-d554-42e7-88d8-aeac560b9d8f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ill-being (Constitutional symptoms)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baf82bcb-897a-49e7-847c-60c073471f15"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607765">
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a547561a-25ca-4d4a-962c-5856d48f5bde"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607765</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bff90ef3-1d43-4674-9b85-045bfa1ee09b">
        <rdfs:label>Abnormal urinary steroid level</rdfs:label>
        <dc:identifier>HP:0012030</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012030</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5ba130a5-d332-4bbf-a316-0228dba20d0c">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d25b5d52-4979-424f-97ba-750bf314cbf2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1dc72fe7-f705-441b-819a-71af064e2d22"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2464ef8e-6401-4dc2-a288-040f84f55cd1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1531c63-2b20-4e27-af04-634d50947040">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:label>Failure to thrive</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001508</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e58916ee-5c61-4857-b6ba-73491be6c342">
    <dc:identifier>DB01393</dc:identifier>
    <rdfs:label>Bezafibrate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0625b987-38ec-4229-91db-0ed7adf44a37">
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
        <obo:RO_0003304>c.1528G &gt; C</obo:RO_0003304>
        <obo:RO_0003304>c.914 T &gt; A</obo:RO_0003304>
        <ddiem:failedToContributeToCondition>c.1528G &gt; C</ddiem:failedToContributeToCondition>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee576832-b743-4ee2-b4b4-42f50609adbf"/>
        <obo:RO_0003304>c.180 + 3A &gt; G</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dd1ebc4-82d8-4781-a490-6e6d266d252f"/>
        <obo:RO_0003304>C2129-2A &gt; C</obo:RO_0003304>
        <obo:RO_0003304>c.982G &gt; A and c.1072C &gt; A</obo:RO_0003304>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bb6d5cd9-2ee2-4d22-b46f-7231d752f071"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0003304>c. 1393_1479del-Del exon</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3fb0ab73-cf4d-43d0-8ac3-3c121ff39267">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e731f8b0-b078-4018-9508-323979ae89fa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21354122</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17f84492-8f3b-48d6-a669-b5ddb511f67c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/61f4d4f0-c486-4579-adaf-cf16240979f6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695963</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bb6d5cd9-2ee2-4d22-b46f-7231d752f071"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27286958-5551-4ec5-a702-e1448996dd38"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28279226</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1017b322-be22-4ef2-82d6-573ce5455c64"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01393</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0907cf77-fce3-4f7a-9ed5-98f7068de5f1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3287f1f-e5c0-4585-ba5c-1144012bcb80"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e3ce9c6-96a3-4e98-a8af-f97f89c40c71"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bb6d5cd9-2ee2-4d22-b46f-7231d752f071"/>
        <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd60f9b5-08bf-4937-8293-db227d8b7ad6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3eba4a39-7cf3-408f-ab8c-5bd0d8713ada"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b7d156fa-a206-4de1-ba6f-e3343317baa9"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0da86fec-9c90-44aa-ba00-8b4dc4c2dc03">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c1d6f17a-e90e-4016-a113-4ce68977b488">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ddf0d56c-77d8-47af-b8c5-c0003fbfd4e4"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83d03909-83f6-48b1-89ea-d70c3f7826a3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006279</ddiem:url>
    <rdfs:label>Pancreatic beta-cell dysfunction</rdfs:label>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <dc:identifier>HP:0006279</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45a74ebc-bca0-4b6a-9b6c-c7ce9bf33795">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54166565-77d9-49f8-8437-d36936482fcd">
        <rdfs:label>Neurological abnormalties</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f90b6be-678e-4397-bebe-08d76eabd12e">
        <rdfs:label>Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*</rdfs:label>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0012535*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f6b3ddf-dba8-4d23-b95a-5f5e6268a722">
        <rdfs:label>Abnormal growth</rdfs:label>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <dc:identifier>HP:0001507</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309400">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/199</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/309400</dc:identifier>
        <rdfs:label>MENKES DISEASE</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/037ef9e7-a5b0-4120-a9aa-93e4cacc7f43"/>
        <ddiem:iembaseAccessionNumber>199</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29a94dfa-f38a-4d88-a3de-2edc4c465229">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <dc:identifier>HP:0010836*</dc:identifier>
        <rdfs:label>Low brain copper levels (Abnormal copper levels)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9027c43f-7a57-4b9c-9883-ef51a523eb64">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Behavioral abnormality</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ab67fc1-173b-4db2-b4d5-fcfefad1c3f6">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0003287*</dc:identifier>
        <rdfs:label>Brain mitochondrial abnormalities (Mitochondrial dysfunction)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f1e02808-6978-4b3e-866c-75333330506e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5cf30840-dcfc-4587-a4f1-0d940ca92631"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9cd394f2-3d0a-4c18-a102-d33682a25ef9">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/806eca2e-05f9-4bc0-98de-d01c7dc64b1a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29503270</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c75e0261-0823-4331-909c-4a87e0244c23">
        <rdfs:label>avascular osteonecrosis</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0010885</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010885</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fb0e312-4ca2-4601-b88e-0f363e5d142c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
        <dc:identifier>HP:0004348</dc:identifier>
        <rdfs:label>abnormality in bone mineral density</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c968b70-5bbc-4983-930e-0119a1c5a8ea"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/870090f7-7fba-401a-bfc4-2ff27add7f00">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67c4cd09-a962-4479-a862-af65d014c933"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38a203bf-ab58-4ad5-9697-77b6f3a39517"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78c53d08-4508-4686-96df-8a11c7083902">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0100712</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100712</ddiem:url>
        <rdfs:label>changes in lumbar spine (LS)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3a2122e-76d4-4ad4-a7ed-9f9d8dbe8dfa">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>growth faliure</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b952cd1a-5a8e-4130-afc2-ffce823c5518"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/98e32a7d-e144-4622-904f-6dd69e67b686">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30d3f8b0-4090-420a-9270-6059c1071579">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>biochemical abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31314ead-af8a-40f6-b0ae-c7e05ed7b242">
        <dc:identifier>HP:0500014</dc:identifier>
        <rdfs:label>Histological abnormalities (Abnormal test result)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76c89a2d-6e5f-4ed7-a694-d22075c0ed8a">
        <rdfs:label>production of toxic bile acid metabolic intermediates</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/179add65-4c8e-4380-894a-6a10b8f662e5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0500014</dc:identifier>
        <rdfs:label>Histologic abnormalities in liver(Abnormal test result)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/100435b6-f035-4fff-ace7-6021f7cb8105"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8173b10-c750-4495-841a-5114c3a12404">
        <rdfs:label>Liver biochemical abnormalities (Laboratory abnormalities)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/637d15c3-1292-4f57-a558-a0f757591572">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:label>fat soluble vitamin malabsorption (Fat malabsorption)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19cc165b-bc2d-410c-af0e-e99f49312e78"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00540989-a70b-4ac3-9e00-8c267a1cb85a">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>synthesis of atypical bile acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c4c6d0e-a95c-41c3-bddf-1d46de140c93">
        <dc:identifier>HP:0001396</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Bile flow defect</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/175a3bf5-89da-4705-a45a-0a3f32f10f07">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Atypical bile acid synthesis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/edb97f8c-e46b-4f3e-850d-924815cf7016">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected bile flow(Cholestasis)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <dc:identifier>HP:0001396</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2759e962-0e85-41ab-a097-52b89e10ee2b">
        <rdfs:label>fat soluble vitamin malabsorption*</rdfs:label>
        <dc:identifier>HP:0002630</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/552a5f39-f834-462c-b135-a76e4b2f8228">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>production of bile acid toxic intermediates</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/919b4338-69d6-491a-88f2-2da901d3705f">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005242">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005242</ddiem:url>
        <dc:identifier>ECO:0005242</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f84cffa0-b61e-4ebd-bf13-1acfc40c3cfe"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81d489ea-ae3a-4867-bea3-8f63da521d9a"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20195241</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c712c5e-d205-4ac0-b064-30a22d85fe5c">
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <dc:identifier>HP:0003676*</dc:identifier>
        <rdfs:label>Renal disease progression( Progressive disorder)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9cb81e0-2b2b-4108-a3d1-7c385d692f80">
        <rdfs:label>Abnormal renal function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <dc:identifier>HP:0012211</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1e548bd7-d3fc-4a64-81bc-bc869836d6f9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9811fb78-29ba-43d3-92e4-1f6d5f219c8f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e8641b12-926b-4497-bdb9-b26c5f2ef766">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3743f10e-a44d-43c2-826e-591846c998a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/413b6418-e8a2-4803-aca7-499de10f14cf">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002093</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002093</ddiem:url>
    <rdfs:label>respiratory insufficiency</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e18c6578-9392-4a38-a306-125fa1820046">
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12f5d479-86aa-4085-9d57-218836c89003">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001958</dc:identifier>
        <rdfs:label>Acute decompensation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/439a9774-d084-4f23-aa56-b5d983445ddb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001958</dc:identifier>
        <rdfs:label>Nonketotic hypoglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246450">
        <rdfs:label>3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/246450</dc:identifier>
        <ddiem:iembaseAccessionNumber>62</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/656c5966-c6cc-4034-a0ee-63c9d2e88ee9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/62</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7fd0fecd-8a92-4bcb-af70-8e65c2c73b31"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258450">
    <dc:identifier>https://www.omim.org/entry/258450</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1</rdfs:label>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/00dace53-b78b-45e5-9b17-48727d09a210"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/691748e4-cc7c-4304-a092-d8ddc1f10b5e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615511">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615511</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/129a0a9e-27aa-4e9d-9a4a-321afb9a6040"/>
        <rdfs:label>MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8e18126-eca2-43d6-906f-d3bd09248fe2">
        <dc:identifier>HP:0003738</dc:identifier>
        <rdfs:label>Exercise-induced myalgia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003738</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e7301c1-54b1-4402-813e-ab601c86f782">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0003690</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003690</ddiem:url>
        <rdfs:label>Limb muscle weakness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8f4e141b-af37-4dbc-886e-0b7cd29186ca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/acc9914f-8cce-4f6f-b3fb-158407c41efb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/943475e8-6c48-4357-bc01-9f592937efe9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
        <rdfs:label>Exercise-induced muscle fatigue</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0009020</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3144d802-702e-42a2-a7d9-ee719b4bdbf4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003394</ddiem:url>
        <rdfs:label>Muscle cramps</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0003394</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e2658284-6a89-4c32-84e3-9dd1a7d4dc25">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15505381</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01463215</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99082cbf-1c71-460e-8990-f7c5bf667520"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fc06f2c4-bb3c-4a87-9e29-dc40e822b8df">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d821a19-5e83-4f76-8146-4d379952a18a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fc0895c-cc0e-4511-ad80-441489b5a827"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acde71ee-55ff-43bd-a3dd-0c17cfdb6c4b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>Splenomegly</rdfs:label>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16199246</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91c86fcf-8349-412b-b7f8-f9835b730b58">
        <rdfs:label>High chitotriosidase level</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was used in a pilot study.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12064906</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13e72236-d68a-4ffd-b520-5b6d2d98e881">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:label>Thrombocytpenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42aab52a-c496-446b-bc78-3278c6faba65"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/984967bf-9973-40dd-a0f0-d28bc4bc1468">
        <rdfs:label>hepatomegly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16285070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b249562c-530a-4dd4-8d59-c1c777dfd069">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002415</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
    <rdfs:label>Leukodystrophy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7ec86aba-f75f-4c4c-9505-f47291916ecf">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8a16b7b-d52d-4ebe-ab0e-cea0ebeca228">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030353</ddiem:url>
        <rdfs:label>Decreased serum IGF‐1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1531c63-2b20-4e27-af04-634d50947040"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24579575-9738-45f9-82b6-ba9dd1c4b57c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f9955fc-5971-4eb9-bbee-e38c21c1c84b"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fe23d9d-0137-4473-9ca3-fdf95933f193">
    <rdfs:label>Bleeding tendency</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001892</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/85b73591-6665-4bb7-8ff6-498da262d58e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c62b6683-5dac-42a9-b242-5800cf87c1f0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Motor function impairment</rdfs:label>
        <dc:identifier>HP:0002275</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52a1376d-08cb-4c04-a2d0-71d41754afeb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25400034</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/407f7a0a-4b9f-4428-b94d-4bb1524ebf8d">
        <rdfs:label>Cerebeller neurodegeneration( neurodegeneration)*</rdfs:label>
        <dc:identifier>HP:0002180*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fc0895c-cc0e-4511-ad80-441489b5a827"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7ad08ad5-a381-4ba8-bcfb-3799f285fe36"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31248418</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23948640</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c6fdfc5-cbaf-4347-87c8-54b183887892">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of lipid metabolism</rdfs:label>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aa63fc85-2a99-4d7d-adb6-851c7ae9f9f0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/37076601-2922-4da7-b67c-a07dc220449d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f48ebbee-4a64-4b15-a113-f0e8b3f88103">
        <rdfs:label>Increased number of splenic myeloid cells</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/33b39528-b2d9-4958-8602-e1d68f64e626">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/56daa269-79df-4970-a0a5-7a4f5f97d9a9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfb2a50a-aee9-4285-8a17-35aced9d7d96">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:label>Calcium makes phototherapy more efficient</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adb4ab0a-c833-45da-9906-a61c84590c3c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
    <dc:identifier>HP:0012026</dc:identifier>
    <rdfs:label>high ornithine level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9822dcc5-2bd1-41da-bf90-59ea64a7a9db">
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <rdfs:label>High lactate ,pyruvate ratio</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b86d31eb-3fba-48b9-9bf7-d2002f022938">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80f6b2d4-007a-4961-9f80-879789299121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28053874</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1531c63-2b20-4e27-af04-634d50947040"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/611283"/>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2861f911-6f20-4f98-add4-9e8cde25d325">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1787a727-6f73-4361-9f52-99540fe0a90a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abormal liver size</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a584e3a-a947-460c-8fdc-623be9dd5348">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:label>Cardiomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001640</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/09fadcb7-13ea-4113-9121-88e823b4ddea"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88c0e5e8-a22b-41df-ab4d-28edf5f4b1e3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/769b75e8-60ec-48a0-af5e-f9f921887fbf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c634e67b-d154-4908-897f-d34870f377c1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c06adc2b-d949-4f95-ab58-129a404418d3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/085c2464-f549-41f4-910b-718913aa87ae"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20981509</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2fae039-eaec-43af-a09f-3703a44e71a7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
        <dc:identifier>HP:0012664</dc:identifier>
        <rdfs:label>Reduced ejection fraction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e5b7ef2-243c-4552-8bb9-978150c7101e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f03c408-90f7-4663-9aef-f8c8becba1c5">
        <dc:identifier>HP:0001735</dc:identifier>
        <rdfs:label>Acute pancreatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001735</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66d768bc-3899-4bf0-9dec-1fe58d6e8da8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145750">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4461613d-26ac-4053-8910-4b1c8e59299b"/>
        <rdfs:label>HYPERTRIGLYCERIDEMIA, FAMILIAL</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/145750</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1800965</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9e1fd8d-90bc-4cf5-9752-a3a7c4b29017">
    <rdfs:label>Abnormal circulating porphyrin concentration</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
    <dc:identifier>HP:0010472</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b1455e95-814b-4f38-b695-419c193d2975">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f392474-58d6-4857-bd6a-69e4dfef88fb">
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:label>short stature</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d586f4c-4404-49bc-bad5-811db942e84f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b09eaa05-aca6-4591-93bf-94738835e69c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/212d8a7c-7362-4f81-964e-232081f0d116"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b47c7f5b-49de-4890-99ba-ce50624a3b8b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f3c68883-3f23-4050-b259-ee0807fcb058"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8276f584-b8f9-4ed5-a7d6-85d25a24d482">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Low developmental score</rdfs:label>
    <dc:identifier>HP:0012759*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/973f0eb2-7d4a-4aa5-aa15-cfc2a48e32bc">
    <dc:identifier>HP:0012211</dc:identifier>
    <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
    <rdfs:label>Abnormal kidney function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6acd19f6-8073-4c78-a86b-2b9a4b7b8bd1">
    <dc:identifier>D07A</dc:identifier>
    <rdfs:label>CORTICOSTEROIDS, PLAIN</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad5d65c9-d118-41b6-8e54-c9b665f2b9b9">
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b5cace4-cf31-4894-b705-91b62109460f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59574948-7c0e-4964-8127-3a0ccf3dd0b6"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=D07A</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1c84c233-cc3d-43b9-a3e5-e6afddd5446b">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615398">
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3e54f8c5-4c4c-4e0e-a0da-8ab051da8112"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1147</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1147</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/615398</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9491f06-540d-4bb6-8f47-639723c5d8c7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011167*</dc:identifier>
        <rdfs:label>tonic seizures ( Focal tonic seizures)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011167</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82dbc08a-d06d-4d10-ac8e-70f7c944f8f9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2283cc7-edad-4dc1-ace8-a69e611dbec2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89322347-9e0e-4b12-b58b-1ea908badbf0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10925336</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/33bc7e1a-c38a-4f6d-a1b6-1afe4d19c4a6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/de272b2f-b711-4044-9b43-3687787e84f4">
    <dc:identifier>DB13961</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13961</ddiem:url>
    <rdfs:label>Fish oil</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3dd430e5-b4d6-4fba-9386-aa477f0501b4">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cd74f4c-cd2d-4757-9989-a0fdf6ea739a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e0f8a824-d037-4346-b417-006d2dd5e357">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a44f9fc7-ff53-4ce4-b9a9-750f949cebc0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98222d62-6c2f-49a6-a47c-aaf7ff19fae8">
        <rdfs:label>High plasma levels of hexacosanoic acid</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16949688</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb9b3e85-642b-4753-a567-bc67fa5f3fa7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0003455</dc:identifier>
        <rdfs:label>High plasma level of very-long-chain fatty acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089986</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e39ef700-a95c-465d-923f-b0a360f9765e">
    <dc:identifier>MP:00011911</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_00011911</ddiem:url>
    <rdfs:label>Cutaneous abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/268200">
    <ddiem:iembaseAccessionNumber>750</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/750</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/36f71f72-b6c2-46bd-b734-b88ff49b9e2a"/>
    <dc:identifier>https://www.omim.org/entry/268200</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a868eea-9368-4662-b107-f7dcbc4da420">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <rdfs:label>Low IQ</rdfs:label>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <dc:identifier>HP:0001249</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6b585b46-fcef-4789-b5b0-3976152ed52b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8f0cbf8-699b-4247-bafa-8c2f9edee465">
        <rdfs:label>Alopecia</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001596</ddiem:url>
        <dc:identifier>HP:0001596</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a8aaa7a-c9db-4200-8e18-a4e2d734e023"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/959dfa46-f791-4d19-b31b-210d42b4cfbb">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
        <dc:identifier>HP:0000712</dc:identifier>
        <rdfs:label>emotional disturbances</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dd4dc823-d14b-4339-97c5-d67c463a1f6e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67bc45d9-e598-49a7-96a2-0a84eb8940ea">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>skin inflammation</rdfs:label>
        <dc:identifier>HP:0011123</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef8cea65-913b-4840-b880-749ffbc9318d"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/275ad30b-1d5d-4e7f-9a15-029c4c1dfc68">
        <rdfs:label>diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8d3cda4e-4c72-407d-9df9-b73b287f9b11">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5c2ff21-2d72-4a24-b7cc-2433a1c24adf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000739</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000739</dc:identifier>
        <rdfs:label>anxiety</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21126241</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0c6e98b-b56f-4496-9a32-3919a638a538">
        <dc:identifier>HP:0003808</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal muscle tone</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003808</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0003304>Spa</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/953e83ff-4ff8-464d-a51e-276415257b54">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/953ad751-a505-4cbb-93e6-945330aa553f"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e7bc15d7-8aff-4676-a90e-0185972449a8"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ab9fdea2-592d-43ed-b52f-825528b943ae">
    <rdfs:label>Amitriptyline</rdfs:label>
    <dc:identifier>DB00321</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e4c72f2b-0da8-4822-912c-deec1583c550">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb396713-e9a9-4fd6-9300-97ef2f66d5e5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/228000"/>
        <rdfs:comment>The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18376404</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5e97b65-cd44-46ea-9722-a9d72653f1b5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00321</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2126b31d-7421-41dc-a0ee-d28e5c61c953">
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
    <dc:identifier>HP:0012100</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012100</ddiem:url>
    <rdfs:label>Abnormal circulating creatinine level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/db4641c6-42f8-400f-ad68-1e773be34443">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4b0ba7-0654-4cd1-a6df-644af85ccee6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84eb1f6f-2786-47cb-b7bc-96485c0017e0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:label>Myoclonic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/348f23bb-b5b9-48a5-8d88-6c2b4b08104e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <dc:identifier>HP:0000735</dc:identifier>
        <rdfs:label>Impaired social interaction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70519cde-5e8b-405b-81aa-da3862e01d5b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010819</ddiem:url>
        <rdfs:label>astatic seizures</rdfs:label>
        <dc:identifier>HP:0010819</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613068">
        <dc:identifier>https://www.omim.org/entry/613068</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6555c4ea-7367-4031-a014-333ccf23068d"/>
        <ddiem:iembaseAccessionNumber>71</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/71</ddiem:iembaseUrl>
        <rdfs:label>NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ad550cd-e601-49c6-a1d4-701af184ef25">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Movement disorder</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93dc92e9-7f93-4c80-9038-55658b2e920f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734130</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c7c8f344-6019-4010-8ed2-c7e422fbedc0">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4fd4d48a-cebc-400f-a9ac-3b830e23025e">
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23190330</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0002929707613470</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301835"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3453d0e-3e72-4b12-a506-e8a3ec31d7d8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb3d0a5f-5a46-49ca-9ad0-a2a14bad8a7b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/917a82ee-8ad0-4a0c-b1fe-499fdd8b319d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29def92e-5516-4bb6-b5a0-0d593dd76c72"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a63e2f99-457d-4735-a4b5-0d55cc34367e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c13556e-8a2e-4e65-9738-fd0a34c941ba"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71207d8a-5bda-4e5b-ba01-589867f54340"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17701896</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55aaa97c-b997-4ed9-b454-5ccd8f3aeaef"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20380929</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a67993a-48e6-4c97-a902-653a99b1fb6c">
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a868eea-9368-4662-b107-f7dcbc4da420"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed705acd-bf64-4bea-b7ca-01a56d183d19"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b37f33e-58f9-4e24-bce2-d7e586c65675"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671894</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe4c0af5-1395-42c8-b2f5-755f8a766920"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70f751f4-666a-434a-9306-87557418ef48"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8cb301e7-e69e-4e79-9974-d2726763b8bb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671893</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b15e173-fb74-47f9-acb0-da57cae202c3"/>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671891</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6de31f14-2baa-485b-9da6-4fb11775d69a"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c126bc6c-42f1-44fc-8bd0-ffc45b29275e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7812a678-0179-4883-9846-d5b62f01c26b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671892</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5bd91e87-0822-43fc-8bc6-731636b73e27"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e396864-6189-4ea3-8a8d-23dbf11c9b45"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250850"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f0c805e-5f47-4d53-81c9-ca6f4015a607"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30389272</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671895</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42d007cb-1fa7-43f2-b58a-f03ea2abfff4"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29def92e-5516-4bb6-b5a0-0d593dd76c72"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f429dd25-c536-4de4-a55a-cb670fc08a3d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50f16c19-2f23-4132-8752-e1b8cb55e82c"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7066d890-559e-4241-a9e8-5af0f67e1ab7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671896</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/763e850e-6410-487b-9974-efe16ef8a14e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00118</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4cee987f-0143-4235-b513-d29538f13bbf">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20506325</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29def92e-5516-4bb6-b5a0-0d593dd76c72"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d61b0a6b-7c0e-487c-9701-ad33b3efd371"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00118</ddiem:url>
    <rdfs:label>Ademetionine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9f8ec33-f0a8-4fcf-a022-8a990c8317d6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24055166</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24001191</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29def92e-5516-4bb6-b5a0-0d593dd76c72"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46d2dfe3-57bd-461a-a293-11531b761696"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16906475</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68a964e5-d392-4939-93e6-b7cca5acc0d1"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6bc0d496-3aa7-4d98-8080-11bf05a2e814">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>deteriorating pulmonary function</rdfs:label>
    <dc:identifier>HP:0005952</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f8fcd19-82af-4c66-a6d2-6f1ca7ac3cd3">
    <dc:identifier>HP:0001395</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
    <rdfs:label>liver fibrosis progression</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/82b78b4e-5ba1-48dc-a073-19bf55e62928">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9491f06-540d-4bb6-8f47-639723c5d8c7"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c6c6292d-89d5-414c-bb7a-1c87f78ca878"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cae81557-e668-4c22-bdc9-113788179909">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/68442f21-ea90-43e5-9f50-bfaab706f2ca"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c65f0983-4c76-4afb-b322-cce3b2ab79d1">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d7b8b4f-0f04-4d98-b188-952d762db11e">
        <dc:identifier>HP:0012433</dc:identifier>
        <rdfs:label>abnormal interactivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012433</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609056">
        <dc:identifier>https://www.omim.org/entry/609056</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/360</ddiem:iembaseUrl>
        <rdfs:label>SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/23b60be1-7e62-4a31-b5ed-a83c9629da31"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>360</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22990144</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b90f14f1-0f9d-4c19-8d78-fc314266505c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1554b71-84e0-4f73-9562-6eaf494f6393">
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <rdfs:label>Generalized tonic–clonic seizure</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d0dfafb8-2b69-448b-b8ef-f23e8a2a0553">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dd3973c-6633-4d89-b6c6-6f96be34a7cf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low hemoglobin concentration</rdfs:label>
        <dc:identifier>HP:0001931</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbb2a8b9-4670-415b-9d22-f1acd2273d15">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
        <dc:identifier>HP:0011031*</dc:identifier>
        <rdfs:label>Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/224120">
        <rdfs:label>ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/224120</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/048efba9-1008-40ff-be21-bdcd0abe59be"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4699c5bd-3feb-44be-9d1e-8ac7c00f2789">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e1a1a46d-b046-4bc7-8db7-39c4cbdc697d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed06fe7a-6721-45ec-ac5f-ebd279f6b65d">
    <dc:identifier>HP:0025464</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <rdfs:label>Oxidative Stress</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18ced697-d907-49e6-838c-631986089737">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300971">
        <rdfs:label>BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/300971</dc:identifier>
        <rdfs:comment>Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9dc638ba-576e-4430-a8fe-e7746dfa3e6a"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1a2d404-b82b-4ce1-88f0-e0e490ca39e3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08af73ce-7801-47e6-9387-f72674f5c7ec">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45a850c0-b43a-4ee7-9940-3a3b34945ff0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Accumulated  plasma porphobilinogen</rdfs:label>
        <dc:identifier>HP:0011009</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7e7cb79-9bbf-4cf2-8498-eb1d86a72ceb">
        <rdfs:label>Accumulated  urine porphobilinogen</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0012217</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17375984</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8461a41c-cf13-412e-852f-ebed4b0d5f27">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aefa60cd-2c4b-42c0-af1c-01d4e85c727c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176000">
        <rdfs:label>PORPHYRIA, ACUTE INTERMITTENT; AIP</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/112</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>112</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/176000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/809cdea5-90bd-4edc-bb76-32deba3ff8f9"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93f29abb-72e1-4e29-8cad-47d1f3618442">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High plasma guanidinoacetate levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9678fc72-ca79-4e1e-b3eb-7bf4bb4bf6c1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c6f4bd1-ee9e-4f59-b03b-aa63d2df5926">
        <rdfs:label>Fatty liver</rdfs:label>
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fba027d5-b844-4ed1-8444-4716c59a171b">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>DNA hypermethylation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ce253b5-246d-4745-8069-180d20e9cefc">
        <rdfs:label>Liver steatosis</rdfs:label>
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606664">
        <dc:identifier>https://www.omim.org/entry/606664</dc:identifier>
        <ddiem:iembaseAccessionNumber>25</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.</rdfs:comment>
        <rdfs:label>GLYCINE N-METHYLTRANSFERASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/da36c1f7-09b8-4104-ad9d-000cf941da8e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/25</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4cbbc885-d9da-4a64-84e7-a69ea36ba2a4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e40ad2a3-2b38-4ed0-b2b4-cb905f029fd1">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Liver fibrosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
        <dc:identifier>HP:0001395</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf516853-d0c8-48bb-a1ad-508759967e3c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
    <dc:identifier>HP:0003165</dc:identifier>
    <rdfs:label>Elevated circulating parathyroid hormone level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ced1f50f-7a93-437a-bf10-f2e08a5b377f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e683de2e-5d55-4e8c-af92-9c46bac98b77"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248600">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1252</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/676d3812-e2b8-46f4-82cd-a11c384a5d67"/>
        <dc:identifier>https://www.omim.org/entry/248600</dc:identifier>
        <rdfs:label>MAPLE SYRUP URINE DISEASE; MSUD</rdfs:label>
        <rdfs:comment>In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.</rdfs:comment>
        <ddiem:iembaseAccessionNumber>1252</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/261ccdb8-28e1-4e51-a326-22c8e619f41d">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>High plasma branched chain keto acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5712406-b651-41d7-9eba-4e4b0417f6fe">
        <rdfs:label>High plasma branched chain amino acids</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <dc:identifier>HP:0008344</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2d9a09ce-6bf8-44ee-998a-7918213dce35">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/577c212c-538c-4314-a084-d9900395d701"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/929a96e9-b4b6-4112-ac5d-7c5565b23868">
        <dc:identifier>HP:0000934</dc:identifier>
        <rdfs:label>chondrocalcinosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000934</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c85e538b-5caf-4e20-b77e-60dbb06bf3b7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002917</dc:identifier>
        <rdfs:label>hypomagnesemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e1f5795-1762-4102-a01e-e1e3d24899b4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27928778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43cd9b0d-2b07-469c-aa26-3ffc8b9f227d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/09fadcb7-13ea-4113-9121-88e823b4ddea"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88c0e5e8-a22b-41df-ab4d-28edf5f4b1e3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/650080bc-f589-4d8b-a300-5f8e583603cb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610198">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1012</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/68eb49b2-1a90-4362-86e4-bd18d6b85fca"/>
        <ddiem:iembaseAccessionNumber>1012</ddiem:iembaseAccessionNumber>
        <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/610198</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/57393bef-0b0c-4a61-b898-81e92ede3676">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7915305</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b9ce02bf-7e7e-4669-8ea2-05a0f6bad72d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/75832c35-21bc-4e02-88cb-a1ec79e5f17d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baf82bcb-897a-49e7-847c-60c073471f15"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/51004fec-5e13-4c0e-88b7-5d7dfe230564">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/830d7b46-0b96-4f45-a8c6-e793afb60af4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee72b01b-0d3a-42bd-9341-f10d7b3fe9ca"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e40a102c-783f-4f70-8d6d-b3025e044cf1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03112889</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40c70283-f926-4d0f-81dc-32ca59139b01"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4f3cacc-4e2d-496b-be7a-3153ffaa73c7"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/96858be9-15ce-4592-abe1-48295684843a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40c70283-f926-4d0f-81dc-32ca59139b01"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/321b231f-f343-4dc2-a059-6d139812133a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00313</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6b8f8944-b746-471d-96c6-d732446c7974">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275972</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0414292-5aa7-4e8c-be32-bf47664d40db"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/627ed782-013f-471f-821f-2c06ef4a9ca0"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>HP:0000750</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b28b7fa-91e0-4bc0-b3fe-71a5bf39da16"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40c70283-f926-4d0f-81dc-32ca59139b01"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77e66412-3d83-4d32-9cab-ad35fe65b1a0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eab0f610-7d49-418d-bffd-14d600d4c708">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40c70283-f926-4d0f-81dc-32ca59139b01"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
        <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Valproic Acid</rdfs:label>
    <dc:identifier>DB00313</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fdf9db7c-0dbc-4716-9b8d-a89ff63d25c0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40c70283-f926-4d0f-81dc-32ca59139b01"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8e6e4f13-0b58-4f94-bf37-3888f7867954">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/633f06b5-affc-4bf6-a571-5b761c3d7a9c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40c70283-f926-4d0f-81dc-32ca59139b01"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250850"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1d6ae3a2-74ca-4b53-9a9b-81f5af923800">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06168</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e511aab5-2354-416f-b713-ce1725c48bdf"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/efce7aee-5e72-4cc4-9db0-c544b17f7a43">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd609f51-5db7-45bb-8398-edb18a190327"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/203f3123-efdb-4211-9981-cdb8be77acd3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af2917b4-6861-4d20-9395-9c32ee501360"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07bcef06-b54c-4af9-a883-73c87326d372"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Canakinumab</rdfs:label>
    <dc:identifier>DB06168</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9e1dc7d7-1318-4148-b8ed-dcb4571ead4a">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/249866bc-1f9a-41c1-8aa5-eb8380eb114a"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e42567e1-83e1-42d7-b29f-c70e79273605">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012321</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012321</dc:identifier>
        <rdfs:label>D-2-hydroxyglutaric aciduria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24687295</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e6a3394-2968-4fce-9964-01d85cf8d21b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8afa3253-7436-4763-bc18-b9d646a4730c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
        <dc:identifier>HP:0040144</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low urinary excretion of TCA cycle intermediates malate and succinate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb9aa06e-3085-411c-b0b4-cfe6fa81b254">
        <rdfs:label>Hypocitraturia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012405</ddiem:url>
        <dc:identifier>HP:0012405</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615182">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/96325b78-f9f3-4fc0-bad0-7470dd401745"/>
        <rdfs:label>COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD</rdfs:label>
        <ddiem:iembaseAccessionNumber>924</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/615182</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/924</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3743f10e-a44d-43c2-826e-591846c998a6">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_2786</ddiem:url>
    <dc:identifier>CHEBI_2786</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1e548bd7-d3fc-4a64-81bc-bc869836d6f9"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a63e2f99-457d-4735-a4b5-0d55cc34367e">
    <dc:identifier>HP:0003678*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <rdfs:label>Hearing impairment progression(Rapid progression)*</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aae49135-1dc5-487e-8ed4-a68994200325">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54403bad-a450-4ea8-8952-949baca46ec7">
        <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a3008a5-2879-4912-9f35-995088468c72"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e6d8b558-148e-4b74-b5b9-5b3c0fcce6fe"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03517085</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>DTX401</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9fa19499-5b5e-4f1b-a85e-c0bc7911cfa0">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/80a1eba9-3940-4472-a892-1b152604074c">
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23388701</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc4235b3-07bd-4065-b959-92596d7eb98c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f4d54750-8763-41bc-9f10-bac1fae584c0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e402c0c8-9dcb-4f2e-aa9e-5beb6cab9daa"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25474440</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af5ba1da-196e-45e4-af77-84eaa2659c21"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>AAV-based gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e26f6fd-01ac-48e6-977e-3eebbfa0dbed">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263700">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/111</ddiem:iembaseUrl>
        <rdfs:label>PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>111</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0fabd277-755e-46bc-b0b5-8c2c1c2012a7"/>
        <dc:identifier>https://www.omim.org/entry/263700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24145442</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b76c29da-0f02-44db-9d73-b03c6be72195">
        <rdfs:label>premature degradation of misfolded UROS mutants</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334762</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cec75a4-32a7-4d48-a22e-8f5db97191b8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <dc:identifier>HP:0012187</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>high porphyrin accumulation in circulating RBCs</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50751f5a-c553-4edd-86df-8053fb848816">
        <rdfs:label>abnormal porphyrin accumulation in urine</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010473</ddiem:url>
        <dc:identifier>HP:0010473</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b7b480e-92e2-4068-a835-36fc626f33d7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2202c48d-6632-4af1-93d0-748c3fd79c52">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:label>skin photosensitivity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d11c0c4d-2578-4982-87d8-1298f95304ee">
    <rdfs:label>Ferrous sulfate anhydrous</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13257</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3735385-5c90-4da4-8a2a-242b6f50e72f"/>
    <dc:identifier>DB13257</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1282787-1fef-4df8-baae-c21f74db737c">
    <rdfs:label>Hepatomeglay</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <dc:identifier>HP:0002240</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/63c24114-27a7-43f5-ac65-85d2766afeea">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03642860</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&amp;rank=1</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232800">
        <dc:identifier>https://www.omim.org/entry/232800</dc:identifier>
        <ddiem:iembaseAccessionNumber>491</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/491</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE VII; GSD7</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e2b13025-aeb2-4d19-b7e1-335fc819e756"/>
        <rdfs:comment>The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42ca283f-e5db-4c34-a1c8-1106250455b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e2005a6-a28a-4b10-a81f-343eaca54174"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ca489c0-2c08-4596-84be-1f209c0232af">
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>Trial is still in the Recruiting stage.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6af3919-d664-4bd3-b792-54444a482309">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/296289cc-2f99-4466-8eee-ba030099b93f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a8db5674-15df-4471-af6d-dc6d78eaf9f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2cdac22-d11d-4e0c-9055-d810afe322ce"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fccb7bb7-273d-407f-a354-59aa269bc420">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01267422</dc:provenance>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86b40035-fab1-4e32-a56d-7f5d68b3586c">
        <dc:identifier>HP:0030532</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal visual acuity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030532</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d7fadb0-e12d-4849-89dd-287177a3c8fc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91506b7a-08b6-4ef9-96c1-4c947fa92273"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8cfd1fa4-7589-4382-9a55-d2bde4c4f4b5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/36938914-897f-48f3-b931-e9af05151cba">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f20d7ede-2eb2-4499-9093-693575fdb12e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8af4ad4-06d7-4428-8ea9-a88ff516d504">
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Excessive Reactive Oxidative System</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f384ac16-a125-4be7-8299-0f46417b7142">
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:label>Low ATP synthesis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0a655402-ac9e-4aa9-ab43-14b290d67a1b">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7cb82db5-d14a-4843-85b2-6c5afd2414ce">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
        <dc:identifier>HP:0001251</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Ataxia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94fc37f3-9094-4098-afc5-1826de4d3bb0">
        <rdfs:label>Neurological abnormalitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19cc165b-bc2d-410c-af0e-e99f49312e78"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301419</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9931538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277460">
        <dc:identifier>https://www.omim.org/entry/277460</dc:identifier>
        <ddiem:iembaseAccessionNumber>658</ddiem:iembaseAccessionNumber>
        <rdfs:label>VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8dbd6624-313c-4dfb-8ed0-83ecb96420f6"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/658</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f385c31c-fdda-49f5-9cf7-dc08addf098b">
        <dc:identifier>HP:0100513*</dc:identifier>
        <rdfs:label>Abnormal vitamin E level(Vitamin E deficiency)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100513</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11554913</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/76c9b06d-09c2-4a52-8ccd-8cb811e329d4">
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258870">
        <dc:identifier>https://www.omim.org/entry/258870</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>562</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3b03411a-ff41-4513-8e3b-59463dfa310a"/>
        <rdfs:label>GYRATE ATROPHY OF CHOROID AND RETINA; GACR</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/562</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9da98189-eef6-4aa3-a3fa-4c341e7323fa">
        <rdfs:label>decreased visual acuity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007663</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a490ae78-f73e-443f-b3ce-ef88e2d40308">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000504</ddiem:url>
        <rdfs:label>abnormal central vision</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000504</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28560651</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15d3a57c-cde9-47be-89ac-cf6e07bd4715">
        <rdfs:label>choroidal neovascularization</rdfs:label>
        <dc:identifier>HP:0011506</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011506</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/719b524c-6faa-47ab-86a7-f3ea3abfab25">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/68271fdc-9335-4b6c-90c6-652c1f26193c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/664953e9-af75-48bc-8726-5b4a32305124">
    <rdfs:label>Regramostim</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43613542-7133-4f07-8df9-3f52c99335f3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05386</ddiem:url>
    <dc:identifier>DB05386</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e6f976d3-acd0-4edd-8889-ccbd7e1d2c7a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57439600-de95-47c2-9805-0058481e426c">
        <rdfs:label>Vasculitis</rdfs:label>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002633</ddiem:url>
        <dc:identifier>HP:0002633</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28213743</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a005e20-e819-4769-a8cc-dee51746e2de"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d42cf843-960b-435d-91a4-8768e178cbc8">
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <rdfs:label>Decreased apolipoprotein AI level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031799</ddiem:url>
        <dc:identifier>HP:0031799</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/946e41a6-a26f-40be-b51f-096578d7576c">
        <dc:identifier>HP:0002621</dc:identifier>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
        <rdfs:label>Arterial pluque</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/151c3ca5-515d-45b7-bdfd-e980a168d09e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9ae05e9f-c8ab-461e-9089-6e60a3852c20"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00055442">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00055442</ddiem:url>
        <dc:identifier>ECO:00055442</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/99400896-2303-4d11-a1a8-334d0fe79dd6">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/77c8a7bc-fe4c-41ab-889c-5dac9e884e0b">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/307dd2e2-ec43-4adc-ab4e-7a3293ff5c63"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01076</ddiem:url>
        <rdfs:label>Atorvastatin</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d95897ec-ddd5-4418-8323-94755d776137"/>
        <dc:identifier>DB01076</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/679b1b60-2f1b-4cc9-8260-0b98ad6cbabc"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3fb0ab73-cf4d-43d0-8ac3-3c121ff39267"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8cbadad2-c029-4568-ac0b-048119eb9aa2">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/daf5dba6-ab76-4899-b05f-c5ecfc7c3b9b"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/679b1b60-2f1b-4cc9-8260-0b98ad6cbabc"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/adfa1bf5-a1a9-459a-a8d0-16a2d67a9e45"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01098</ddiem:url>
        <dc:identifier>DB01098</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0855079a-dc40-49ee-92ad-b697c673c18b"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a0c1d7b-70d2-4d12-918f-730e7512d977"/>
        <rdfs:label>Rosuvastatin</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c6c963b-2bff-4545-80fa-19976d8995cd"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3c69ada4-8ee7-41c5-ba96-d8a94c719d02">
    <dc:identifier>DB01592</dc:identifier>
    <rdfs:label>Iron</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1ca0642c-65fe-4a74-b063-d1ab25ff2b91"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01592</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/32745b5f-4a11-43d8-a183-b8de5794a689">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02979249</dc:provenance>
        <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bfa034bf-5ada-4b1c-9222-8a97539ce016"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bf8619da-7c0a-4693-b916-6eea3d25a40c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8da0b819-a923-4cec-b173-2e9260fc503b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6c7b0eb-33da-4191-9d6d-729bd53e0e1a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/82a9d000-5bdb-4926-b3ee-e895a1939ff6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/151be5f7-feb3-406a-b7c1-8a240a66e45d"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/56daa269-79df-4970-a0a5-7a4f5f97d9a9"/>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e6af077-1ffc-422d-b23f-4dd659328c0a">
    <dc:identifier>HP:0012120</dc:identifier>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
    <rdfs:label>Methylmalonic aciduria</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b04751a-7afa-4333-b972-e2b7a2e5585b">
    <rdfs:label>Ad-hBUGT1</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e630214d-2591-4173-bbe8-14f56a98c522">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c6331c6-8af3-4bbf-928d-bd1c3478aa42"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8900123</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2fa75935-c72e-481f-a430-1bb088b2fc2e"/>
        <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/99587bf4-4994-4402-b63f-69378703d307">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/86c0c041-c6e3-4ac2-9060-4589718972e5">
        <dc:identifier>DB00393</dc:identifier>
        <rdfs:label>Nimodipine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00393</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ea0ecde2-f8db-4262-a5f4-d00eea142fd1"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1b6793b8-c7ff-4f4d-85bc-56cc3d9687e0">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614080">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1145</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/614080</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/64a3cccb-66f9-47d2-9a18-303da28bd4ac"/>
        <ddiem:iembaseAccessionNumber>1145</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6164a5ef-dbf5-4cbe-b8d1-72efb3c40bb1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac21e295-456a-4fcf-a700-38c8d334e9de">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300438">
        <rdfs:comment>Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/64</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d603f945-aeef-479d-b2df-46d023fc1077"/>
        <ddiem:iembaseAccessionNumber>64</ddiem:iembaseAccessionNumber>
        <rdfs:label>HSD10 MITOCHONDRIAL DISEASE; HSD10MD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/300438</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6a028715-4fb6-4f60-b9f1-533b691d3c45">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8a043c75-f97c-47a5-b296-89a00073bda3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d08d2c1e-f8b4-4732-a69c-bcc0b8260f7d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of the nervous system</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dea65027-682e-4c3d-b82b-bc00aaf17fc6">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8d4924b6-8a19-4d1c-9ae0-4cc7f6efed33">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c771145d-0314-4329-b292-a1ac5b74a960"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/668730</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75e2f30a-baa6-49b4-bf12-bcd751ed1ca7"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0914afae-31dc-400b-abf7-3f9f0dfbcbcf">
        <rdfs:label>Defective argininosuccinic acid excretion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93dc92e9-7f93-4c80-9038-55658b2e920f"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e2e0922-3ea1-4f29-85af-4bd6c6b8730a">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/edff39b6-fa36-4820-8a5e-3a7bf3804093">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64e22111-d47e-4d09-820d-b2c69c905f09"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d9f985e-7095-4e0f-9d5f-ee384bcc252d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008222</ddiem:url>
        <rdfs:label>Female infertility</rdfs:label>
        <dc:identifier>HP:0008222</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a4ae640c-b06c-4029-8cd1-f3b3c9383a2b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e50edfe1-379d-43af-96ad-fc38e0b05e71"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5f591363-c66d-471b-b9a6-fa3907815826">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/74b9b86b-d7d2-4000-bd9b-4da2d0931366"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/671aff78-97fc-48c3-a696-7ae82b0485b5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6068b2a7-c5dc-4542-a8f0-85aa061f3612"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c620b734-6eb7-4cc8-8462-c031696e20fe"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/410feb8b-edb9-4d03-ac99-0bde10adc89c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c065d391-9921-475a-aced-979a271ce521"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Rotigotine</rdfs:label>
    <dc:identifier>DB05271</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05271</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac416cd5-46e1-43c4-92d4-0cc11960e2ce">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4d53c11-ee68-477b-bb1b-18d2833b4506">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/76f38785-2411-41c0-a549-0db43c7ac2f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/487b328e-bb8b-4c96-a7ef-c601b2d2536b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/babc6022-fe56-405c-8d99-830f3259fd3f">
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:comment>Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <rdfs:label>Brain damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2775502c-5918-4232-9556-82a13fc1a40a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10630918</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72269e6e-fa81-4c2d-9344-2c32d1f1a8ab">
        <dc:identifier>HP:0100021</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100021</ddiem:url>
        <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <rdfs:label>Cerebral palsy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23326493</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/be25ed7f-9f1c-4b1d-8c23-79d30d1a1da4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9585615</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9760199</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/280429a6-726a-4203-9d47-97a9d3a45351">
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>Growth failure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95a3161d-8e66-44f7-8b86-1918985138bb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eaa749d3-0274-4866-b455-b38fc391bf84"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/865fe573-b32a-4dae-91c0-a07765a7a891">
        <dc:identifier>HP:0001252</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001252</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscular hypotonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1691971-0ed3-4f73-bd0e-bef7d49f58e3"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-012-9506-x</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/264070">
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/14d0357e-a06d-49f1-b54e-9dbb0f976147"/>
        <ddiem:iembaseAccessionNumber>6</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/264070</dc:identifier>
        <rdfs:comment>Protein and phenylalanine restriction should be maintained in order to avoid disease progression.</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/6</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6015e07-5b62-45e1-ac79-c6de32b56639">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High urinary levels of primapterin (7-biopterin)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/47890180-7047-4db8-9359-f3e1d85f75a0">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/523cdc0b-c2be-46a1-b77e-5927c59f516e">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9afb226d-56f3-4ca4-aa85-f599b4b5fd58"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b77c6287-2a13-4c13-8ba1-faa70985fd7f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27783330</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60015586-1a87-4e55-9fed-0f0c77affbe6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dc77c7d9-ca4d-4257-b828-db084904c2c4">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60015586-1a87-4e55-9fed-0f0c77affbe6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e697f80-9d86-4108-b5d7-43fd71990dc5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c13556e-8a2e-4e65-9738-fd0a34c941ba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15098233</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00020</ddiem:url>
    <dc:identifier>DB00020</dc:identifier>
    <rdfs:label>Sargramostim</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18d11b93-cb35-4d4a-ad35-2fc2f66f3b0b">
    <dc:identifier>HP:0001903*</dc:identifier>
    <rdfs:label>primary low heamoglobin level</rdfs:label>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b8682971-e50f-4a86-92af-c9db09824987">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e3035fe1-5d11-49a7-9d77-be35987814aa">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29273094</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615181"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/983620da-647e-4bef-8f93-59acb546ac43"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/96cddb68-fa95-4ae6-ba5d-a08055198b56">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/983620da-647e-4bef-8f93-59acb546ac43"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794688</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01174</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/830d7b46-0b96-4f45-a8c6-e793afb60af4"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/087f0425-85b7-4ef1-b02a-39d0c1164f2b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/983620da-647e-4bef-8f93-59acb546ac43"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1f853f9-1169-45d5-b3b5-9682fb72e299"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23162302</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f38970c0-2d27-420f-9702-90c81e000da9">
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9491f06-540d-4bb6-8f47-639723c5d8c7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/983620da-647e-4bef-8f93-59acb546ac43"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/403a1793-41c1-4f82-9a76-89dfc9140675">
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/983620da-647e-4bef-8f93-59acb546ac43"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Phenobarbital</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01174</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0c00d779-37b4-485a-8c27-8c067df050aa">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/983620da-647e-4bef-8f93-59acb546ac43"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45948e19-94c5-451f-9c2a-46be22ecce3b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a063a03d-99a2-4c11-8cd1-3f92cd3506ca">
        <rdfs:label>Corneal scar</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000559</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0000559</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656398</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8eddb7be-7c9e-458a-afad-9adccf13a4c9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000491</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Nummular keratitis(keratitis)*</rdfs:label>
        <dc:identifier>HP:0000491</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/260920">
        <ddiem:iembaseAccessionNumber>191</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/191</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c5921f5e-e89e-4091-af27-e5b21f4200d1"/>
        <dc:identifier>https://www.omim.org/entry/260920</dc:identifier>
        <rdfs:label>HYPER-IgD SYNDROME; HIDS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7077cd70-3ba1-47c2-a22f-26f522227aa5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/343a5189-f0ea-47aa-aa96-1ea76d73cb8e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbc1f76b-222b-4b44-955f-2fe252e8cacc">
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Decreased visual acuity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9c76b0e9-738e-4a23-92b7-0ce66ba4f9fa">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28126686</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc7f8cdd-3aae-4f3d-9d25-9d422d07f8f0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/db05e389-408f-43db-a44e-2d57f1922861"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9391fa13-83ca-4b73-97a6-2cb82fb59d0c">
        <dc:identifier>HP:0011990</dc:identifier>
        <rdfs:label>Partial correction of neutrophil dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011990</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3635cd1-3b91-412b-9c97-5603c1165159"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/13ae8755-99f6-4c92-9758-82f2b0347325">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237300">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c32d1534-f897-41d0-b90c-f5933a4b9c67"/>
        <dc:identifier>https://www.omim.org/entry/237300</dc:identifier>
        <ddiem:iembaseAccessionNumber>11</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/11</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d22f999b-4e15-45e2-8c45-1f6042686a11">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/27cc3d3c-6a8b-4e3c-bb8a-893c01e503bd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83badaeb-1c5c-4a4d-8075-8cc91f2d0b70"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70f751f4-666a-434a-9306-87557418ef48">
    <rdfs:label>Delayed mylination</rdfs:label>
    <dc:identifier>HP:0012449</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012449</ddiem:url>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eaa9a044-2a01-4c8b-8854-96b0b3e954cf">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46982e74-087a-44ab-858a-b24ef1efe5e5">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac05cff1-57dc-4556-9fc0-2ba1ed9719fd"/>
        <rdfs:label>Milrinone</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00235</ddiem:url>
        <dc:identifier>DB00235</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89bedbc7-a3f5-4560-ac79-9cbb4c1f2fc3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001114</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Xanthoma</rdfs:label>
    <dc:identifier>HP:0001114</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac0f9a96-305d-4fa8-b627-d2722b22c69b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94802ea5-4b53-4e4b-9621-658bcc9fa618"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86968c4a-2fcf-4100-95f6-a6cf3c47c4da">
        <dc:identifier>HP:0002329</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
        <rdfs:label>unalertness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2df9c51-f27c-4ba4-b202-1807509d986d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000657</ddiem:url>
        <dc:identifier>HP:0000657</dc:identifier>
        <rdfs:label>Oculomotor apraxia</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0eb01b4-e787-4698-81cf-fe073da695ac"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613163">
        <rdfs:label>GABA-TRANSAMINASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/36</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/613163</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>36</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ff9bd34f-9a2b-46c9-b404-9d61b23fa34f"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3400ea97-37f2-47ca-b42b-8b0f01477c02">
        <rdfs:label>hypersomnolence</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
        <dc:identifier>HP:0100786</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a03b3dbd-4410-4fe2-98e2-45aadc7bc4c7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28411234</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bb07665-0fc9-4b94-8c1c-ed39ba38981c">
        <dc:identifier>HP:0100022*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>excessive adventitious movements</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dd6d5c30-02b4-484d-830e-30e47c4acb79"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dbf0f6e8-51d5-4c7b-9251-0aa49fb00c90">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24b29900-5574-4737-ae38-6d5aaefb7551">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:label>secondary carnitine deficiency</rdfs:label>
        <dc:identifier>HP:0003234*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33fd2926-7f9f-4ef3-be1e-875e94f664ab">
        <rdfs:label>high  short chain acyl-carnitine metabolite level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023%2FA%3A1024031714659</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b07909e-8b29-4fe6-ba0f-e3a3f345a96f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02ff4a9f-0df3-4925-8cb6-d7b80a018f8b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/740a7023-61ad-4d20-af46-992194b1687c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fc0895c-cc0e-4511-ad80-441489b5a827"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/feda961e-64e0-4b8b-8a15-5b5a4890a3a2">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0004348</dc:identifier>
        <rdfs:label>Low lumbar spine bone mineral density(bnormality of bone mineral density)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42aab52a-c496-446b-bc78-3278c6faba65"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608013">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8d84618c-2ff1-4a3c-8aee-e89eefc6d4c2"/>
        <dc:identifier>https://www.omim.org/entry/608013</dc:identifier>
        <rdfs:label>GAUCHER DISEASE, PERINATAL LETHAL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f21aa42-405f-4f79-9298-88572999b642"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/83a51cd9-b823-4b18-965a-1d496121a0fb">
    <rdfs:label>AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f73dbb7e-c50b-4f0a-b980-f6c2bb70feee"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000005">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T17:59:32+00:00</dc:date>
    <rdfs:label xml:lang="en">mechanistically predicated therapeutic procedure</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure which directly addresses the effects of a protein defect produced by the mutation, its structure, activity or end product. Therapies which target the local interaction or regulatory network or pathway in which the affected proten lies are also regarded as mechanistic therapies. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab2a532c-d6c6-4011-a555-ae3b8b815306">
    <rdfs:label>Behaviour abnormalities</rdfs:label>
    <dc:identifier>HP:0100851</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a0cbbac-c67d-403f-9f55-0658eef88309">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/100435b6-f035-4fff-ace7-6021f7cb8105"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c4c6d0e-a95c-41c3-bddf-1d46de140c93"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f2700b9-2815-4ca5-85cc-aa005242a7ff">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Atypical bile acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00540989-a70b-4ac3-9e00-8c267a1cb85a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/168864af-e2b9-477d-b79e-b39cac651dba">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>production of toxic intermediates</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16819396</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0653a1f6-b8ee-4205-b1f5-4a9f86ebab2f">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>progression of the disease (Rapidly progressive)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95cfae18-4528-4e0e-a306-d71f0a78fbc2">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>fat soluble vitamin malabsorption(Fat malabsorption)*</rdfs:label>
        <dc:identifier>HP:0002630*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373615</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6989d1f0-36c4-4d23-a4dd-02102ffe7a9f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001394</ddiem:url>
        <dc:identifier>HP:0001394</dc:identifier>
        <rdfs:label>Cirrhosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99a353c6-be8d-42fb-9eeb-d1dd82698424">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <dc:identifier>HP:0001396</dc:identifier>
        <rdfs:label>Defected bile flow</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00386d3e-9849-4a66-97f3-cbfb79ba517a">
        <rdfs:label>Histologic abnormalities in liver (Abnormal test result)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
        <dc:identifier>HP:0500014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c84814e-2432-4850-88ea-db6bafa7cdf5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1bf82ab-b535-40b7-aec5-fccbb43dd14f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11241071</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65771e65-f7b5-426d-9c34-2ed14dc88bae">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:label>lack of eye contact</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605407">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a234286b-e8ab-42e1-83cd-6d5d0fa43b5c"/>
        <dc:identifier>https://www.omim.org/entry/605407</dc:identifier>
        <rdfs:label>SEGAWA SYNDROME, AUTOSOMAL RECESSIVE</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/234e4416-a16e-43b8-9d21-1e3dd2df29cd">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003785</ddiem:url>
        <dc:identifier>HP:0003785</dc:identifier>
        <rdfs:label>Decreased CSF homovanillic acid</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/329e1525-5e9a-463a-97bc-91859c4f6a35">
        <rdfs:label>Abnormal epinephrine,norepinephrin ratio</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>(926T&gt;C</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8817341</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20399390</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e90b6a71-98ea-41cb-9025-35214dedf58a">
        <rdfs:label>Delayed mental development</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815559</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1b8d562-2676-46df-bdee-c75d87814b34">
        <dc:identifier>HP:0001336</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myoclonus jerk</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2974d5f6-f12f-4b40-8780-d10ce1a32a88">
        <dc:identifier>HP:0002194</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed motor skills</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10753262</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10407773</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72728d3c-630c-4785-a724-e7906fa2eddc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/987ce869-269a-4ca8-ab20-b1b462b34426">
        <rdfs:label>lack of gross motor function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002194</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cae82e2-0c53-4fa3-b402-ac12ee37f141">
        <rdfs:label>Hypokinesia</rdfs:label>
        <dc:identifier>HP:0002375</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1691971-0ed3-4f73-bd0e-bef7d49f58e3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/671aff78-97fc-48c3-a696-7ae82b0485b5">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002421</ddiem:url>
        <dc:identifier>HP:0002421</dc:identifier>
        <rdfs:label>Poor head control</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10585338</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d227460-22ec-4aa6-addc-24712cfc72e5">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c66c1d58-90e4-4dc9-be8d-07659850c4c3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027, HP_0002017</ddiem:url>
        <dc:identifier>HP:0002027, HP:0002017</dc:identifier>
        <rdfs:label>"(abdominal pain, nausea, vomiting)"</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23605132</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ee9bd3c-a89e-41f4-9346-76c8718c1afa">
        <dc:identifier>HP:0012825</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Mild attack</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012825</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/033bc881-e7d2-45ef-85f7-cf902d5c8144"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0617007a-4fce-4dac-af31-1c7beaf32420">
        <rdfs:label>Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <dc:identifier>HP:0010472</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4dd82091-918d-4f25-9eab-c6e3df0c6a7e">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9cbd067d-0a7a-46ba-92d5-440a71ce2c81">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0396e121-157c-4b53-a8be-e8b72a002a8f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b83d5b6-c186-45ad-acc8-154a08f3ea35"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/228898fa-883d-4ff1-9035-113d9670722a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/56513bf6-6130-4ae0-b5e5-7a470380f7c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c8aca26-d1c0-437a-a57a-7bddfc790f52"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318010</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c13556e-8a2e-4e65-9738-fd0a34c941ba">
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:label>Recurrent infection</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a366007d-9f79-40c8-b1c1-11a93639d08c">
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <rdfs:label>orotic aciduria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003218</ddiem:url>
    <dc:identifier>HP:0003218</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3287f1f-e5c0-4585-ba5c-1144012bcb80">
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>muscle weakness</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f3171786-8dde-4e2e-9f91-cfa76373c090">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602541">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9a500002-117b-4ddd-adc2-2148af735ea1"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602541</dc:identifier>
        <ddiem:iembaseAccessionNumber>1047</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1047</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59131206-1a57-45a5-a8a2-b613fa00d8cb">
        <dc:identifier>HP:0003287*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:label>Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc60a224-ed7c-452e-bee2-4ecf1acd6a03">
    <rdfs:label>Lower extremity weakness</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007340</ddiem:url>
    <dc:identifier>HP:0007340</dc:identifier>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23171ff7-86f7-4662-9991-cd71acb93ac9">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/080bfdbe-7148-48ad-beba-9ded28bcb917">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ec5c7d2-50b6-43e2-a2cd-2f36a0a2129e"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1700ca22-31f9-4945-89b2-2a8ab01e7c39"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b07909e-8b29-4fe6-ba0f-e3a3f345a96f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21726969</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dd6c5f89-240f-4766-a4b8-608711b5a510"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00288</dc:identifier>
    <rdfs:label>Amcinonide</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/de403e66-1372-4b3b-9851-6ea724489d6d">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc622bf1-30e1-416a-9f4e-0a5d0455c587"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9ec2b24-604f-4569-a702-cb87bab6703c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27139922</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ec5c7d2-50b6-43e2-a2cd-2f36a0a2129e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/716c1ef7-abab-4179-880a-f7eada53b5a5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a1fbf13-6d1b-4671-96fb-c09ceb853786"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ec5c7d2-50b6-43e2-a2cd-2f36a0a2129e"/>
        <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00288</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/edd210a7-08ce-4c75-b251-3e9907939ab4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23644316</dc:provenance>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ec5c7d2-50b6-43e2-a2cd-2f36a0a2129e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcf56e53-8f9b-4ac6-a114-28888c679f12"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ca7a6ba3-a519-46b3-9158-ab828d39cc7f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bab0f9bf-2ff5-41f7-b426-28d5af59e185">
        <dc:identifier>HP:0001941*</dc:identifier>
        <rdfs:label>high-anion gap acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/789de476-0677-4d73-8393-cfff899e499c">
    <rdfs:label>Pegunigalsidase alfa</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5addf18-ba54-4593-978f-473ec4db7b56">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
        <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/973f0eb2-7d4a-4aa5-aa15-cfc2a48e32bc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT02795676</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2fb9d723-eae5-48fa-b511-b478b1e1cf01"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d936a7cc-1464-4316-91b5-1a9350fa4434"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/41685bc9-012f-4ce0-9989-9a61fb2cb185">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2fb9d723-eae5-48fa-b511-b478b1e1cf01"/>
        <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03180840</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01981720</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01769001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/973f0eb2-7d4a-4aa5-aa15-cfc2a48e32bc"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01678898</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14992</ddiem:url>
    <dc:identifier>DB14992</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6a4219ff-a57d-4fbc-b44a-801459eb732d">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65542f39-1939-4b25-959d-d0a6df27f95b"/>
    <dc:provenance>https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec8fcd0e-593e-4a3b-93be-9e7de1762c4c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1e4016c9-e3ef-4494-8b84-dbe04ff1c12a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baa5bc29-097a-4f7f-9bd7-b4056e03d8d4"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69604a95-abd8-4c41-a97a-7b3c7fff0bfa">
    <dc:identifier>DB00051</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/be6041bd-491e-4c70-a7c9-232aa343fcda">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18172743</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36e061e1-98ed-403d-a8bf-f8f0cd6eb04f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6ba69ef6-ba83-4ecf-81aa-bdbe9bcd0997"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Adalimumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00051</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1f0db5f8-1cad-4afb-9823-70181cca07e1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d9a09ce-6bf8-44ee-998a-7918213dce35"/>
    <dc:identifier>DB14513</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d113689b-a5a8-47e8-b72b-f680267aae04">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20803213</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/09bf3da9-52db-439e-96ce-eb717b592a7d"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203700"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/577c212c-538c-4314-a084-d9900395d701"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14513</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8136b13d-6db4-4065-b224-d545e8290752"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb699e73-7111-4444-863e-65ed6b738b61">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/577c212c-538c-4314-a084-d9900395d701"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ceeed8e1-8755-496d-a0a0-080fd3850a17"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Magnesium</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c1831988-6787-4699-ab0c-ebffb54036ab">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9ec3dc7-d5d9-46e2-9985-fea1d8b68366">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1e8917ff-bf32-439b-89fb-555946f42ef9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2464ef8e-6401-4dc2-a288-040f84f55cd1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12930917</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/334b6661-4a81-48a6-8c93-fdb7f04c8f9a"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613027">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1259</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9143fd32-0479-44c6-bb13-cb21305cff3c"/>
        <dc:identifier>https://www.omim.org/entry/613027</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXc; GSD9C</rdfs:label>
        <ddiem:iembaseAccessionNumber>1259</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b6c7201-cf67-4902-b22d-09168d9b255a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030178</ddiem:url>
    <rdfs:label>signal abnormality of the cortex</rdfs:label>
    <dc:identifier>HP:0030178</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/83c27bfe-822b-4ce6-a7e7-9ebc627bc1d3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e832cd8-8b59-4f29-a0fd-a73154c5397f">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
        <dc:identifier>HP:0007166</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/49191678-ecb2-49ca-9b1c-8a1c14c3036c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca4b222c-02ca-4a81-97a6-acb1e411f093"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d2f3f80-0608-4568-882e-84500c85c30a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <dc:identifier>HP:0004302</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Abnormal motor function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606777">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/480</ddiem:iembaseUrl>
        <rdfs:comment>The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract</rdfs:comment>
        <ddiem:iembaseAccessionNumber>480</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/606777</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c2da5b56-c237-437e-82dd-b4e2450c0119"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f360129d-9b1d-4bbe-9932-bf637e3436cf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031884</ddiem:url>
        <dc:identifier>HP:0031884</dc:identifier>
        <rdfs:label>Abnormal CSF glucose levels</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb75978a-860f-4611-8fdd-574da0e33e32">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Abnormal H50 (The erythrocyte resistance to oxidative stress)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236200">
    <ddiem:iembaseAccessionNumber>27</ddiem:iembaseAccessionNumber>
    <rdfs:label>HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c93516e9-010d-4d9f-a769-bb7ba02b2ee1"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/27</ddiem:iembaseUrl>
    <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/236200</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f41b784b-6fbd-4bfd-8da8-1ef670885a01">
    <dc:identifier>DB09210</dc:identifier>
    <rdfs:label>Piracetam</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1fc95b27-91c9-4332-a68a-1dca142f5126">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28717435</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3da51f46-a5b4-47c8-9bf9-7cf2dcbf51a1"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84eb1f6f-2786-47cb-b7bc-96485c0017e0"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0003304>m.8344A &gt; G</obo:RO_0003304>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09210</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1edeb54c-0d64-420a-abc7-562a419f14c2">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c73e3f14-de56-41a1-8cde-f63757073338">
        <rdfs:label>Orlistat</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/821ad117-36ca-4d69-a84c-357959a44c1b"/>
        <dc:identifier>DB01083</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9be94cc-c464-43cd-a1ff-d35c7bec5083"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01083</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4335240a-369c-41eb-8b18-b96a8ac6a49d">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d3d30bd-f2fa-4156-8eab-86b426d2351b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c9d372d6-1ba7-4f49-8e0f-af85950130fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c39bf8e5-5dcd-411c-8615-b7c70df180f6">
        <dc:identifier>HP:0012048</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012048</ddiem:url>
        <rdfs:label>oromandibular dystonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe421138-d1fd-4e92-b792-5ed90e842181">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
    <dc:identifier>HP:0001877</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low RBC count</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd20e54d-1bf7-4235-b7cd-108b88fc2a52">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1142496a-ae70-40b5-9447-d92c65405660">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>sleep cycle disturbance</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1d66ab7-adb0-48e2-aff2-21417234c18b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:comment>The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dcae3e91-49a5-4163-92b6-31ade45cb127">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22b47281-4d34-451a-b8d3-82b146e61aae">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e9f22d2-3cd7-47f9-b5b5-cc751402e238"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a4f3ffb-d548-4b26-8581-6dd62e7b16af">
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <rdfs:label>High mean number of GL-3 inclusions,kidney interstitial capillary(KIC)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/978e5cc3-bee6-4cbe-8036-59ea87f6ae7e">
        <rdfs:label>High plasma lyso-globotriaosylsphingosine level</rdfs:label>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e78cc31-de9b-493a-bbd0-2668e4411cae">
        <rdfs:label>Left ventricular hypertrophy</rdfs:label>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
        <dc:identifier>HP:0001712</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0003304>"p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27509102</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30765910</dc:provenance>
    <ddiem:failedToContributeToCondition>"E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S"</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30875019</dc:provenance>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e311cc2-ebd3-48bb-b6bb-c8da3a82da93">
    <rdfs:label>The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <dc:identifier>HP:0004356*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6fb57652-d719-400b-9099-21e4cdbe02b4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eaa749d3-0274-4866-b455-b38fc391bf84"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab2a532c-d6c6-4011-a555-ae3b8b815306"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00935753</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cd76293d-a0d3-49f1-ac98-01eeaefed550">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11135</ddiem:url>
    <dc:identifier>DB11135</dc:identifier>
    <rdfs:label>Selenium</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c1f0f039-5bf5-46b5-9a2d-51e6fcc7d706">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/310a7f40-db1e-436a-8be8-aa92d97ae0b7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/68f1454e-4e15-4233-ba3b-0b290eb199ff"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/475243e9-000f-401b-8953-25948fa871fb">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01783</ddiem:url>
    <rdfs:label>Pantothenic acid</rdfs:label>
    <dc:identifier>DB01783</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c9b54612-a1ea-4c69-9fdd-cebf8cfa0d5f">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e78efdb0-6fe1-4c8d-9efb-d2c3d3c09080"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e697f80-9d86-4108-b5d7-43fd71990dc5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57c09e32-b11e-4b94-8721-f0cf0d565720"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/be0a6778-6e93-4ecb-b416-8bcb5605fdb0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7833193</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/570fc74b-c712-4d99-a41f-4740c60f3e5a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4bfa9f8f-1ac7-461c-bdd6-28fe320e1542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/741d9133-34f4-4e1b-81fe-b50297fa2781"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a9287b5d-edb0-44c3-b50c-40cccd94881b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36667118-3ad6-4bba-bfb9-cb4505561602">
        <dc:identifier>DB01345</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bdfd26b5-b413-4cff-aa39-0de86d52b524"/>
        <rdfs:label>Potassium cation</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01345</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a7ed7a0-a339-4f7a-82f3-3a0e1dae46c1">
    <rdfs:label>psychosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000709</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000709</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b8dae78a-3c37-4093-a22e-4dbf7c3662c6">
    <rdfs:label>Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/72ab1e19-baea-4ebc-a2fd-5aa4e7a82a21">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/120e1c32-5887-4a29-a3f6-9bfbdea97272"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30127521</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6f7142e-c9d8-4f85-ab9c-fe4d73c62c0a"/>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/12ae193d-a7a9-498e-9426-df7d805bccbf">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/396d104d-4d36-47d6-a038-9ddd097586f2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a53e94da-e15d-42a4-9bf5-6e542b08c26d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3bd95a65-e948-48bf-9620-803f73b0fb0f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52cfa0c4-8df4-43a5-aa03-68fbb19fce9d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001913</ddiem:url>
        <dc:identifier>HP:0001913</dc:identifier>
        <rdfs:label>Granulocytopenia</rdfs:label>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f21aa42-405f-4f79-9298-88572999b642"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c43cad0e-5326-41bd-98ef-8e3a40d59729">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>Elevated plasma homocysteine concentration</rdfs:label>
        <dc:identifier>HP:0002160</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a03b3dbd-4410-4fe2-98e2-45aadc7bc4c7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ce1dc87-d303-420a-a88e-c349887388bf"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bc4bdb62-db67-49e5-9a41-eb41540a0658">
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17541659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a63e7e45-70c6-4ac2-a107-ed872048f462">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <dc:identifier>HP:0001369</dc:identifier>
        <rdfs:label>acute arthritis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1bc86550-6c8c-45be-b501-444db9985da9"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118610">
        <rdfs:label>CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/118610</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3120dca5-a013-4e1c-8c8d-1bedbe9e1a5c"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5f0b58f-e23e-4c06-9018-90e3c4ab73dc">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>Low serum testosterone levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_004017</ddiem:url>
    <dc:identifier>HP:004017</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2283cc7-edad-4dc1-ace8-a69e611dbec2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1c84c233-cc3d-43b9-a3e5-e6afddd5446b"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32030</ddiem:url>
    <rdfs:label>Kaliumbromid</rdfs:label>
    <dc:identifier>CHEBI_32030</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bfd6ac61-d061-404e-9305-58274ad9cc60">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fb79a98e-7bea-4680-9648-46efdbb47425">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/162534b3-0dce-4b85-946b-d7ebda67d0d0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/befc7da3-827a-4f71-a068-da4ac0b1605a">
        <rdfs:label>No result is  added</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00244582</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230900">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8d84618c-2ff1-4a3c-8aee-e89eefc6d4c2"/>
        <dc:identifier>https://www.omim.org/entry/230900</dc:identifier>
        <rdfs:label>GAUCHER DISEASE, TYPE II</rdfs:label>
        <rdfs:comment>By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8143ff86-7a7d-49d2-9939-fedd95a708b6">
    <rdfs:label>Probenecid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0b8703e0-3cf1-4f10-a390-b24ba0c47ce3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f7cf24a4-1e73-4e42-81d8-2e565fa5c339"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc3298b2-7af2-47c1-9319-2a74dee8c02e"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01032</ddiem:url>
    <dc:identifier>DB01032</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e3d4978f-d0b4-4116-bb14-3c3328eecc6c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7520501</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f7cf24a4-1e73-4e42-81d8-2e565fa5c339"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62189108-4c04-4c9b-ad4d-d5dbef663633"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/841f9c47-025d-466c-8515-9872db49c872">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010977</ddiem:url>
    <rdfs:label>defected phagocytic function</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010977</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a4709e04-c3a4-4f00-a9fd-9f515c235ca8">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00947960</dc:provenance>
    <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263570">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7bae13fa-12bc-456e-9e43-1752da353b9a"/>
        <dc:identifier>https://www.omim.org/entry/263570</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42ca283f-e5db-4c34-a1c8-1106250455b1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bdb8eb2-225b-49a3-b5ea-d6b4a4fca9de">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
        <rdfs:label>muscle pain</rdfs:label>
        <dc:identifier>HP:0003326</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8af80af-bd9d-45cf-b670-a1ccf4681ee3">
        <rdfs:label>Lack of energy</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0012378</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5add8c0b-c659-4aef-ad68-d93517eb89d8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>defective heart function</rdfs:label>
        <dc:identifier>HP:0011025</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c79cb4d-7ff2-47f7-85a0-53c1f0d57198">
    <dc:identifier>HP:0001959</dc:identifier>
    <rdfs:label>Polydipsia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cfd7c89a-fdd2-4af3-b7e7-4ec3a64cb1ab">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8999e8c5-38e9-463c-90be-ab6de160f171">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e2e28f08-0984-4f19-ad39-59c691cd9f84"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e547bea8-dcae-4614-8715-acde4386ab30"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/cholesteryl-ester-storage-disease</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac7a7dd9-ef80-4de9-a507-14d7d2e9fd19">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>hypertriglycemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99ba6e96-be29-4a5d-b98d-36043b4604b5"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02376751</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/daa98f12-a847-4e2d-89da-f865685dc0be">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003107</dc:identifier>
        <rdfs:label>High plasma cholesterol level*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/858fa6a6-1558-4340-aeca-67ad17a10c80">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24579575-9738-45f9-82b6-ba9dd1c4b57c"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60317c0e-147d-409d-b823-96369efaddf5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>retarded growth</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4af0a16-85e5-4f5f-929d-431a83d505b5">
        <dc:identifier>HP:0000117</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000117</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>low phosphate reabsorption</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/acb67fb7-96bf-45d0-af29-7f0ebe56f342">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29651749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f4d6b6f-a3ab-4175-8d42-974523e3f03e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
        <rdfs:label>High plasma citrulline levels</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0011966</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a45c8b7a-a945-4b0a-b370-d50e46e8e9e3">
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>High blood ammonia level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f0415b3-9909-44f9-979d-67456199b5cc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d795319-1b7d-40ea-8d1b-fe547c7db0d5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Relapse of hyperammonemic encephalopathy</rdfs:label>
        <dc:identifier>HP:0001298*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26427088</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afc35260-9623-42d7-8f2f-3232b7cc46c4">
        <rdfs:label>low plasma glutamine levels</rdfs:label>
        <dc:identifier>HP:0010903</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c34967cc-8819-4516-9ca2-8b762b01c815">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00175</ddiem:url>
    <dc:identifier>DB00175</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8d34d61e-2ca2-4227-bafb-1716031b86ae"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6412e78b-4eca-4f0a-89a8-a409670d767c">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131f6cb2-8d13-41be-b95d-4485ac53fc80"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24636183</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6266946-4ce6-47c6-aacd-95fe3be1cec5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Pravastatin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/24563e0a-8c62-45ce-87b7-0e64c6db1d00">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3ef1281-9a00-46e2-8d22-b8fab8378462"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89bedbc7-a3f5-4560-ac79-9cbb4c1f2fc3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26790a3a-3426-44a6-83eb-28e897143864"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7964884</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9239b602-6a8d-46a3-aacf-16af28feec6d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131f6cb2-8d13-41be-b95d-4485ac53fc80"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eacaf8f7-5e99-4a8f-a532-4f50aaeb3514">
    <rdfs:label>Vasopressin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c833508b-d0fe-48ea-9928-d9a16ac4fb1c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70f9b211-d7a1-4b97-9f2d-3481c6a1a89e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd9c9eff-8cf7-437d-8e56-d8b24afab5d8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9993a541-2498-4a1d-9f4b-a0d5c76950dc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://academic.oup.com/jcem/article/98/10/3958/2833930</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00067</ddiem:url>
    <dc:identifier>DB00067</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/27d14754-5e4f-4c1c-b0ff-90b646d776a1">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8b3123d7-360a-48a4-8d1f-cf439fb07d47"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21b293a8-2943-4ae7-81d3-8ec96cacbdb3">
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>High VLDL triglycerides</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a51a5b34-b91f-4325-b61a-ef1f346afe34"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c83c8d7c-e70e-4d5b-8e50-ab837061cfa8">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af5ba1da-196e-45e4-af77-84eaa2659c21"/>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e6a43a3c-9f58-4038-bfd2-319e8a911426">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c1945632-493c-4491-8b6c-cf256d174567">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3df624bc-c36a-464a-930c-de7ef06caf5d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/37376725-a061-474d-bc91-2d64fb306317">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6438e12a-25b1-4230-be9d-7df34b927d79">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f1b621e5-77c3-4b41-925d-e8e7b19b00dc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73c3bd63-7956-4388-a436-5fe57f4c6f33">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011505</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0011505</dc:identifier>
        <rdfs:label>cystoid macular edema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28708224</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60ff6c1c-45ad-490c-959e-4dabf7cb7516">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9d2b401-d787-4e04-ba28-e4123e41f294"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9defa2e1-881b-41dc-887a-6ad47070e7a6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:label>Low muscle mass</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a7f0839f-d56e-459f-86f8-d0f11bb55a5d">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/643f5ccc-b2bc-40c1-8a77-ddbc72eb0945">
        <rdfs:label>abnormal Biotinidase activity in plasma</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c7ef80d-9872-4a36-b414-81965a9b9fd7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f16473b-2e07-4ed9-a00a-c33c7b7547ab">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased 3-methylcrotonylglycine excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94802ea5-4b53-4e4b-9621-658bcc9fa618"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c87e0d2e-5303-42fc-b15c-8d6341ac48cf">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased 3-hydroxyisovaleric acid excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e87169b7-2ac0-4036-957e-b83f15323a3c">
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e202c2a8-2ae8-4eee-b7f0-050afc883fd6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>mitochondrial proliferation in the muscle.</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
        <dc:identifier>HP:0003200</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6304e1e1-8f67-46c1-924c-e3bb8b175687">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/65245101-ad1b-44b9-b076-00a1404fcb02"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc25228f-6e42-4e53-89d3-39e013ef9a36">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97c64bcc-a41c-4d8c-a618-6858986b58e7">
        <rdfs:label>Abnormal renal nitrogen elimination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004364</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0004364</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/892461e0-2af9-4c98-8e6f-f022f28c72d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e15cb9b8-7662-4b5e-a7d8-74ed9ed459de"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c49889f2-0bcb-4434-acbe-dd72818e60b5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1577f6c3-ac99-48b3-87a0-355cf11af13e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/225523a7-a77f-45e0-a02b-e8a3efd83a55"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756474</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/050bd9f1-2dce-4aca-9906-a984d3225c7b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <rdfs:label>Diabetes</rdfs:label>
        <dc:identifier>HP:0000819</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0635f878-be87-41fb-b332-c428aadf92ee">
    <ddiem:failedToContributeToCondition>GK-Y214C(De novo muttation)</ddiem:failedToContributeToCondition>
    <ddiem:failedToContributeToCondition>Y214C</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>M197I</obo:RO_0003304>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602485"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15277402</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0003304>A456V</obo:RO_0003304>
    <obo:RO_0003304>G68V</obo:RO_0003304>
    <obo:RO_0003304>(Val455Met) at codon 455</obo:RO_0003304>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15fbc68d-b8fa-4389-8113-2e23df2c223b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27380971-83b4-4de9-b1b6-09f02df33a2b">
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>https:,www.ncbi.nlm.nih.gov,pubmed,19336674</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15133749</dc:provenance>
    <obo:RO_0003304>S64Y</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/334b6661-4a81-48a6-8c93-fdb7f04c8f9a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <obo:RO_0003304>T65I</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>ins454A</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>W99R</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19336674</dc:provenance>
    <obo:RO_0003304>V452L</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/006340d1-713a-4add-9146-42ba4a1c2434"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c68be2d6-7899-4302-baee-c2d54309ec64">
    <dc:identifier>HP:0002160</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
    <rdfs:label>High total homocysteine levels</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/502d0e99-fba1-405a-a75a-d62bb9a5b353">
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
    <rdfs:label>Short nocturnal tonic seizures</rdfs:label>
    <dc:identifier>HP:0031951</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031951</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/833d841f-5631-4e5f-b5d0-ae1888869d52">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54c1d61a-6285-4496-875b-d82db036f16b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eaa749d3-0274-4866-b455-b38fc391bf84"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b478968-aadc-482a-b15a-102b6ab703b5">
        <rdfs:label>unalertencess</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
        <dc:identifier>HP:0002329*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/338dacd5-05fb-4bc7-ba19-99e311b4d2cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430801</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4b0ba7-0654-4cd1-a6df-644af85ccee6"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/010abe84-4958-4559-9ba0-c5effa11b2e5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13f8eb83-7bcb-4eb5-b396-a2b39500e668">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
        <rdfs:label>Receptive language delay</rdfs:label>
        <dc:identifier>HP:0010863</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d99e4c56-7d6a-406c-90ac-b08c3482089b">
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>High plasma phenylalanine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/74e0ba12-b9de-4172-bcb4-6980cdbdfaf8">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3694da2d-2502-4146-964f-84cdd7c729b2">
        <rdfs:label>Amlexanox</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01025</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c783fc3-6c40-4c51-b2e0-04ac342b7066"/>
        <dc:identifier>DB01025</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/afed8b4c-261e-45b6-b19a-5e1e7d8f8978">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/778a3891-1ae2-4878-8cda-820b0ad0a72a">
        <rdfs:label>Hypokalemia Metabolic Alkalosis</rdfs:label>
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/601678"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1d86299-2a85-4baa-ac16-8b1879d840bb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200114</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0200114</dc:identifier>
        <rdfs:label>Metabolic alkalosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eb3f8598-5f6d-4433-9a02-db4f7a993f03">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17fa10c3-894a-4371-8bc1-1cdc4c003797"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC:0007121">
        <dc:identifier>EC:0007121</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC_0007121</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://clinicaltrials.gov/ct2/results</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d3a611fc-9faa-4df8-813b-048135d098b3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91bba6f1-bda1-4f0e-a390-b173e575e870">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>High serum bilirubin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/pr1989488</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>http://pediatrics.aappublications.org/content/86/1/152</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29fca628-78c6-4e3e-8813-b5e3f4eca852">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74659699-4ff3-442c-bf93-012989318adc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The drug is effective in conjuction with phototherapy</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/202fc029-148d-4377-868a-3492becc0df2">
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22b47281-4d34-451a-b8d3-82b146e61aae"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0005542">
        <dc:identifier>EC0:0005542</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0005542</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609242">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/263</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/609242</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6a8fd555-cdc1-4f9e-921b-5ae176ce3025"/>
        <rdfs:label>KANZAKI DISEASE</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>263</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53f77c6e-df17-49c5-8362-d84b074fb5a0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
    <dc:identifier>HP:0001260</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>dysarthric speech</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8bb7c67f-0057-4a3a-80e3-4e7394c6cd95">
    <dc:identifier>DB00130</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac416cd5-46e1-43c4-92d4-0cc11960e2ce"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00130</ddiem:url>
    <rdfs:label>L-Glutamine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44e25880-0cac-4d44-b371-49f1ee2f10c4">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef9c1f27-af9d-4dbf-95ae-4149506b99dd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf7cbaec-f52e-4751-ab3f-b56a2a9a5740"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7640647b-4339-4600-9fca-66643247efd7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/487b328e-bb8b-4c96-a7ef-c601b2d2536b"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36ff058d-38f6-4582-8989-7a116fe2e155"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86968c4a-2fcf-4100-95f6-a6cf3c47c4da"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b041fa84-0355-4ef9-9394-f1a881eb9cc3"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0faeee0d-3152-4a1a-a565-260aa9773e6a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7c783fc3-6c40-4c51-b2e0-04ac342b7066">
    <dc:provenance>https://www.semanticscholar.org/topic/amlexanox/510418</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/74e0ba12-b9de-4172-bcb4-6980cdbdfaf8"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. "This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. " It posses the ability to cross the BBB. "Our data show for the first time that Amlexanox might provide a valid therapy for AGU." https://www.ncbi.nlm.nih.gov/pubmed/29247835</rdfs:comment>
    <obo:RO_0003304>Ser72Pro/Trp168X</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c382fbd-4998-47be-b8a1-081b4c974f69"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5c0a1b7-3825-49aa-a7ae-872724036375">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>Neurological abormalities</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1e8c45fa-68c2-48e8-b532-a25ea5a05528">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d1903b5d-3a9c-4a7c-8e78-c69fa98596b8">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C07</ddiem:url>
        <dc:identifier>C07</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0ec199b-c9bc-44c3-9d20-8e11df73c851"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/326c9991-2a34-4e4b-ad88-d99056551405"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0fd09e75-b756-4bba-b4e4-3408e2f1d2d2"/>
        <rdfs:label>BETA BLOCKING AGENTS</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cddf9225-00d0-4e26-82ea-65f342fdde96">
    <dc:identifier>MP:0003949</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0003949</ddiem:url>
    <rdfs:label>dyslipidemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/74f0b6c4-c58b-4abe-bb18-e433d5aa4c71">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb52d3c0-d895-4ee0-b55b-c46a40409f6a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7997f088-3492-45e6-bc3c-66b9cdd70ece"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230600">
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE II</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b91ef82b-6f42-49e4-8ce1-4856f8ed9f85"/>
        <dc:identifier>https://www.omim.org/entry/230600</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9009092-16c1-47e8-aef4-a75eedc8f3d0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:label>Brain pathology</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23337983</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5cbe198-6be0-43fe-8d37-14907b4c6aa4">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003141</dc:identifier>
    <rdfs:label>Increased LDL cholesterol</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bf11f4c5-14ae-4feb-9b56-9304f542ffac">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17395561</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49264a40-e24b-47b8-a983-f35beffeb3d6">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Seizure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cdee51ce-39ed-4e4f-aaf1-9527c2457731">
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/275630">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/14cd9cdf-09ca-4198-b50c-8b6ab27aa610"/>
        <dc:identifier>https://www.omim.org/entry/275630</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/753</ddiem:iembaseUrl>
        <rdfs:label>CHANARIN-DORFMAN SYNDROME; CDS</rdfs:label>
        <ddiem:iembaseAccessionNumber>753</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9ce02bf-7e7e-4669-8ea2-05a0f6bad72d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f786fbae-66ab-480e-911e-986b886d90dc">
        <rdfs:label>steatohepatitis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001397</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f124413f-bd8b-4288-b112-73e5866ab330">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03196765</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28200172</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4565238-aa22-4bad-9bb5-0637d2fa511e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3e5e9eb2-86fe-4c39-bfca-9e55f26fc566"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94f8049c-4028-49d6-bed3-d113df9d7a7f">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Elevated long chain fatty acids</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <dc:identifier>HP:0003455</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/71a5b40d-0d67-434e-843e-67fe20afed36">
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48526519-7ff9-4f48-8de1-c12a119c9cbf">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal levels of urine total alkanes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4cbbc885-d9da-4a64-84e7-a69ea36ba2a4"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b87b87d-1831-4d81-a377-2f51ae5d6bea">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100036</ddiem:url>
    <dc:identifier>HP:0100036</dc:identifier>
    <rdfs:label>proximal femur pseudofractures</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ceca1f5d-d80d-44ac-b3b5-c1233e3ba110">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8efdcdf-ac90-467d-9295-e254556044a4">
        <rdfs:label>Low cell autofluorescence</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01551e9b-0974-4417-8a6e-f45e5a3406f7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Blood-brain barrier (BBB) impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204200">
        <dc:identifier>https://www.omim.org/entry/204200</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3</rdfs:label>
        <ddiem:iembaseAccessionNumber>307</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3de8ff71-9a1f-4c0d-8d07-b3dcde812eee"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/307</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45947886-f069-4676-b3a7-7a79cd070f68">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011018</ddiem:url>
        <dc:identifier>HP:0011018</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>extended G1 interval</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8c30c29-1db0-486c-8ef6-bdd6e2e94007">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/681cd7a6-e712-4de0-b921-86f969b67f91"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1600999-2ae4-4932-901e-61a8e1dc4d5a">
        <rdfs:label>membrane fluidity alterations</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29660499</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad20502c-211b-4489-95e3-d245aa5a2f29">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/69336441-31c1-48a3-93a6-8c39e7c69472">
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d7adddd-2f09-4caa-bf43-b84628b11912"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24873726-ae88-40da-a171-752293433d82"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
        <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad964fd1-4121-4c26-b539-12aa25198ecf">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b668883-956e-4b57-bb10-5792150a1818"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24873726-ae88-40da-a171-752293433d82"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d7adddd-2f09-4caa-bf43-b84628b11912"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3219ea8-29a0-405d-bf3b-3d7b2578b25e"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11251</ddiem:url>
    <dc:identifier>DB11251</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa09411f-e9ad-4936-9560-61cd6f250c84"/>
    <rdfs:label>Tocopherol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03234c01-2578-49c8-8486-3468e489a67e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Joint inflammation</rdfs:label>
    <dc:identifier>HP:0001369</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ae00dede-294d-4cc1-94df-e4a33c2d254e">
    <dc:identifier>DB00334</dc:identifier>
    <rdfs:label>Olanzapine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00334</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ce79100-23e0-4b63-b44f-5e25aaa25902">
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a7ed7a0-a339-4f7a-82f3-3a0e1dae46c1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9c84e39-6fa8-412d-bb42-cc8e5c60dbd2"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21fa6a67-653c-4b81-98dc-9eb2439bc963">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417300086</dc:provenance>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9c84e39-6fa8-412d-bb42-cc8e5c60dbd2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b01ae937-1dd7-4145-942f-05e51e09cebd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68a964e5-d392-4939-93e6-b7cca5acc0d1">
    <rdfs:label>Self-injurious behaviour</rdfs:label>
    <dc:identifier>HP:0100716</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f31def9-6dc3-48ca-a0c4-d4f87761d3fc">
    <rdfs:label>movement disability</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/490c747c-432a-47c3-a81a-a24f0f5695c8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03085</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fac5a4c5-8c5f-4da8-8b5d-908d455ea6cb">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17082bdd-c7c4-4514-b278-59e6423d8983"/>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a44f9fc7-ff53-4ce4-b9a9-750f949cebc0"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69f563a0-3577-4ca5-ac5d-fb1eeb0177a3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c093448-0390-4e18-9ae3-d76ebe276929"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Glycolic acid</rdfs:label>
    <dc:identifier>DB03085</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b9840834-9053-49e8-83be-61097fb2f5ea">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/86e30c12-95a4-441d-b7a0-31530e7c5686">
        <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b89d953-8b65-4815-931f-14ea2bf987d1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208740</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/284e04fc-22bd-42e5-97e4-a77d4cb6a878"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>rhPBGD</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eef25ea5-6a92-49dc-ba13-70d127587316">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42213bd2-0b10-410e-b892-6fba836b62bb">
        <rdfs:label>Arthralgia</rdfs:label>
        <dc:identifier>HP:0002829</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002829</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/618d1ccb-723a-4f49-8836-90d374861e71">
        <rdfs:label>Arthropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003040</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003040</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9195122</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e60c4b2-eae0-4e1f-b739-3ea007c811b4">
        <rdfs:label>swollen joint</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001386</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/621f4343-4d8d-4dfa-9bcd-daca7d6fb844">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/62f1ee9a-4463-49d9-b451-88b08a7a0509"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ed2effdc-eb3b-4773-b943-af50b488d58e">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f1e877e-fb38-4478-b4ab-85e1b76d4c2c">
        <rdfs:label>Intellectual disability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001249</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/010abe84-4958-4559-9ba0-c5effa11b2e5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95a3161d-8e66-44f7-8b86-1918985138bb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7812a678-0179-4883-9846-d5b62f01c26b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:label>Neurodevelopmental abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/396d104d-4d36-47d6-a038-9ddd097586f2"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dabf38d-e110-49a4-ba86-8152a8db464f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eaa749d3-0274-4866-b455-b38fc391bf84"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9bf716cd-452c-4edb-a900-a81203286e58">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002188</ddiem:url>
        <rdfs:label>Delayed CNS mylinaton</rdfs:label>
        <dc:identifier>HP:0002188</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be1b0dd6-1909-478e-8390-65d42acf8661">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Slow background activity in the EEG(EEG abnormality)*</rdfs:label>
    <dc:identifier>HP:0002353*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5ccb8967-b77a-41bf-a288-b3822c19aa21">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7483726</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cc9d3eb-f131-41aa-91e8-31cc0640fe8d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef7dcd2d-b04f-4a6c-be09-d95926e14705"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf121511-3775-4269-b8cb-ee60e6dec50e">
    <dc:identifier>HP:0001337</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>tremor</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/23d32d63-6727-4901-be7d-fd703e4ad64b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/249866bc-1f9a-41c1-8aa5-eb8380eb114a"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/144223df-0e68-4374-bf98-6888c6f4a548">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1884cefc-b8a3-4fe9-bd4e-309271691755"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e463ef9a-d5bb-4185-805d-5c4b1d0ae868"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/892461e0-2af9-4c98-8e6f-f022f28c72d8"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3da51f46-a5b4-47c8-9bf9-7cf2dcbf51a1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f41b784b-6fbd-4bfd-8da8-1ef670885a01"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19ebbb66-bf73-4a3e-b7fe-6318dbae4828">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3483883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1282787-1fef-4df8-baae-c21f74db737c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1531c63-2b20-4e27-af04-634d50947040"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff279d44-3012-4245-b9bc-190557833a02"/>
    <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec5d63c9-461a-4e78-a642-091dd21f359e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/52eaa10b-186a-41bb-965b-f01a032625b6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f436789-f64a-48b2-aba8-b892f12e2d8a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Increased erythrocyte glycogen content</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/821ad117-36ca-4d69-a84c-357959a44c1b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17957158</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1edeb54c-0d64-420a-abc7-562a419f14c2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de4f0c03-01c0-4603-af33-cdc9c748d9ae">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
        <dc:identifier>HP:0008282</dc:identifier>
        <rdfs:label>high plasma level of unconjugated bilirubin concentration</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/91254244-582a-4a66-811d-af1c5ec6bf82">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d82799d0-d54f-46fc-8c88-621e89f8b674"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eaa749d3-0274-4866-b455-b38fc391bf84"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e386bf81-d3f9-4cbd-879e-1c90116b4b4a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c0d007e-6dd4-4a90-b09f-d075ec656ed8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/010abe84-4958-4559-9ba0-c5effa11b2e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176100">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6630951e-cec2-457a-9bbd-412650641604"/>
    <ddiem:iembaseAccessionNumber>114</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/176100</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/114</ddiem:iembaseUrl>
    <rdfs:label>PORPHYRIA CUTANEA TARDA</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b4c0327-aeba-49fb-9824-3b21421478c2">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2b34968f-9a20-47f0-abf6-a061ddef8b1f">
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da588ead-0424-4da0-a6c7-00dca2fa8e50"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0233b36a-b7eb-4867-9976-3f08f16a0124"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9ec2b24-604f-4569-a702-cb87bab6703c"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs00198-015-3272-1</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089612</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4c3d475-c4f0-460d-b27c-aec71157a44e"/>
        <dc:provenance>https://academic.oup.com/jcem/article/95/12/5174/2835157</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
        <obo:RO_0003304>compound heterozygotes for a p.G339R and p.E191K ALPL mutation</obo:RO_0003304>
        <ddiem:failedToContributeToCondition>N461L</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f283c262-90b2-49ed-ae3c-d72526c85e12"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27042741</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7ff59a8-abb9-45b9-ab15-5178c0e3745f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/47b97556-404b-4084-a8e9-94fe7e495808"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29174c89-bd31-439c-8a1d-f54ec4a94eeb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/43c33d70-ae8e-48ad-9fbe-d08ea5c12e63"/>
        <obo:RO_0003304>Ala176Thr/Val423Ala/Val522Ala</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b87b87d-1831-4d81-a377-2f51ae5d6bea"/>
        <obo:RO_0003304>D378V /G339R/E191K/A176T/V423A</obo:RO_0003304>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Teriparatide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06285</ddiem:url>
    <dc:identifier>DB06285</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cfe74bb6-829a-4729-91e1-b49e3420ec8f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b81dd25-1fe6-431e-a21d-d59d96dc1a99">
        <rdfs:label>gross motor dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007015</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007015</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce194430-7f8e-4fb2-8120-4470208d1c3f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
        <dc:identifier>HP:0000002</dc:identifier>
        <rdfs:label>delayed growth(stature)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/266707cb-f638-4a46-9a4e-1f361ebe7833">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>growth delay</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f729017-4ad1-497e-b8f9-02a740a774a8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
        <rdfs:label>poor skeletal mineralization</rdfs:label>
        <dc:identifier>HP:0006462</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/834d8c25-deeb-45de-8ff4-b9887d980921">
        <rdfs:label>fine motor dysfunction</rdfs:label>
        <dc:identifier>HP:0007010</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3287f1f-e5c0-4585-ba5c-1144012bcb80"/>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b511f37-3b10-4e1c-a507-dac901ce6b9b">
        <rdfs:label>Defect of bone mineralisation</rdfs:label>
        <dc:identifier>HP:0004348</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29405935</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86c463c2-b373-4a76-b1ba-bc6e22d4380e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d316ff81-2003-4ede-bd12-7f6a26de694f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/413b6418-e8a2-4803-aca7-499de10f14cf"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc99a9fc-39ef-4fea-a593-6141cd80b679">
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>cognitive impairment</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d448309d-54ff-44fc-9b61-66d1a4fde126"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30083035</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4926e2e7-dffe-464b-bc02-bae5f8bef4ec">
        <rdfs:label>rickets</rdfs:label>
        <dc:identifier>HP:0002748</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac6b3afa-61cf-432a-a388-354b4d13e1c2">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b07909e-8b29-4fe6-ba0f-e3a3f345a96f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a5e9f43-0e4c-41e1-822a-152a0c37433e">
    <dc:identifier>HP:0040129</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal nerve conduction velocity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb7917ca-4fa4-417d-8f1f-d8e9b203059f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ded6a37-4d24-4e89-8264-047b49b3bbfb">
        <dc:identifier>HP:0007359</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Focal seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007359</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c7ef80d-9872-4a36-b414-81965a9b9fd7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1554b71-84e0-4f73-9562-6eaf494f6393"/>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/311fd0a1-67d6-464a-8796-fd753acfe59b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>neurological disease</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17fa10c3-894a-4371-8bc1-1cdc4c003797">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00819</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/53fe3095-f5c6-4657-b416-ad6e8cf6b5b6">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb3f8598-5f6d-4433-9a02-db4f7a993f03"/>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21749991</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fcfc3ce-562f-4dd9-871f-424d461ef284"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc5e7fdb-5158-4a79-97d6-00e09ba756a6">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb3f8598-5f6d-4433-9a02-db4f7a993f03"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/111301c0-4648-481f-aceb-e99a90077dfb"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00819</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/afed8b4c-261e-45b6-b19a-5e1e7d8f8978"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/793ab618-75ed-4fca-bae8-3fe47f3377d3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb3f8598-5f6d-4433-9a02-db4f7a993f03"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c85e538b-5caf-4e20-b77e-60dbb06bf3b7"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Acetazolamide</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02479a32-fdaf-45f8-8c41-28a999fca6c3">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/150c361d-a3c4-4956-a598-2cbab12fee49">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/beb18e6e-00e8-4446-aa55-4456deced9a0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02725580</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601780">
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/601780</dc:identifier>
        <ddiem:iembaseAccessionNumber>311</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/311</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/11749cac-dc3e-4068-bf22-2febbd4a1a23"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31331814</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e3a74729-5b00-484d-bd92-5cc718096e50">
    <dc:identifier>DB01037</dc:identifier>
    <rdfs:label>Selegiline</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01037</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1bf82ab-b535-40b7-aec5-fccbb43dd14f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a3e1f5d5-fa49-4b40-b147-0009650d4139">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9a11684-f9ad-4f37-ae42-76bc09ef6812">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25832663</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba887d54-d562-439c-8ebf-ab828fc0128e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17ade3ee-d1d1-4c6b-81e2-f75e1c02a66d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB04173</dc:identifier>
    <rdfs:label>Fructose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04173</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0128be07-0f09-49f8-aa48-9b39536d16aa">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0e72615c-5d73-4b6f-ba7c-f3f04ce4a0a7"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/829de308-f9c0-411d-b1ed-a0d873476ada">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
        <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56699ab9-9e45-4ecc-85fe-bf53ab332f6b"/>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d67c41b-22e7-4f22-9069-f8901f795625"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93ceb0a7-dd15-49a9-bf0d-18c40e860642">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d67c41b-22e7-4f22-9069-f8901f795625"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f9955fc-5971-4eb9-bbee-e38c21c1c84b"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aef3f10e-56da-4c85-9059-0f8a24821d80">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d67c41b-22e7-4f22-9069-f8901f795625"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044915</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1680417-9c34-49d8-8223-55d646b35318"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b7e6b1de-a03e-4922-8949-beae8d60c7ba">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e87b478-f4c3-44e8-916f-24def00a0d6b"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d67c41b-22e7-4f22-9069-f8901f795625"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2592f96-e776-48ec-8f8e-74e83b841816"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB11094</dc:identifier>
    <rdfs:label>Vitamin D</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11094</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee5f3b63-4799-44c2-bbaf-93b9c2a7b5f9">
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f6a5dce-6af4-4a8f-90f7-1e2e2d73644b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d67c41b-22e7-4f22-9069-f8901f795625"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/57041edf-5b1a-4aa9-9c3a-8e01812a611c">
    <dc:identifier>DB01241</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27d14754-5e4f-4c1c-b0ff-90b646d776a1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01241</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cb38fb38-cce2-41fa-9c58-da137f24db73"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ceeb470c-ce66-41aa-b320-98dcc0df2871">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8b3123d7-360a-48a4-8d1f-cf439fb07d47"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15251700</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7143ca57-ac0a-4f63-b651-11f4f89993ee">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2702860</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25729805-decf-4817-a8bf-f150fe68813a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/210c8447-f9a2-4d99-96bd-819cdfaa08c1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e485633-bbc5-44a8-9e9b-e5cae77c2e87"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83cb08b0-212b-4bd6-9a6c-721135211b31"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a0a3c48-8d30-4959-b8a6-ebbaaa7eae9f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8b3123d7-360a-48a4-8d1f-cf439fb07d47"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
        <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b944ba2a-fbd0-4e4c-87b4-df37caa1ef91"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Gemfibrozil</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4227a61-405c-48d0-888b-90e2113570b5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3900744-4943-49e9-8155-95730c2e2cf8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/745ad223-a747-459f-9001-c93d79fcbd50">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Neuronal death</rdfs:label>
        <dc:identifier>HP:0002529</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002529</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7df0d3ca-f3f2-4d10-bf7f-3163b6dd3093">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/867377f0-3b56-4f70-9a82-dd96d321459b">
        <rdfs:label>myopathy</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0003198</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8245377</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec367b7f-4815-4eb7-9b0f-fe9af6498e90">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>delayed growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/127d369b-1cf6-463b-a463-52f7aff8c8ae">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f68826d7-a762-4258-a7f7-d7798e50c64f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91312603-ffbc-4c29-ab7c-6a920180446f">
        <rdfs:label>cardiomyopathy</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <dc:identifier>HP:0001638</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f8c07b4-4e8a-43c8-a41c-80c979f4be6e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a48e2ea-b4b4-4935-8f9a-5f1940e8590e"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b491465-a240-4154-b969-08683aeb5e4d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d5bbdac-41fe-4e21-9044-767164b1b823">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>infertility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000789</ddiem:url>
        <dc:identifier>HP:0000789</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fe1cc59-6e8d-496b-b937-36aefd4502fe">
        <rdfs:label>edematous</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0000969</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256540">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/319</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>319</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a9260e7e-181c-4cb9-a8ff-f1f7afc8a20e"/>
        <dc:identifier>https://www.omim.org/entry/256540</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GALACTOSIALIDOSIS; GSL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ebf77e18-d6c4-4c69-aea4-de7fe3b1cf8b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a896a7f9-17a8-4ded-9da9-862737b9134f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c638101-860f-4946-ac0c-63625231593d">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>gait abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <dc:identifier>HP:0001288</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9156acf3-8de8-46e0-b834-59a01bf9a5d2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0002311</dc:identifier>
        <rdfs:label>incoordination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5caf50bb-75bd-4f8e-954d-a6b4d19e12fb">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02030015</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9863c81-e67e-4f3d-a124-748c9dece46a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High ganglioside accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b91ef82b-6f42-49e4-8ce1-4856f8ed9f85"/>
        <dc:identifier>https://www.omim.org/entry/230650</dc:identifier>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE III</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30c123e3-8b71-4fb3-8345-606b8e9ac977">
        <dc:identifier>HP:0002066</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
        <rdfs:label>ataxic gait</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52a1376d-08cb-4c04-a2d0-71d41754afeb"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dfafb223-ca7c-4de7-a10c-051d35734492">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4adcec41-bb95-432b-b440-f595b5aa49ce">
        <dc:identifier>HP:0000842</dc:identifier>
        <rdfs:label>Hyperinsulinism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000842</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20936362</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/006340d1-713a-4add-9146-42ba4a1c2434"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23295286</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15fbc68d-b8fa-4389-8113-2e23df2c223b"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/758c6eb9-9aeb-47ca-a1e9-9e07fe26fafa">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>epileptic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d2adb9f7-7a61-440c-abe3-cc79bd691d09">
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9b3cf7d3-56e4-4c8b-ad05-a16efa8f9035"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1acfd3aa-038e-4c19-a308-818366181c9d">
        <dc:identifier>HP:0000938</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
        <rdfs:label>Osteopenia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40441412-448b-49f2-b2c8-53d677bbd8ab">
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:label>Mitochondrial myopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003737</ddiem:url>
    <dc:identifier>HP:0003737</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36add6ef-408c-49a7-b8d0-7e3b9a1708d3">
    <rdfs:label>Tocilizumab</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e6a60bd7-b2a0-4b79-9cbc-afc1e76f9664">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7413b36-70b7-43f9-ab63-d4269033def2"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cc8bb54-05f8-4463-8b56-888ca8e531a7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/da70a26e-85d5-4af3-81c7-aef594fb4cba">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af2917b4-6861-4d20-9395-9c32ee501360"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25173351</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a25247fe-6049-4239-8414-e22c55252f57"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30225156</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9ec2b24-604f-4569-a702-cb87bab6703c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cc8bb54-05f8-4463-8b56-888ca8e531a7"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d15deb6f-38b6-4e1f-9997-9701298b850f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ada7dfda-169a-4a21-a0ae-7da2af03dac1"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06273</ddiem:url>
    <dc:identifier>DB06273</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a1ec301-9d00-4879-804d-13a7ec0e14f5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001903</dc:identifier>
    <rdfs:label>anemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3396803c-b45d-4dc1-ba14-de8ea35b3334">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe509ce9-81d3-4c8d-85f2-f30a2e25cfad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3567b7de-43b0-4137-b32c-0afab0e5317d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf4aebf1-7a2d-41f1-90bc-908ca850e805">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Epileptic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612736">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/104</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/612736</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a072b5bc-510d-49d9-bb3c-d31793ed464d"/>
        <rdfs:label>CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2</rdfs:label>
        <ddiem:iembaseAccessionNumber>104</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be1b0dd6-1909-478e-8390-65d42acf8661"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11749046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9111708-b8c0-4529-a888-c2fab751f9f9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e5ffa037-5212-47a2-aa7c-741a14e321a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce0e20d0-449f-4b7a-a348-96eb7e375409">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002453</ddiem:url>
        <rdfs:label>Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*</rdfs:label>
        <dc:identifier>HP:0002453*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6050556f-5a0e-4c1b-a924-0a887ce24ca6">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c111b94-7ecf-49fc-847c-927f04889d31">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee5c4380-d980-4db4-83f3-a33e6aedb7b2"/>
        <rdfs:label>Complex Carbohydrates</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/74f53c6d-9521-4254-890a-927c9ef0988f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d67c41b-22e7-4f22-9069-f8901f795625"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95cfae18-4528-4e0e-a306-d71f0a78fbc2"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/597a511e-9671-48f6-a080-771b6a71e9c7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:label>Abnormal gait</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9ce02bf-7e7e-4669-8ea2-05a0f6bad72d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da43e5a3-939d-43e6-9afa-dc08821ae030"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3ef1281-9a00-46e2-8d22-b8fab8378462"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3097391a-577a-4b69-b3a3-2b3233444822">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e12cc407-6df7-4e5d-b0c5-09051e23d67e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b07909e-8b29-4fe6-ba0f-e3a3f345a96f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e615ec8-2294-4ced-9e55-09206fc30fcc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002011</ddiem:url>
    <rdfs:label>nervous system abnormalities</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0002011</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55a8d36d-7cf3-48a3-b361-f38c57815ec6">
    <dc:identifier>HP:0012279</dc:identifier>
    <rdfs:label>Low plasma serine levels</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012279</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/450c5e76-b27f-4018-9705-4120267f4aed">
    <rdfs:label>Chloroquine</rdfs:label>
    <dc:identifier>DB00608</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/625624e3-2eae-4ebc-bc68-e24a01c84d79">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e547bea8-dcae-4614-8715-acde4386ab30"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38baf4e5-7028-4d25-9faa-69359df66316"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6bbb024d-c571-4158-9f0b-48c88c1bd59f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7c3e0f7-9859-4f87-a250-9105b223035c"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12622622</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7324107</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5776f65-6de7-4e7e-8846-91a03eff71ab"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5080345</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15441491</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24d1a065-8bf4-4775-99bd-9cc67f68e16d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176100"/>
        <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <ddiem:failedToContributeToCondition>C282Y(Homozygous mutation)</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4739135</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5a923e2-6a95-430f-b876-78c738353ef6"/>
        <obo:RO_0003304>C282Y/H63D  heterozygosity or compound heterozygosity</obo:RO_0003304>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00608</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fcfc3ce-562f-4dd9-871f-424d461ef284">
    <dc:identifier>HP:0002066*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
    <rdfs:label>paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia )</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/637f1a84-cd1f-4356-b17a-5237166bb398">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
    <dc:identifier>HP:0040189</dc:identifier>
    <rdfs:label>Scaling</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcb07aa9-ad4e-40a4-9486-7d230d50db0d">
    <rdfs:label>acidosis</rdfs:label>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <dc:identifier>HP:0001941</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b72fbd78-86f0-458f-952d-cde937f93324">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a53e94da-e15d-42a4-9bf5-6e542b08c26d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d32a8a7-4186-44de-9a1e-63249ee3a69c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002317</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Gait instability</rdfs:label>
        <dc:identifier>HP:0002317</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e6af077-1ffc-422d-b23f-4dd659328c0a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71d14136-3cad-4db5-8e68-75eb57e42193">
        <rdfs:label>Elevated blood homocystine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0002160</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11503bbf-250e-4d10-9d8b-cba1c2304c95"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f8eeb08-63c3-44d5-9666-4470ee3e825f">
        <rdfs:label>Myelopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002196</ddiem:url>
        <dc:identifier>HP:0002196</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ce1dc87-d303-420a-a88e-c349887388bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6749192</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7357085</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b919094f-0c8c-44fc-aa5e-393d99e38604">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95534dba-8575-4e40-90d2-240cbef60cb2">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/acbbc2cc-7bca-4944-b0d7-a90ee6b323a4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43cd9b0d-2b07-469c-aa26-3ffc8b9f227d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e1f5795-1762-4102-a01e-e1e3d24899b4"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bf320967-26ee-4f3d-8d21-34c3c64fb5e8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <rdfs:comment>The drug was accomapined with fat-restricted diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/080077be-b24a-428b-90d5-7524734b926c"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23522979</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9cb81e0-2b2b-4108-a3d1-7c385d692f80"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43cd9b0d-2b07-469c-aa26-3ffc8b9f227d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/797f7b20-2a25-4334-bfda-481a1181921b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eaeed061-6d87-4061-a06d-8ae6afd2a012"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>C09C</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09C</ddiem:url>
    <rdfs:label>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/de895648-6d1b-4307-9ac7-2a728f03cc91">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ea1818b-f3e0-41a4-b222-8ec9e7552f0a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02346461</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a6e9baf-dd57-423b-8240-6971a5577ff8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4d4fec2-5395-47fd-bb9d-7376dcff5112"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be6b7b5e-816d-4d01-9039-62b37d21e9b8">
        <rdfs:label>Low circulating levels of free sialic acids</rdfs:label>
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012363</ddiem:url>
        <dc:identifier>HP:0012363</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605820">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>NONAKA MYOPATHY; NM</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/605820</dc:identifier>
        <ddiem:iembaseAccessionNumber>1299</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1299</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b43c8bbf-3a50-4741-8b8e-fe76f9acb197"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0eae102-654c-410b-8e26-b11607442743">
        <dc:identifier>HP:0012350</dc:identifier>
        <rdfs:label>Decreased sialylation of muscle glycans</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012350</ddiem:url>
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1eacf63a-cfa3-42ff-9803-a44d614bfb9e">
        <rdfs:label>Amyloid deposition</rdfs:label>
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
        <dc:identifier>HP:0003216*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003216</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/adb438aa-d2dd-4c9f-a447-f5da78dfb08e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f483af63-b17e-4861-be11-892d1ec644eb">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0009020</dc:identifier>
        <rdfs:label>Abnormal exercise physiology</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b0b19858-9ee4-421e-a8c5-9d6e44ae379c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4e0ec5d7-fa01-4fb5-9d26-20b106fc45d6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ea2ca4d-5574-4c83-807b-16bb06549618">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <dc:identifier>HP:0004302*</dc:identifier>
        <rdfs:label>disability(Functional motor problems)*</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18098237</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5b69faee-0254-43cc-bd4a-7825b7273239">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/867377f0-3b56-4f70-9a82-dd96d321459b"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/043f4a45-79fc-4c18-90b3-6fc77d0541d8">
    <dc:identifier>HP:0010876*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Defect in protein synthesis (Abnormality of circulating protein level)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010876</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59bd13dd-cd20-4c4c-8cab-b3ae9460c424">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3fb0ba9-c800-4f03-a641-601d7aab9b97">
        <rdfs:label>Dysuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100518</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0100518</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e8b90d6-4b44-4e92-be0e-4274d1e43c1f">
        <dc:identifier>HP:0000787</dc:identifier>
        <rdfs:label>urolithiasis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000787</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://academic.oup.com/ckj/article/9/6/800/2709623</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614723">
        <dc:identifier>https://www.omim.org/entry/614723</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba4521c3-51da-4121-81f2-1b0d5915e0bb"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34c73594-1ca0-4024-bbe5-0a0691ef9436">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000010</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
        <rdfs:label>Recurrent urinary tract infections</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3f64ab3-3fe6-4571-ac7f-7ba7da2fb6f0"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8f46c8b-865d-491b-af77-ea4d6800b22b">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000112</dc:identifier>
        <rdfs:label>crystalline nephropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efde8beb-6075-4128-8138-fa6923b2f15f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <dc:identifier>HP:0012622</dc:identifier>
        <rdfs:label>Chronic kidney disease</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b97c4944-d072-4dc7-bdae-3f44a4cd32ac">
        <dc:identifier>HP:0000790</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000790</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Hematuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/921f940f-a40e-421f-9684-8f06528a115d">
        <rdfs:label>Elevated Urinary DHA excretion</rdfs:label>
        <dc:identifier>HP:0012622</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38dfd93b-885b-4db9-ab93-7a37d2688a47">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:label>Kidney stones</rdfs:label>
        <dc:identifier>HP:0012622</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/640a962b-ada8-4e73-865a-94a8f43b8c6f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b322e17-2393-47f1-ba57-ec97159b15db">
        <rdfs:label>Organic aciduria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001992</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1110863016300763</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203750">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/65</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/203750</dc:identifier>
        <rdfs:label>ALPHA-METHYLACETOACETIC ACIDURIA</rdfs:label>
        <ddiem:iembaseAccessionNumber>65</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fd474b3b-a38a-499b-a7ce-7c0e7b13c910"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>Abstract</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f58140ca-e45f-477c-b321-d3ec313489c6">
    <rdfs:label>Vitamin B-complex with vitamin C</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EB</ddiem:url>
    <dc:identifier>A11EB</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b6eb34d9-2985-4536-b516-17f5865ec05f">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77eb1f3a-c389-4bb0-ad7e-0923fb9ea65f"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a076fae-88db-4c0c-a4d0-9f9ddd4d74ab"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/97feaeee-513b-4072-8f60-33a110c05d8a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67c86ed4-cd87-4093-afff-f18cba7b7eac">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
    <dc:identifier>HP:0003128</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hyperlactatemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f05a32f-f489-46bb-909f-83f175b96a63">
    <dc:identifier>DB00571</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81376dc8-85c6-43dd-b915-d7908886f34e">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4cba297-4f46-4ebd-9d1c-dda9d8328837"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/baa6814e-2896-4ba1-a20d-50117dd69c39"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10048-015-0444-2</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Propranolol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00571</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28fd15a9-c58a-4474-a8d4-3c62b51653e1">
    <rdfs:label>increased dopamine and serotonin levels (neurotransmitter levels)</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012654</ddiem:url>
    <dc:identifier>HP:0012654</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c98deb11-192c-4e94-a31a-274da0e92362">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/83c6d370-530b-4180-9ece-2665b2ad89cf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ddc0aad-927f-4ccf-b569-16be2f243f2f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004314</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/908ece03-1239-4488-9837-3703ec287ba3">
        <rdfs:label>No result was added</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100851</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e4e6b9d-c606-46bf-bae0-db5a203a6926">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b124190-2301-408f-8228-148ed7a24e51">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008936</ddiem:url>
        <dc:identifier>HP:0008936</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>axial hypotonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7705cf09-ef71-4d71-821f-02567e2be87f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6068b2a7-c5dc-4542-a8f0-85aa061f3612">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002459</ddiem:url>
        <dc:identifier>HP:0002459</dc:identifier>
        <rdfs:label>Autonomic dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc674436-c1bc-416e-8448-aebe4f2457c6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
        <dc:identifier>HP:0010553</dc:identifier>
        <rdfs:label>Oculogyric crises</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20898899-8a6c-45b6-b664-8fc73428bc9e">
        <rdfs:label>limb hypertonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002509</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002509</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f536ff6-03d4-43f7-9e93-2e2da6d1d5c0">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:label>Abnormalitilty in voluntary movements(Abnormality of movement)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/671aff78-97fc-48c3-a696-7ae82b0485b5"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4603316-f460-4dea-a272-cfacb33ea56c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/de3190ea-d2bb-45b6-9cc5-9118b32993dc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db2c590b-021e-4752-aed6-939f71064bea">
        <rdfs:label>hypokinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002375</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a047d3a8-23c0-42b4-a195-4de50e271aa6">
        <rdfs:label>choreoathetosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001266</ddiem:url>
        <dc:identifier>HP:0001266</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b688e86-f4d7-4b33-8ce1-10df1b08f43c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:label>High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*</rdfs:label>
    <dc:identifier>HP:0003119*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/80e20b7b-7bcc-4b0d-9d07-c2739c7f653b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/efbc4be4-b686-45f4-b0b5-bc38115ad527">
        <rdfs:label>Afamelanotide</rdfs:label>
        <dc:identifier>DB04931</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB04931</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe9c44d6-d304-432a-aa26-fd962aa6153f"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc26e1e8-946d-4c3b-9dbe-5cb2f5cd8841">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69c1e634-ccf9-44c9-8182-07a576fb14bb"/>
    <rdfs:label>AT342</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f4ce3188-85db-487f-8087-ad3ff5a5a9f0">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/297b53c5-ffa1-4d3f-b33a-28462f304f45">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/36616737-5fda-40a6-9fc6-ba905ce5a4d3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02b3132f-0b7a-408e-a117-e42061606b0c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated serum ferritin concentrations</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <dc:identifier>HP:0003281</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/38c55386-8c65-4df2-9267-d3cef8f1da65">
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/48e6f55e-23fc-47cf-896f-61208578ebf4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dd76222e-2c01-484c-92ae-8c82bb8ed359"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be22d4ec-3894-4d04-ba3a-c5bb40a5bbc3">
        <dc:identifier>HP:0040006*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Low survival rate (Mortality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d5a3b71-6a82-4ebd-a818-3848170d03ad">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1e15445d-54bf-4236-9bb4-629f4a3ebf7d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d316ff81-2003-4ede-bd12-7f6a26de694f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfe74bb6-829a-4729-91e1-b49e3420ec8f"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/017196c6-e72b-4378-8746-71873a01fb4a">
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86c463c2-b373-4a76-b1ba-bc6e22d4380e"/>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85b73d3a-16e0-4c5f-b7d6-d6b93c7e075e"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e51f9b7f-51d0-4e1f-92d4-3eeded20bb87"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bc0d496-3aa7-4d98-8080-11bf05a2e814"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22397652</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241510"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbd057c1-87bb-431c-9f0d-a9728aa2e44d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa0b6b4a-fef5-46e7-b431-fbc8ad2d5bd2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB09105</dc:identifier>
    <rdfs:label>Asfotase alfa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09105</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/693313e6-ecc8-47b0-bc17-0ce88402721a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/676be4fa-da35-4f14-9b82-983652d60668">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d46c6c61-c4ce-4d4e-a68d-0fab4a6c0d05"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01034592</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4e0177e-4e20-44c1-bf03-cdf291323d19">
    <dc:identifier>HP:0001997</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001997</ddiem:url>
    <rdfs:label>gouty arthritis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ec4bbe0a-0bed-4e78-9cc5-81897db520d9">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23016163</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/310cb91e-1c1f-4ebe-8eed-e1a77739c8e6">
        <rdfs:label>Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <dc:identifier>HP:0010472*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/07732efb-f949-4c80-9392-edbb7694f9ca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/593cedbd-d0fc-4114-af12-4131ef718035"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/71717604-13cf-459f-99e3-f5732516d7b3">
    <rdfs:label>Carglumic acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ed602e96-8ff0-486e-8f3f-500bef75f83c">
        <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/243500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21403788</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/153edf8f-e798-4c30-a94f-51e5de61fe89"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/438c0ed5-138c-4d1d-b0e3-e6dc6519a07c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21207059</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06775</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/099b4270-753e-4cb2-bbfb-86eb21fe46fc">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28281899</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/438c0ed5-138c-4d1d-b0e3-e6dc6519a07c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d1ec00d-fe63-46dd-97b8-1541001b8050"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB06775</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/283550da-1464-44fd-ba82-913e96b01916">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd60f9b5-08bf-4937-8293-db227d8b7ad6">
        <rdfs:label>ER (endoplasmic reticulum) stress</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3191399-5b58-4233-af93-c9d9265e127b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High triglyceride levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef12e8d2-ec1f-4cb4-847c-82baccbab8fb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/72e0106d-17fb-4b2a-9cd7-6657afcff582"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b07909e-8b29-4fe6-ba0f-e3a3f345a96f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c0dff28-6543-4315-99a9-37ee0108c667">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003343</ddiem:url>
    <rdfs:label>GSH deficiency</rdfs:label>
    <dc:identifier>HP:0003343</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3169e07f-9993-4aa7-93df-38d36e63e660">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d92f1d42-7fb5-4fe5-be82-714678d036a4">
        <ddiem:url>https://www.drugbank.ca/drugs/DB14151</ddiem:url>
        <rdfs:label>Phosphorus</rdfs:label>
        <dc:identifier>DB14151</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad8a2145-a4ef-4f4c-b66b-1dd0edc89c1c"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606175">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/606175</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/671</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>671</ddiem:iembaseAccessionNumber>
    <rdfs:label>CARNITINE ACETYLTRANSFERASE DEFICIENCY</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0f2bf92d-33c6-42d2-9ac0-d3522b64a5b5"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b25fbfaa-c6ba-4944-9d4f-74e1513acb25">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97233d3c-5a66-40d7-8d47-e68dc206e142">
        <rdfs:label>Hypsarrhythmia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002521</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002521</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
    <obo:RO_0003304>"heterozygote missense mutation, MCCA-R385S"</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94802ea5-4b53-4e4b-9621-658bcc9fa618"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <obo:RO_0003304>MCCA-R385S(heterozygote mutation)</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108</dc:provenance>
    <ddiem:failedToContributeToCondition>MCCB-(IVS16þ1G&gt;A)/ MCCB-missense mutation E99Q Homozygous mutation</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6304e1e1-8f67-46c1-924c-e3bb8b175687"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b322e17-2393-47f1-ba57-ec97159b15db"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601987">
    <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/601987</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b99da675-4944-4686-a865-2044e7e6d93f"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2e79e5e8-54e3-4dc6-b01b-bc314517e168">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/16952e9d-e528-409d-9a07-001d18b7a6ac">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64a179a5-6cb6-490f-a688-9f9e94af72f2"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/32d5182e-6374-4a42-9661-4ef7f999b92e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d32eb2e5-8968-4c34-90a6-d19725a9a46f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00603</dc:identifier>
    <rdfs:label>Medroxyprogesterone acetate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00603</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dcdf5bd9-0ca7-49e6-82ae-235132a37d3d">
    <dc:identifier>DB01119</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dfafb223-ca7c-4de7-a10c-051d35734492"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0635f878-be87-41fb-b332-c428aadf92ee"/>
    <rdfs:label>Diazoxide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01119</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc02637a-97f1-4e83-928c-1012fd0e6c97">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/240800"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/006340d1-713a-4add-9146-42ba4a1c2434"/>
        <obo:RO_0003304>E1506K</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15356046</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <obo:RO_0003304>delSer1387</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15fbc68d-b8fa-4389-8113-2e23df2c223b"/>
        <obo:RO_0003304>R1353H</obo:RO_0003304>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe6641d1-1d10-4407-8fa5-becea5ae29c9">
    <dc:identifier>DB14002</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f2d62116-265f-45a3-b286-b73023613478">
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb725e7c-69f2-4bb5-a77a-bf92b5b519ba"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277460"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699704245</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9a6c49f-f4cc-4e18-aa1d-506d00f22ca1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb75978a-860f-4611-8fdd-574da0e33e32"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14002</ddiem:url>
    <rdfs:label>D-alpha-Tocopherol acetate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1e8917ff-bf32-439b-89fb-555946f42ef9">
    <rdfs:label>Uncooked cornstarch+ Beneprotein</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c1831988-6787-4699-ab0c-ebffb54036ab"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a0179b63-47ff-4024-acbb-8b2cb3f924ae">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1ec35227-3931-412b-ab3a-3329464bb8d4">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0a684fb-6346-497f-a7df-e081a03f3780"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7ad08ad5-a381-4ba8-bcfb-3799f285fe36"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e0db13d-237c-471a-8848-bdf4f0ef791c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b4b65d8-890d-477d-88f1-34256d2bf9f3"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/26561487-e3fb-4f6e-a61a-135b29ece838">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e0db13d-237c-471a-8848-bdf4f0ef791c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff93abde-fa6e-42b1-9be0-9b5803b6ad91"/>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c171d70b-1fdf-4d15-bdf4-b0d55117df91"/>
        <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607625"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e803632-cfb1-49d5-bed3-1a5252f12ec4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB15146</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18c8cf3c-ea2c-4090-a7e1-295afaca2cb8">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9870ee68-a7db-4d07-9f78-d8b6db44fe2b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e0db13d-237c-471a-8848-bdf4f0ef791c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf8b2b2d-8a46-440c-8cf6-7d9bacd6bbe9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0618bb32-35fc-4298-b052-b0d99980f84a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db79c848-d699-4bdd-97de-6acc84788763"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0631b78-62c9-423b-9bbe-9661ab8635b5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f90f5d6-fc10-4aa8-a531-c859785bf9af"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26027824</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff93abde-fa6e-42b1-9be0-9b5803b6ad91"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29429782</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5f8c393-5ab9-47bd-8041-42ff65df3a70"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e803632-cfb1-49d5-bed3-1a5252f12ec4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Adrabetadex</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15146</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/df21a0d0-67be-4a0e-bafb-99205d815dbf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5993e6d8-a7b6-4d75-8604-cebb41ddf16d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5403eb4-ac6f-4285-9158-2e17cb90aef7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20943885</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77eb1f3a-c389-4bb0-ad7e-0923fb9ea65f">
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:label>Mitochondrial dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ad8794b-44c5-4f04-a5b1-987f0de2c2fd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/901ab7a1-3bc4-43d4-838d-57a26ee4df82"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/462f4ffe-d9a1-43b5-b9ff-c2d232f7cf8e">
    <dc:identifier>DB00115</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/440953d0-304c-4b29-aaa8-bff53813fe24">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25308559</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261000"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87961b08-722c-4642-8d38-aec9cda90fdb"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a5c7949-5cbd-4ff1-be82-0a2535b58d13"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/854ad32c-ab91-4cfd-af73-3a3249484d4c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44352f17-ae4b-462a-a76c-e04c8c4a7b94"/>
        <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a540f2a5-701c-4a71-80de-5623081cc8b3"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1ca0642c-65fe-4a74-b063-d1ab25ff2b91"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00115</ddiem:url>
    <rdfs:label>Cyanocobalamin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1874c641-94a3-4749-9ed6-a69b7124e8f7">
    <dc:identifier>HP:0040189*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
    <rdfs:label>waxy scaling plaques</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55c84033-7af0-4536-ab1d-959de1029e72">
    <rdfs:label>Potassium Citrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e1dc7d7-1318-4148-b8ed-dcb4571ead4a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b6e6b72d-5c2b-43c5-bb16-edd8237f90e1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09125</ddiem:url>
    <dc:identifier>DB09125</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/42b8adb7-ade4-493f-b07f-1129effa361e">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613490">
        <dc:identifier>https://www.omim.org/entry/613490</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f22da568-30e8-47fe-af1a-878f2b1d908e"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02363946</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23527792</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fac4c93e-2208-4966-897b-411a55d8a668">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8cf172e8-83ac-4396-ae42-7ab5fff51e9e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a5307c5b-f236-4b60-930f-ee46854b9b11">
    <rdfs:label>L-Citrulline</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00155</ddiem:url>
    <dc:identifier>DB00155</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/956390c5-8f27-413c-beb9-c1bb78daa609">
        <rdfs:comment>Citrulline should be given in "Low-dose" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d1ec00d-fe63-46dd-97b8-1541001b8050"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4bb6646c-64f8-4457-a379-fba640c179e4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a9b1dcc-5da7-401e-b220-4c186b7374a8">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
    <rdfs:label>Diabetes mellitus</rdfs:label>
    <dc:identifier>HP:0000819</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1c2f6c03-54de-4c95-b3d1-1b81853eec57">
    <rdfs:label>L-Lysine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00123</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3f88711a-207b-4da9-9218-7ad9e8442588">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f09c3fe-38e3-4f38-a480-f42c024f7f5d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a92c0a0-cb06-4931-968e-ea1f63402bf3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/73c3bd63-7956-4388-a436-5fe57f4c6f33"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/52c930ff-8b86-40ff-95ef-9a3530cf86d0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a366007d-9f79-40c8-b1c1-11a93639d08c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffce60b8-9af4-45c8-b2f9-5ceedaaae774"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d511275e-4a4a-4d83-947f-5164e1de4f4d"/>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76757cb8-87e4-4b2a-bcac-db93d194965d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b5204d4-604b-4446-8451-2feaada6c5cf"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00123</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4705fa4a-db7f-4205-834f-3984e1d20271">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a92c0a0-cb06-4931-968e-ea1f63402bf3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d511275e-4a4a-4d83-947f-5164e1de4f4d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c34fed74-6831-4a40-9bdf-a295fac03ac5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e547bea8-dcae-4614-8715-acde4386ab30"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cc9d3eb-f131-41aa-91e8-31cc0640fe8d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f8b6b36-425f-401a-aaf2-96a2ae3835ee">
        <rdfs:label>Increased inflammatory response</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0012649</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d7b7406-d67a-46cf-9906-1832f0b95a20"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bce9dbda-b351-4242-8f95-57be53b1ba2f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d7d7946c-789d-48b2-923f-28e89d796e1a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6f25f04-9cad-4ccc-8748-f2fe698f7441">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261515"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/370d70b9-60ac-495c-b144-f2b019a2ea98"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5f6a1424-033a-4b5a-825d-c676bfd4b890">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/043829be-fbd1-422e-9235-c24bcd0483f6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/100435b6-f035-4fff-ace7-6021f7cb8105"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe9c44d6-d304-432a-aa26-fd962aa6153f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28003770</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb19e35d-cc47-4f7f-9c31-78a3c2ab0497">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:label>Cutaneous photosensitivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/80e20b7b-7bcc-4b0d-9d07-c2739c7f653b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b37ec182-9fec-485b-ad8d-12c89f91cbc5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c7533576-9582-4e6f-8f7b-d7963a33aaaa">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/425df0e6-64b4-44cd-9b57-ba7163f5ccac">
        <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a51a5b34-b91f-4325-b61a-ef1f346afe34"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a44f9fc7-ff53-4ce4-b9a9-750f949cebc0"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e0f8a824-d037-4346-b417-006d2dd5e357"/>
    <dc:identifier>DB00227</dc:identifier>
    <rdfs:label>Lovastatin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00227</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd9e3dfa-7786-4bde-b438-d58676b115e4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9be4c9ce-ce35-46c6-8f6a-0c7417662b3b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a44f9fc7-ff53-4ce4-b9a9-750f949cebc0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5cbe198-6be0-43fe-8d37-14907b4c6aa4"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08107414-2609-4e77-a3da-03ea69cbed0a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a7c1da1-0ffb-4574-a2e8-ccd8ae67da3d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e59d42ad-b3a6-4e09-a3dd-72f6524a8c4a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12205338</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc3298b2-7af2-47c1-9319-2a74dee8c02e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3f64ab3-3fe6-4571-ac7f-7ba7da2fb6f0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8c88f49-b70d-4b01-adc6-8d870eb73b3b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <dc:identifier>HP:0003676</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Disaess progression(Progressive)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09309523-8511-4579-9aef-a3d2870a2dc7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040006</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:label>Mortality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/546b9fb7-ff49-48fe-8e81-d4c23a4ca1f6">
    <dc:identifier>HP:0002621</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Atherosclerosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b882240-0913-4e11-8796-26c6b0fba53b">
    <dc:identifier>HP:0000708</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:label>Psychiatric disturbance</rdfs:label>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236270">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/31</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ad873cfc-4504-45d6-b73f-1d633d5ba146"/>
    <ddiem:iembaseAccessionNumber>31</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/236270</dc:identifier>
    <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE</rdfs:label>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000008">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:52+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with or depleted in molecules  closely related to the products or end processes of a genetically defective protein which occur as natural products in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">dietary regime modification</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ace068c8-eca0-4862-98bf-9d942e90f9e4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b585b46-fcef-4789-b5b0-3976152ed52b"/>
    <dc:identifier>DB01593</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b82a5bb6-169d-4850-b559-64842c0fa392">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef8cea65-913b-4840-b880-749ffbc9318d"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78560ee8-6f2a-4abe-8a08-e27d871129a4"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01593</ddiem:url>
    <rdfs:label>Zinc</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd43fb21-8592-4198-a99e-6f261c07fa6d">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ca5120a-be3e-4ea1-a73f-3cefa06b2cdc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef8cea65-913b-4840-b880-749ffbc9318d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da40f06d-8421-45e8-83e5-f5d96a1b7255"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/06cf7c79-9c5a-49e7-bb18-983cc32c859c"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604290"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1c18ca3-8f07-4d39-b108-90fc1369a7e2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbf7baf2-c061-48c1-806d-b2ea3a1d7b4e">
        <rdfs:label>defected excertion of 3- MCG</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7474896</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e66c71a-7374-45d1-baf3-c15de90914f1"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5af1e6f0-0f8d-44ef-94e2-34fc3144cbc2"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f49d96e3-a13d-4ebe-a311-6bd86a1a0d83">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d1ff0a0-b013-4a78-980c-f9c15111582a">
        <rdfs:label>UDP-glucuronosyltransferase gene defect</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/845945a9-459c-4ee2-812a-213e1135ec11">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/53edf0f9-29e0-4ffb-9721-37449ca93c15"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10468611</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c7c8e2c-ba32-4ee3-b6ab-dc17a48b4f53">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/976fac24-835f-4bcd-9ec8-adb2dcb60aa3">
        <rdfs:label>High serum iron</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003452</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03395704</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76c4f683-edc1-433d-8693-1c056ce96e49">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f614f9b-77cf-422a-9fad-1c28dccb6166"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6a4999ac-2701-4ac6-a25d-8ff2aad62413">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29702557</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266265">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb6bfbb2-7cfa-4c3c-a668-27b779339c3e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/341</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>341</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/266265</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://www.bloodjournal.org/content/94/12/3976.abstract</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/10048d45-bb7c-468b-85dd-fb4eb18f09a5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/011b2dd9-860b-4b03-a2a2-46197f724c5a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>correction of the delayed psychomotor development was expected to be more difficult to achieve. However</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/deb2603f-3e67-4fc2-b404-f4edfd750c44">
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <rdfs:label>low neutrophil count</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17276979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9389720b-1111-43c0-8248-f4a95c8a64e5">
        <rdfs:label>Abnormal Golgi located fucosylation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c28536a-c273-4251-8254-f2e66caf02c3">
        <rdfs:label>recurrent infection</rdfs:label>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f024eabc-4c47-4f10-ad4c-077035845768">
        <rdfs:label>Abnormal fucosylation state of glycoconjugates.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/841f9c47-025d-466c-8515-9872db49c872"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>http://www.jbc.org/content/282/14/10762.long#ref-14</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e697f80-9d86-4108-b5d7-43fd71990dc5">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <rdfs:label>Neutropenia</rdfs:label>
        <dc:identifier>HP:0001875</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbc26a2d-3d02-4d2c-98ca-7bc81e81cfd4"/>
    <dc:provenance>"espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II)</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f78d8ca-ebfc-4252-bc08-5f1d08b546ac">
        <rdfs:label>abnormal expression of E- and P-selectin ligands</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>the patient showed significant psychomotor improvement while on fucose therapy."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a5c0b48-8604-4527-97e7-cf69bdaf7453">
        <rdfs:label>Abnormal selectin ligand function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/935c1f4c-9aa0-4ec9-9714-563835f634c1">
    <dc:identifier>DB11735</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/90563881-0620-43ae-96e7-7ffeaa2e8985">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3635cd1-3b91-412b-9c97-5603c1165159"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607091"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e4b5c19-9b0e-4e44-842a-b29588ed9b82"/>
    <rdfs:label>Galactose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11735</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f3511ef5-9325-4d17-b81d-21e4b828d382">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aabc1a16-2eec-4a57-ac6e-49a1310fba3c">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c2db1c3-de24-41e0-9113-6d9938f02d12"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d59d6ce-17ee-4cf7-97bc-f793a6a534da"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ae1496-faa8-4323-9e1a-d63575b8e421"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24935455</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6ba69ef6-ba83-4ecf-81aa-bdbe9bcd0997"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Etanercept</rdfs:label>
    <dc:identifier>DB00005</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00005</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/75e6f57c-4625-4ef6-ae4b-2faab75f7b84">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c13556e-8a2e-4e65-9738-fd0a34c941ba"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/56513bf6-6130-4ae0-b5e5-7a470380f7c8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/62f1ee9a-4463-49d9-b451-88b08a7a0509">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eef25ea5-6a92-49dc-ba13-70d127587316"/>
    <rdfs:label>Hydroxychloroquine</rdfs:label>
    <dc:identifier>DB01611</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01611</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9c557f90-3e7a-4a4d-bd3f-540a7ac388fc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b3f4750-75ca-465c-95b6-8a086fe60dd2">
        <rdfs:label>"Frequent, severe infections"</rdfs:label>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/980a2ebb-aec9-4c78-bbf4-cf58a7a8a47e">
        <rdfs:label>Recurrent bacterial infection</rdfs:label>
        <dc:identifier>HP:0002718</dc:identifier>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8447561</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1709246</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e697f80-9d86-4108-b5d7-43fd71990dc5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1719175</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6277417b-895e-4621-a375-e9a19f697c4c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3f12ff78-af04-47cf-97b1-316522858f96"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8de505a-d6c3-4338-ad44-c16607e2761e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230500">
        <ddiem:iembaseAccessionNumber>284</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/284</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/230500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b91ef82b-6f42-49e4-8ce1-4856f8ed9f85"/>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE I</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ed54cfb-420c-47c8-8f26-d20d814eeed9">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurologic abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b8f19a7-ddb5-43af-80b9-471e647b27ca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e0d9a0d4-e4d2-411d-8c9c-b7183f7dea67"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9e70f5b4-f785-49de-bc2c-50af6c0e857e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2126b31d-7421-41dc-a0ee-d28e5c61c953"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdfs:comment>The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her age‐mates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/24d11bb4-dd80-4e72-9af2-74a5e1e52193">
    <dc:identifier>DB00390</dc:identifier>
    <rdfs:label>Digoxin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00390</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/62fc3b50-15de-4767-bf69-fdda802d35f9"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f30d773-b490-496f-9fcc-b3801a4efa54">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3ef1281-9a00-46e2-8d22-b8fab8378462"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00465751</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3b7eda4-e7a3-486c-b45b-87bc92c0f78f">
    <dc:identifier>B01</dc:identifier>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21ef10ca-9689-41d6-bb3e-4ccb6270e563">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1da0a842-bc3d-4264-803a-965c15d686d5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16767100</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28019685-b70c-4e61-91a9-f9c0cf83eb2a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/456095c8-31cc-4ade-ad04-fc741c14f007">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/89e72f66-666c-453b-8dfb-7112689799c4">
        <rdfs:label>Diiodohydroxyquinoline</rdfs:label>
        <dc:identifier>DB09115</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/16a337cc-992f-4aa1-a71a-7e52710fabd5"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09115</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9223bc28-17d6-4b37-ad57-54478352918b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5586fdca-c8b4-4b8e-b421-025b4f47eaae">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001271</ddiem:url>
        <rdfs:label>Diabetic polyneuropathy</rdfs:label>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <dc:identifier>HP:0001271</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2d9d17b2-b2fa-4007-8a31-4f699216a7be">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99646926-7506-4d6b-82cf-ea0b66c89ab4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87961b08-722c-4642-8d38-aec9cda90fdb"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/56a6fcb4-d820-482d-8b02-fbdd68771725">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b498c6fc-d024-4761-ad7e-58073e996776">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2464ef8e-6401-4dc2-a288-040f84f55cd1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7160758e-4dfc-4338-a6ec-24de3c0f9e23"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Complex carbohydrates+Beneprotein+Low fats</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/72d913ef-54df-4c66-b0a9-c60497dde823">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b07909e-8b29-4fe6-ba0f-e3a3f345a96f"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250950">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>58</ddiem:iembaseAccessionNumber>
        <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/58</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/250950</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/df8571b4-0c01-4d33-ab1c-6d214bf08545"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11400757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e78efdb0-6fe1-4c8d-9efb-d2c3d3c09080">
        <rdfs:label>Delayed Growth</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a702b3a-89a1-4817-8f33-2d1f50b3de07">
        <rdfs:label>Metabolic Decompensation</rdfs:label>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d48c0df0-0bbf-4e4e-afdf-8067287e17bd">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:label>Abnormality of movement</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e00ced8a-6b0f-4d96-9a2e-3b0ed1b4d5b1">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e6635e94-c0bd-4358-86a8-60c163050ab6">
        <dc:identifier>DB06756</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35257cee-cd63-4d64-a589-c2485b14caf9"/>
        <rdfs:label>Glycine betaine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/abddf098-a793-4e93-a312-1ba879330696"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB06756</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f17dc0c-fc55-497a-a367-f0acdf57d5d0">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00165</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35257cee-cd63-4d64-a589-c2485b14caf9"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd93fdf1-f460-428a-8840-f5131a86b9a6"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a948d558-4a17-41cf-ae97-29aa5a972d90"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ef57078-492d-4e59-88b4-e1f111e8cf3b"/>
        <dc:identifier>DB00165</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05a0086b-a39d-4da9-98e7-8b74d8712215"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/536436d1-71d5-410d-9f3e-3a4d33d1aa8a"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7ee61d5-4ee9-49b6-a97f-9c44ff19cd82"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ddc0cd1e-e1c2-4f64-991a-7053195921b0"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf11f4c5-14ae-4feb-9b56-9304f542ffac"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e269da9-3962-41c0-aef3-f4a00b2628a2"/>
        <rdfs:label>Pyridoxine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f29918d7-65bf-4d04-9d65-4d4e10b555e1"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/32e7e5b7-bdc0-4ed4-b7bf-fc28ab20b59c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e66c71a-7374-45d1-baf3-c15de90914f1"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23601642</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c382fbd-4998-47be-b8a1-081b4c974f69"/>
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a1e8d12a-f395-454e-a530-04457eb21852">
    <rdfs:label>Ad5-LARGE-eGFP</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/42c1272c-2576-4429-ae9f-7ec8bc9a70b4">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07f368e3-ffb6-4e99-bce4-f82ca4a1d3e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15184894</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da7dc67b-2e19-4f43-b7ea-1de6f4150296"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c6e6a7d-aa12-41b4-93fa-1e021e7cba0b">
    <rdfs:label>apoptosis induced in chondrocytes</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5d7be776-85e9-4822-8d1e-74fb3e116c2c">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9678437</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eda7e7e5-74a3-42ee-83db-3498edcace1b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c5c83b3-1739-48af-bfe8-ee106e623527"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc3298b2-7af2-47c1-9319-2a74dee8c02e"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3f64ab3-3fe6-4571-ac7f-7ba7da2fb6f0"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61702080-bb56-48a0-86c6-6d597a987676">
    <dc:identifier>HP:0002150</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High calcium excretion</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be81f276-800a-4fcb-9b02-e5d6e7f27841">
    <rdfs:label>Susceptibility to Bacterial infection</rdfs:label>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
    <dc:identifier>HP:0002718</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ab2264e1-4cee-4a87-83ec-e69558954d9e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04076</ddiem:url>
    <rdfs:label>Hypoxanthine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07f1fbf0-154e-4910-921c-3a328973286b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eaa749d3-0274-4866-b455-b38fc391bf84"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3728152</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/490e2db1-0414-486d-8c66-0c4e129fe042"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/180de5d1-58b7-4a06-a5e4-f61f378b1402"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB04076</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/087c929d-e223-4849-ad29-fa854cc76e7e">
    <dc:identifier>DB01348</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01348</ddiem:url>
    <rdfs:label>Spirapril</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87181041-8b19-4f5b-924b-866a8620e1dc"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f6116555-4b52-4cbf-aa32-ec9826f595fd">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3b7558f-19a0-4130-bbd2-569e7621aefb">
        <rdfs:label>Diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e75c0cdc-2ee9-40c3-869f-5d38cc856f09">
        <dc:identifier>HP:0004325</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low weight,growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f0415b3-9909-44f9-979d-67456199b5cc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb5333f7-506c-467d-9c78-5729a713f3d6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004395</ddiem:url>
        <dc:identifier>HP:0004395</dc:identifier>
        <rdfs:label>Malnutrition</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X16302044</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9239b602-6a8d-46a3-aacf-16af28feec6d">
    <dc:identifier>HP:0003124</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated serum cholesterol</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2278b6d1-9cbd-4467-8d51-87c83cff9a16">
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38192d48-f26e-47f3-a6a9-f1dbdbb394dc">
        <dc:identifier>HP:0002027</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027</ddiem:url>
        <rdfs:label>Abdominal pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c807a831-b785-4e0c-ac61-9d45f2b92ad9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal liver function test</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f579558-0bfc-4209-be37-379cdd4c7d57">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Photosenstivity</rdfs:label>
        <dc:identifier>HP:0000992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e479e41d-0267-4a03-8c9d-332f09d47eb6">
        <rdfs:label>Hepatotoxicity</rdfs:label>
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be0d99ae-41c2-44d2-b539-619a96037e82">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c6e574d2-25b9-4674-a7b7-5e839f9b45b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20375647</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a81963ff-a25b-4ef5-9ae6-fa93ae6360c7">
        <rdfs:label>Pruritis</rdfs:label>
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/631be2fc-71dd-43a5-b8be-af6852d5db50">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fluid retention</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <dc:identifier>HP:0000969</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b041353-63f6-49e8-8e29-6609bf2e8dfd">
    <dc:identifier>HP:0012647*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High macrophage infiltration into tissues(Abnormal inflammatory response)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2bc3fda1-2f35-4132-bc59-ed16673fb9ec">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239500">
        <dc:identifier>https://www.omim.org/entry/239500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e725d631-8ac8-4d17-9925-a70da0cceda3"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/40</ddiem:iembaseUrl>
        <rdfs:label>HYPERPROLINEMIA, TYPE I; HYRPRO1</rdfs:label>
        <ddiem:iembaseAccessionNumber>40</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S075333221630645X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2fde4fe8-4485-4b5a-89ed-1960b9d2f935">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/db89104a-9ece-4f76-8ab4-b9ede94b1baf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed06fe7a-6721-45ec-ac5f-ebd279f6b65d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/acc9914f-8cce-4f6f-b3fb-158407c41efb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/691748e4-cc7c-4304-a092-d8ddc1f10b5e"/>
    <dc:identifier>DB02053</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02053</ddiem:url>
    <rdfs:label>Ribose-5-phosphate</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5218987a-ebf4-4538-978b-86ba27c2a540">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d6452d54-a67e-4b2d-afe3-6ec899fc4701">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a6289472-e6b7-426d-9fd1-2ee17a2716a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1d71f9b-db27-4629-a08c-18e80c22188b">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2ff3804-fcc9-4c24-8ad9-dd6131bbba6f">
        <rdfs:label>accumulating substance aspartylglucosamine from ( Metaboic abnormality)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14f77275-9477-4929-86b5-aae261505a04">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000924</ddiem:url>
        <rdfs:label>pathology in many somatic tissues</rdfs:label>
        <dc:identifier>HP:0000924*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10657992</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <rdfs:comment>There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18ed6af7-9774-4faf-876e-bafe9fb75e57">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*)</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8a9d5bf1-497a-4674-9ae3-3e0c7eeb4979">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/820696d3-2e97-40be-97c6-ee773c54c9aa">
        <dc:identifier>DB04854</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB04854</ddiem:url>
        <rdfs:label>Febuxostat</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/170939ed-6b61-46f2-88cf-b19856e07e18"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/301c1ff6-86ff-4cba-97f7-20d597ed093e">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6428df5-6a67-4b00-ac59-c83b611f53e0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0030095-caa1-4aa7-9bef-d8cfd5e66af7"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/361c4001-e946-4b47-8e22-24b0fc0982b5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/836ec4e6-c19d-4c7c-b052-7c43550958b1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26790a3a-3426-44a6-83eb-28e897143864"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/72d913ef-54df-4c66-b0a9-c60497dde823"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6dca2b25-3f92-4a0c-bea1-c2a03b120c73">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/09a7b5a3-380f-469e-ab4b-833061769f20"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc99a9fc-39ef-4fea-a593-6141cd80b679"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606175"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a211a502-2c81-42f7-99b4-a104f945de37"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ee16ce0-152b-498a-b591-47bdf7850c55"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2fda526e-814e-4afe-97de-0181ee678b14"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b86d31eb-3fba-48b9-9bf7-d2002f022938"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b3196018-24c6-47ab-b964-333bc7176555">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b04ceaef-0651-4ed0-95d3-4267ed6e3845"/>
        <dc:provenance>https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1480</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e775ef1a-f402-48aa-bd6c-74f2c63e1452">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d1ec00d-fe63-46dd-97b8-1541001b8050"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e0f76f31-9f67-4c6a-bba2-bd2bedc4da42">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24b29900-5574-4737-ae38-6d5aaefb7551"/>
        <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d5bfaba-2222-4aeb-882f-4ae012371053"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155631</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17968484</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10485305</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93564753-bc66-4d8a-9d13-5059b03b8ce1"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dbf0f6e8-51d5-4c7b-9251-0aa49fb00c90"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/062aebe0-f5be-4269-994a-419a3a33f888">
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/59131206-1a57-45a5-a8a2-b613fa00d8cb"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/10d94284-7e9d-487e-8921-f50077c384ca">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28317891</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ba7ae92-79ab-44e0-b726-e231876cae23"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/daaf17a7-60e6-454e-8c6b-e006640a230a">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e776d7d-566a-40fe-84fa-b566a673404c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25620325</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/471393ca-db67-4d83-bbda-749c5fa340d3"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff065fb3-dc09-4879-853c-b129649d0f8f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b064b74-25e9-468e-a72d-60b1a5eec409"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Levocarnitine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e70f5b4-f785-49de-bc2c-50af6c0e857e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a07b603-7aa8-42db-a318-d597ce0b656d"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a6388bf2-62fc-4e14-8bc6-20f59017acb1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54d8c709-e629-4030-bcca-29554433cbd4"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8be47966-1bac-4db2-9c3d-cf7233b5370a"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4ac698d8-1ee7-4fad-8684-9077669aeaaa">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610006"/>
        <dc:provenance>https://www.newbornscreening.info/Parents/organicaciddisorders/2MBC.html#4</dc:provenance>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d5bfaba-2222-4aeb-882f-4ae012371053"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/43a9ca12-493d-409b-a354-1d595d8d3c60"/>
        <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/2-methylbutyrylglycinuria</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/34f87781-670c-43c1-9857-1d380f5ec8e8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48e4f774-10d2-4006-8e7f-39e13770fa32"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00583</ddiem:url>
    <dc:identifier>DB00583</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/640a962b-ada8-4e73-865a-94a8f43b8c6f"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb5b8c01-48fd-4d70-b8bb-3e91e24fdab3">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/09eaf995-10d6-4610-a23f-7d71fe625656"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e98d421-dd82-45b9-bebf-6c79946500eb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b669816e-7179-45b2-8e72-00812caab757"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600721"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28396261</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc592232-ce9b-4aa6-a506-8ff384e75c11"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/351b5169-032e-4329-92ea-1af53b0c997f"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/52c930ff-8b86-40ff-95ef-9a3530cf86d0"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17a15a02-0f1f-46af-a2df-58d531215023">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/051fdc8d-4c0a-4d92-a086-02884b23d79e">
        <dc:identifier>DB06210</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8c9fba98-86ad-46fa-8274-bb1bc44d9ac8"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB06210</ddiem:url>
        <rdfs:label>Eltrombopag</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bbbb1761-5d66-4c7f-adee-ad03aa996273">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1f013b45-0dbd-492e-b4e2-5e40e940a6bf">
        <rdfs:label>Cerliponase alfa</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB13173</ddiem:url>
        <dc:identifier>DB13173</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87114159-026a-4123-adc5-5d8b5d7c6359"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95b38d69-d382-4904-90dd-af785544d2f1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9cc6d6f-6fa8-457b-ae5d-525b2c60c9e4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e7892b2-aeaa-4e1f-ac4f-6f8ae3407816"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a48e2ea-b4b4-4935-8f9a-5f1940e8590e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91455ec6-84f4-4570-a300-659086401040">
    <dc:identifier>HP:0002240</dc:identifier>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <rdfs:label>high liver volume</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4f2ecdfe-01a5-46ad-891f-f941a12c3d7d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c2207e68-1768-499c-a86a-b98910067cbb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f2227517-183a-440f-9c2d-1835ccb1051c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c0dff28-6543-4315-99a9-37ee0108c667"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231950">
        <ddiem:iembaseAccessionNumber>214</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLUTATHIONURIA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/214</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d107f3f7-47d2-4fcc-9652-33fdd65114e5"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/231950</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d9a1203-e9bd-417f-8721-b36e11fd925b">
        <rdfs:label>behavioral abnormalities</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdd709ff-4b5c-4ccc-9d79-7120499e0669">
        <dc:identifier>HP:0010918</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <rdfs:label>low intracellular cysteine*</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/12757858</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c49b166-1522-4727-afe6-89dc367b6596">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0de52245-d225-449c-bcae-fcf59bba042c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f78824fe-ebc5-4d2c-ba03-f3a7fdceada5">
        <dc:identifier>HP:0011943</dc:identifier>
        <rdfs:label>abnormal thiosulfates level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011943</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c5266eb7-4001-42c7-a955-a688ffa7974f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/93bd3ed6-b62a-4975-b88c-4c84e178d3f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6ea1414-b105-4f56-b735-cc0db9cfaddc">
    <rdfs:comment>Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7413b36-70b7-43f9-ab63-d4269033def2"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2913a3b1-2390-49e1-8fb3-4f20a7b6d8da">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74a1dea8-ce67-44cb-9900-45e1ad4e3b61"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42213bd2-0b10-410e-b892-6fba836b62bb"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3bf910e4-0f25-4d95-86d3-e86c8b88a070">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e8f5111-c789-423b-b634-3a83564811e1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e56f0bbc-91a7-4113-92a7-a63cbee99f61"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2ca450a-3028-46e3-a53d-fd2e39ee237d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010832</ddiem:url>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>Neuropathic pain(Abnormality of pain sensation)*</rdfs:label>
        <dc:identifier>HP:0010832*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b4582c6e-8393-4a13-845c-a8c6aa6452c0">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d25b5d52-4979-424f-97ba-750bf314cbf2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1531c63-2b20-4e27-af04-634d50947040"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/102843f6-0376-43b9-9060-2c4ca3bc20ac">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66cff593-e8f8-43e2-a3f8-c7f7f786d22a">
        <dc:identifier>HP:0003073</dc:identifier>
        <rdfs:label>Hypoalbuminemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003073</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5664e3e-ceaa-465e-bf55-c75db2a8bf0f">
        <dc:identifier>HP:0002028</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Chronic diarrhea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25526748</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc631c02-2c3c-41c8-bebd-07fd6316c8d8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Exfoliative erythema</rdfs:label>
        <dc:identifier>HP:0001019</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/234500">
        <ddiem:iembaseAccessionNumber>50</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8701a715-6567-4ec5-9f62-aa275ae960dc"/>
        <rdfs:label>HARTNUP DISORDER; HND</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/50</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/234500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a48e2ea-b4b4-4935-8f9a-5f1940e8590e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/51e74382-b33a-4ee3-b09f-e926b79dda48">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14098</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2c9f493f-ba6c-4be8-94b8-c89b133bba78"/>
    <rdfs:label>Cobalamin</rdfs:label>
    <dc:identifier>DB14098</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42326e84-1028-4cef-bb39-cf461fa9f48e">
    <rdfs:label>bone fructure</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002757</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002757</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/48b75725-1e78-41ef-859d-a492c1eca8ca">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca645a59-ac13-49d0-a537-1a5a101c20c1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004818</ddiem:url>
        <rdfs:label>Paroxysmal nocturnal hemoglobinuria</rdfs:label>
        <dc:identifier>HP:0004818</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300818">
        <rdfs:comment>PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/300818</dc:identifier>
        <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/50060d00-4d39-4fd7-a0a7-e0ce03002b47"/>
        <rdfs:label>PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28516949</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd204c20-824d-4e4d-a681-e7691fa8f0a8"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9cf4899-092d-4be3-9fe3-14aef0be7e8c">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a5e9f43-0e4c-41e1-822a-152a0c37433e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb6eca7e-5744-4514-a4f5-e529d4fac11c">
        <dc:identifier>HP:0002311</dc:identifier>
        <rdfs:label>Incoordination</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89bedbc7-a3f5-4560-ac79-9cbb4c1f2fc3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2448e2c-4852-4d66-af51-81e391427eea">
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>neurological dysfunctions</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c4bb643-79bb-4b7a-9405-a472c2667f42">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
        <rdfs:label>cataracts</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000518</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9239b602-6a8d-46a3-aacf-16af28feec6d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29260356</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25424010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980151</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc4ba5ab-b5f3-412d-bbc3-600dd3d15bdf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>EEG abnormalities</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0618bb32-35fc-4298-b052-b0d99980f84a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3ef1281-9a00-46e2-8d22-b8fab8378462"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f759f413-1a45-481b-915a-92e7c6cafb8e">
        <rdfs:label>chronic diarrhoea</rdfs:label>
        <dc:identifier>MP:0001665</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001665</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31115677</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93dc92e9-7f93-4c80-9038-55658b2e920f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/385900a0-3336-4b79-885c-16259abc5e40">
        <dc:identifier>HP:0001288</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal gait</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/213700">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/183</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>183</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b2bdd40d-6b44-4e8f-a573-088490178fa4"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CEREBROTENDINOUS XANTHOMATOSIS; CTX</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/213700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ad550cd-e601-49c6-a1d4-701af184ef25"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dca892dc-ca47-46ff-8129-3daa7b2319d3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00814cd8-2dcb-4eb3-8d83-056ad170b689">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>low energetic state of skeletal muscle</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37edbb5d-6d14-4d44-855e-3e96855fc9bc">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:label>high creatine kinase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/872a75ff-e948-4226-b7c7-d50ebc264e13">
        <rdfs:label>Increased creatine kinase activity</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a08b35e5-a1ea-4743-8005-106ef11db16a">
        <rdfs:label>abnormal blood levels of ketone bodies</rdfs:label>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f060b54f-c986-45d9-8772-bc0415bc58de"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0e5e723e-8db0-4bcb-bf3b-bfd24ee3212f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7f2f5cc-2401-4391-a007-ad0781d95b58"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff7ec403-9721-44d4-a19f-caaefce657ea">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Abnormal blood levels of  fatty acids</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <dc:identifier>HP:0004359</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91312603-ffbc-4c29-ab7c-6a920180446f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b25ed229-f1d3-4e0a-abcd-7e730a442dda">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22541557</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d2d0d858-fd49-4608-886d-c22509447831">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a2421e2-9980-42d9-9037-f208147dcc29"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42205bfc-54c7-4a8b-a3dc-1b1f530d2471">
        <rdfs:label>hypertension</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <dc:identifier>HP:0000822</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20ebf5e5-49e1-4f3b-8149-a11f7bf38e63">
        <rdfs:label>endothelial dysfunction</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1e8c45c-5bf6-4be0-a185-d93ae50de171">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>absence of flow-mediated dilatation of brachial artery</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2ee856c-f35a-4dc9-b2d3-6576edab0eff">
        <rdfs:label>Cardiac hypertrophy</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e29b5db6-b1cd-4d47-9718-209e7b8b057c">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af5afcfa-4bc1-4c74-afea-b6ada175c895">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/df4bf2a4-4a4d-474a-9171-4a3ebc653f54"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a7c1da1-0ffb-4574-a2e8-ccd8ae67da3d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>Increased plasma triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4a2635c5-0dc1-4751-9f7e-4438fb767f96">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be81f276-800a-4fcb-9b02-e5d6e7f27841"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17206463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e697f80-9d86-4108-b5d7-43fd71990dc5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f396a12-3539-4013-a0e6-14edbefd306f">
        <dc:identifier>HP:0007367</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007367</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>CNS damage progression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ee0d289-5dc6-4819-a18f-7ae15dae1c3a">
        <rdfs:label>abnormal polymorphonuclear leukocyte function</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0001874</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001874</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddc87e87-61e6-4a07-8b00-72f26491772b">
        <rdfs:label>abnormal microtubule assembly</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2942e17d-75a9-4793-875f-537963f0993e">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0000556</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000556</ddiem:url>
        <rdfs:label>retinal dystrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eff4cc41-1835-44d9-86f1-c12a3cad8a94">
        <rdfs:label>Short erythrocyte survival (Abnormality of erythrocytes)*</rdfs:label>
        <dc:identifier>HP:0001877*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e396864-6189-4ea3-8a8d-23dbf11c9b45">
    <dc:identifier>HP:0000737</dc:identifier>
    <rdfs:label>Irritability</rdfs:label>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/46a6949d-3a76-4b77-bb20-d355e284ea9e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d1ec00d-fe63-46dd-97b8-1541001b8050"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e683de2e-5d55-4e8c-af92-9c46bac98b77"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14cad0d9-ca42-41b6-a9c0-cd2ba2b30a97">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f786fbae-66ab-480e-911e-986b886d90dc"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/35a7dc2c-e274-4f32-b09b-7a0a1a08d9e1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e547bea8-dcae-4614-8715-acde4386ab30"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f68826d7-a762-4258-a7f7-d7798e50c64f">
    <rdfs:label>high protein diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7df0d3ca-f3f2-4d10-bf7f-3163b6dd3093"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/484bd694-80c4-4f12-a0fa-02a0c6e0d67d">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9667588</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205003057</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eaa749d3-0274-4866-b455-b38fc391bf84"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fad850b-8f65-401c-8442-74167d9a81f9">
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high serum phenylalanine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/53e6ef61-fd2a-4966-bd98-88361f7920f9">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c53ed6c9-4b28-41f4-834b-d0c9fa9569eb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
        <dc:identifier>HP:0012647</dc:identifier>
        <rdfs:label>Abnormal inflammatory response</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34588c23-e181-4ac0-9f97-1a4578038df0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/77df1127-8167-4dc0-aad4-633049044b5c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd69de66-aaf9-47e3-8d85-54f327007677">
    <dc:identifier>HP:0001332</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
    <rdfs:label>Cerebellar dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4a2072c-f74b-47a9-97b1-5705142e0af3">
    <rdfs:label>Methyclothiazide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00232</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac05cff1-57dc-4556-9fc0-2ba1ed9719fd">
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a90ac572-25ca-48f0-b799-3dbb05f8d201"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b1d19a9-6e8e-4f30-8592-a75f666ef295"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/be1c7b8b-6327-4acb-8d03-60db7ff3521a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eaa9a044-2a01-4c8b-8854-96b0b3e954cf"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac688a8f-9320-4667-8582-60fd2acec57a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00232</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d2c0d925-42d7-44c1-b1df-921cc8ebed69">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c2f25b6-afa7-42e1-85d5-512dea9e31e7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased lateral ventricular lactate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/765e11e8-deaa-450e-b5b8-c23954ba102f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87903ebd-940f-4308-8611-1c6a018661f5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
        <rdfs:label>High lactate ,pyruvate ratio(Mitochondrial respiratory chain defects)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0200125</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60db2403-5985-49fc-8b1f-8723377d29eb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <dc:identifier>HP:0002069</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Generalized tonic-clonic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c168b759-7be4-4277-b46c-f3057a107ce6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum GDF15 level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62488394-8945-4f6f-b53e-e0461fd70212">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002151</ddiem:url>
        <dc:identifier>HP:0002151</dc:identifier>
        <rdfs:label>Elevated serum lactate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1e15445d-54bf-4236-9bb4-629f4a3ebf7d">
    <rdfs:label>Copper</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fea3f8cb-dc0c-406c-af24-5fa0a3b62369">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/121270"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d91e73b4-a123-4468-ad10-41d6c45eb396"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d5a3b71-6a82-4ebd-a818-3848170d03ad"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB09130</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09130</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/57dcb855-2b70-453f-ae37-6d34cb1c8ba2">
    <rdfs:label>Other antiinflammatory and antirheumatic agents, non-steroids</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M01AX</ddiem:url>
    <dc:identifier>M01AX</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c924500a-b941-4daf-bbfe-54edd7cec2b8"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe7d6914-d155-4dda-82e3-26bbb7986779">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Paroxysmal movements</rdfs:label>
    <dc:identifier>HP:0007166</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/170939ed-6b61-46f2-88cf-b19856e07e18">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b97c4944-d072-4dc7-bdae-3f44a4cd32ac"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/921f940f-a40e-421f-9684-8f06528a115d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/efde8beb-6075-4128-8138-fa6923b2f15f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8f46c8b-865d-491b-af77-ea4d6800b22b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a9d5bf1-497a-4674-9ae3-3e0c7eeb4979"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3fb0ba9-c800-4f03-a641-601d7aab9b97"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34c73594-1ca0-4024-bbe5-0a0691ef9436"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614723"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e8b90d6-4b44-4e92-be0e-4274d1e43c1f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/471393ca-db67-4d83-bbda-749c5fa340d3">
    <rdfs:label>Increased ROS production</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025464</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69b174a2-5d94-46a3-8f7a-bb8fb4d48253">
    <rdfs:label>IMMUNOSUPPRESSANTS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82c47514-475e-4a3d-b462-5b47e8cdc98d"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=L04</ddiem:url>
    <dc:identifier>L04</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dd85b471-bc6c-48f8-b254-a5ee254e4cdf">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88a78bf2-4779-41e9-8566-1a7ef8cb9197">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025373</ddiem:url>
        <rdfs:label>Eplieptic discharge (Interictal EEG abnormality)*</rdfs:label>
        <dc:identifier>HP:0025373</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ede7254e-ba13-4401-b14b-37cb0c13b4c9">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Appendicular hyoptonia</rdfs:label>
        <dc:identifier>HP:0012389</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012389</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c28c7e7-5627-4133-b77b-b2f60622b31f">
        <dc:identifier>HP:0012759*</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Socio-cognitive abnormality(Neurodevelopmental abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/666d36dc-1e0b-4160-8303-0b714a5e41eb">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormalities.</rdfs:label>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <ddiem:failedToContributeToCondition>Q1385X</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d72664e9-a33e-4211-b476-1af0fbb12bbd">
        <rdfs:label>Hypopigmented skin</rdfs:label>
        <dc:identifier>HP:0001010</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4499e466-3461-4585-a0f9-b136fd68717f">
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Low muscular tone</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d4425d2-df1a-4d37-ac7e-c6015ac87d78">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
        <dc:identifier>HP:0002344</dc:identifier>
        <rdfs:label>Neurologic burden</rdfs:label>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652413</dc:provenance>
    <ddiem:failedToContributeToCondition>2757delAG</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61246f54-d4b0-46dc-8369-c7bec94fdb3e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:label>Rapid disease progression</rdfs:label>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d56d190-95d4-4530-aecf-680b624fadf4">
        <rdfs:label>Woolly hair</rdfs:label>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0002224</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002224</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>N1304S</obo:RO_0003304>
    <obo:RO_0003304>"IVS9,DS,+6T→G"</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddbc960d-9376-4adf-adc7-64781c6a156a">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Abnormal brain electrical activity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cb301e7-e69e-4e79-9974-d2726763b8bb">
        <rdfs:label>Poor weight gain</rdfs:label>
        <dc:identifier>HP:0001508</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e31efb7f-f2b3-4c83-beec-ec01f82340ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e176db95-096a-4f1d-96bb-e5de2b06c68e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001262</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0003304>G666R</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>Del ex20–23</ddiem:failedToContributeToCondition>
    <rdfs:comment>The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10401004</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8223785</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6bda71d0-0bcb-4b66-b938-5e1e07fc78d5">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6703020-99a0-4dda-800a-d938b3e43349"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/43559ff1-be86-4302-869e-0d2f6ac2075d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615395">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/abf9b520-fb37-46a8-b136-17596cdcae86"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/961</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/615395</dc:identifier>
        <ddiem:iembaseAccessionNumber>961</ddiem:iembaseAccessionNumber>
        <rdfs:label>COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d6df4f3-6864-4a49-9cf2-b56ae9a6ac7f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb1031a4-7def-4666-93dd-0e53e20f4a15">
        <dc:identifier>HP:0025142</dc:identifier>
        <rdfs:label>Low physical capacity (Constitutional symptom)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f939721f-e88c-4b01-b45f-92b2a88e415b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d67c41b-22e7-4f22-9069-f8901f795625"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/87eae9dd-32aa-41d1-9f07-c4fa9d5938c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c27a337c-1558-424f-8c07-42b25a54269d"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a8e66a4b-d7d7-44f9-90e0-17109bfd5ae9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eab959d8-99e8-4018-8e3c-89f9b220641e">
        <dc:identifier>HP:0100529</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
        <rdfs:label>Phosphate imbalance (Abnormality of phosphate homeostasis)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43c33d70-ae8e-48ad-9fbe-d08ea5c12e63">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001376</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
    <rdfs:label>mobility problems</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1419693a-b4d5-4cf4-a559-f001d3930e38">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77eb1f3a-c389-4bb0-ad7e-0923fb9ea65f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df00d887-98b4-40fa-aba3-595898970fa1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
        <rdfs:label>Decreased cellular ATP level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011925*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aacef40d-16ee-4437-9ca8-e9b111924316">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5be9c2ee-bb44-4972-b74f-1ea403bdb267"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d83c572e-4a7a-43ef-a07c-5bc69ca6abad">
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fd2e20e-ae9f-493e-b4c4-c13e6e41ba20">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
        <rdfs:label>subclinical hypothyroidism</rdfs:label>
        <dc:identifier>HP:0000821</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/296289cc-2f99-4466-8eee-ba030099b93f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17132287</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/28a3847f-13d9-4693-b5c9-f46897553ad2">
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/32ae1511-b333-40d6-bf25-a6fce11b3ab9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af87473d-f388-4db3-a3e8-9cfc5c6a05d0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c53ed6c9-4b28-41f4-834b-d0c9fa9569eb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/459928b6-fc70-4b49-8e96-831e3148ce32">
    <rdfs:label>Gene Therapy ??</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b31ffc05-f6ce-4167-be2d-366b28fd2970">
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73cadc5b-000f-442e-9b49-eab527552436"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d1ec00d-fe63-46dd-97b8-1541001b8050"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2dd1ebc4-82d8-4781-a490-6e6d266d252f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b36bf83-d101-48fe-b3a8-64e6e7ddea76">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a453042c-c4d1-4970-b6a4-60f7c59f3c1a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0d927831-73d5-4ecb-a2d8-8d0e912e9a19"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300233</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97fad832-944b-4f76-9921-69d21a4f50a7"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48d78a37-187f-48e7-aa66-927264aab24c">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/979e6021-278c-4921-8161-8928130327aa">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d32eb2e5-8968-4c34-90a6-d19725a9a46f"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/793c2145-5f36-469f-9939-fdd4bbca8011"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1db544c2-e49d-48d4-b50a-1ed29aa946c4">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28160246</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2cbf3d7-09be-422b-8454-ba1cb28bec30"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/793c2145-5f36-469f-9939-fdd4bbca8011"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7c9ab69-8fb3-4fe3-954b-f934928f6d6e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/797052b2-9099-4f29-b7b7-1796c40ca3f3"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00624</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5d65a7b7-8372-4996-9c6b-227c56fca019">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19217094</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5f0b58f-e23e-4c06-9018-90e3c4ab73dc"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/793c2145-5f36-469f-9939-fdd4bbca8011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Testosterone</rdfs:label>
    <dc:identifier>DB00624</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7f348ff-4b4b-4730-a1a0-ebe362c1eb49">
    <rdfs:label>failure to thrive</rdfs:label>
    <dc:identifier>HP:0001508</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d3d37d0-d85b-404b-bc19-ecb17ddcbd1d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:label>Decreased muscle mass</rdfs:label>
    <dc:identifier>HP:0001324</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fd061ba6-5d6f-4eed-8f67-d1354a3fa9bc">
    <rdfs:label>Probucol</rdfs:label>
    <dc:identifier>DB01599</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/483b0d31-97e5-4715-a959-07d89468e8a6">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9f32a311-4cdb-4d63-a5b2-ebbc33498587"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9185508</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/546b9fb7-ff49-48fe-8e81-d4c23a4ca1f6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01599</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8ebb9344-9c61-4d6c-bf2b-8331882d6136">
    <dc:identifier>DB00746</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1edae939-2f1a-4b08-9442-63f508e25e60">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2aee4353-721c-43ef-8f64-a4e9a42bc31a"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2c7b03d-c9c8-4e65-a722-cc4fc1f89ddf"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36230340-83f2-409c-af8f-a505d7454a35"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/db002c16-be67-402f-99b1-a7e470b9db49">
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88cf1e1b-908d-4b38-b0f0-325a006f3910"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs12185-017-2365-3</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2c7b03d-c9c8-4e65-a722-cc4fc1f89ddf"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00746</ddiem:url>
    <rdfs:label>Deferoxamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d3bded0b-d256-4a9b-8764-8f233eb2e399"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e369239-5c15-4895-b381-f11bbda9034b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Reduced hematocrit</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031851</ddiem:url>
    <dc:identifier>HP:0031851</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2db8abbe-2ac4-4d50-9739-3ac3689f8bf6">
    <obo:RO_0003304>comp. htz c.1523 T &gt; C exon13 + del exons 3 to 15 p.Phe508Ser</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbe890a3-fe2c-4989-aa4f-9e2ca2c754b6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ab49dff-ad2e-4f07-9a4f-ccb1ef637b64">
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:label>Gait abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5c0a1b7-3825-49aa-a7ae-872724036375"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1f2a43f-2676-4e84-af0f-34d4eb80cc8a">
        <rdfs:label>Speech problem</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
        <dc:identifier>HP:0002167</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0003304>Homozygous deletion (c.504del_CT)</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/963d3a7b-5c87-4945-af29-eba243e421c6">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0004144</ddiem:url>
        <dc:identifier>MP:0004144</dc:identifier>
        <rdfs:label>Drawing inabiliity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>comp. htz c.[895C &gt; T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24]</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1691971-0ed3-4f73-bd0e-bef7d49f58e3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/467eaeac-3dc2-42a7-ac3d-2b7c810e4fa0">
        <dc:identifier>HP:0001251*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High ataxia score ( Ataxia)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0003304>homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47cc6692-3165-4100-9e4b-19b641e79d18">
        <rdfs:label>Myoclonic abnormalities(Myoclouns)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001336*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53f77c6e-df17-49c5-8362-d84b074fb5a0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612016">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/82c03500-0cae-4e34-997f-4fe92db305a0"/>
        <rdfs:label>COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/612016</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67c86ed4-cd87-4093-afff-f18cba7b7eac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba887d54-d562-439c-8ebf-ab828fc0128e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf121511-3775-4269-b8cb-ee60e6dec50e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30c123e3-8b71-4fb3-8345-606b8e9ac977"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d15deb6f-38b6-4e1f-9997-9701298b850f"/>
    <obo:RO_0003304>Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs)</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29159460</dc:provenance>
    <obo:RO_0003304>Hetero c.[1541A→G] + [1750_1752 delACC]</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18319074</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26818466</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fb14e86-bafe-41bc-86f7-e0d18f5d173c">
    <dc:identifier>HP:0004305</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
    <rdfs:label>involuntary movements</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c81e6bf-0551-40b5-838d-16378adb2b19">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/29116606</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a9b1dcc-5da7-401e-b220-4c186b7374a8"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1577f6c3-ac99-48b3-87a0-355cf11af13e"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/081b18d7-436a-4d81-90b5-13d4392bf335">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3adcb2a4-0dd5-4ab3-8b3c-28c2a8613ced">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/35f55e7d-9c0a-4a18-9bee-a36494e084a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e9ee04b-23bc-4952-a957-c4a9aa6ba04f">
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>polyuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8ef0634-9609-4539-aa48-78ac5b97f2c6">
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>affected functional activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69ddb981-89fd-4009-b8b4-0385122298f8">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b911b6e9-5827-499e-bba4-9aa42f5c0153">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12937245</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f7581c5-e52f-484c-89a2-dbec0ec8f5fe"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6857098-9cc7-4bbe-81ce-5e6019f8edb6"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7909105d-5301-414d-8868-2f4ab5efd53a"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8c45acde-0714-4fdc-8881-e1d2a35ba819">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7d28311-a15d-46e4-a0a6-76f86ccfe373"/>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f7581c5-e52f-484c-89a2-dbec0ec8f5fe"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22970607</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603358"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44bbec6d-f7b1-498d-9c32-577489fa9171">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26247153</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e463ef9a-d5bb-4185-805d-5c4b1d0ae868"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220120"/>
        <dc:provenance>http://www.scielo.br/scielo.php</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f7581c5-e52f-484c-89a2-dbec0ec8f5fe"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01390</dc:identifier>
    <rdfs:label>Sodium bicarbonate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ef8fd2c0-83b6-47ea-9883-a45f953f2e28">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f7581c5-e52f-484c-89a2-dbec0ec8f5fe"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/986a63c1-86f0-412c-a7cd-58f94dfdde25"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-016-9963-8</dc:provenance>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01390</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c589e161-87eb-4aa3-b152-52c7b18cd410">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f7581c5-e52f-484c-89a2-dbec0ec8f5fe"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e463ef9a-d5bb-4185-805d-5c4b1d0ae868"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76757cb8-87e4-4b2a-bcac-db93d194965d">
    <dc:identifier>HP:0005961</dc:identifier>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <rdfs:label>intracellular defect of arginine</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f3a46543-1626-4a13-a9a3-25f51f02cd03">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b717a5cd-4e6a-431f-bb4b-5bf55ca184e8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e98df495-1c68-4258-98b9-163f4bea9b80"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a23f9244-f649-4abb-9e05-7c98e4b3db57"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11320193</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Warfarin</rdfs:label>
    <dc:identifier>DB00682</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00682</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e56f0bbc-91a7-4113-92a7-a63cbee99f61">
    <rdfs:label>Pregabalin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00230</ddiem:url>
    <dc:identifier>DB00230</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3bf910e4-0f25-4d95-86d3-e86c8b88a070"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241200">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/95bd3945-376d-474a-a473-244df4b4d7bf"/>
    <dc:identifier>https://www.omim.org/entry/241200</dc:identifier>
    <rdfs:label>BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac21a3de-a0ef-4d3a-a4ea-5e2a4eedcf82">
    <dc:identifier>DB14573</dc:identifier>
    <rdfs:label>Phosphate ion P-32</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14573</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/275f6810-f4cb-444b-8439-4e59e412c9e6">
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/16d27315-92ac-4c7c-b9db-46284f7459d4"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b8856ef-b343-4ca7-92da-d02be5abbb52"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-016-9963-8</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/476e55b2-afb5-4171-86b0-a476c5435b9a">
    <dc:identifier>HP:0001019</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Erythroderma</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220120">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/220120</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a140ea5a-bca6-41ef-80d2-2cd23448237f"/>
    <rdfs:label>D-GLYCERIC ACIDURIA</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80f416aa-06e5-4b0a-931a-bf2c370cf082">
    <dc:identifier>HP:0003648</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
    <rdfs:label>high lactic acid level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f29918d7-65bf-4d04-9d65-4d4e10b555e1">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4993ccc3-eeb8-4e8c-a940-4dfb7aaa6201">
        <rdfs:label>abnormal muscle phosphorylase activity</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba887d54-d562-439c-8ebf-ab828fc0128e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22334182</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a11fdbd0-24c1-4609-afca-8f0fda9d600d">
        <rdfs:label>insufficient anaerobic glycolysis of skeletal muscle</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003547</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0003547</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c89bec3d-9005-47ca-a907-49522e3ae7c1">
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal cardiac function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac6d2d8a-b6db-4c37-a6ef-aca962fc4b1a">
    <dc:identifier>DB01202</dc:identifier>
    <rdfs:label>Levetiracetam</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b31c3a4-c115-40bf-a8ea-16085d1e0ef3">
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66ba728c-bb25-40f2-855b-ea26c278656f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d1ec00d-fe63-46dd-97b8-1541001b8050"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f30827c9-7ac5-4b67-956e-00e8e82c4b35">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a1a5c49c-4f7d-4127-8d0a-d3d452e59c8d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c3335e4a-a6a6-4b6b-a92a-3452060d5f3a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14981187</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01202</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb048a6e-7f4a-4e2a-929b-f2c7a6fe54eb"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4ff660ab-9c9e-45e0-86fe-42d5d08bfc9a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25558587</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66ba728c-bb25-40f2-855b-ea26c278656f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf4aebf1-7a2d-41f1-90bc-908ca850e805"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/da60f3af-32e9-4bac-b2bf-f5fd2768d248">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66ba728c-bb25-40f2-855b-ea26c278656f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b6b4e39a-6fb0-452c-88f0-06231f5de322">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66ba728c-bb25-40f2-855b-ea26c278656f"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28662915</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/568fdcad-42b8-4de3-b784-f8ee2e8009bd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/391da696-5b99-455d-8a45-01d6805ebb71">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02931f50-0c6f-40bc-9619-662b63aca346"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27790033</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7413b36-70b7-43f9-ab63-d4269033def2"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb14e56d-7d2e-4dc4-aef6-8aba0bc16590">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Low IDUA activity(Abnormal enzyme activity)*</rdfs:label>
    <dc:identifier>HP:0012379</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ce07ae9-7ba2-4cb1-94f0-06cb81c4fa2a">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6297ec5c-f8d3-42bd-8265-30c4b99690ea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f393f48-50e1-425e-a763-f2f167a7db0f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20db7c48-72ae-42e4-8556-75090e4517f0">
        <rdfs:label>Decreased lung function</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad7c341d-2f64-407b-a9c8-3bace03ecf17">
        <rdfs:label>Progressive emphysema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002097</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002097</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c13556e-8a2e-4e65-9738-fd0a34c941ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4e380b6-903e-4b62-ad99-96a6c15e2bb2">
    <rdfs:label>Abnormal mental status</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
    <dc:identifier>HP:0100543</dc:identifier>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/de3190ea-d2bb-45b6-9cc5-9118b32993dc">
    <dc:identifier>DB01200</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e4e6b9d-c606-46bf-bae0-db5a203a6926"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01200</ddiem:url>
    <rdfs:label>Bromocriptine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b944ba2a-fbd0-4e4c-87b4-df37caa1ef91">
    <dc:identifier>HP:0012238</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
    <rdfs:label>Hyperchylomicronemia</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f147acd7-c84c-49e6-bba6-dce6c278494c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3287f1f-e5c0-4585-ba5c-1144012bcb80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38baf4e5-7028-4d25-9faa-69359df66316">
    <dc:identifier>HP:0010472*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
    <rdfs:label>Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f531166-3666-4f59-bcbf-5d9bc1452dd5">
    <dc:identifier>HP:0003124</dc:identifier>
    <rdfs:label>High total plasma cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a48afd2-fb65-4a63-b681-3a1f1b25cf36">
    <dc:identifier>HP:0004359</dc:identifier>
    <rdfs:label>abnormal fat metabolism</rdfs:label>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7b809b6-2a67-4fb7-998f-9fd6e8a7b8c6">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e271a7f8-7afd-43ed-b54f-6816b34463cf">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Optic nerve damage</rdfs:label>
        <dc:identifier>HP:0001138</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001138</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d507700-70c7-43be-a718-5e309a2f0c75">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9ec915a-c5a3-4145-ba20-a391884e0e7b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/327d3eb9-2100-439a-b292-827de56ef8fe">
        <rdfs:label>Mitochondrial oxidative stress</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17296905</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/79b4889e-9eda-47c3-a911-320213d21f37">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ad18244c-0a14-426f-912f-296906cd695c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/adfdf709-a3c7-46a9-8391-c287d9fab1ab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c23f730-488c-4016-8ac0-5c68210dbe51">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>epilepsy</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241510">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOPHOSPHATASIA, CHILDHOOD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/32182380-a2be-4223-860c-38f61a119062"/>
        <dc:identifier>https://www.omim.org/entry/241510</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78d8575f-e6f6-48ca-945c-cae48d47b073">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000972</ddiem:url>
    <dc:identifier>HP:0000972</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Palmoplantar hyperkeratosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88093cbc-8b32-4701-ba26-7320dde3db4c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>congestive cardiac failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/158c4dd4-ef2b-48da-9b13-37fcc8648d56">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9457971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c6331c6-8af3-4bbf-928d-bd1c3478aa42">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>Hyperbilirubinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ae89c069-bb06-478a-89a3-675e470e96dd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0bdc290e-7ffe-4a6c-b765-8625b875414d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d95897ec-ddd5-4418-8323-94755d776137">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12801620</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ee3159f-a4b9-4bf5-a7fe-3f9807c6102c">
        <rdfs:label>High serum triglyceride</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7747514-34d1-4ec2-b945-61acc32870cc">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>High remnant-like particle (RLP)-cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2fba4826-3f52-431c-9a08-f2752f86735e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d013f2f6-bcbb-40ee-ac93-95040838b825">
        <rdfs:label>Elevated apolipoprotein B level</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0031798</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031798</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c835e91-2881-4d5b-8750-0768788c7e7d">
        <rdfs:label>High remnant-like particle (RLP)-TG</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/645e47e0-3dda-4f37-a26f-d8613300b595">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <rdfs:label>Elevated VLDL-cholesterol,serum TG ratio</rdfs:label>
        <dc:identifier>HP:0003362</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8de0bc22-494a-4344-9ae8-68157aa55dbd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:label>High serum total cholesterol</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0003124</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a0c1d7b-70d2-4d12-918f-730e7512d977">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229300">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/31d998d3-0996-42b0-a947-548d3304762d"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>FRIEDREICH ATAXIA 1; FRDA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1241</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/229300</dc:identifier>
        <ddiem:iembaseAccessionNumber>1241</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8771284-0cb6-43be-a7d9-d829e9ffe76b"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02705547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/66569eaf-23d9-46be-8ce1-f874aa17e5fd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11767031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffaafd7b-3112-4a2a-aeb3-a3dfc1b2b2d4">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000546</dc:identifier>
        <rdfs:label>Retinal degeneration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000546</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da43e5a3-939d-43e6-9afa-dc08821ae030"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14749227</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5528424e-1ef1-4407-a1a5-9d1c3997c637">
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:label>high serum ferritin concentration</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/170a7be9-04e3-4672-b84b-1dd3e9f90c79">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a05c495-c683-4080-8b50-03d8faf829b5">
        <rdfs:label>Carbidopa</rdfs:label>
        <dc:identifier>DB00190</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5b8e795-d3f9-4106-a6d5-74fe3b07d7b5"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/833d841f-5631-4e5f-b5d0-ae1888869d52"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d58dc6fc-d5bc-4a84-9979-6f2aefa3fe43"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00190</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b4b8a5c-e76b-4ecc-8bb3-fed1a8c10256"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa865077-9eaf-4f02-ba68-c41c72145650"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/90e18917-a693-42a4-90d3-53de6a4e0315">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c3da297-8a50-4dec-a8ff-7993e3b4fb64">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/27d19c48-cdc1-412f-98d2-433fd42acef9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5c69482-2bf2-4dca-935c-b43914acab48">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Sulfide toxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <rdfs:comment>It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bcd8aaf5-54aa-465d-bc9d-861fcc56f75a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02aa72cf-ad1a-48f8-975e-bf54c10fd78f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9758646-fcfe-4969-a098-cc5d3feda74d">
        <rdfs:label>Abnormal  protoporphyrin enterhepatic circulation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012187</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/20a513c1-2306-4a1f-b6b9-bb36b1f7fe2c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28833550</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c341fab1-785e-4820-9cc4-bcfb08eec6b7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3ce4ba43-97ca-4414-a98e-d8f17ff72e6a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145981">
        <dc:identifier>https://www.omim.org/entry/145981</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d73402a5-a661-43ee-ab46-d0c6de58565a"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42a82e52-6479-4e99-8daa-a6112a16a1ad">
        <rdfs:label>abnormal parathyroid hormone level</rdfs:label>
        <dc:identifier>HP:0003165</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/402d302a-dc4b-4e20-9130-ad7058cb369d">
        <rdfs:label>high serum ionized calcium concentrations</rdfs:label>
        <dc:identifier>HP:0003072*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/162ccdcc-7d88-4f0f-88a2-ad7a1ef16dce">
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0941603b-a2ae-457c-b6c2-4072ec64eabd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7034fe03-18c5-4a66-8457-5d3e651862b5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/799cb20c-f35e-43b4-ac92-59a69ba4301a">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>High α-ketoisocaproate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7d16e6ff-5ec9-4071-9138-a605221ae310"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d0d32cd-01cf-4e21-beaa-ac60d9c6964e">
        <rdfs:label>Encephalopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001298</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/043829be-fbd1-422e-9235-c24bcd0483f6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c6f25f04-9cad-4ccc-8748-f2fe698f7441"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14555</ddiem:url>
    <dc:identifier>DB14555</dc:identifier>
    <rdfs:label>Ursadiol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f9eea78-b444-436d-8985-1d25f53a0650">
    <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
    <dc:identifier>HP:0002149</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
    <rdfs:label>High plasma uric acid levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1816edb7-bade-45dd-a0dd-f90d376cb1a5">
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cc9d3eb-f131-41aa-91e8-31cc0640fe8d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8e2dc30d-37e3-47fc-8df8-ad10df602a21"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7d7991b6-8c52-4783-805b-998d9aee1aad">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30d306fc-5efb-4a75-8353-7c14795da755">
        <rdfs:label>Low Frataxin expression level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17702040</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c253155-04b2-4dda-8b02-89f250712fc8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:label>Tiredness</rdfs:label>
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a1a590c-7d5c-4206-a7c4-2cedf5d26efb">
        <dc:identifier>HP:0003254</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
        <rdfs:label>High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08ade565-e136-435b-94fd-9efecffe4e94"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45481ba3-00d4-486e-b32b-a94255df9c61"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16269021</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa79405f-48bd-4d5f-8c02-c2abfbbadfe4">
        <rdfs:label>Low NADH,NAD ratio(Mitochondrial dysfunction)</rdfs:label>
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e13497f1-474c-4567-81a8-aef86d957d26">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f5bf881-47ab-4931-8528-bf857e44e2f2"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8a4976e-d242-4823-8451-9e79a9c6cc06">
    <dc:identifier>HP:0000467</dc:identifier>
    <rdfs:label>neck muscle weakness</rdfs:label>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000467</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e2957043-f430-4cb2-9a76-e7b8eb907020">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125370">
        <dc:identifier>https://www.omim.org/entry/125370</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/24e32e6f-e411-4916-98a8-335583111802"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8d723b6e-66af-4f34-a5d3-ea29fa87ed02">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d0816d6-691b-47a0-9ff1-0a81ac0f7d2d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d983769-e768-4cf7-8a4e-fa216eee0458">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:label>myoclonic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c707391-ca5c-4f14-b85b-173596be22ce">
        <rdfs:label>inability to walk</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
        <dc:identifier>HP:0002540</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab97f62e-22cc-43ac-afb7-d4ad9a31158a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:label>Diminished intellectual abilities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d11d1d6b-5264-4341-8b07-373ccf6798be">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b07909e-8b29-4fe6-ba0f-e3a3f345a96f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0eae102-654c-410b-8e26-b11607442743"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bbf2e163-d9d4-4f7f-9546-91a548ec4f1d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b6c19ca-f54e-425d-b5a5-423400e7ded1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a6e9baf-dd57-423b-8240-6971a5577ff8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee424926-e4ba-4898-950e-f89b5b4021b7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/901ab7a1-3bc4-43d4-838d-57a26ee4df82"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94503d55-4157-41a0-9c27-69788aad99cc">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f7e7b39-5a8f-4aa4-a21b-774c8ea22eb0">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e16f343-1deb-471c-98c3-d30b29cced18"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8becd843-3978-4cdb-9334-c4f47a28d572"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eea48d2f-dea0-4002-94b8-1dad102eda81">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK442019</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e16f343-1deb-471c-98c3-d30b29cced18"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8becd843-3978-4cdb-9334-c4f47a28d572"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00761</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00761</ddiem:url>
    <rdfs:label>Potassium chloride</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12c8e098-f45b-456a-be7a-b5dbc4ccf80f">
    <rdfs:label>pruritus</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000989</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e2b5f0a8-7c5e-4b2c-92ac-7083bf8882aa">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95dc51e6-9dd9-46a5-94f9-ac7abee15229">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/35639fb0-84b4-46b2-a200-181ecfb9b50b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7d997762-9a1e-45cf-bde6-c1b2cd611d8d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00476</ddiem:url>
    <rdfs:label>Duloxetine</rdfs:label>
    <dc:identifier>DB00476</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1051cb9-1c41-47d7-82ba-c9ec986e6218">
    <dc:identifier>HP:0010836*</dc:identifier>
    <rdfs:label>Copper storage abnormalities (Copper storage abnormalities)*</rdfs:label>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59dfc651-c4a3-4d04-ad8c-3ba6cbd846f7">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609242"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/afde1fe4-0bdc-4723-b4e3-644be6ebf59a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a1382e70-2f7d-4f98-9e1d-b8294918d196"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20597c59-c527-4819-bae3-51262b0dae2d">
        <rdfs:label>Abnormal enzyme activity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002069</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0a00e36-da56-40c9-9792-00f5fb3694ba">
    <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001513</ddiem:url>
    <rdfs:label>obesity</rdfs:label>
    <dc:identifier>HP:0001513</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9d2b401-d787-4e04-ba28-e4123e41f294">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00586</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37376725-a061-474d-bc91-2d64fb306317"/>
    <dc:identifier>DB00586</dc:identifier>
    <rdfs:label>Diclofenac</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab2dcfc3-c175-4725-9389-b347ae8212a2">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x</dc:provenance>
    <dc:provenance>Abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/033bc881-e7d2-45ef-85f7-cf902d5c8144"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7899a335-be11-4ec0-a3c4-bcb7df781008"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ae973e37-627f-4c2e-98c6-854df18d82b2">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51b17a56-62d1-4bd3-b6fb-841fcf459191">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/43a1045e-4390-4d36-8b5e-843880a40134"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8892ab4b-65e8-48e4-9fad-c53f000c03ce">
        <rdfs:label>Abnormal Hcy level</rdfs:label>
        <dc:identifier>HP:0010919*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52083313-db42-444d-802c-61f5af815215">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Homocystinuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
        <dc:identifier>HP:0002156</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>S466L /I278T</obo:RO_0003304>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608099">
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/608099</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f3c0c70f-97aa-40a3-becf-6019d88a3528"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c2c8bd01-cbd2-482b-a019-4083d177bca8">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24933563</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f1762602-cb61-4462-9cdd-817c9c93b2b8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9c3a1f1b-21fc-4f63-865f-a52b3733ad84"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20e443bc-5071-43a4-855f-301778ee102a">
        <rdfs:label>Low PBGD expression in liver</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d57b3b9f-bd3c-41b4-9ede-ebc83635bab8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab2dcfc3-c175-4725-9389-b347ae8212a2"/>
    <rdfs:label>Dextrose, unspecified form</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09341</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d227460-22ec-4aa6-addc-24712cfc72e5"/>
    <dc:identifier>DB09341</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/213cd643-7fa5-414e-a68a-350580181a20">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00091</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbc44c09-5b70-46e9-8521-0ed03c0837d8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2adb9f7-7a61-440c-abe3-cc79bd691d09"/>
    <dc:identifier>DB00091</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/062c6ad7-35be-497e-be2d-e43330cd2683">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24161764</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9b3cf7d3-56e4-4c8b-ad05-a16efa8f9035"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26790a3a-3426-44a6-83eb-28e897143864"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Ciclosporin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa0b6b4a-fef5-46e7-b431-fbc8ad2d5bd2">
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>Decreased physical function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71841b8e-c568-44d5-a869-c2503acfab13">
    <dc:identifier>HP:0040189*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
    <rdfs:label>Diffuse scaling(Skin Scaling)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7a19f96d-d21e-4518-af9e-7954d55aaf4f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4930958f-4296-4475-850d-2ef6ad774766">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>elevated CSF GHB levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/45eae480-ec85-4519-bb5c-ded178f446b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d458930-9fd1-4d3d-8e6b-e6db8651fec3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24578415</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/310a7f40-db1e-436a-8be8-aa92d97ae0b7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0d6a2991-b608-4451-9da6-b6677e3f9d8a">
    <rdfs:label>Oxcarbazepine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1b6793b8-c7ff-4f4d-85bc-56cc3d9687e0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00776</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4f85ef66-4733-4e1c-bd72-5241c0f3fe3d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6164a5ef-dbf5-4cbe-b8d1-72efb3c40bb1"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00776</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/668cb364-05c4-4f14-a050-c58fe9bb68f2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6164a5ef-dbf5-4cbe-b8d1-72efb3c40bb1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/502d0e99-fba1-405a-a75a-d62bb9a5b353"/>
        <rdfs:comment>The drug has some effects but hyponatremia is a troublesome side effect.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ccdf40c9-437c-48bb-a167-2245c2beec1a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01277</ddiem:url>
    <dc:identifier>DB01277</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fefccdac-036c-4aad-ad96-e6c25d60446f"/>
    <rdfs:label>Mecasermin</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0efa1dc0-f494-4332-9b48-2848d144279d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613150">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/353</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c84998fd-a1f8-4421-8fb7-d589e87f05f6"/>
        <ddiem:iembaseAccessionNumber>353</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/613150</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a293a86-b4df-4490-979d-e87e9012adfa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ba03807-4438-4c2e-8d29-5c26e666f2ff"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88093cbc-8b32-4701-ba26-7320dde3db4c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2334bfb0-ed1a-4b68-84d0-ee3449814ae5">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002789</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002789</ddiem:url>
        <rdfs:label>tachypnea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980384</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/04d81839-a7d2-4559-bb2f-39b1dacbc8cd">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f80240c-27a0-44af-8d5c-f108ef30e0f9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <rdfs:label>Functional motoe deficit</rdfs:label>
        <dc:identifier>HP:0004302</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03570931</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a404ac46-a491-4a78-b66c-ee43e39bbb6d">
        <dc:identifier>HP:0001283</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001283</ddiem:url>
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <rdfs:label>Bulbar dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e0071d2-591c-414a-a228-a9b3b7b5aadb">
        <dc:identifier>HP:0000496</dc:identifier>
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000496</ddiem:url>
        <rdfs:label>Defective eye motor function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ae8e22c9-edd7-4d39-a519-14870f47ed86"/>
        <dc:identifier>https://www.omim.org/entry/256600</dc:identifier>
        <rdfs:label>NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A</rdfs:label>
        <ddiem:iembaseAccessionNumber>760</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/760</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5253e874-1c53-49be-bd39-16e91757e888">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012450</ddiem:url>
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <rdfs:label>Chronic constipation</rdfs:label>
        <dc:identifier>HP:0012450</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/671aff78-97fc-48c3-a696-7ae82b0485b5"/>
    <rdfs:comment>The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42e6d4cc-c39c-4004-b698-688d0f824d62">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/521b7aac-bdbc-411f-a960-1bd4fd48475b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://n.neurology.org/content/90/15_Supplement/P3.327</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cbe9012b-f1e3-448b-bf71-15ba99ccb085">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c66864be-84cb-4fc2-ac5a-7c1950bb4dfd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9fcafd6e-bedc-49ed-91bf-a11be8554495"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/343a5189-f0ea-47aa-aa96-1ea76d73cb8e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00065</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45948e19-94c5-451f-9c2a-46be22ecce3b"/>
    <dc:identifier>DB00065</dc:identifier>
    <rdfs:label>Infliximab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3aff086d-aa4f-4f1e-8cad-4e466c6524cb">
    <dc:identifier>HP:0040006*</dc:identifier>
    <rdfs:label>Decreased life expectancy (Mortality)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28019685-b70c-4e61-91a9-f9c0cf83eb2a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001977</ddiem:url>
    <dc:identifier>HP:0001977</dc:identifier>
    <rdfs:label>Thrombosis</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9b30c507-f8c7-4edb-9581-c382ed907c7d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c065d391-9921-475a-aced-979a271ce521">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0010553</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
        <rdfs:label>Oculogyric crisis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aae06e95-846b-45e0-b376-f0c4d77d437d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/edc02353-b80e-4a90-a772-dd84b86cd6cf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/41a6cd3c-af78-4cff-8ac8-79f82653dd2a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/671aff78-97fc-48c3-a696-7ae82b0485b5"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c620b734-6eb7-4cc8-8462-c031696e20fe"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6068b2a7-c5dc-4542-a8f0-85aa061f3612"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0233b36a-b7eb-4867-9976-3f08f16a0124">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001832</ddiem:url>
    <rdfs:label>metatarsal stress fractures</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001832</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9dc45c02-4cc8-47d9-b681-4defcba780f3">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ed78d76-a3e6-4d83-a69c-ac9947f57af0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011443</ddiem:url>
        <rdfs:label>abnormal coordination of movements</rdfs:label>
        <dc:identifier>HP:0011443</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2db5333c-5a24-4a26-9f8c-4d07b1be4ee5">
        <dc:identifier>HP:0012113</dc:identifier>
        <rdfs:label>low urinary creatine excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b952d2b7-7e3a-45e9-b8f2-2fdf997145aa">
        <rdfs:label>low brain creatine phosphate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/234b3fce-a1ef-4568-81a9-1f6eba66a798">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025051</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low cerebral creatine</rdfs:label>
        <dc:identifier>HP:0025051</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/acac7d13-b71a-49a7-9328-20d28ae4d560"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19d207b9-f6fa-4fd2-af26-d56a6281799e"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3dfb6e43-b532-44e9-b8df-f6f3065cad18"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93f29abb-72e1-4e29-8cad-47d1f3618442"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24071436</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b55948b-796a-42ed-bea0-5c407c00d7c1">
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>behavioral abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa56e997-ea39-4bb5-b8fc-8aca37b13143">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Deleterious prognosis</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/605b5870-24b5-49e8-b116-1f36795713f3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f34dc074-8341-4da6-998e-fd685fb86a2d"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e12cc407-6df7-4e5d-b0c5-09051e23d67e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/74f53c6d-9521-4254-890a-927c9ef0988f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01022</ddiem:url>
    <rdfs:label>Phylloquinone</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/948bc269-6dc3-456f-a993-1a2bf8395ea1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fe23d9d-0137-4473-9ca3-fdf95933f193"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b1940db-437f-4e27-a679-0c2ebeaccb74"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3097391a-577a-4b69-b3a3-2b3233444822"/>
        <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01022</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad8a2145-a4ef-4f4c-b66b-1dd0edc89c1c">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe28508f-bd6b-48b5-9d12-1cfa009f09d2">
        <dc:identifier>HP:0002748</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Rickets</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3169e07f-9993-4aa7-93df-38d36e63e660"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a672cced-80dc-452a-919b-53e1fc886c6f">
    <rdfs:label>Nifedipine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01115</ddiem:url>
    <dc:identifier>DB01115</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/77651b75-e586-48ad-8b1e-2cf0e91bb088">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00712738</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ae07acec-0680-4ae4-a392-bf193638d4b0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88cf1e1b-908d-4b38-b0f0-325a006f3910"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f899e245-4174-4a4c-b6c7-4dfa14fa5d5c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040129</dc:identifier>
    <rdfs:label>Defected neuronal plasma membrane</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c03d31f6-c278-491a-ad21-16665fbc8349">
    <rdfs:label>cerebral cortex acetylcholinesterase inhibition</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5a2f702a-69ee-4a7a-888f-2c0547cee097">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ff44a6c-cd22-4b6d-9f64-fb9e17e938d5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
        <rdfs:label>Involuntary movement</rdfs:label>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <dc:identifier>HP:0004305</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c6c6292d-89d5-414c-bb7a-1c87f78ca878"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756475</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/823d9c1a-8b66-408b-b600-8b7aac54d32e">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>high brain and liver iron stores</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <dc:identifier>HP:0003281*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adf1ddd7-856a-436f-9fab-7a6f2af38d48">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003797</ddiem:url>
    <dc:identifier>HP:0003797</dc:identifier>
    <rdfs:label>Muscle atrophy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f6a5dce-6af4-4a8f-90f7-1e2e2d73644b">
    <dc:identifier>HP:0100512*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100512</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>concommitant low vit D level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b8a56f47-f142-44c9-a573-3f86427a647b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220111">
        <rdfs:label>LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/220111</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/425</ddiem:iembaseUrl>
        <rdfs:comment>Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/06153792-4b74-48fe-9323-ddd06c321ccc"/>
        <ddiem:iembaseAccessionNumber>425</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed425d9c-6997-454b-b93e-ae518dfbcdee">
        <rdfs:label>Palmitate plus lactate-induced cell death</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed44de4f-cea1-4307-a151-2d0ba8d0305b"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b7e5437e-b5f4-4fe5-81d5-786aee58a283">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f240a42b-04ed-4b3f-8989-9d579454afff"/>
    <dc:identifier>DB00200</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12ae193d-a7a9-498e-9426-df7d805bccbf"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5d739b6a-1383-4864-9d3a-a3f541757a55">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a53e94da-e15d-42a4-9bf5-6e542b08c26d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236270"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00200</ddiem:url>
    <rdfs:label>Hydroxocobalamin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b72fbd78-86f0-458f-952d-cde937f93324"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/307dd2e2-ec43-4adc-ab4e-7a3293ff5c63">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00145431</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0cc9d273-60a0-4bb6-ac16-6864dc3d215b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/796da9ca-6fd0-4d75-a76d-991a65249168"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Study was terminated due to safety issues.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2fba4826-3f52-431c-9a08-f2752f86735e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ae9df943-3a2c-408c-a10f-3e55ca622782">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa1e9582-1d45-4658-a38f-e6ece5c24da6">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a45676b3-448c-46bd-a485-139b7fb48adc"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c6c6292d-89d5-414c-bb7a-1c87f78ca878"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1490314</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f30827c9-7ac5-4b67-956e-00e8e82c4b35"/>
    <dc:identifier>DB01068</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c176db2a-b65b-4852-87ce-f0bde51aad1e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01068</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/830d7b46-0b96-4f45-a8c6-e793afb60af4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82b78b4e-5ba1-48dc-a073-19bf55e62928"/>
    <rdfs:label>Clonazepam</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a2f702a-69ee-4a7a-888f-2c0547cee097"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0702a853-5950-49b5-8e7c-533f6502df70">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300753</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1d6f17a-e90e-4016-a113-4ce68977b488"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19cc165b-bc2d-410c-af0e-e99f49312e78"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86b40035-fab1-4e32-a56d-7f5d68b3586c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d6001f2-188c-4c35-8fed-8861e9fde97e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:label>Low endurance</rdfs:label>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/49435b16-803b-4eb0-b428-93825c39091b">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95cfae18-4528-4e0e-a306-d71f0a78fbc2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6061c149-678a-4e0e-b374-06ca48a70399">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b598135e-a9fb-45f5-a8ad-f2b56bea23b8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1531c63-2b20-4e27-af04-634d50947040"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6b1717d9-350f-4804-8414-0fc839d29dba">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7f8ef26e-cd08-4eeb-aa03-c1af425e2286">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a64e1c1-47a5-4d55-89bd-9d50bec66fcf"/>
        <rdfs:label>purified recombinant human -GalWT</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a97b72ee-5f35-4b74-956e-c72e350bbf4a">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d06cc2de-ad0a-4c8b-b8c3-78c15d585eec">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd1585ae-cf56-495a-80ca-435d28731843"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00151</ddiem:url>
        <dc:identifier>DB00151</dc:identifier>
        <rdfs:label>L-Cysteine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b01ae937-1dd7-4145-942f-05e51e09cebd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:label>behavioural disturbance</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b8856ef-b343-4ca7-92da-d02be5abbb52">
    <dc:identifier>HP:0002148</dc:identifier>
    <rdfs:label>Hypophosphatemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8206491a-abc8-46eb-ba7d-87ee9a3511b3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01280188</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e9ee04b-23bc-4952-a957-c4a9aa6ba04f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/626447</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9498fc89-ba84-40cd-801d-8a3c4dac7737">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased urine output</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3adcb2a4-0dd5-4ab3-8b3c-28c2a8613ced"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99a23473-56d0-4ce6-ba16-87500d4af4b1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/db3bac08-c0ad-41ee-ae38-a5b75c764dd8"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e8efb698-11da-4833-8143-5911aff35b5c">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/97aaa65a-3f9a-407c-9710-a4fb03b0a19f"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64a0d3ac-0105-4369-ac97-5d15ce6a94b9"/>
        <rdfs:comment>Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Cysteamine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9c9f16fe-b583-46ab-84da-6050c1db7460">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/97aaa65a-3f9a-407c-9710-a4fb03b0a19f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1929112</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12488257</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d747426-1dbc-4f28-a4d2-16c2a6bb6da1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12370309</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00847</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1d0cc771-2f7e-4acb-be10-11949e2046dc">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02023866</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/97aaa65a-3f9a-407c-9710-a4fb03b0a19f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c248a5c-0ca7-4f77-a5f3-287c416ead24"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00847</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/37454527-55f4-4daa-9037-1d7d2aa2a3c6">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8a4976e-d242-4823-8451-9e79a9c6cc06"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25674260</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02931f50-0c6f-40bc-9619-662b63aca346"/>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efeb026a-e289-4591-83d7-9fb4b39d04a4">
        <dc:identifier>HP:0001260</dc:identifier>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
        <rdfs:label>dysarthria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcf75c11-5dea-459e-8d3f-015f5b5e9829">
        <dc:identifier>HP:0009071</dc:identifier>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>Inflammatory myopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009071</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fefdd903-9c0a-48d9-ab80-e24dd65654a5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>dysphagia</rdfs:label>
        <dc:identifier>HP:0002015</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa2db852-321c-42d7-81cc-5aa0ba48fbe6">
    <dc:identifier>DB01325</dc:identifier>
    <rdfs:label>Quinethazone</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac60b3d2-139c-402d-845e-3090d33734ed">
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26251718</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/61702080-bb56-48a0-86c6-6d597a987676"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8ed0193-d5f2-41f5-9677-835fbf20ed50"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01325</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a1a5c49c-4f7d-4127-8d0a-d3d452e59c8d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac6d2d8a-b6db-4c37-a6ef-aca962fc4b1a"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e5482320-6aa9-474b-ab45-5c533f1580a7"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ae9df943-3a2c-408c-a10f-3e55ca622782"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/31f8d4ed-e5a3-4b29-88b7-dc29eef1920b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f88f2860-aa00-467b-bf4b-40c38bb10398">
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <rdfs:label>Hypertriglycerdemia</rdfs:label>
        <dc:identifier>done</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/280429a6-726a-4203-9d47-97a9d3a45351"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f0415b3-9909-44f9-979d-67456199b5cc"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc3298b2-7af2-47c1-9319-2a74dee8c02e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4c696a62-b93a-46d4-a0cb-240167dfd4f2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3dc0b69b-23c9-437f-bcf3-6adc760c0a34">
        <rdfs:label>Behavioural Disability</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ba678fe-813d-45fa-b91c-b86b6ebbea7b"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98c1de61-779f-4b06-b26a-450091d76012">
        <rdfs:label>High prolactin level</rdfs:label>
        <dc:identifier>HP:0000870</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a87dcb5-8e08-4fcf-81a1-37cb10fd53cc">
        <dc:identifier>HP:0100022</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Movement Disability</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19704083</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d06d21a4-a86e-42b1-8b00-bceedb84159a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5021eb28-b1ec-40b8-b71a-aeb3289ce50f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c88f5c7-f365-4cf8-bd44-76e607f12819">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/079dd36c-a5ac-4fb8-911c-108318371ca5">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3069a73-d8d3-4ce3-b6a5-6495c5b2ce43"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/297b53c5-ffa1-4d3f-b33a-28462f304f45"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00350662</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f0fba050-9354-43a2-8988-5fb359be7456">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/234a1a61-f558-4ae3-bc72-ed55c27c8d05"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23040521</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82789092-bfc6-4527-b379-e188d9e17d78">
        <dc:identifier>HP:0008281</dc:identifier>
        <rdfs:label>Acute hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585269</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4129a2f7-5064-49f1-84d8-a0f4a78511b4">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Low plasma arginine levels</rdfs:label>
        <dc:identifier>HP:0005961</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/173e6cab-9284-4e88-97bd-d2a4ce0823bd">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>abnormal hepatic function tests</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54732b49-0425-407e-9daa-815e4f80d31b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83932ddb-89e6-4e54-af4c-6862d0fdfe25">
        <rdfs:label>behavioral disability</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00407a91-a011-48bd-8043-a72d151e18f8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hyperprolactinemia</rdfs:label>
        <dc:identifier>HP:0000870</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22325981</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6a927c0-5688-4e87-aae3-da244b3b5b83">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
        <dc:identifier>HP:0012656</dc:identifier>
        <rdfs:label>dopamine deficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d06d21a4-a86e-42b1-8b00-bceedb84159a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022510X16303495</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f31def9-6dc3-48ca-a0c4-d4f87761d3fc"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c862c8af-ba2f-45d0-9391-8d7a9298b6ee">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a323a2b-8bbe-4354-9d65-30ee5e8c69a5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Accumulation of toxic metabolites in cholesterol biosynthetic pathway</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/300d02e1-c67a-49dc-b0be-9a2eab2dd55e">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001845</ddiem:url>
        <rdfs:label>inflammation</rdfs:label>
        <dc:identifier>MP:0001845</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29269efe-943a-44ab-abb2-e436679a4934">
        <rdfs:label>ichthyosiform erythematous plaques</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
        <dc:identifier>HP:0008064</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1874c641-94a3-4749-9ed6-a69b7124e8f7"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82ee7077-0312-44a6-902e-b095e79f250f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8ec9ede-0d7a-4b1d-8a45-55abc78e4d01">
        <dc:identifier>HP:0100725</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>skin thickening</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100725</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>NCT00744042.)."</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5dfaae0e-d448-4580-9834-34f58c62e68b">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:label>Acidosis</rdfs:label>
    <dc:identifier>HP:0001941</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85b73d3a-16e0-4c5f-b7d6-d6b93c7e075e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal developmental milestones</rdfs:label>
    <dc:identifier>HP:0012759</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca4b222c-02ca-4a81-97a6-acb1e411f093">
    <rdfs:label>AAV-GLUT1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/83c27bfe-822b-4ce6-a7e7-9ebc627bc1d3"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f4bcdf7b-ee40-4d83-abd3-672a72deccf3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d997762-9a1e-45cf-bde6-c1b2cd611d8d">
        <dc:identifier>HP:0000716</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Depression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000716</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db296b0a-0822-4bd7-b13a-57fd6ee604c9">
        <rdfs:label>Serotonin deficiency</rdfs:label>
        <dc:identifier>HP:0003117*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/010abe84-4958-4559-9ba0-c5effa11b2e5"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/128230">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a234286b-e8ab-42e1-83cd-6d5d0fa43b5c"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/128230</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb3721c7-e100-4eb3-82a0-5a09841510ed"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb33917a-72c1-45f8-bab6-18478ea88778"/>
        <rdfs:label>DYSTONIA, DOPA-RESPONSIVE; DRD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/498c4697-a64c-470f-adee-385d07325108">
    <dc:identifier>HP:0002715</dc:identifier>
    <rdfs:label>immune dysfunctions</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002715</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6d2ec37f-b8e4-430d-8fbb-87a4a5ad8b95">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd83c363-eccc-4298-99bd-a0f007970edf">
        <rdfs:label>Renal rickets</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <dc:identifier>HP:0002748</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b8856ef-b343-4ca7-92da-d02be5abbb52"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebaf6db7-2f28-450f-a2bb-fda87c27d59c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperparathyrodism</rdfs:label>
        <dc:identifier>HP:0000867</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/16d27315-92ac-4c7c-b9db-46284f7459d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac21a3de-a0ef-4d3a-a4ea-5e2a4eedcf82"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2017228</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca02ce5a-7156-4ce5-9057-31c33fe3c577">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/71b60668-422a-410f-b760-c7f51160ddf0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/359d6017-769f-408c-adcf-1ac913682a01">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0eded305-f65b-44e1-814f-a90eb2223998">
        <dc:identifier>HP:0008028</dc:identifier>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <rdfs:label>Macular cystoid changes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008028</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86b40035-fab1-4e32-a56d-7f5d68b3586c"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/abcdd114-a4dd-4b9a-b1a1-ca5595f4429b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3ebfe97-d39f-4162-ab36-1786a8245720"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b402554-4b59-4c74-b7b0-8d75e1bb5e0e">
        <rdfs:label>Intraretinal cystoid spaces (Retinal disease)*</rdfs:label>
        <dc:identifier>HP:0000479*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/040fdd17-ce28-4fe2-a63f-15d8b49e5781">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03756</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/953440ee-4e59-452c-a763-6fe677bd61a3">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16040264</dc:provenance>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/986a63c1-86f0-412c-a7cd-58f94dfdde25"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfaca255-b768-41ba-b14b-47928f08109e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB03756</dc:identifier>
    <rdfs:label>Doconexent</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77e66412-3d83-4d32-9cab-ad35fe65b1a0">
    <rdfs:label>EEG with parito-occipital spike waves</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012011</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012011</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/43a1045e-4390-4d36-8b5e-843880a40134">
    <dc:identifier>DB11991</dc:identifier>
    <rdfs:label>Oprozomib</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae973e37-627f-4c2e-98c6-854df18d82b2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11991</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fe3d213-7f57-40fe-b527-eb5ee95ca47e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:label>Abnormality of cardiovascular system physiology</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1700ca22-31f9-4945-89b2-2a8ab01e7c39">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Muscle inflammation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
    <dc:identifier>HP:0100614</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36616737-5fda-40a6-9fc6-ba905ce5a4d3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/079dd36c-a5ac-4fb8-911c-108318371ca5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08826</ddiem:url>
    <rdfs:label>Deferiprone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f4ce3188-85db-487f-8087-ad3ff5a5a9f0"/>
    <dc:identifier>DB08826</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7afa0ddc-bd89-4a6d-938f-28a1045420dd">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29555514</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee7e65cb-0faf-4e29-8a12-c85effc5ac0a">
        <rdfs:label>strabismus</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000486</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000486</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfb1cdcc-f994-43b5-bd75-faaa0cea1447"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253280">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/354</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/253280</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0782cf8c-bb7a-4af1-b0d7-e77bff88ef15"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>354</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88e20015-65d2-4c1a-8577-6affa9c1b065">
        <rdfs:label>esotropia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000565</ddiem:url>
        <dc:identifier>HP:0000565</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/18a6bc70-9e55-4571-8f41-1436c8708fd5">
    <dc:identifier>DB13873</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cae81557-e668-4c22-bdc9-113788179909"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13873</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/43d85f34-0534-4049-a73f-bf9ab21ea490">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ebee71bb-713f-462e-b178-92329624d5a0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b9f05af-d412-453c-b18f-2baf7a1fa90c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/68442f21-ea90-43e5-9f50-bfaab706f2ca"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e2787bb-2d69-4fe8-bfc8-7621bfa87b56"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6d0f82c-deec-4db5-9711-51b1ac995c4f"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Fenofibric acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa8794c6-5cc3-4433-aa66-4e1140e962d2">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607330"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82ee7077-0312-44a6-902e-b095e79f250f"/>
    <obo:RO_0003304>p.K148E and p.D210E</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30097991</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/338dacd5-05fb-4bc7-ba19-99e311b4d2cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient .</rdfs:comment>
    <ddiem:failedToContributeToCondition>c.479C&gt;G p.(Pro160Arg) and c.630C&gt;A p.(Asp210Glu)</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fd2e62e-fcc9-4105-bcec-996f33dd21d8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal neurodevelopmental profile</rdfs:label>
        <dc:identifier>HP:0012759</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ddc0aad-927f-4ccf-b569-16be2f243f2f">
    <rdfs:label>aminomidazole carboxamide riboside</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c98deb11-192c-4e94-a31a-274da0e92362"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a1fbf13-6d1b-4671-96fb-c09ceb853786">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
    <rdfs:label>hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*</rdfs:label>
    <dc:identifier>HP:0010978</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ba4c6c1-d498-461a-b7c1-0db7287a1067">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3f64ab3-3fe6-4571-ac7f-7ba7da2fb6f0"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f9eea78-b444-436d-8985-1d25f53a0650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/28165a5d-8223-45f2-bc57-bbdcabf55f72">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adfd638b-2f62-4d31-9167-d2afec6b5672">
        <rdfs:label>Abnormal Fukutin function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21979053</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253800">
        <ddiem:iembaseAccessionNumber>642</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/253800</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/642</ddiem:iembaseUrl>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b0185df9-7ec6-4b06-9aec-b281b49dc3d8"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a293a86-b4df-4490-979d-e87e9012adfa"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f26406be-b3fa-4624-9194-b5bd22d74e43">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26259553</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6233ba33-c82f-493e-a59e-97d4d95d465a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8ce58f0-07ca-4fb5-a1fb-730941ed58e4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256540"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddc5a27a-c674-465d-900c-1de3e58c30ae">
        <rdfs:label>Low β-gal activity (Abnormal enzyme,coenzyme activity )*</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <dc:identifier>HP:0001288</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <obo:RO_0003304>SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6bbb024d-c571-4158-9f0b-48c88c1bd59f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/450c5e76-b27f-4018-9705-4120267f4aed"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/33daa5b8-c7ee-4b61-8008-7727bec44c93">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ed57c5c7-5665-4ab8-a0e2-abee21c8852f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f6d4cc6-b3b3-4064-844d-8058cf522e5e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/320e1897-41a0-44e0-ab9a-e92fd2d04397">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007103</ddiem:url>
        <dc:identifier>HP:0007103</dc:identifier>
        <rdfs:label>White matter changes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d67980f-4051-438b-b284-f2d263e8efc4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26823911</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10601810</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fc75a5f-5541-49ff-9ee8-219c58ad22db">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008972</ddiem:url>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <rdfs:label>Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*</rdfs:label>
        <dc:identifier>HP:0008972*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e3ce9c6-96a3-4e98-a8af-f97f89c40c71"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/53edf0f9-29e0-4ffb-9721-37449ca93c15">
    <rdfs:label>Chimeric oligonucleotide(oligonucleotide-based gene therapy)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f49d96e3-a13d-4ebe-a311-6bd86a1a0d83"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/259c7d8d-08dc-470b-a873-ed81004c39c3">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001735</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b5b7c64d-1151-4b0b-849d-8df31d521dcc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3ade4700-97b1-498d-a7d4-681e2e1dc14d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7bc11285-6f0f-4e3b-a695-a3062d9a0390">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfb1cdcc-f994-43b5-bd75-faaa0cea1447"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612319">
        <ddiem:iembaseAccessionNumber>1054</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/612319</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1054</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/db3d865d-5c85-422d-967f-445bd0a4e461"/>
        <rdfs:label>SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b8502a5-9b5b-41bb-9127-6110a08554b8">
        <rdfs:label>abnormal muscular co-contraction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001257</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/72448ed1-f134-441e-aa2d-fc6857fcc36b">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:comment>A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7cc3fa6a-bd5a-4068-bd5c-ccb1723912c7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97549989-1e80-47f0-a3ac-cdcbcbac0875"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acb291de-6757-44f8-923a-9a4f2a4efc59">
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <rdfs:label>Decreased niacinamide level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52f7dbc3-b7c6-47f3-b89a-d9644cee12fe">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low Apo B protein level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
    <dc:identifier>HP:0025201*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c83e41c4-d401-4e42-87ba-637166f8fe88">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
    <dc:provenance>Abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5dfaae0e-d448-4580-9834-34f58c62e68b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/892461e0-2af9-4c98-8e6f-f022f28c72d8"/>
    <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/457db156-13ed-4f0c-8f35-f915c97379c8">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B02BA</ddiem:url>
    <rdfs:label>Vitamin K</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b6eb34d9-2985-4536-b516-17f5865ec05f"/>
    <dc:identifier>B02BA</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82113074-07a6-497f-84b7-6ed233e1106f">
    <dc:identifier>HP:0000982</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
    <rdfs:label>Keratoderma</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e82a950e-b391-4ae1-9645-b5783a55cade">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66f17444-16ba-4113-8cf3-9ee36bf20693"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c303b716-bd7c-44e5-a362-7a7629eb4068"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baa5bc29-097a-4f7f-9bd7-b4056e03d8d4"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cc9f431b-2651-4517-86c7-5ae29ed2bebd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/07aea259-f1c5-4323-92d5-ab1d7cc85170"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f0cc4bd-254d-4f8a-b72d-175167253f5f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/31d72f16-4c2c-4481-b4b2-40f1d7284a51">
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52a1376d-08cb-4c04-a2d0-71d41754afeb"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02520934</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a535919-b7ad-4dca-bfb6-d9ae4407216e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/184b9ff4-161b-4554-933e-f33f0aeb55c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/301cc899-a699-493d-993a-132992fa7572">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0002167</dc:identifier>
        <rdfs:label>speech impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4d67736-c883-408e-b82a-8b97f78af254">
        <dc:identifier>HP:0002069</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>generalized tonic-clonic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b5672d8-2046-490d-bfb4-154b24f605f8">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>neuropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
        <dc:identifier>HP:0009830</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17433057</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a1dd878d-a5e8-4917-95fa-4b9f7885bfeb">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/140350">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6f9d6060-ffff-49a0-9aff-2d7cac6101df"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HAWKINSINURIA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/22</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/140350</dc:identifier>
        <ddiem:iembaseAccessionNumber>22</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9046addd-c582-4a31-ac8d-33e1d963d4e2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.degruyter.com/view/j/jpem.2016.29.issue-1/jpem-2015-0132/jpem-2015-0132.xml</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2736fd04-7af0-4248-9348-2e3bac31d635">
        <rdfs:label>Low activity of the immature 4-HPPD enzyme</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3fd77688-a589-4344-91c9-d72ffa6133c7">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44fec4dc-6e27-4884-b165-dc02dae35c72">
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/249900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6ae459dd-202b-4a99-bb34-f754d08ea8eb"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>No medical treatment is available in DDIEM</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd6c5f89-240f-4766-a4b8-608711b5a510">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003713</dc:identifier>
    <rdfs:label>Muscle necrosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2454199c-8871-4fc1-bbb2-cc4761d129af">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/856aa450-6c26-4761-9752-23fecd40ce9d">
        <dc:identifier>DB6756</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB6756</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8c754474-4f25-4da4-b22c-c2874bea9e68"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/855d5a2c-57f7-4d41-8996-671eb6faa359">
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02931f50-0c6f-40bc-9619-662b63aca346"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa34acea-8ae5-4264-984e-e0487e262ea3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
        <rdfs:label>Impaired nerve conduction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040129</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f899e245-4174-4a4c-b6c7-4dfa14fa5d5c"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7748366</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d15deb6f-38b6-4e1f-9997-9701298b850f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef453c5a-1496-403e-8dd2-7fbdcfb9526e">
        <dc:identifier>HP:0040129</dc:identifier>
        <rdfs:label>Defected mucle plasma membrane</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eaeb86a5-34df-4780-8ac6-257c2f996622">
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c882b2ea-d782-4aa5-859d-5db637ade865">
        <rdfs:label>hallucinatory-paranoid state</rdfs:label>
        <dc:identifier>HP:0011999*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011999</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1edbd308-e433-4449-93f4-a96ec1839f64">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad0daecf-dea0-4e1f-8dab-370549fbbc56"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c4dc4361-6536-4bcf-828e-8ccdb20374dc">
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5bec45a1-5f70-4a62-8b13-58e3d72d29e2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e9f9e741-6079-4f68-bffd-5dfd564952c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e39ef700-a95c-465d-923f-b0a360f9765e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5eff4318-5a6a-40a3-83d1-b6b240de4e9b">
    <rdfs:label>High cermaide level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0020582</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91901072-3df5-476e-bf87-37f88814d7d4">
    <dc:identifier>DB00915</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc914b69-a7d0-49d5-99bd-c2f98efc692f">
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e94f7e8-88d7-478d-b97c-aafb86c235df"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f84d6a38-d67b-447d-9daa-517159d50702"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22550086</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7cb82db5-d14a-4843-85b2-6c5afd2414ce"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6fb14e86-bafe-41bc-86f7-e0d18f5d173c"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c1961d1-0147-468b-b24c-a5be9fb21a8b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/43e10118-658b-4eb5-b207-402fdb370811"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e94f7e8-88d7-478d-b97c-aafb86c235df"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15389992</dc:provenance>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00915</ddiem:url>
    <rdfs:label>Amantadine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3335e4a-a6a6-4b6b-a92a-3452060d5f3a">
    <dc:identifier>HP:0002123</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Myoclonic epliepsy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/886611bb-6e12-4d1e-b6fe-b8dd719b1ca7">
    <dc:identifier>HP:0025454*</dc:identifier>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <rdfs:label>Abscent 5-MTHF(Abnormal CSF metabolite level)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025454</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c31f8455-cccf-4655-9816-8540d65e4807">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30788385</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77eb1f3a-c389-4bb0-ad7e-0923fb9ea65f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cf32ba3-eaf5-4b43-89bf-7d82dd8aca0f">
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mueculoskeletal dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40010c85-9d38-40d9-8959-e4205427e28c">
        <rdfs:label>Abnormal cardiac protein (TAZ) expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/230a1d61-408a-4e88-aabe-21995a2db780">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a8b4fb9-17de-4ba0-9370-b9c2ae71964c"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e2e28f08-0984-4f19-ad39-59c691cd9f84">
    <rdfs:label>Sebelipase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfd7c89a-fdd2-4af3-b7e7-4ec3a64cb1ab"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11563</ddiem:url>
    <dc:identifier>DB11563</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b2f6605-4177-4f9e-85ee-c7a604bc99ff">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee424926-e4ba-4898-950e-f89b5b4021b7"/>
    <rdfs:label>Topiramate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ad8794b-44c5-4f04-a5b1-987f0de2c2fd"/>
    <dc:identifier>DB00273</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/be7b0928-3e3c-48a8-a873-2a26d9224aa5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
        <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/901ab7a1-3bc4-43d4-838d-57a26ee4df82"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00273</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7a10442f-05ad-4dce-be71-4799d95a90c3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16830281</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5afcfa-4bc1-4c74-afea-b6ada175c895"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0950e20a-9e19-45b7-9b83-d8d7d1eb0538">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:label>Drug wasn't effective (Insignificant effect)</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/24ee7408-aa13-4e91-9974-5d67a11480cb">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/043be9e8-282f-4ee5-b8f7-dcc4df13ab72">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e89dcf68-39bb-4d80-901e-71624f0e1d49"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c815a0a6-9e2b-4ee6-bdd4-c68fb13e89ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5021eb28-b1ec-40b8-b71a-aeb3289ce50f">
    <rdfs:label>Pramipexole</rdfs:label>
    <dc:identifier>DB00413</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00413</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4c696a62-b93a-46d4-a0cb-240167dfd4f2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54732b49-0425-407e-9daa-815e4f80d31b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d1a55ef-6f84-4d03-a743-63512788e253">
    <rdfs:label>Axial dystonia</rdfs:label>
    <dc:identifier>HP:0002530</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002530</ddiem:url>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6151fe98-6dde-441c-a590-fa9e3a7db20e">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12747882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc926f6d-1742-4d6f-8d84-e3eba110d255"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a03b3dbd-4410-4fe2-98e2-45aadc7bc4c7"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad7b0af0-ee23-41ec-87ff-00fe74e53ebc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/33230b8b-a5a7-45e6-a1de-044fec419155">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8ca4e194-8003-414b-858b-c60d066cc7f7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/536436d1-71d5-410d-9f3e-3a4d33d1aa8a">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cace90f-632e-4ad2-af5a-7097505df6b8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e21f5579-2510-4739-9cd8-9846b53bb1fc">
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cfff282-1c7e-434d-a7a2-9ebc4c85a5cb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/928f5f4e-2e31-4b6f-93b2-f0805228a9e8">
        <rdfs:label>Low tumor response rate</rdfs:label>
        <rdfs:comment>The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8497ae6c-64c7-46d2-ab34-74b99d151754">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>phospholylation of RET</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e30da0b-db42-4a23-a0ae-9b0f6810ef08">
        <rdfs:label>overall survival( premature death)</rdfs:label>
        <dc:identifier>MP:    ....</dc:identifier>
        <rdfs:comment>Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_    ....</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/835ea497-c93d-44ac-8f58-d680a3116b7f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf40369c-f4df-42b2-abe4-038fc0d19f81"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24002501</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00215605</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6922939d-ae18-44a0-b90f-a1901c8a8111"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21606412</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4c6fb84-745a-4305-96ec-bcd8db0eb68e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000083</ddiem:url>
    <rdfs:label>Kidney failure</rdfs:label>
    <dc:identifier>HP:0000083</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3e5e9eb2-86fe-4c39-bfca-9e55f26fc566">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f124413f-bd8b-4288-b112-73e5866ab330"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB07425</ddiem:url>
    <rdfs:label>Sobetirome</rdfs:label>
    <dc:identifier>DB07425</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b598135e-a9fb-45f5-a8ad-f2b56bea23b8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02691</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/49435b16-803b-4eb0-b428-93825c39091b"/>
    <dc:identifier>DB02691</dc:identifier>
    <rdfs:label>Glycocholic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/75aed908-eabe-43b2-b01d-2cc012f72b2b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12449</ddiem:url>
    <rdfs:label>Tempol</rdfs:label>
    <dc:identifier>DB12449</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/919b4338-69d6-491a-88f2-2da901d3705f"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/adfa1bf5-a1a9-459a-a8d0-16a2d67a9e45">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/307030">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3b9dba3c-58af-4423-8bc2-8c9218b6e57d"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/542</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/307030</dc:identifier>
        <ddiem:iembaseAccessionNumber>542</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCEROL KINASE DEFICIENCY; GKD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8771284-0cb6-43be-a7d9-d829e9ffe76b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a8e66a4b-d7d7-44f9-90e0-17109bfd5ae9">
    <dc:identifier>DB14502</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14502</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f939721f-e88c-4b01-b45f-92b2a88e415b"/>
    <rdfs:label>Sodium phosphate, dibasic</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/60e078ca-49b9-43de-88c8-417a5cf7dad2">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93165bd0-7267-4574-a548-abeecd612c17"/>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/feace97a-22c1-4fe3-8d87-777a5adbc8ad"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e369239-5c15-4895-b381-f11bbda9034b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15795909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/60effe55-d074-4f34-8cea-dc0539bdb8ce">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc27a84d-9d27-43ec-9776-094df4cbb24d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <rdfs:label>Poor eye contact</rdfs:label>
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b0b10fa2-98d3-4a17-9053-e2a35d52e0f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b88664ee-e688-40f4-b98f-41c757448d00"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c913cb3-bf03-461b-908c-180cf55425de"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/66738762-4e03-4fe5-b2fd-93b46c5fb025">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15fbc68d-b8fa-4389-8113-2e23df2c223b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0a00e36-da56-40c9-9792-00f5fb3694ba"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28973635</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a17ae89-28d5-47a5-84ca-91f8fe5c498a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d06d20e-3f02-426a-a18b-91a8a6faa6fe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07af1449-7799-4db3-9b90-8a342cf8ac99">
        <rdfs:label>age-related insulin resistance(Insulin resistance)*</rdfs:label>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <dc:identifier>HP:0000855*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f985abe2-3286-45a0-9354-1bdf009703ec">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <rdfs:label>hyperlipidemia</rdfs:label>
        <dc:identifier>HP:0003077</dc:identifier>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb85eb99-3118-4286-8c46-fefd6b00f32c">
        <rdfs:label>lactic acidemia</rdfs:label>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <dc:identifier>HP:0003128</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c482cb1-22f9-4db5-a34e-ac302092922f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9fbc310d-1671-4216-976c-0a727578c9be">
    <dc:identifier>DB14712</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c0dbbf5-fa56-4380-ae4b-f2d72bad2eb8"/>
    <rdfs:label>Elapegademase</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14712</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b1700ea6-17ca-44ab-be30-8bdd641dedcf">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01524757</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235200">
        <rdfs:label>HEMOCHROMATOSIS, TYPE 1; HFE1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/235200</dc:identifier>
        <ddiem:iembaseAccessionNumber>203</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/203</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6630951e-cec2-457a-9bbd-412650641604"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30586c07-16ee-4f37-9cf3-c2c6688983e9">
        <rdfs:label>High serum ferritin</rdfs:label>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/783c1686-a66b-4ebd-b2a3-1a26052fae8a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9cc899f4-9539-43e0-8e57-0fa4a6523f37"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b77d136-ea14-4815-8258-704c5fd71adb">
    <rdfs:label>Aggressive periodontitis(Sever periodontitis)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000166</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000166</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/812819f4-c213-4118-a0d5-6c697409c126">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bbf2e163-d9d4-4f7f-9546-91a548ec4f1d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b07909e-8b29-4fe6-ba0f-e3a3f345a96f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b2a250f4-93fb-4476-9b29-1754ba11daaa">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a650927b-656a-4624-b0a8-cb794724c892">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f2401a7-a332-4d14-b0f8-87246eeac65f"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24321868</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e6a3394-2968-4fce-9964-01d85cf8d21b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0618bb32-35fc-4298-b052-b0d99980f84a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Riboflavin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f3171786-8dde-4e2e-9f91-cfa76373c090"/>
    <dc:identifier>DB00140</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/58c0b611-28e7-4711-9cd1-391a69d46e2c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10581232</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7a79fa8-76a9-4c3a-a8af-3b7036e06dc2"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df632b91-9862-400b-a71b-94357212cf24"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6bda71d0-0bcb-4b66-b938-5e1e07fc78d5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff6e5e9d-4fd1-427e-bfb7-caee0ed94fb5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00140</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4eac2432-e82d-4024-bd9c-9af53f289f52">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95c1a396-9bda-467a-bd2d-34fb86186250">
        <dc:identifier>HP:0100716</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
        <rdfs:label>Self-injurious Behavior</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01751802</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b54f18f8-ea40-4f5d-9ff1-0ab5c0ff13f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a49d3468-bf74-4a27-8f24-540ad5d8651d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6d6ed5e-566c-4f3c-b3db-626299208464">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50334084-a6e6-4f45-b303-f1d528bdd90a">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002086</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002086</ddiem:url>
        <rdfs:label>Lung inflammation (Abnormality of respiratory system)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e35d6ecf-b772-44f8-afab-cbf5d703c93e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006530</ddiem:url>
        <dc:identifier>HP:0006530</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Alveoli damage ( interstitial pulmonary abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36eae59b-8e57-44b0-bf65-f8d4fc6c3e30">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
        <rdfs:label>Difficulty breathing</rdfs:label>
        <dc:identifier>HP:0002098</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22282548</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ad9ce21e-f0fb-4efe-a029-6a88a1f56dfa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca09921f-d5b5-4efb-a730-1e24bbe256a3"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c71e83c1-f30d-46af-9e5f-86a3136d643e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00419</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5caf50bb-75bd-4f8e-954d-a6b4d19e12fb"/>
    <rdfs:label>Miglustat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/31d72f16-4c2c-4481-b4b2-40f1d7284a51"/>
    <dc:identifier>DB00419</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9bbd93d-4ec1-4193-957e-93d766b13381">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002749</ddiem:url>
    <rdfs:label>bone weakness</rdfs:label>
    <dc:identifier>HP:0002749</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/531a6062-e538-4230-ae5e-75d6dcacb4f8">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High serum osmolality</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3db0de1f-88f2-49cb-99c8-d2bd2b9ef8fb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ccb8967-b77a-41bf-a288-b3822c19aa21"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd06fc7c-2e4b-4f58-88fc-5b8adfb9b7ff"/>
    <dc:identifier>DB00636</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00636</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18eaed58-1d51-4b5a-97a6-0dd28661a3db">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5974e527-1cd0-435a-8d40-7e35438d02e4"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884783</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef7dcd2d-b04f-4a6c-be09-d95926e14705"/>
        <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0f02fb9-f385-4ea4-b9a0-2d7139fbfdf1"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Clofibrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0855079a-dc40-49ee-92ad-b697c673c18b">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b688e86-f4d7-4b33-8ce1-10df1b08f43c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151670">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LIPASE, HEPATIC; LIPC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/151670</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6ef00ad1-d9a6-4738-9b90-d19d625098ff"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8771284-0cb6-43be-a7d9-d829e9ffe76b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f6cd9d6-e2ff-43e1-8553-faae5cc72e61">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>High atherogenic lipoprotein(Abnormality of lipid metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd0740a4-8c4c-4547-88f9-13c263982a34">
        <rdfs:label>High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22798447</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>http://www.malacards.org/card/hepatic_lipase_deficiency</dc:provenance>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de057fb1-9f07-40cd-a7f0-393629a24594">
    <dc:identifier>HP:0001939*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>Abnormal blood lathosterol level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7cb34be1-8c51-40e9-a09e-82606365fa37">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44ca5f47-5151-422a-97d8-3575d5518afa">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000742</ddiem:url>
        <rdfs:label>Self-mutilation</rdfs:label>
        <dc:identifier>HP:0000742</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8870064</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f0670b81-a688-43f6-8f4e-a5348037d5eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b79391b9-196c-447b-b0fa-1a62ccad2a0e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00252</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ceab7b2f-47c0-4bef-b8bb-5b56f752f8aa"/>
    <rdfs:label>Phenytoin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/20f15606-5c05-4ada-a683-d9e1bd06e351"/>
    <dc:identifier>DB00252</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7c69e41a-7566-4e11-8751-bc39a8dea2df">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/402d302a-dc4b-4e20-9130-ad7058cb369d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42a82e52-6479-4e99-8daa-a6112a16a1ad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600740">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fc3f499e-142b-487e-9b2d-2f784f3001ce"/>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/600740</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29959cd1-fd8c-4e24-a876-f6bef7846ca4">
        <dc:identifier>HP:0003127</dc:identifier>
        <rdfs:label>low calcium urine excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003127</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c341fab1-785e-4820-9cc4-bcfb08eec6b7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27050234</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ddf0d56c-77d8-47af-b8c5-c0003fbfd4e4">
    <dc:identifier>DB11917</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11917</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0702a853-5950-49b5-8e7c-533f6502df70"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0da86fec-9c90-44aa-ba00-8b4dc4c2dc03"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3379e4c-419c-43b2-94bc-7b866cf48cd2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1d6f17a-e90e-4016-a113-4ce68977b488"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277410"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Vatiquinone</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e4965650-0784-4713-952a-141088dd720a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf1fcf57-6aba-4fd5-96ed-f47d8565f305">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>Nocturnal Hypoglycemia(Hypoglycemia)*</rdfs:label>
        <rdfs:comment>Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917</rdfs:comment>
        <dc:identifier>HP:0001943*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96e4753b-bfbc-4b99-a54a-88870525e892">
        <rdfs:label>Poor sleep quality(Sleep disturbance)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment>Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917</rdfs:comment>
        <dc:identifier>HP:0002360*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b0aa1c2f-597f-44a4-b5a3-296405b0a47c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/240600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ccf5bb9-081f-4ec5-b11b-63bb61b92af3">
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4216e31-4d7a-49da-9c01-1ce09c7971e7"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/765e11e8-deaa-450e-b5b8-c23954ba102f"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/35257cee-cd63-4d64-a589-c2485b14caf9">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e9b97a2-e27e-4574-9846-845933ccb564">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>High total cysteine levels</rdfs:label>
        <dc:identifier>HP:0010918</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55a8d36d-7cf3-48a3-b361-f38c57815ec6"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43e51f75-48b0-42aa-bd6b-77a975b5f7ea">
        <rdfs:label>high blood S -adenosylhomocysteine level</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e00ced8a-6b0f-4d96-9a2e-3b0ed1b4d5b1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c68be2d6-7899-4302-baee-c2d54309ec64"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/260e414a-a52f-4774-9fc3-654ccbec52cb">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1d66ab7-adb0-48e2-aff2-21417234c18b"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/92657919-02b7-49e0-9bd1-277a75b0ddd2">
    <dc:provenance>https://academic.oup.com/hmg/article/22/15/3003/652530</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d33c2fe1-46df-487b-a6b2-f07909bad548">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9edf6f68-39f8-4716-974a-c2d451a3eaae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28cf1bab-b754-41e1-84ba-7375d8b66765">
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:label>Imapired muscle function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea886e7b-56da-4144-90c5-5fe5f0db4b5e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00328</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3bd1e1e3-d0ff-408b-bc12-03ecb8bafe5d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3649ea79-b0f4-4226-9519-da57482eaab4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa56e997-ea39-4bb5-b8fc-8aca37b13143"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1a2d404-b82b-4ce1-88f0-e0e490ca39e3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3aff086d-aa4f-4f1e-8cad-4e466c6524cb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eff4e886-1403-47b6-b30d-fdf69230395f">
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab44e824-ad62-4810-9439-fc9e6a27b908"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da1b1ec4-96f5-4340-830a-dcf73a14d31e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1a2d404-b82b-4ce1-88f0-e0e490ca39e3"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/205bfa1e-cb2f-4a30-aed0-2cc294ff026f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25852896</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/338dacd5-05fb-4bc7-ba19-99e311b4d2cf"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Indometacin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18ced697-d907-49e6-838c-631986089737"/>
    <dc:identifier>DB00328</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f726c017-e22d-488d-ac20-e119b455c050">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e9ee04b-23bc-4952-a957-c4a9aa6ba04f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1a2d404-b82b-4ce1-88f0-e0e490ca39e3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39652466-9fbc-4a3a-822b-f4700619d3d3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a55cff45-24db-4296-9a45-4cfdeae47268"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d92dd97c-d900-4617-82d7-f6c448684a34"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/88ab34e5-744f-4f68-a839-0fdeb75e6347">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/de7d98c9-99c8-4943-bacc-7d468cd43f0a"/>
    <rdfs:label>Gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/88bdbeb2-62d1-4268-baef-e92068cfd3a9">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/554</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/237500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/80a4a40c-a8ce-4181-819d-bbe0309b2e45"/>
        <ddiem:iembaseAccessionNumber>554</ddiem:iembaseAccessionNumber>
        <rdfs:label>DUBIN-JOHNSON SYNDROME; DJS</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8c799648-87a9-4052-802f-700d4f67ab57">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91fc6485-5027-4f5b-82ad-1e991fc96eac"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9ce02bf-7e7e-4669-8ea2-05a0f6bad72d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12771356-ae89-4206-8c65-bba652eaae54">
        <rdfs:label>high serum alkaline phosphatase</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003155</ddiem:url>
        <dc:identifier>HP:0003155</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16083704</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16952291</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71a27a13-d162-429d-a636-8e6eb64436c9">
        <dc:identifier>HP:0012202</dc:identifier>
        <rdfs:label>elevated serum concentrations of bile acids</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012202</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974C→G nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26264947</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/12c8e098-f45b-456a-be7a-b5dbc4ccf80f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/524decb7-6404-4856-996b-6ff86ae66535">
        <rdfs:label>High biliary cholesterol saturation index</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c17c0996-17af-4226-b10a-a9657eae7625">
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hyperbilirunbinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12012642</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a8468dc9-bed3-420d-a968-818e1b76639c">
    <rdfs:label>Sodium acetate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09395</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c714bb81-0a90-4ed7-ac05-1239e05df869">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c8be4c40-288e-495d-889f-cde233a55219"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8eb9fe5f-817a-4209-8cb0-5ab809d06605"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB09395</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1954b0ac-2125-486a-bdf6-fd1241548bb3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00348</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05bbedef-c68f-404e-abed-7ac65add4c22"/>
    <rdfs:label>Nitisinone</rdfs:label>
    <dc:identifier>DB00348</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5b20132d-a354-412d-b925-f2ccefb64b7f">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07621479-228d-435d-a301-13b7e4ba5143"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/623c1175-0084-4c2d-a0f8-0313f25f2b32"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <dc:provenance>https://pubs.acs.org/doi/abs/10.1021/bi1008112</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20677779</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5f933877-4287-4f5f-838e-94afbc813f28">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7e9ae57c-3701-404e-b579-2b2d5e738b35">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/41886e1a-866e-44bb-a942-c1f5dbca051c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3940717</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5974e527-1cd0-435a-8d40-7e35438d02e4">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:label>Ployuria</rdfs:label>
        <dc:identifier>HP:0000103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e1cbee7-bc5c-4eed-b34f-791e9ab92e47">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003434</ddiem:url>
    <dc:identifier>HP:0003434</dc:identifier>
    <rdfs:label>Progressive ataxic neuropathy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610006">
    <dc:identifier>https://www.omim.org/entry/610006</dc:identifier>
    <ddiem:iembaseAccessionNumber>63</ddiem:iembaseAccessionNumber>
    <rdfs:label>2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/63</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/263ada67-f2bc-4e79-b7d9-d9badcd7a61f"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ceea5acf-6fef-4179-8434-f327d14d8802">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5b998882-b7a1-4eb7-9456-f8fb49d175ad">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cddf9225-00d0-4e26-82ea-65f342fdde96"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/088b2f23-d54d-41fc-93b3-25e7099b2b9a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/181bf6ea-7d67-4e81-9b82-b12a5195c957"/>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea19348f-53d3-4cda-a08a-4929542080c3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1f47100-dece-4525-a9cb-2e8d21403482"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29a675fb-fe97-4916-a2a3-4accf0ee1540"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a01a1b0-38d1-4ba8-8046-1d2db32453ed"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/52f7dbc3-b7c6-47f3-b89a-d9644cee12fe"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4605bd1-99dd-448c-9929-cded69d2d93d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a1ec301-9d00-4879-804d-13a7ec0e14f5"/>
        <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2a065c8-2888-4a44-b31f-c0053113d5a3"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>recombinant human LCAT (ACP-501)</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4bad7605-4336-457e-ab25-cc6b4143163b">
    <rdfs:comment>Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a8ca3dd9-1292-4b23-9d78-65232f3fc17c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/026d0f9c-5d64-4d55-bb60-180c855bb8e4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09eaf995-10d6-4610-a23f-7d71fe625656">
    <rdfs:label>Protein oxidation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/36b95f1a-df91-467c-a50b-c87ec779adf8">
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42cc703e-c02d-43ca-9e33-9b94536acae0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/119fbc1b-e450-4d9b-ae31-6a5eb4b47987">
    <dc:identifier>HP:0008282*</dc:identifier>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2cbf3d7-09be-422b-8454-ba1cb28bec30">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>low physical activity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/836ec4e6-c19d-4c7c-b052-7c43550958b1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <dc:identifier>HP:0003234</dc:identifier>
    <rdfs:label>Decreased plasma carnitine</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd844373-1320-4740-b502-9b709d6bf178">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb85eb99-3118-4286-8c46-fefd6b00f32c"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dd8fd83-d599-4f9b-945f-3ce139176893">
        <dc:identifier>HP:0001941</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pyruvic acidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3900744-4943-49e9-8155-95730c2e2cf8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK220444</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8477f821-2d14-49e8-b3d2-b0d01dc8f1e6">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01362595</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/96f755ef-89e4-4c07-bf7e-81875ecd3201">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64cd6464-d803-414c-bae0-d0bd204b0ece"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8ea904d-ada4-433d-9b7b-19e48c337d9e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>low heamoglobin leval</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c9a0cc5-5588-4877-92aa-12d408137515">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012133</ddiem:url>
        <rdfs:label>Decreased red blood cell production</rdfs:label>
        <dc:identifier>HP:0012133*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/043f4a45-79fc-4c18-90b3-6fc77d0541d8"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02386267</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a3ee60b5-77e3-48df-9380-9596654aed9c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/228000">
        <rdfs:label>FARBER LIPOGRANULOMATOSIS; FRBRL</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1297</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/228000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6221b727-dad1-4017-8032-ed99832ecf9f"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1297</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b4e2898-6bc8-4470-84e5-f7dc5158aea3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal spleen size</rdfs:label>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67a7610c-c0b6-48fb-84c4-6d2eaefb5a5c">
        <dc:identifier>HP:0003119</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72277be7-067f-45a1-84ce-b230f929b0b9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0020582*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <rdfs:label>High intracellular cermaid level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5eff4318-5a6a-40a3-83d1-b6b240de4e9b"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2331fa7f-8ff9-4e18-aae6-4109d2f24f14">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d6de6995-fbd7-4ecb-9a8b-9f5af75b3bc8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b041353-63f6-49e8-8e29-6609bf2e8dfd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09c8351d-b71a-4e3d-a2db-4d008d95c482">
        <rdfs:label>high plasma MCP-1</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03234c01-2578-49c8-8486-3468e489a67e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23681708</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8db7cc4-1ed0-4f0c-912c-4abaced3f0aa">
        <dc:identifier>MP:0009587</dc:identifier>
        <rdfs:label>abnormal sphingosine level(Abnormality of lipid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0009587</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a211a502-2c81-42f7-99b4-a104f945de37"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcf56e53-8f9b-4ac6-a114-28888c679f12">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005340</ddiem:url>
    <rdfs:label>spastic bladder</rdfs:label>
    <dc:identifier>HP:0005340</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f07ce68b-d27a-4397-b241-14186ca5c426">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a40abd0-42ff-4130-9631-9ff64a330549"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/edcc016c-2012-475d-8b4d-b795fc28dd80">
        <rdfs:label>Polyurea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8c754474-4f25-4da4-b22c-c2874bea9e68">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2454199c-8871-4fc1-bbb2-cc4761d129af"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d868c500-3bc6-4698-9ffb-48fe3ff419bd">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Developmental abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20356773</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00dead0e-58e7-44ec-93b7-fbc81dab0bb0">
    <rdfs:label>Glycerol phenylbutyrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08909</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/154da675-9501-4d8e-9f9a-2bcfa4c1cbef">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3a73e4ae-cc6e-4489-901c-887f58290999"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7adcd04-0cc3-4eff-8d8b-b21a7fbdffe1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB08909</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b05134df-ff75-4503-a55c-5f19b9076e67">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0040087</dc:identifier>
    <rdfs:label>Abnormal Folate level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/038e9d9e-c878-4757-b572-43bb5ec82ba3">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ada7dfda-169a-4a21-a0ae-7da2af03dac1">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0012649</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <rdfs:label>Inflammation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52214572-9ab7-47c4-b6f3-04e1de35dd93">
        <dc:identifier>HP:0011118*</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>concentration of TNF-alpha in plasma</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011118</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5801c77-988e-4b59-8337-80a7221352d3">
        <dc:identifier>MP:0012604*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0012604</ddiem:url>
        <rdfs:label>Low blood glutathione redox ratios</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0de52245-d225-449c-bcae-fcf59bba042c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02583672</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01427517</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fdf11a6-56be-464b-acf3-8e31ab9ddceb">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025460</ddiem:url>
        <rdfs:label>concentration of myo-inositol in brain</rdfs:label>
        <dc:identifier>HP:0025460</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/01efe5ae-17c3-4f0b-9b33-46519bd97bc4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc60a224-ed7c-452e-bee2-4ecf1acd6a03"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d32a8a7-4186-44de-9a1e-63249ee3a69c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd31abbc-ba65-4d6e-8d48-61299b00e5f0"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6f8c7eb5-a378-4e83-bb52-31a1ac3cdcc5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f3c2a85-b7ca-40dd-a048-8131e7d8fe30"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f11e9a37-9c02-44cf-8b43-be0a8d2015bb"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4b0ba7-0654-4cd1-a6df-644af85ccee6"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a53e94da-e15d-42a4-9bf5-6e542b08c26d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day)</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c9be94cc-c464-43cd-a1ff-d35c7bec5083">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/119fbc1b-e450-4d9b-ae31-6a5eb4b47987"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de4f0c03-01c0-4603-af33-cdc9c748d9ae"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae4305f9-f2ec-45bc-8cb8-8ab6f332fcac">
        <rdfs:label>increased fecal fat excretion</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002570</ddiem:url>
        <dc:identifier>HP:0002570</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1edeb54c-0d64-420a-abc7-562a419f14c2"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72dfdf39-edf7-458f-93ad-f95bb8dec998">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Six Minute Walk Test</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a7978d04-3eae-4af5-beac-8603fff76d00">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e3863e53-2da2-44b5-9ac2-2a311a8f605a">
        <dc:identifier>DB00376</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd0777d6-e534-4ae3-8a6e-6ed6aa83369b"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00376</ddiem:url>
        <rdfs:label>Trihexyphenidyl</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/55b0076e-b867-4c74-9b70-425b8c7ee411"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/326c9991-2a34-4e4b-ad88-d99056551405">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e217f5c-169d-4c7f-ad61-bb49635d2254">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ccb38efc-f62d-4bff-b892-6e0c4425d9b2"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10f49877-1012-4b56-b226-81e3a5eaa8de"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d1903b5d-3a9c-4a7c-8e78-c69fa98596b8"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ab0b594-0336-49bd-92cf-df1cea291a8c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9682d097-e478-4421-9c60-d6a49cc51b44">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005110</ddiem:url>
        <dc:identifier>HP:0005110</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Atrial fibrillation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff690c5e-5663-419f-824f-d36d41db3cd1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f9c81d97-653b-46d4-9a29-9a05dc136bdb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5ed68499-305c-4902-ac37-3b52963af006">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24579575-9738-45f9-82b6-ba9dd1c4b57c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16775724</dc:provenance>
    <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f9955fc-5971-4eb9-bbee-e38c21c1c84b"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7743c158-fa18-498f-abbe-3359df9908f2">
        <rdfs:label>growth impairment</rdfs:label>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a5ee1ca-99bf-46e1-8ee8-1a211fed86c9">
    <dc:identifier>HP:0002572</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>recurrent vomiting</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5776f65-6de7-4e7e-8846-91a03eff71ab">
    <rdfs:label>Elevated transferrin saturation</rdfs:label>
    <dc:identifier>HP:0012463</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012463</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/623c1175-0084-4c2d-a0f8-0313f25f2b32">
    <dc:identifier>HP:0012378*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Extreme frailty (Fatigue)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b3c4893c-911f-4aeb-a43c-03226f343d90">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05134</ddiem:url>
    <rdfs:label>Tanespimycin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a77fad9b-ec8f-4780-8ccb-7217b37108bc">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f7cd3f95-7ef2-405a-8e7c-73c5b7cdffc6"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3cc68a88-19c2-498c-a5d4-ea28e1d6610c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c392f4dc-3258-4309-acf8-044f0c34a52b"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c815a0a6-9e2b-4ee6-bdd4-c68fb13e89ba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3667276b-4bc5-4881-a32b-19855e732391"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1d86299-2a85-4baa-ac16-8b1879d840bb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1abb668a-b6a8-4df1-ae1d-177469962cf3"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB05134</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1c18b315-2888-474d-b658-f559f8a14875">
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/280429a6-726a-4203-9d47-97a9d3a45351"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03177556-9574-4fbb-8ec0-127a3aa12b64">
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <rdfs:label>Hyperuricemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>done</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f0415b3-9909-44f9-979d-67456199b5cc"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a583c728-3399-47d6-b191-001b2709f96e">
    <rdfs:comment>It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26790a3a-3426-44a6-83eb-28e897143864"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06e2479f-e70e-4f93-a0da-31523e3ad18d">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Functional disability(Constitutional symptom)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c6fc8b3-b667-46b3-bb41-95ea1efc60c7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal elevated level of VLCFA in plasma</rdfs:label>
        <dc:identifier>HP:0003455</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.myelin.org/tag/lenti-d</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16009761</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00545597</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03727555</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7666063</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a78bd46e-2078-469d-83c9-72e39e3d50a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe2d0428-e06c-4c37-8f86-7fe4a1692996"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c171d70b-1fdf-4d15-bdf4-b0d55117df91">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <rdfs:label>Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*</rdfs:label>
    <dc:identifier>HP:0003107*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/51b6a003-5934-40b8-8534-86d4be24e61c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d6d0416-4cc9-4735-8292-e1c7387858b7">
        <rdfs:label>motor malperformance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002275</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28fd15a9-c58a-4474-a8d4-3c62b51653e1"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02926066</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/98522678-ff87-49cf-81ad-bc61038d4c0b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/958fa7b7-e627-4c36-8dfd-bfe2386747b4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/df4bf2a4-4a4d-474a-9171-4a3ebc653f54">
    <dc:identifier>DB01039</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/519444a8-69db-450f-8acc-63d7dd36c520">
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24524914</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af5afcfa-4bc1-4c74-afea-b6ada175c895"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01039</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e29b5db6-b1cd-4d47-9718-209e7b8b057c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7a10442f-05ad-4dce-be71-4799d95a90c3"/>
    <rdfs:label>Fenofibrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3d147d4-b8dd-4d48-80ed-13c14dbb52e6">
    <rdfs:label>Low HDL-C  level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003233</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/763e850e-6410-487b-9974-efe16ef8a14e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <rdfs:label>Delayed development</rdfs:label>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <dc:identifier>HP:0001263</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6125cbaf-7c05-478d-8f1d-c9287ee6ac61">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612953">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ae8e22c9-edd7-4d39-a519-14870f47ed86"/>
        <rdfs:label>PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/612953</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613933</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.</rdfs:comment>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f84d6a38-d67b-447d-9daa-517159d50702">
        <rdfs:label>parkinsonism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <dc:identifier>HP:0001300</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5658199b-6ae8-4784-afdb-6a323f8f46a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/377f0c31-a8a7-477a-aec1-c999de5e0c01"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25178b7f-2610-41d8-9f29-03cc7cb20d6d">
    <dc:identifier>HP:0008064</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Ichthyosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/045201af-3f3e-4f15-bf61-446f086f209e">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2ab5a836-1ac1-42e4-96a2-e030113585b5">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/06cdc0d6-0a93-4156-a8eb-346c97383c5a"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e8bed6d-805d-40be-a6c5-4b444152e011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001962</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00111</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00111</ddiem:url>
    <rdfs:label>Daclizumab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3cdfc36e-135c-4609-921d-278c9dc2968c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00182</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd0777d6-e534-4ae3-8a6e-6ed6aa83369b"/>
    <dc:identifier>DB00182</dc:identifier>
    <rdfs:label>Amphetamine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/917a82ee-8ad0-4a0c-b1fe-499fdd8b319d">
    <rdfs:label>Noctornal difficulty breathing</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
    <dc:identifier>HP:0002098</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/31b156db-b03d-45df-9be0-60e78e9b0953">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4216e31-4d7a-49da-9c01-1ce09c7971e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19d207b9-f6fa-4fd2-af26-d56a6281799e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000012">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:23+00:00</dc:date>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which  generally small molecules are delivered to the organism in order to to directly increase, decrease or alter the activity or stability of a genetically defective protein.[PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0596d554-20c9-4f30-b83c-59dcfe5ae886">
    <rdfs:label>elevated Chemokine Ligand (CCL-18) Level [ng,mL]</rdfs:label>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/797052b2-9099-4f29-b7b7-1796c40ca3f3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:label>decrease muscle strenght</rdfs:label>
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3bad093-fc11-4a6e-9ab6-4415d6731e7d">
    <dc:identifier>HP:0040300</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040300</ddiem:url>
    <rdfs:label>abnormal free fatty acid levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/923cbeac-b004-4544-8323-604721f9f503">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0cfe0010-0dd2-4d5d-bfa5-49f2aba0e38a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef73d6ce-55d3-47e1-9c86-360aeaa4e173"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/268bc27f-82f4-415a-af09-aa1434342439">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004910</ddiem:url>
        <rdfs:label>low proximal tubular reabsorption of bicarbonates</rdfs:label>
        <dc:identifier>HP:0004910*</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c84e643-ea44-4206-b010-4bb950bbc74c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17e4f501-0dde-4d86-8eec-f71b201c8ea0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11504824</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87578c36-c7c2-4fb2-aef1-6bb0273adf70">
        <rdfs:label>Limited Efficacy of the drug.</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0001954</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e87b478-f4c3-44e8-916f-24def00a0d6b">
    <dc:identifier>HP:0000938</dc:identifier>
    <rdfs:label>Vitamin D insufficiency</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbe42ad8-7efa-4d75-b241-834f62207736">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <dc:identifier>HP:0002630</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Fat soluble vitamin  Malabsorption (Fat malabsorption)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bdfd26b5-b413-4cff-aa39-0de86d52b524">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f7581c5-e52f-484c-89a2-dbec0ec8f5fe"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dcb07aa9-ad4e-40a4-9486-7d230d50db0d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9287b5d-edb0-44c3-b50c-40cccd94881b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e795b9f9-a76f-43f3-b499-1ded96d003eb">
    <rdfs:label>Antiinflammatory preparations, non-steroids for topical use</rdfs:label>
    <dc:identifier>M02AA</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/575b6b59-0b00-4437-b65a-06aca37b6b8e">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c798d8a-cdae-4a31-8e45-d0608a9544cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b402554-4b59-4c74-b7b0-8d75e1bb5e0e"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M02AA</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfa034bf-5ada-4b1c-9222-8a97539ce016">
    <dc:identifier>HP:0012187</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high erythrocyte protoporphyrin levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245010">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6b7b9a4c-5731-4c1e-b43f-6ec2042ec5d6"/>
    <rdfs:label>HAIM-MUNK SYNDROME; HMS</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1110</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/245010</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1110</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08107414-2609-4e77-a3da-03ea69cbed0a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated urine mevalonate levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bf56a36b-aafb-4ca4-947c-c786d81b6184">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e53c4b3-48e8-42b8-9c08-2b4d59c41411">
        <dc:identifier>HP:0012379*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0003304>I278T</obo:RO_0003304>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b7b480e-92e2-4068-a835-36fc626f33d7"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7d4d8bc8-b22d-44c4-b048-5166e4a12d51">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/498c4697-a64c-470f-adee-385d07325108"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f1d8390a-10bd-434e-a9e8-5dc1ed04fb7f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/86987cc5-e43f-48cf-934e-2ca06aca5d0d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7cdda78a-73eb-4b0d-b0f8-9f91745c3d5f">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>neurological malfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97f97345-0388-4f8a-a86e-69ba4487dc7a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00098</ddiem:url>
    <rdfs:label>Antithymocyte immunoglobulin (rabbit)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbc44c09-5b70-46e9-8521-0ed03c0837d8"/>
    <dc:identifier>DB00098</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/87114159-026a-4123-adc5-5d8b5d7c6359">
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29688815</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc4235b3-07bd-4065-b959-92596d7eb98c">
        <rdfs:label>cognitive dysfunction</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/13a831a7-4594-4cdd-8101-3ba601dab22a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8fa9c06-7894-4ec4-ac4a-8fa0a32a832e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bbbb1761-5d66-4c7f-adee-ad03aa996273"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cc97f84-1e66-49a9-a1b8-f7bb6355975f">
        <dc:identifier>HP:0002540</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
        <rdfs:label>loss of ambulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9edf6f68-39f8-4716-974a-c2d451a3eaae">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/92657919-02b7-49e0-9bd1-277a75b0ddd2"/>
    <rdfs:label>AAV9-MCK-fukutin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f63cc1fe-8fcf-47a0-9f3a-f9c3a3153139">
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:label>Rigidity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002063</ddiem:url>
    <dc:identifier>HP:0002063</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/effa89f1-3530-4a76-b82e-8e6fd4874845">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b09f973-fd85-4c3d-bfe4-b9273dea90aa">
        <rdfs:label>Obsessive-compulsive behavior</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000722</ddiem:url>
        <dc:identifier>HP:0000722</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7d997762-9a1e-45cf-bde6-c1b2cd611d8d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8c5a4324-cec2-4ca9-ad9b-c22ca2ebedd9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261750">
    <rdfs:label>GLYCOGEN STORAGE DISEASE IXb; GSD9B</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/44a62397-5fe5-4c00-a6b2-fbba26670891"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1258</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/261750</dc:identifier>
    <ddiem:iembaseAccessionNumber>1258</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000305">
    <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000305</ddiem:url>
    <dc:identifier>ECO:0000305</dc:identifier>
  </ddiem:Evidence>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/94b2cfb5-8332-4efa-8a00-acccca0e8714">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b5eb522-de17-4013-a056-a982ef4562e9">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000488</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
        <rdfs:label>Retinopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e615ec8-2294-4ced-9e55-09206fc30fcc"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30358967</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecf453fc-9c24-43e6-8271-2cb78cd88792">
        <rdfs:label>neurologic dysfunction</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5b0d282-b71b-47fd-a382-b7a552793f1d">
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a26b5db-67de-40fc-ae83-1ea42757d365">
        <rdfs:label>Trial is no longer available</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb79a98e-7bea-4680-9648-46efdbb47425"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00705939</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f91d8138-3fb0-40ef-8590-3f2624203bea">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f9955fc-5971-4eb9-bbee-e38c21c1c84b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24579575-9738-45f9-82b6-ba9dd1c4b57c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b910b8c8-281b-4f62-8f85-5d3de5366b9e">
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4216e31-4d7a-49da-9c01-1ce09c7971e7"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19d207b9-f6fa-4fd2-af26-d56a6281799e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/75832c35-21bc-4e02-88cb-a1ec79e5f17d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01586</ddiem:url>
    <dc:identifier>DB01586</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cdee51ce-39ed-4e4f-aaf1-9527c2457731"/>
    <rdfs:label>Ursodeoxycholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57393bef-0b0c-4a61-b898-81e92ede3676"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd8c1ece-8d63-4907-a7f7-4c47eebc0a03">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5658199b-6ae8-4784-afdb-6a323f8f46a8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/410feb8b-edb9-4d03-ac99-0bde10adc89c">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Voluntary movement abnormalities (Abnormality of movement)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/671aff78-97fc-48c3-a696-7ae82b0485b5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c065d391-9921-475a-aced-979a271ce521"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c620b734-6eb7-4cc8-8462-c031696e20fe"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6068b2a7-c5dc-4542-a8f0-85aa061f3612"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17c97d6b-838b-4736-9501-6249a54ee112">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04159</ddiem:url>
    <dc:identifier>DB04159</dc:identifier>
    <rdfs:label>Beta-Hydroxytryptophane</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/56082aa2-ffce-4efc-bd6a-ddca65d31e08">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c69b6fb-da21-486c-918f-2ac50c189397"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9cf9e2f7-5eaa-4518-b7ff-b02a2e164008"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc063306-975b-4cc6-a293-9f512fe43e85"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5182b3d3-d161-4891-a2af-829e1b717080"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/954510a3-bec9-40b4-b2ff-9938d47e4332"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c7c192cd-7214-45d3-bf64-5663cf62986f">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a96484b9-01bd-4563-9427-af9e4d911637">
        <rdfs:label>Renal salt wasting</rdfs:label>
        <dc:identifier>HP:0000127</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a53b4896-b31f-45b0-932f-df36ca397d44">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/72b9faa3-3472-4141-8e62-238b68e6387a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ada91d49-f682-4454-bf7a-9e6ea55c513c">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42213bd2-0b10-410e-b892-6fba836b62bb"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5255a502-df0b-4917-9a3e-8e7290da396d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
        <dc:identifier>HP:0001386</dc:identifier>
        <rdfs:label>joint swelling</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20712835</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/120af984-5521-4cc6-8324-448e6cce9bff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4cc70fa-629a-43c6-8f50-8f103139579e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4dcf60c-d317-4744-b377-1b10077f6314">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9adef28d-3df3-49ea-9bd6-ab6c3a5bca76"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615558">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615558</dc:identifier>
        <rdfs:label>HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/01299a9d-cf13-44eb-8fa0-269f6166c7c6"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8281952-c2a9-4dc7-8dae-14eef7b62a6c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007009</ddiem:url>
        <rdfs:label>Central nervous degeneration</rdfs:label>
        <dc:identifier>HP:0007009</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e1cbee7-bc5c-4eed-b34f-791e9ab92e47"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffaafd7b-3112-4a2a-aeb3-a3dfc1b2b2d4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0891584915002671</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ebde1ee-6129-4172-a25f-16d8ef62698a">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939*</dc:identifier>
    <rdfs:label>ipsilateral brain neuronal storage abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/92973068-fbcd-4a09-b6cd-addbe924bc3d">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11c09989-4b0f-4ad5-9c08-429445806203">
        <dc:identifier>HP:0031429</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031429</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low bone formation biomarkers</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/06b65a14-fe83-460b-ac16-c5ad0f4ba4a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f777c4a7-a5db-4c56-bf5c-8153c3997417"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9bbd93d-4ec1-4193-957e-93d766b13381"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/375109de-ef15-459c-bd1f-c540148990d5">
        <dc:identifier>HP:0004349</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004349</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low bone mineral density</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01406977</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42326e84-1028-4cef-bb39-cf461fa9f48e"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e803632-cfb1-49d5-bed3-1a5252f12ec4">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003119*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:label>Increased free sphingosine accumulation(Abnormality of lipid metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab4b53a1-dd70-465e-a93f-8075622b81b0">
    <dc:identifier>HP:0002135</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Progressive basal ganglia calcification</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002135</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/86987cc5-e43f-48cf-934e-2ca06aca5d0d">
    <dc:identifier>DB13178</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d4d8bc8-b22d-44c4-b048-5166e4a12d51"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13178</ddiem:url>
    <rdfs:label>Inositol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/34ed2d01-2361-42aa-972a-4b1b3f43a0c1">
    <rdfs:label>AAV-cG6PGH</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/912dbe7b-8145-4ba7-bf1d-527b0fc92180">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/334b6661-4a81-48a6-8c93-fdb7f04c8f9a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9e9e804-cc3b-408e-ac7f-0c8674158489"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0bb144f-274b-445e-981d-b02e31a48ffb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16672983</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dd3860d1-937e-4b95-9865-c4529ce34437"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/040e9c4d-3fe6-4f13-85cd-9917b95cdac7">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/47cc0111-9593-4a72-84a6-9a687cd14037">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42213bd2-0b10-410e-b892-6fba836b62bb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/212d8a7c-7362-4f81-964e-232081f0d116"/>
        <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1bc86550-6c8c-45be-b501-444db9985da9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc4bdb62-db67-49e5-9a41-eb41540a0658"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1dddedbf-19fb-4213-99bb-9670b1ff50d1"/>
    <rdfs:label>Naproxen</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00788</ddiem:url>
    <dc:identifier>DB00788</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c9fc23e-421f-4970-a54d-15edc9bc2144">
    <dc:identifier>HP:0001263</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <rdfs:label>psychomotor retardation</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a49d3468-bf74-4a27-8f24-540ad5d8651d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4eac2432-e82d-4024-bd9c-9af53f289f52"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12273</ddiem:url>
    <dc:identifier>DB12273</dc:identifier>
    <rdfs:label>Ecopipam</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7cca3e14-d87f-426e-aa10-42621e7b046b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/521cf69d-81b2-4ff3-839e-283afded28b9">
        <rdfs:label>Decreased life expectancy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7a6c07c-b275-4337-ad53-b1e3841cf451">
        <rdfs:label>Growth retardation</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa56e997-ea39-4bb5-b8fc-8aca37b13143"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3649ea79-b0f4-4226-9519-da57482eaab4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <rdfs:label>Salt wasting</rdfs:label>
        <dc:identifier>HP:0000127</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/129de517-d5a0-42ce-9fee-3ed115990d4f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/84b7a55d-b7d1-4a68-a515-f9f6407dff6d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4ea778b7-d326-4457-856a-90b1ad4716f5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/698be91c-0710-4c0f-acc0-7218030953b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a67a25f0-5a18-4f17-b9d0-88ac40f7aa04"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2464ef8e-6401-4dc2-a288-040f84f55cd1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca09921f-d5b5-4efb-a730-1e24bbe256a3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c6d6ed5e-566c-4f3c-b3db-626299208464"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00755</ddiem:url>
    <dc:identifier>DB00755</dc:identifier>
    <rdfs:label>Tretinoin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d66c5f1-0aec-4b66-ba71-f4da66f27f48">
    <rdfs:label>Serine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00133</ddiem:url>
    <dc:identifier>DB00133</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/721eba43-fa4c-495d-bec1-d5048519fa10">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9c3123a7-9627-47d5-a9f2-c1743b0f3ac8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1abb668a-b6a8-4df1-ae1d-177469962cf3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low plasma membrane expression of R8Lin kidney</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17cbff01-44df-4b92-8173-15b9f7d9e14a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e683de2e-5d55-4e8c-af92-9c46bac98b77"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17442906</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a29c1da-0f5c-4a42-b02c-9828736b673e">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c1dac5c-5b48-4b78-b1d1-28fd42c61df7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002071</ddiem:url>
        <rdfs:label>Extrapyramidal movement disorders</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002071</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d6df4f3-6864-4a49-9cf2-b56ae9a6ac7f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21c2d4b9-052f-44cd-ba97-b8595d0624f7">
    <dc:identifier>DB11599</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fab8ca6e-3e7f-447e-a3a2-bc2644ec1705">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d25b5d52-4979-424f-97ba-750bf314cbf2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15669684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>PMC2676979</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/334b6661-4a81-48a6-8c93-fdb7f04c8f9a"/>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e2f3a6c-7ae4-402a-a9b4-17e8dfe7a43e"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b20d2032-88df-43c8-989d-84ab22855911"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2a90e379-8e0f-4f43-a489-434786216d2a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a024037e-99c1-4a13-b24e-43d1ce01b8d1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e99f380a-71f2-428d-a911-d3576b738869"/>
        <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4dcb6f7f-1c50-4d0b-b995-42e17bdcd8c7"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d25b5d52-4979-424f-97ba-750bf314cbf2"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b4582c6e-8393-4a13-845c-a8c6aa6452c0"/>
    <rdfs:label>Starch, corn</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11599</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/58b1f39d-03da-4001-b580-b57e0dd0c379">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f392474-58d6-4857-bd6a-69e4dfef88fb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1531c63-2b20-4e27-af04-634d50947040"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301760</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c91a035-c6c3-4052-81ce-80cebe3e6877"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff279d44-3012-4245-b9bc-190557833a02"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d25b5d52-4979-424f-97ba-750bf314cbf2"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b194dc8-d685-4ef9-b086-fa3625bc8981"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/681164d5-c0e2-4016-a99b-19c9c42823db">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0de52245-d225-449c-bcae-fcf59bba042c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c6e6a7d-aa12-41b4-93fa-1e021e7cba0b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1001f21f-dc2b-4445-a1d2-fee306bf9a12">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/83dc4150-136b-47cb-8e0d-6e0908dd53fb"/>
    <rdfs:label>Gemcabene</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05123</ddiem:url>
    <dc:identifier>DB05123</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c59e88f-d346-4fd7-8cea-91599f65ba85">
    <dc:identifier>DB01306</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3396803c-b45d-4dc1-ba14-de8ea35b3334"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01306</ddiem:url>
    <rdfs:label>Insulin Aspart</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/50447082-4bdc-4417-81cb-32cd7c5d6a82">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a145da0e-71ce-4bfb-a89c-0440c1c76342">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/92b0b584-728d-476f-a246-b97ca2b5b14e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb14e56d-7d2e-4dc4-aef6-8aba0bc16590"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29122734</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607015">
        <rdfs:label>HURLER-SCHEIE SYNDROME</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/607015</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0b8c1fd4-df81-44b5-a497-03cfc2225b81"/>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609283">
    <ddiem:iembaseAccessionNumber>1372</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1372</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/26fae327-b7cd-416c-a6d8-fdfdf607a6b3"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/609283</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/61be833f-7252-4c1c-ba42-e7e5476a8623">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01161576</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/97853040-a57e-4195-b957-0cda3f3dc2a0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c6fd51ea-b017-4fe3-8709-003190066f63"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a213966e-29ae-418d-add4-555669e85f6a">
    <rdfs:label>high glycogen levels in muscles</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009051</ddiem:url>
    <dc:identifier>HP:0009051</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9fdc233c-8aea-4ee6-8472-3e92a051237d">
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03f606cd-968d-4af0-9d09-702050dc95f8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000570</ddiem:url>
        <dc:identifier>HP:0000570</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Saccadic ocular movement abnormality (Abnormality of saccadic eye movements)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17826341</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/396d104d-4d36-47d6-a038-9ddd097586f2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7cb82db5-d14a-4843-85b2-6c5afd2414ce"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18234531</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26f3d96e-38a4-47f5-979a-95dd91f902bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11907009</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771264</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0db6529-48de-4100-b08e-7019468dfc75">
        <rdfs:label>High left ventricular mass index ( Left ventricular hypertrophy)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001712*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771265</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12368988</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c993ed6d-4510-4ac6-be3c-cf1651034fec">
        <rdfs:label>Interventricular septal thickning (Ventricular septum abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010438*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010438</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/503dcb15-b447-4e46-80af-9c8cbe067505">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:label>Disease progression (Rapid progression)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069112</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c31a9b4-e161-4c00-a97c-959e0d4cf8ba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000639</ddiem:url>
        <rdfs:label>Nystagmus</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000639</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd69de66-aaf9-47e3-8d85-54f327007677"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18f0720c-357a-4aab-8436-2fc53ccc4607">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/feb1a430-44fd-4493-8bfe-2f8974ffb5ca">
        <rdfs:label>low reproductive capacity (infertility)</rdfs:label>
        <dc:identifier>HP:0000144</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000144</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11095909</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0de52245-d225-449c-bcae-fcf59bba042c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20868666</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a211a502-2c81-42f7-99b4-a104f945de37"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27864a22-0783-41ac-90b8-3bc44fc09a7b">
        <rdfs:label>Cataract</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0000518</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11089562</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9c52ea2f-5ba1-4d3e-b75d-a78c1ab29d5b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
    <dc:provenance>http://www.medlink.com/scripts/mpdf/print_friendly.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c7ef80d-9872-4a36-b414-81965a9b9fd7"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99646926-7506-4d6b-82cf-ea0b66c89ab4">
    <rdfs:label>Imipramine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00458</ddiem:url>
    <dc:identifier>DB00458</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9223bc28-17d6-4b37-ad57-54478352918b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d91e73b4-a123-4468-ad10-41d6c45eb396">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>hypocupraemia</rdfs:label>
    <dc:identifier>HP:0010836</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600890">
    <ddiem:iembaseAccessionNumber>178</ddiem:iembaseAccessionNumber>
    <rdfs:label>HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/600890</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/178</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d0d4d5d6-b1f2-4696-a618-161460a1fc84"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/255120">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7d81da2f-4ed6-4e6f-856a-9faa30ebd99c"/>
    <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>228</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/255120</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/228</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c402ee46-4c10-4445-af8c-a16d764509c5">
    <rdfs:label>Cholic Acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/98e32a7d-e144-4622-904f-6dd69e67b686"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02659</ddiem:url>
    <dc:identifier>DB02659</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a0cbbac-c67d-403f-9f55-0658eef88309"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8ca4e194-8003-414b-858b-c60d066cc7f7">
    <dc:identifier>DB00993</dc:identifier>
    <rdfs:label>Azathioprine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad7b0af0-ee23-41ec-87ff-00fe74e53ebc"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00993</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/328323dd-97c5-4fdd-a03a-4c7cc7bea68d"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64cd6464-d803-414c-bae0-d0bd204b0ece">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00149</ddiem:url>
    <dc:identifier>DB00149</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8477f821-2d14-49e8-b3d2-b0d01dc8f1e6"/>
    <rdfs:label>L-Leucine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ceeed8e1-8755-496d-a0a0-080fd3850a17">
    <dc:identifier>HP:0002917</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
    <rdfs:label>Hypomagnesemia</rdfs:label>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000004">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T10:19:07+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <rdfs:label xml:lang="en">direct complementation of genetically defective protein</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a genetically defective protein is replaced by a canonical source of the same protein, genetically as in gene therapy, or by some other means of delivery, whose completion is hypothesized by a health care provider to eliminate a disorder or to alleviate the signs and symptoms of a disorder or pathological process. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dd1585ae-cf56-495a-80ca-435d28731843">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c148cbb0-817b-4f10-9d3c-b70cddcec5bd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>photosensitivity</rdfs:label>
        <dc:identifier>HP:0000992</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a97b72ee-5f35-4b74-956e-c72e350bbf4a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12535027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e6c9187-facb-40cc-b4d7-af4fd4b62c69">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8bd5fea8-0474-4aac-bd8f-7c65cc66539d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f66bd106-bc68-4b36-a4e5-2cb14e854073">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad10cc7d-c4e0-4825-86a5-375ace181f71"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa4f61f1-acba-4010-bef9-563d1d78b249">
        <dc:identifier>HP:0040006</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:label>mortality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29908244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/924d19d6-da2c-43c5-8ce7-ae39c0a5171d">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00912925</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72dfdf39-edf7-458f-93ad-f95bb8dec998"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7ffdf848-cc90-4fef-be67-e9795baa632f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42aab52a-c496-446b-bc78-3278c6faba65"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e28402f0-808f-4317-805e-3eb0e330eb99">
        <rdfs:label>Decreased pulmonary function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11cf64cc-71e7-47f7-a954-2bc0de70ede6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002111</ddiem:url>
        <rdfs:label>Low Forced Vital Capacity</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0002111</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b024010-12c1-4f35-958a-c894f50485b8">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0010535*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
        <rdfs:label>High Apnea,Hypopnea Index(sleep apnea)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/558fc494-bc5a-43c3-a199-27051a265e5e">
        <dc:identifier>HP:0001376</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Limitation of the Joint range of motion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bfa9f8f-1ac7-461c-bdd6-28fe320e1542">
    <rdfs:label>hyperuricaemia</rdfs:label>
    <dc:identifier>HP:0002149</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21ca69f5-0d38-44d1-8a23-84534c54d966">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c815a0a6-9e2b-4ee6-bdd4-c68fb13e89ba"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27918a38-5398-4b52-9250-e62f8de8bb21"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f1b621e5-77c3-4b41-925d-e8e7b19b00dc">
    <rdfs:label>Ethoxzolamide</rdfs:label>
    <dc:identifier>DB00311</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37376725-a061-474d-bc91-2d64fb306317"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00311</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/96f33b6a-1233-46a0-946d-a29cd7cfd180">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/67288004-ac46-444e-9dc9-5f10962a113d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/232d961e-6226-4dc9-b7d7-492c8cb6ac15"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de08ba47-e87d-40b8-98fe-0f7c426de859">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0010836*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:label>Copper accumulation in kidney(Abnormal copper levels)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e6f0344-c570-4138-a197-36859741bfac">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/396513ca-9008-4a43-ac8b-4126635e81ce"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815746</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71c53d15-902b-4d02-94b6-f671530bc5a2">
        <dc:identifier>HP:0010836*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Low Brain Copper (Abnormal copper levels)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d5a3b71-6a82-4ebd-a818-3848170d03ad"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f8fcfec-7c46-4df4-9d71-d3b3dad9b82d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c7df8813-36c4-4b7b-8e7a-4a952d72b5c6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6f30d773-b490-496f-9fcc-b3801a4efa54"/>
    <rdfs:label>Chenodeoxycholic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06777</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab64781c-b21a-4d9e-9116-a602c8c5a8e3"/>
    <dc:identifier>DB06777</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9cf4899-092d-4be3-9fe3-14aef0be7e8c"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c30587ef-0d72-442e-8b50-7a5632334a26">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dec8b089-abc7-4413-b65a-cc6fdbdfba48"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c909a90d-a6cd-4c29-b301-cb8e2bbdad1e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a213966e-29ae-418d-add4-555669e85f6a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24509886</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45eae480-ec85-4519-bb5c-ded178f446b3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f8fcd19-82af-4c66-a6d2-6f1ca7ac3cd3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e55d0215-afc5-4553-9f74-ed01d12c46fa">
    <ddiem:failedToContributeToCondition>A209D-alpha</ddiem:failedToContributeToCondition>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f96fe379-8027-44c5-b2f8-0d28bf56a7d6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea26bd34-12ed-42fe-8dd2-c1698a521747"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>F364C- alpha</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11507102</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9900d3b-a9dd-4459-97ae-9082a2c0447b">
        <rdfs:label>No phenotypes were mentioned in the study. In vitro Study.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0003304>Y393N- alpha</obo:RO_0003304>
    <obo:RO_0003304>Y368C- alpha</obo:RO_0003304>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/495ea521-9fc8-45c8-9aec-6345c0479389">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3eaf153e-c318-4193-b86b-775a95948aec">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/094bde76-4d71-42ba-9f22-7eb3dbf926e9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82113074-07a6-497f-84b7-6ed233e1106f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b77d136-ea14-4815-8258-704c5fd71adb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10738634</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2e9d1253-88be-4142-89d9-5516fe4a3979">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/992d9fd7-3eef-43a7-b2ff-2e9c66f876cd">
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:label>Elevated Phe level in blood</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/396d104d-4d36-47d6-a038-9ddd097586f2"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eaa749d3-0274-4866-b455-b38fc391bf84"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8433887</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3bdfa5fc-a54a-4a96-9372-1b62cc2f726b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cdcbc1d-2611-46ca-8c75-6382ded765d3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>secondary glutathione deficiency(Abnormality of metabolism,homeostasis)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0de52245-d225-449c-bcae-fcf59bba042c"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-016-9963-8</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/986a63c1-86f0-412c-a7cd-58f94dfdde25">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001942</dc:identifier>
        <rdfs:label>metabolic acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8934f744-e441-4ca1-8537-7783a461c6f4">
        <dc:identifier>HP:0001992*</dc:identifier>
        <rdfs:label>pyroglutamic aciduria(Organic aciduria)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cba5f3a-0894-4756-a2d9-7c362a54bf21">
        <dc:identifier>HP:0004396</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>decreased appetite</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0c3c20a0-77e5-4d83-bc68-9717b29d1217">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4cbbc885-d9da-4a64-84e7-a69ea36ba2a4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b041fa84-0355-4ef9-9394-f1a881eb9cc3">
        <rdfs:label>Secondary NAD+ deficiency in leucocytes</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/094bde76-4d71-42ba-9f22-7eb3dbf926e9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00926</ddiem:url>
    <dc:identifier>DB00926</dc:identifier>
    <rdfs:label>Etretinate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/495ea521-9fc8-45c8-9aec-6345c0479389"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eada773a-713a-4693-90f6-660d1768c920">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003158</dc:identifier>
    <rdfs:label>Reduced urinary osmolality</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d275771-1cef-4efb-8e1b-c2a69fa0564c">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfa759fc-3468-4045-9104-a2330962db00">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003688</ddiem:url>
        <dc:identifier>HP:0003688</dc:identifier>
        <rdfs:label>Decreased activity of cytochrome C oxidase in muscle tissue</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9046addd-c582-4a31-ac8d-33e1d963d4e2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02f1c411-cf4d-4752-8d7a-6e706c0b85d1">
    <dc:identifier>DB00145</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1c18ca3-8f07-4d39-b108-90fc1369a7e2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/32e7e5b7-bdc0-4ed4-b7bf-fc28ab20b59c"/>
    <rdfs:label>Glycine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00145</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4068c445-fbad-4a74-b128-f8b4a51796f2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10510995</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eada773a-713a-4693-90f6-660d1768c920"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5974e527-1cd0-435a-8d40-7e35438d02e4"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4b5b2832-dcfc-4733-932b-b74d029d4246">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/de2d9b5c-0270-4f37-b52e-be363aaee057"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/531a6062-e538-4230-ae5e-75d6dcacb4f8"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/10790e8a-2ff5-4ef2-b173-1243a06c5593">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8becd843-3978-4cdb-9334-c4f47a28d572">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94503d55-4157-41a0-9c27-69788aad99cc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76f6cac7-0065-49fb-bd03-81023b701205">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6aafa420-9cef-4d26-8729-ab2e4219c266"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a4428ab5-0132-4f8c-b275-f679daa320fc"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1255fa44-293d-4af9-88e7-f8315de302a7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01146197</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eee0e6b6-361b-42bc-97d2-d8757085684a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91fc6485-5027-4f5b-82ad-1e991fc96eac">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/88bdbeb2-62d1-4268-baef-e92068cfd3a9"/>
    <dc:identifier>DB01045</dc:identifier>
    <rdfs:label>Rifampicin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01045</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f3c68883-3f23-4050-b259-ee0807fcb058">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06372</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b09eaa05-aca6-4591-93bf-94738835e69c"/>
    <dc:identifier>DB06372</dc:identifier>
    <rdfs:label>Rilonacept</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eae0b3b6-3e42-4a65-96c7-61f01015946c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac05cff1-57dc-4556-9fc0-2ba1ed9719fd"/>
    <rdfs:label>Dopamine</rdfs:label>
    <dc:identifier>DB00988</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00988</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8e59f97-08a1-44b0-aea7-79819394dde6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031377</ddiem:url>
    <dc:identifier>HP:0031377</dc:identifier>
    <rdfs:label>Abnormal cellular proliferation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5eb6b191-461c-49a6-b9e9-e8865b5c61cb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a1c7556-b4bb-4411-a8cb-b25bc671bee8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/43e9faa6-6a84-4594-9375-87e1e76a42aa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00528151</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/73bf8348-437e-49c0-bb08-26e548629cbb">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00181</ddiem:url>
    <dc:identifier>DB00181</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48177d94-d3e3-40b1-927c-1c025b88246b"/>
    <rdfs:label>Baclofen</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19aa47fa-cd8d-481f-b0f7-57ae7bfc1cf5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4564bd3b-979f-474e-9998-dbfd773b4a22"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16549399</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ab959336-4ff3-4517-aedb-40d0cfa07163"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ba03807-4438-4c2e-8d29-5c26e666f2ff">
    <rdfs:label>DIURETICS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28165a5d-8223-45f2-bc57-bbdcabf55f72"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0efa1dc0-f494-4332-9b48-2848d144279d"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0fd09e75-b756-4bba-b4e4-3408e2f1d2d2"/>
    <dc:identifier>C03</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/16a337cc-992f-4aa1-a71a-7e52710fabd5">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66fc6714-1f0d-4325-be51-b39a789e5a68">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0040181</dc:identifier>
        <rdfs:label>Perioral dermatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040181</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8f0cbf8-699b-4247-bafa-8c2f9edee465"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14354277</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/456095c8-31cc-4ade-ad04-fc741c14f007"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4e09427-5ac6-4e99-bea3-73070b847caa">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Acrodermatitis (Dermatitis)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <dc:identifier>HP:0011123</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3b7558f-19a0-4130-bbd2-569e7621aefb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eb13706f-6664-4d58-a882-8068ac6717e7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d275771-1cef-4efb-8e1b-c2a69fa0564c"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eec63829-bf8a-442f-918b-8b35ab74754b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10540864</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236800"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9046addd-c582-4a31-ac8d-33e1d963d4e2"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b2b36f84-d0d1-4723-866d-1a9c4b268fa8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7df696fa-e2dd-44c9-bbfb-3dad4457a11b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <rdfs:comment>Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9046addd-c582-4a31-ac8d-33e1d963d4e2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9718357</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19cc165b-bc2d-410c-af0e-e99f49312e78"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4d69e8d-711d-4ba6-ae2c-5cbc3806a96a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00126</dc:identifier>
    <rdfs:label>Ascorbic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00126</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1dd878d-a5e8-4917-95fa-4b9f7885bfeb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac68cac4-e406-4e85-ac7b-1c7baa6d3abb"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a183fc96-1469-4ac2-9583-93a18069dae8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608099"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7d3d37d0-d85b-404b-bc19-ecb17ddcbd1d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/83346d22-5b82-4332-b72d-0accc48d6d3e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b064b74-25e9-468e-a72d-60b1a5eec409">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008347</ddiem:url>
    <rdfs:label>Decreased activity of mitochondrial complex IV</rdfs:label>
    <dc:identifier>HP:0008347</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa0f8b6c-c1bd-442d-91ea-4f58857a9969">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/296d96b0-598b-4305-a990-d38fc96fc277">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low 5‐MTHF level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5afa4b3e-a73d-4e24-92cb-c37c0de5aa3a">
        <rdfs:label>White matter alteration</rdfs:label>
        <dc:identifier>HP:0002500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f148732-8d02-4850-a227-f4f4126206cf">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>deambulation</rdfs:label>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4b0ba7-0654-4cd1-a6df-644af85ccee6"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16365882</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1e9d07ec-1254-4af8-b97c-e975b3a5ef96">
    <rdfs:label>Isocarboxazid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7c1ee564-91ac-4630-821e-6dead1de7deb">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24e9df42-0e87-41ae-acd1-797942a61eed"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7dd00ea0-654b-478d-a23e-13edaf479f8a"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01247</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01247</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cad854a7-6fe4-48f4-b0f0-240d23f51a98">
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43abbbd5-0048-4665-87bd-3ee33ca762b4">
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <dc:identifier>HP:0001640</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:label>cardiomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9f438c1-dc6c-4ab8-9026-42980978f572">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <dc:identifier>HP:0012213</dc:identifier>
        <rdfs:label>low renal glomerular filtration rate</rdfs:label>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d936a7cc-1464-4316-91b5-1a9350fa4434">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c33f7162-f403-4efa-b160-9e2c06db2e1a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03018730</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8a040a7-c003-4ed5-8d6a-0171f7d5db1c">
        <rdfs:label>pain</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0012531</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/087e8e36-fc43-45c7-9bb9-d859361963cd">
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6dd139f4-df56-4b64-92a0-defd94133520">
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>Low energy level</rdfs:label>
        <dc:identifier>HP:0003473</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003473</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40441412-448b-49f2-b2c8-53d677bbd8ab"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44d08b6d-1ab0-42ce-94c9-f38ad918aa4e">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001928</dc:identifier>
    <rdfs:label>blood coagulation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001928</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42d007cb-1fa7-43f2-b58a-f03ea2abfff4">
    <rdfs:label>Delayed motor milestone</rdfs:label>
    <dc:identifier>HP:0001270</dc:identifier>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d1368145-f552-4445-aa4e-a5fed0c6a3b7">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/55c5fbad-dfe1-407c-8505-3c8756943083">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a44f9fc7-ff53-4ce4-b9a9-750f949cebc0"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60ffed6a-7b69-4c80-91b0-cc3b96238851"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69f563a0-3577-4ca5-ac5d-fb1eeb0177a3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e39ef700-a95c-465d-923f-b0a360f9765e"/>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84095002-127a-46b0-98b1-16104c97bb90"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9333797-af03-4cff-841a-45657378d054">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69f563a0-3577-4ca5-ac5d-fb1eeb0177a3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de057fb1-9f07-40cd-a7f0-393629a24594"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607330"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Cholesterol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04540</ddiem:url>
    <dc:identifier>DB04540</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4525ea4f-be11-4b37-a762-c7bdbe642b73">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3943dcd0-9714-4356-a903-30e95190da25">
        <rdfs:label>Adeno-associated Virus 9 Mediated FKRP Gene Therapy</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d806c492-9f9e-434c-b257-f5a88880e99a"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09a7b5a3-380f-469e-ab4b-833061769f20">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946,HP_0025212</ddiem:url>
    <rdfs:label>fasting ketogenesis</rdfs:label>
    <dc:identifier>HP:0001946,HP:0025212</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/506869ce-6735-4a2d-8e7d-4407bc25d642">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59bd13dd-cd20-4c4c-8cab-b3ae9460c424"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00437</ddiem:url>
    <rdfs:label>Allopurinol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e59d42ad-b3a6-4e09-a3dd-72f6524a8c4a"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/63020569-6dac-4e44-b34d-304683aa5633">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c482cb1-22f9-4db5-a34e-ac302092922f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17065067</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3f64ab3-3fe6-4571-ac7f-7ba7da2fb6f0"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c4e0177e-4e20-44c1-bf03-cdf291323d19"/>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3ba4c6c1-d498-461a-b7c1-0db7287a1067"/>
    <dc:identifier>DB00437</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/055095de-8925-441f-9bf0-763a29c4f913">
    <rdfs:label>abnormal muscle strenght</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ee16ce0-152b-498a-b591-47bdf7850c55">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:label>cardiac dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a4070867-aab0-4588-8643-aa29080652aa">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c168b759-7be4-4277-b46c-f3057a107ce6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62488394-8945-4f6f-b53e-e0461fd70212"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9822dcc5-2bd1-41da-bf90-59ea64a7a9db"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c2f25b6-afa7-42e1-85d5-512dea9e31e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/765e11e8-deaa-450e-b5b8-c23954ba102f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b194dc8-d685-4ef9-b086-fa3625bc8981">
    <dc:identifier>HP:0012378</dc:identifier>
    <rdfs:label>Low energy level(Tiredness)*</rdfs:label>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be866efe-6d18-4ac3-b1af-45a44be93ed2">
    <rdfs:label>high Lactic acid</rdfs:label>
    <dc:identifier>HP:0003648</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65947d63-d09c-43bf-af14-85b8bff50988">
    <dc:identifier>HP:0000010</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>urinary tract infection</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54ea38e9-9403-4197-90f4-85e815ff9921">
    <rdfs:label>Abnormally decreased rate of beta-galactosidase activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008166</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a23f9244-f649-4abb-9e05-7c98e4b3db57">
    <dc:identifier>HP:0002625</dc:identifier>
    <rdfs:label>Deep venous thrombosis</rdfs:label>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002625</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/216df2c3-a4bb-4aba-a932-70361dccd770">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4247578a-2b31-497d-9fe1-4bd80f04f2a7"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432805003657</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c03d31f6-c278-491a-ad21-16665fbc8349"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6df0fdbe-ae6b-4bf4-931e-46f07cb60216">
        <rdfs:label>impairment of reference</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
        <dc:identifier>HP:0100753</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a59b30f8-0061-4a44-8ca8-4e0e5306cba0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a59813ef-20e6-4123-800a-d4470024d8bc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9046addd-c582-4a31-ac8d-33e1d963d4e2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/666b9c3f-2fdd-41d6-ba1a-5ce7541d8835">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"hippocampal Na+, K+-ATPase reduced activity"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1ec0d491-79dd-40ad-bee9-101a2e5e7e35">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49264a40-e24b-47b8-a983-f35beffeb3d6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f179f86b-ab4e-407f-8366-a73697500bd8">
        <rdfs:label>Subcortical calcification</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007346</ddiem:url>
        <dc:identifier>HP:0007346</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2785251</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab4b53a1-dd70-465e-a93f-8075622b81b0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb2ca183-815b-4e46-9791-80170dd281d7"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8c58707-f9d3-4b5b-8a55-46f9af73298b">
    <rdfs:label>Personality disorder</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012075</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012075</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/379b690d-83e4-46c8-8079-5c5c80ea5ac8">
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <rdfs:label>paralysis</rdfs:label>
    <dc:identifier>HP:0003470</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003470</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ef52a6ce-eb60-436a-a475-205ccbc7b8c7">
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12727399</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3ef8d14a-8eb0-455c-950b-fa512d59b5ae">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d2cb7d42-e997-4b00-9e12-4262168185e2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/379b690d-83e4-46c8-8079-5c5c80ea5ac8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91312603-ffbc-4c29-ab7c-6a920180446f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c786fc2b-b3cd-4ea3-8c86-a7150c33feb7">
        <rdfs:label>Impaired myocardial contractility</rdfs:label>
        <dc:identifier>HP:0006670</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/901044b3-3627-4005-8e45-796a464963f3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604369">
    <rdfs:label>SALLA DISEASE; SD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1369</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/604369</dc:identifier>
    <ddiem:iembaseAccessionNumber>1369</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2445f697-eec9-4fff-848a-44629c65ba06"/>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfaca255-b768-41ba-b14b-47928f08109e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/040fdd17-ce28-4fe2-a63f-15d8b49e5781"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617070">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c046327-0cd6-4a12-8650-f1a1fa5cbd90"/>
    <dc:identifier>https://www.omim.org/entry/617070</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af87473d-f388-4db3-a3e8-9cfc5c6a05d0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01606</ddiem:url>
    <rdfs:label>Tazobactam</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28a3847f-13d9-4693-b5c9-f46897553ad2"/>
    <dc:identifier>DB01606</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/377f0c31-a8a7-477a-aec1-c999de5e0c01">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6125cbaf-7c05-478d-8f1d-c9287ee6ac61"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd8c1ece-8d63-4907-a7f7-4c47eebc0a03"/>
    <dc:identifier>DB01186</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01186</ddiem:url>
    <rdfs:label>Pergolide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4cf97478-4eba-4eae-8e7e-fd274d053a6c">
    <rdfs:label>Methotrexate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4404687d-a31f-42cb-bdda-c1c537baaefe">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e60c4b2-eae0-4e1f-b739-3ea007c811b4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5db27d7f-2f60-424a-9a83-c5892844fdcc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42213bd2-0b10-410e-b892-6fba836b62bb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25315665</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00563</ddiem:url>
    <dc:identifier>DB00563</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e9f22d2-3cd7-47f9-b5b5-cc751402e238">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/202fc029-148d-4377-868a-3492becc0df2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcae3e91-49a5-4163-92b6-31ade45cb127"/>
    <dc:identifier>DB05018</dc:identifier>
    <rdfs:label>Migalastat</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05018</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef9c1f27-af9d-4dbf-95ae-4149506b99dd">
    <rdfs:label>Abnormal plasma glutamine levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
    <dc:identifier>HP:0010903</dc:identifier>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbe6cabe-d5ad-4e53-ba35-e8474123e0aa">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0008897</dc:identifier>
    <rdfs:label>Growth impairment</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008897</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0007121">
    <dc:identifier>EC0:0007121</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/EC0_0007121</ddiem:url>
  </ddiem:Evidence>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a8db5674-15df-4471-af6d-dc6d78eaf9f3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00451</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c6af3919-d664-4bd3-b792-54444a482309"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d83c572e-4a7a-43ef-a07c-5bc69ca6abad"/>
    <rdfs:label>Levothyroxine</rdfs:label>
    <dc:identifier>DB00451</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee5c4380-d980-4db4-83f3-a33e6aedb7b2">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6050556f-5a0e-4c1b-a924-0a887ce24ca6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/263d6fec-ae26-4f6f-aebf-8bae26f01959">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>Short Stature</rdfs:label>
        <dc:identifier>HP:0004322</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2464ef8e-6401-4dc2-a288-040f84f55cd1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9f32a311-4cdb-4d63-a5b2-ebbc33498587">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fd061ba6-5d6f-4eed-8f67-d1354a3fa9bc"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1b77eeb9-0e4e-4e1c-87c4-a6d815a0140a">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3f6149f0-b431-4eae-b587-67796cd55ed3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2fb38993-0aa6-49f4-880b-5c571cfc4b6b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a4b044f-a8d1-4efd-8e5c-fb0cce150840"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525984</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10484808</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44d08b6d-1ab0-42ce-94c9-f38ad918aa4e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/292f6b57-8088-402d-8aee-cd74d48b5dbf"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a272b3a9-92ee-4dad-91d0-20430457da9f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602579"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65947d63-d09c-43bf-af14-85b8bff50988"/>
        <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/265de1af-7828-46f5-a598-ced8863b4449"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9ea98f7-5b19-414e-8f9e-37d618daf5c0"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12907</ddiem:url>
    <rdfs:label>Mannose</rdfs:label>
    <dc:identifier>DB12907</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06cdc0d6-0a93-4156-a8eb-346c97383c5a">
    <dc:identifier>HP:0001877</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
    <rdfs:label>NA</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300559">
    <rdfs:label>GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/300559</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5c3b8002-6f22-44a9-8fab-5aec77a28aee"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/563</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>563</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/777bb2b0-b626-48c8-96be-6c7c6895c676">
    <rdfs:label>encephalopathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001298</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/77309851-b999-4e2e-9277-d540468e8fc2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f09338c7-611b-46ce-9252-ea52e7361d4c"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253600">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ff86e590-2864-4f9f-b19f-be1fd4f731fe"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/253600</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c0a6fc88-c3fa-4d4f-8ec9-a91b039f9a56">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13959</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/31f8d4ed-e5a3-4b29-88b7-dc29eef1920b"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c20febc4-7ee9-4b4a-b5f7-e8a07dadb60a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f0415b3-9909-44f9-979d-67456199b5cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/338dacd5-05fb-4bc7-ba19-99e311b4d2cf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/acb67fb7-96bf-45d0-af29-7f0ebe56f342"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eda988aa-eb02-48c8-a12c-4405c9eef905">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/601987"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15fbc68d-b8fa-4389-8113-2e23df2c223b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f0415b3-9909-44f9-979d-67456199b5cc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7dc5333b-258a-4ca1-8f24-08dbbb0d4e69"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6116555-4b52-4cbf-aa32-ec9826f595fd"/>
    <rdfs:label>Medium-chain triglycerides</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1c18b315-2888-474d-b658-f559f8a14875"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/765e7974-4569-4b0b-a583-083fbf99741b">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fbe6cabe-d5ad-4e53-ba35-e8474123e0aa"/>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f0415b3-9909-44f9-979d-67456199b5cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB13959</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/386c2d1a-29c1-49e7-b07f-36da27ea9ffe">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d0bb9bf-a8e7-48c8-9a8d-c964f727c0ea"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71ff8195-9337-43b2-ad2d-be73e8b092f5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f0415b3-9909-44f9-979d-67456199b5cc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5befc82d-4f0d-4704-85d4-d05a15423621"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d6001f2-188c-4c35-8fed-8861e9fde97e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/31dc69ea-2d02-4eb6-ba0a-9e98e2421c65">
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/266707cb-f638-4a46-9a4e-1f361ebe7833"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a4657ea-92ad-4b4a-ad07-c7f946d2ba84"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7658b3b9-637e-4712-bb31-58657ff0295d"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-016-9963-8</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f0415b3-9909-44f9-979d-67456199b5cc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7f348ff-4b4b-4730-a1a0-ebe362c1eb49"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17082bdd-c7c4-4514-b278-59e6423d8983">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/490c747c-432a-47c3-a81a-a24f0f5695c8"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8829ad01-b171-4480-a4c7-c88738a41aeb">
    <rdfs:label>HDAd-G6Pase</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19e450e0-b9e6-4541-a4a0-40b8bdbbb6b2">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/334b6661-4a81-48a6-8c93-fdb7f04c8f9a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17505475</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66f38b64-be28-49fd-a0e7-0e431ffbd22b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a2421e2-9980-42d9-9037-f208147dcc29">
    <rdfs:label>Nitric Oxide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00435</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b25ed229-f1d3-4e0a-abcd-7e730a442dda"/>
    <dc:identifier>DB00435</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f1820bc-016b-496c-a94c-cf94b12db1bb">
    <rdfs:label>Ad-mG6Pase</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e3bbbc7-d14c-4bf6-a4b7-6c573856f609">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/334b6661-4a81-48a6-8c93-fdb7f04c8f9a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26c40c36-ac7f-43ac-b972-03359a71e9f3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a7a6c07c-b275-4337-ad53-b1e3841cf451"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97f774fc-23d3-4497-bda6-18bc870cbffe"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03177556-9574-4fbb-8ec0-127a3aa12b64"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0bb144f-274b-445e-981d-b02e31a48ffb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10625614</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42aab52a-c496-446b-bc78-3278c6faba65"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/519ec94b-75f4-4b48-bc3a-c9d9fa4508e7">
    <rdfs:label>MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus)</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/36a4b93a-c0f0-4d9e-b8b0-a67c78340972">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86b40035-fab1-4e32-a56d-7f5d68b3586c"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f384ac16-a125-4be7-8299-0f46417b7142"/>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c201e71e-879a-4fdc-a150-4690eec5135d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30208599</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/030cc812-aeb9-4238-bc0a-f749e3c6c6df"/>
        <obo:RO_0003304>G11778A</obo:RO_0003304>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1db7f17c-c5ec-447f-9317-03a6ee217cc4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d0d32cd-01cf-4e21-beaa-ac60d9c6964e"/>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/234a1a61-f558-4ae3-bc72-ed55c27c8d05"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4216e31-4d7a-49da-9c01-1ce09c7971e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19cc165b-bc2d-410c-af0e-e99f49312e78"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/56e0c6b7-8506-4f51-b410-11d7cbc22d97">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf8b2b2d-8a46-440c-8cf6-7d9bacd6bbe9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <dc:identifier>HP:0002180</dc:identifier>
        <rdfs:label>Neurodegeneration</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4977e9f7-2b49-4358-9525-2651a1faa415">
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
        <rdfs:label>Lysosomal stress (Abnormality of lysosomal metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <dc:identifier>HP:0004356</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0523eb32-f854-4004-bb26-2be192203b23"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29909971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/853a7a5a-00b4-4376-87bc-f404ddcfe175">
    <dc:identifier>HP:0002180*</dc:identifier>
    <rdfs:label>neurodegenerative astrogliosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36644a18-a833-4c17-b451-0c3f4eeb3576">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00593</ddiem:url>
    <dc:identifier>DB00593</dc:identifier>
    <rdfs:label>Ethosuximide</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9c896a7f-d6e3-43e3-b9c5-3cc64ca8ad11">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/568e03ef-48b2-4c45-a292-816c693e1fee"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e0d9a0d4-e4d2-411d-8c9c-b7183f7dea67">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8de505a-d6c3-4338-ad44-c16607e2761e"/>
    <rdfs:label>5aR)-5a-C-Pentyl-4-epi-isofagomine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07bcef06-b54c-4af9-a883-73c87326d372">
    <rdfs:label>Elevated C-reactive protein</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011227</ddiem:url>
    <dc:identifier>HP:0011227</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/05eb566e-5f9c-42be-978d-207a5c895a60">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/43046733-91c5-4a7a-8580-45851e398baf">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19011501</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4b11a87-9be8-4fa8-ae7d-d003d4cfc7b8"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82ee7077-0312-44a6-902e-b095e79f250f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00641</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ae3857b-a4ae-4b4b-bef5-8da94d38b96b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82ee7077-0312-44a6-902e-b095e79f250f"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16848116</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0bb144f-274b-445e-981d-b02e31a48ffb"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d3e4379c-6e34-4822-b811-35de73864a44">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
        <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82ee7077-0312-44a6-902e-b095e79f250f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a51a5b34-b91f-4325-b61a-ef1f346afe34"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21b293a8-2943-4ae7-81d3-8ec96cacbdb3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Simvastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c862c8af-ba2f-45d0-9391-8d7a9298b6ee"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa8794c6-5cc3-4433-aa66-4e1140e962d2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00641</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff93abde-fa6e-42b1-9be0-9b5803b6ad91">
    <rdfs:label>High intraneuronal GSL storage</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229700">
    <rdfs:label>FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D</rdfs:label>
    <ddiem:iembaseAccessionNumber>483</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/483</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/229700</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/864ad736-e067-48c0-9ed4-45464f827683"/>
    <rdfs:comment>The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&amp;Cmd=Retrieve&amp;list_uids=29390242&amp;dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9</rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b88664ee-e688-40f4-b98f-41c757448d00">
    <rdfs:label>Fluoxetine</rdfs:label>
    <dc:identifier>DB00472</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00472</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60effe55-d074-4f34-8cea-dc0539bdb8ce"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ebf05964-087a-4d93-9627-033360157f48">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5f213ba5-dccb-4725-af03-4ec41f6498af">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4347dfb2-343a-41cd-9f92-8179c4f46690"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:comment>Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99a5fc85-d05d-4450-bc5e-e8762028cbc7">
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <rdfs:label>Low serum ICFBP level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15fbc68d-b8fa-4389-8113-2e23df2c223b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0750ccbc-b2a8-4b58-a000-aaa003d79ff6">
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <rdfs:label>Gastric mucosal atrophy(Abnormality of gastric mucosa)*</rdfs:label>
    <dc:identifier>HP:0004295</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004295</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2fb9d723-eae5-48fa-b511-b478b1e1cf01">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/789de476-0677-4d73-8393-cfff899e499c"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a7ee61d5-4ee9-49b6-a97f-9c44ff19cd82">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29757052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/adb4ab0a-c833-45da-9906-a61c84590c3c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/956742ee-5f4d-49a2-8883-e3f8b11d25ae">
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4e380b6-903e-4b62-ad99-96a6c15e2bb2"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a2f60279-bed3-4f7c-a885-374b51cec6ee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/11c49b2d-4931-4289-991b-74f7055da944"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc4bf23e-11ff-4e99-ac1d-abe999bce4fc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7fd0fecd-8a92-4bcb-af70-8e65c2c73b31"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/334b6661-4a81-48a6-8c93-fdb7f04c8f9a"/>
    <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29203193</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229700"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e189ad2-b151-4792-9c68-c134c779cd37">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eaa749d3-0274-4866-b455-b38fc391bf84"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9027c43f-7a57-4b9c-9883-ef51a523eb64"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8c58707-f9d3-4b5b-8a55-46f9af73298b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95a3161d-8e66-44f7-8b86-1918985138bb"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39652466-9fbc-4a3a-822b-f4700619d3d3">
    <dc:identifier>HP:0004324</dc:identifier>
    <rdfs:label>weight gain</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004324</ddiem:url>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b946393a-202e-47cc-ba91-40f5344d0537">
    <dc:identifier>DB09269</dc:identifier>
    <rdfs:label>Phenylacetic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09269</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c04ef1ef-eb2e-429a-9e63-2eb0d822fc75"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a7dc0fe-1bfa-47c4-b00a-9ccae5a808ea">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14681</ddiem:url>
    <rdfs:label>Cortisone</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2a400382-7d4c-4ee1-b787-d4f1fb01f2d3">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/865fe573-b32a-4dae-91c0-a07765a7a891"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15637709</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e9aa4ae-926b-4967-afe9-9da29800e24a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB14681</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d821a19-5e83-4f76-8146-4d379952a18a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e2658284-6a89-4c32-84e3-9dd1a7d4dc25"/>
    <dc:identifier>DB06742</dc:identifier>
    <rdfs:label>Ambroxol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06742</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8ef2b483-08ef-4576-8923-ec345b32f2bb">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccbc7137-ccec-4f4f-b8b9-cdaa2099d4d2">
        <dc:identifier>HP:0000488</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
        <rdfs:label>Progressive ataxic retinopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da43e5a3-939d-43e6-9afa-dc08821ae030"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c848b8af-9404-4196-8c56-5f1723f0c9dc">
        <rdfs:label>Fat soluble vitamin  Malabsorption</rdfs:label>
        <dc:identifier>HP:0002630</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbe42ad8-7efa-4d75-b241-834f62207736"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0e4df528-7461-4972-9c75-1c5ab7a71feb">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4372e779-7046-4b86-9b95-454ac9d0fbd2">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ebde1ee-6129-4172-a25f-16d8ef62698a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9182c1e-c767-4ad1-8abd-89b4f39324f7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9930336</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4315d0c-f106-40ac-8729-bf690f45a060"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91f5db3e-09a5-4627-8f16-98cf1a0cfd0c"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16518877</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/824f0d26-2414-4b01-a187-0df1e093e912"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Gene therapy (wild-type Ad-AGA)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2b6c19ca-f54e-425d-b5a5-423400e7ded1">
    <dc:identifier>CHEBI_17012</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_17012</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d11d1d6b-5264-4341-8b07-373ccf6798be"/>
    <rdfs:label>NeuAc</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/812819f4-c213-4118-a0d5-6c697409c126"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6aafa420-9cef-4d26-8729-ab2e4219c266">
    <dc:identifier>(DB00328</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00328</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10790e8a-2ff5-4ef2-b173-1243a06c5593"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f2401a7-a332-4d14-b0f8-87246eeac65f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Poor motor coordination</rdfs:label>
    <dc:identifier>HP:0002275</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d5bfaba-2222-4aeb-882f-4ae012371053">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011804</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <rdfs:label>Abnormality of muscle physiology</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a45676b3-448c-46bd-a485-139b7fb48adc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:label>Asterixis-like movement(Abnormality of movement)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1d379a37-c79f-472a-935c-ec15a44e1466">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa53d84c-fd53-44be-b2bc-3d4a45368e56">
        <rdfs:label>AAV-treated βgal</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/88e98f11-5e1c-4654-8766-29e223aac649"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b3cba925-497d-4b3d-a3bd-8233e6c04cf4">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07732efb-f949-4c80-9392-edbb7694f9ca"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42205bfc-54c7-4a8b-a3dc-1b1f530d2471"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0e50f76-451e-4bac-93c3-5b4e0d1267fc">
        <dc:identifier>HP:0001649</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001649</ddiem:url>
        <rdfs:label>tachycardia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02922413</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ba1bb7d-bc37-4e30-8b1c-6958ad74c081">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>abnormal mental status</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f5ea6c4-e8f3-4a5d-971b-d317c480830c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
        <rdfs:label>Acute attack</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0011009</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8a040a7-c003-4ed5-8d6a-0171f7d5db1c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ecc3fdf-82a3-46a7-8a3e-756ec2866e29">
    <dc:identifier>DB09039</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87d9fae8-8dd8-4fd5-a0f4-ba16cff8c354"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09039</ddiem:url>
    <rdfs:label>Eliglustat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02ff4a9f-0df3-4925-8cb6-d7b80a018f8b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b2c282f0-7725-4143-904f-a4fcfb8571d4"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/74f6d862-c934-4c90-a0b0-21ae6aa5a6d6">
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce351f77-3b29-4f98-a9bc-37d7e438c8b0"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16449956</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73434209-d60c-4e64-a05a-0e684aa644f5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b4d2f32-01dc-4433-8b4c-e07c0f9595ac"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/171dd1a7-1e38-46cf-afb2-6b6df6df20fb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5974e527-1cd0-435a-8d40-7e35438d02e4"/>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a40abd0-42ff-4130-9631-9ff64a330549"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2c64f33c-967f-4765-9cca-ccec9abe1df1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d125f137-5da6-4b64-ab27-e58c3b8be92a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d605c45e-f53c-405a-9d81-fb52029a509b">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dce05034-28a1-410f-958d-45464b43b3dc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/90befcde-a2db-43ea-9565-cbe62068e277"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/124aa044-4056-4ac4-8a44-cfb04e243187">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4dcf60c-d317-4744-b377-1b10077f6314"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/14cad0d9-ca42-41b6-a9c0-cd2ba2b30a97"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/530c25ba-8e41-4837-860f-78aa26080fa6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/94b2cfb5-8332-4efa-8a00-acccca0e8714"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c83c8d7c-e70e-4d5b-8e50-ab837061cfa8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a2635c5-0dc1-4751-9f7e-4438fb767f96"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00163</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0a655402-ac9e-4aa9-ab43-14b290d67a1b"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/61205a08-5e4d-439c-ab4f-acdb127fb480">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4eaa21e7-8e2e-43f0-9936-c2ad3d57a727"/>
        <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b3f4750-75ca-465c-95b6-8a086fe60dd2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/facb4505-9d7c-4447-acdc-6ec83bfd4c21"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Vitamin E</rdfs:label>
    <dc:identifier>DB00163</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f6054b72-e2b6-4f54-b25f-d98832f77035">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b1fa480-7c9f-401d-8a83-0cacbbea237f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1525001605000845</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9eb4d7bf-c1b2-4e2b-8050-5f3b9a7655b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7f8aad3b-02df-4fa5-ac14-75e0bf5c7e96"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719218300210</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/56095c63-b3c8-4119-a75a-02062841e258">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe421138-d1fd-4e92-b792-5ed90e842181"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00229619</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e29e51a2-50a0-4172-acc3-23951e9179f0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/753ee70e-078f-46f0-8329-8d7bc9936cd6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ac60b341-3759-4b43-a0d2-a30aa2a5b93f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea496222-f361-44cc-aa1a-c4cbef1276b1"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bb1e4da4-0265-44ed-9835-43790517afff"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1f853f9-1169-45d5-b3b5-9682fb72e299">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <rdfs:label>high serum bilirubin level</rdfs:label>
    <dc:identifier>HP:0002904</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/195abc35-1261-41f7-9dcd-2c5bac1bb947">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19861948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1710cb8c-c69c-403e-96da-cd88af6a1416"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2f1a62f4-f744-4812-883d-65b07f9487b7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f66f9506-4df1-43a6-81a2-f8f56310b7b7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f93a97c3-b1e9-46d1-aeb8-a7616771056a">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>Hepatic metabolic abnormalities ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a639fa8e-ab07-4780-ac55-65be5eff5a94">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25734254</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3bad093-fc11-4a6e-9ab6-4415d6731e7d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a71dec37-324a-4d77-868a-29a463c4c87e">
        <rdfs:label>high facial soft tissue volume</rdfs:label>
        <dc:identifier>HP:0000287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000287</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8d6e74fd-66b7-4154-9a78-a111163ae01f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cca4aa48-9081-4124-b3a6-8c0d98776e8b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d140159d-dc00-4d3c-8693-78faff00eee8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00025883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b733de1b-e102-4516-ab28-1539789e2758"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28993984</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45a50968-e979-4a3a-9a38-185f08671e04">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16882283</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf516853-d0c8-48bb-a1ad-508759967e3c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c79cb4d-7ff2-47f7-85a0-53c1f0d57198"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26a02aa0-768d-4403-9c27-1abb46965c61">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Impaired renal uric acid clearance</rdfs:label>
        <dc:identifier>HP:0004732</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004732</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28459040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17803689</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145980">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/63e9be0f-b90e-4269-bfb8-2c74071ab7cb"/>
        <dc:identifier>https://www.omim.org/entry/145980</dc:identifier>
        <rdfs:comment>In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511</rdfs:comment>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/423f9b8c-207d-415d-ad3e-38358d14eb64">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypercalcemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
        <dc:identifier>HP:0003072</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c341fab1-785e-4820-9cc4-bcfb08eec6b7"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4db0968-ef43-42b3-92f1-26b30a0129b5">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20649569</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a5ff89b0-1cf7-4338-98f9-ab5c7ca1a8d0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9b564889-401f-408b-a47b-62495db38fb3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f492a2d-f41a-4835-a725-d41ad2833a61">
        <rdfs:label>Abnormal ClC-Ka function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0003304>L155/ G345/ A349</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0003304>"L155A, G345S and A349E"</obo:RO_0003304>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <ddiem:failedToContributeToCondition>G167A / F213A</ddiem:failedToContributeToCondition>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2592f96-e776-48ec-8f8e-74e83b841816">
    <rdfs:label>osteopenia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
    <dc:identifier>HP:0000938</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/92b0b584-728d-476f-a246-b97ca2b5b14e">
    <rdfs:label>Nanotechnology-based gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50447082-4bdc-4417-81cb-32cd7c5d6a82"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000011">
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure involving enteral, parenteral or transdermal provision of small molecules closely related to the products or end processes of a genetically defective protein. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <rdfs:label xml:lang="en">metabolite replacement</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:06:25+00:00</dc:date>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/32876b67-ae8c-452a-a5a8-ce877744a0a1">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e83731c6-421b-489c-9718-9522ff644d19">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/546b9fb7-ff49-48fe-8e81-d4c23a4ca1f6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4db3a7cf-6a89-4455-b365-b613010eea40"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11425766</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Recombinant apolipoprotein A-I</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/24e9df42-0e87-41ae-acd1-797942a61eed">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1e9d07ec-1254-4af8-b97c-e975b3a5ef96"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9cc899f4-9539-43e0-8e57-0fa4a6523f37">
    <dc:identifier>DB00213</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1700ea6-17ca-44ab-be30-8bdd641dedcf"/>
    <rdfs:label>Pantoprazole</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00213</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dd3860d1-937e-4b95-9865-c4529ce34437">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/34ed2d01-2361-42aa-972a-4b1b3f43a0c1"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc764f60-b592-4ffe-bfdb-31fc4cb3890d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1d5e2336-a347-460e-b381-51cd392d43f3"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01399047</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e311cc2-ebd3-48bb-b6bb-c8da3a82da93"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204200"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c42e229c-47fc-4f4a-83d3-6549f17cf7dd">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d6fc4eb9-5366-4993-819b-2e0b85ab82b1">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c620b734-6eb7-4cc8-8462-c031696e20fe"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41194c80-fe94-45f8-bdeb-bb36fbf35934"/>
        <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0de52245-d225-449c-bcae-fcf59bba042c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d0fd74-95f3-4d7c-bff1-ebe717e507bc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/275ad30b-1d5d-4e7f-9a15-029c4c1dfc68"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00916</ddiem:url>
    <dc:identifier>DB00916</dc:identifier>
    <rdfs:label>Metronidazole</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/37076601-2922-4da7-b67c-a07dc220449d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85b73591-6665-4bb7-8ff6-498da262d58e"/>
    <dc:identifier>CHEBI_23456</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_23456</ddiem:url>
    <rdfs:label>cyclodextrins</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5befc82d-4f0d-4704-85d4-d05a15423621">
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031544</ddiem:url>
    <dc:identifier>HP:0031544</dc:identifier>
    <rdfs:label>High blood malonylcarnitine level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0923db47-b553-4296-a3ab-24ccffd17487">
    <rdfs:label>Prednisone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/855d5a2c-57f7-4d41-8996-671eb6faa359"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7232993d-8f17-4d38-903e-e6f2bb789774"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00635</ddiem:url>
    <dc:identifier>DB00635</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37454527-55f4-4daa-9037-1d7d2aa2a3c6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/391da696-5b99-455d-8a45-01d6805ebb71"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/953ad751-a505-4cbb-93e6-945330aa553f">
    <dc:identifier>DB00404</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00404</ddiem:url>
    <rdfs:label>Alprazolam</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8d3cda4e-4c72-407d-9df9-b73b287f9b11"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/885f27fb-1ccf-4001-b446-dfccdf1e3d8a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0cfe0010-0dd2-4d5d-bfa5-49f2aba0e38a"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c80ede9-1cce-4cad-a054-983663ccdd28">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:label>Oedema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/153edf8f-e798-4c30-a94f-51e5de61fe89">
    <dc:identifier>HP:0008281</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
    <rdfs:label>acute hyperammonemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20e89f6e-3af1-4fbd-af94-d73b700b0ccc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2f3abba6-53df-4d5c-a86d-3b81178c1ac7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb7917ca-4fa4-417d-8f1f-d8e9b203059f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7f0839f-d56e-459f-86f8-d0f11bb55a5d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01080</ddiem:url>
    <rdfs:label>Vigabatrin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c52ea2f-5ba1-4d3e-b75d-a78c1ab29d5b"/>
    <dc:identifier>DB01080</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9993a541-2498-4a1d-9f4b-a0d5c76950dc">
    <dc:identifier>MP:0001426</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0001426</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>polydipsia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3df624bc-c36a-464a-930c-de7ef06caf5d">
    <dc:identifier>DB00996</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00996</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e6a43a3c-9f58-4038-bfd2-319e8a911426"/>
    <rdfs:label>Gabapentin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13d867a8-6eb8-4a32-a3e1-92cb0e1c5c7f">
    <rdfs:label>elevation of creatine kinase</rdfs:label>
    <dc:identifier>HP:0003236</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9bd4d05-fe10-40b8-a2fd-0e275e0bee01">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2ffb6b77-0433-4e7e-8c3b-c45ec04788c3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/857b3ebd-0a5a-4475-a42e-4acb808c2163"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4aeec52-e4d5-4aab-bfb0-3cb2305747ac">
        <rdfs:label>Decline of muscle strength (Muscle weakness)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74a1dea8-ce67-44cb-9900-45e1ad4e3b61">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c6ea1414-b105-4f56-b735-cc0db9cfaddc"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01394</ddiem:url>
    <rdfs:label>Colchicine</rdfs:label>
    <dc:identifier>DB01394</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d426369d-6e0e-485a-8c39-520b5b95aa42">
    <dc:identifier>DB05990</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67e8ee54-a513-4c65-9de8-38978344bf7f"/>
    <rdfs:label>Obeticholic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05990</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2b41518-cd7e-4256-9369-53a255715fad">
    <rdfs:label>auditory hallucinations</rdfs:label>
    <dc:identifier>HP:0008765</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008765</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea26bd34-12ed-42fe-8dd2-c1698a521747">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_15724</ddiem:url>
    <rdfs:label>Trimethylaminoxid</rdfs:label>
    <dc:identifier>CHEBI_15724</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e55d0215-afc5-4553-9f74-ed01d12c46fa"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe9df77c-a788-4163-88e8-bc662ffcb6c1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24579575-9738-45f9-82b6-ba9dd1c4b57c"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27718492</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/263d6fec-ae26-4f6f-aebf-8bae26f01959"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09bf3da9-52db-439e-96ce-eb717b592a7d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:label>Status epilepticus</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5df87cb2-8302-4ae3-94f7-4196a92aade4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30726693</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30766957</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b132179-0e32-41f7-b7fe-59119c5856f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f10c1d58-35e4-46d6-8212-91366c0068e5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24821812</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02452372</dc:provenance>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9e1fd8d-90bc-4cf5-9752-a3a7c4b29017"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f58ca36-5264-46eb-9102-9db6bfcee0d8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48b75725-1e78-41ef-859d-a492c1eca8ca"/>
    <rdfs:label>Eculizumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/16747996-08f2-4ae1-8c71-08399633830b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01257</ddiem:url>
    <dc:identifier>DB01257</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/41a6cd3c-af78-4cff-8ac8-79f82653dd2a">
    <dc:identifier>DB12890</dc:identifier>
    <rdfs:label>Dihydrexidine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b30c507-f8c7-4edb-9581-c382ed907c7d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12890</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac93228f-a4cd-4dcf-849b-8f4881bc4f01">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:label>intolerance to sunlight</rdfs:label>
    <dc:identifier>HP:0000992</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d999685e-8068-4bd6-a05b-d1135b59859e">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b99c858-bb4c-4624-8c94-c549e66e2a3b">
        <dc:identifier>DB00061</dc:identifier>
        <rdfs:label>Pegademase</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00061</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f93b4c6e-1f3a-4acc-8009-158066ac0135"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9870ee68-a7db-4d07-9f78-d8b6db44fe2b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <rdfs:label>Cholesterol sequestration (Abnormality of cholesterol metabolism)*</rdfs:label>
    <dc:identifier>HP:0003107*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cb6e2b9-374a-4924-8797-7e08f7a78aa3">
    <rdfs:label>acidotic crises</rdfs:label>
    <dc:identifier>HP:0001941*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da3da51e-fe71-4ff9-b3cd-919ac2de0761">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b83246bb-8f17-4e47-9e4f-70b9f3d6a878"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00973</ddiem:url>
    <dc:identifier>DB00973</dc:identifier>
    <rdfs:label>Ezetimibe</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/868344ce-660a-4774-b6b3-11e17672736f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003678</dc:identifier>
    <rdfs:label>Rapid progression</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/284c51a2-f422-45cc-9b01-7f46f25cea5c">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4b0ba7-0654-4cd1-a6df-644af85ccee6"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7f1dce3-2cd3-4bc2-b0a0-919b243b7d43">
        <rdfs:label>Low 5-MTHF level</rdfs:label>
        <dc:identifier>HP:0012446</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8d06814-db25-4c91-8ef2-8db513548c30">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <rdfs:label>Abnormal CSF folate level</rdfs:label>
        <dc:identifier>HP:0012446</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/886611bb-6e12-4d1e-b6fe-b8dd719b1ca7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89812241-82c4-4bda-98a6-5e76a715a0a2"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ce1dc87-d303-420a-a88e-c349887388bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c91cfe0-a8fc-4e5a-acb3-248d2926a701">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001980</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0001980</dc:identifier>
        <rdfs:label>Bone marrow megaloblastic changes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3951351d-7944-447f-aa46-6845ce89e9d6">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d0d32cd-01cf-4e21-beaa-ac60d9c6964e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3287f1f-e5c0-4585-ba5c-1144012bcb80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03028e0c-f932-4d26-a08f-52e21abf5e53"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK220444</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248360">
    <rdfs:label>MALONYL-CoA DECARBOXYLASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>177</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/248360</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/177</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/789562f1-0458-4a1c-914b-777d1c649c36"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e2b1b895-4d3d-410e-873c-6694b528ec75">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cf9b676-3c40-4462-b219-02fbda16aa77">
        <rdfs:label>rhabdomyolysis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
        <dc:identifier>HP:0003201</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42ca283f-e5db-4c34-a1c8-1106250455b1"/>
    <dc:provenance>PMC2676979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18645163</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bdb8eb2-225b-49a3-b5ea-d6b4a4fca9de"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6132437a-2121-4226-82e0-22a477c8c654">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal SF-36 physical composite scores</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a80053c8-8c30-455c-b5ab-522205c91a92">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hypophosphatasia</rdfs:label>
    <dc:identifier>HP:0002148</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d58dc6fc-d5bc-4a84-9979-6f2aefa3fe43">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54c1d61a-6285-4496-875b-d82db036f16b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dabf38d-e110-49a4-ba86-8152a8db464f"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a7ffda5c-45fa-48e0-9d4b-419c68eabea4">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/891c65ee-6cad-4499-98c9-ff3dc4b0f69a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001112</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001112</ddiem:url>
        <rdfs:label>Abnormal retinal ganglion cell function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26f3d96e-38a4-47f5-979a-95dd91f902bf"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00747487</dc:provenance>
    <obo:RO_0003304>"m.3460G&gt;A, m.11778G&gt;A, and m.14484T&gt;C"</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17573650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86b40035-fab1-4e32-a56d-7f5d68b3586c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50f16c19-2f23-4132-8752-e1b8cb55e82c">
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <rdfs:label>Brain demylination</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007266</ddiem:url>
    <dc:identifier>HP:0007266</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607091">
    <dc:identifier>https://www.omim.org/entry/607091</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/338</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>338</ddiem:iembaseAccessionNumber>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/47c14578-abfb-4942-809c-0f142e302865"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/30fe5507-ba0d-4df4-a73e-e0955b9cde74">
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/80976f39-60ae-4723-a04d-c70f40bce39a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8882d774-4255-4b71-9970-42d4abab5c5b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c6331c6-8af3-4bbf-928d-bd1c3478aa42"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525311</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eb5d27f8-d092-48b7-abbc-61b77f74f234">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f287535-270e-4cde-bf21-78dbbf26bd52">
        <rdfs:label>GNeo-IDUA</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/396e3d6a-07ff-48b3-9d4c-d98035242f4e"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e89dcf68-39bb-4d80-901e-71624f0e1d49">
    <rdfs:label>Potassium bicarbonate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24ee7408-aa13-4e91-9974-5d67a11480cb"/>
    <dc:identifier>DB11098</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11098</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb3d0a5f-5a46-49ca-9ad0-a2a14bad8a7b">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>frequent hospital admission</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7a137e3-8976-4fc4-a52d-b2b7755f6d9b">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be866efe-6d18-4ac3-b1af-45a44be93ed2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16376514</dc:provenance>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0de52245-d225-449c-bcae-fcf59bba042c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/210c8447-f9a2-4d99-96bd-819cdfaa08c1">
    <dc:identifier>HP:0003362</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High VLDL-triglycerides</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af9a38c1-7a86-4eab-88dc-e84307714ce5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01403</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59da503c-223b-4daa-a3c0-5a9dd4d6bc34">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8df1d097-3ecf-4e50-8c0c-7632bb1f1971"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2b41518-cd7e-4256-9369-53a255715fad"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2530e119-fe78-4979-aead-8652940cb4c4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Methotrimeprazine</rdfs:label>
    <dc:identifier>DB01403</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/088b2f23-d54d-41fc-93b3-25e7099b2b9a">
    <dc:identifier>HP:0025201*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low APO A level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/292f6b57-8088-402d-8aee-cd74d48b5dbf">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0005567</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0005567</dc:identifier>
    <rdfs:label>hypoproteinemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c91a035-c6c3-4052-81ce-80cebe3e6877">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>Abnormal blood glucose concentration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011015</ddiem:url>
    <dc:identifier>HP:0011015</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/facf414a-e223-4642-b7ef-470e626c6c0a">
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <rdfs:label>High spleen volume</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
    <dc:identifier>HP:0001744</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a4428ab5-0132-4f8c-b275-f679daa320fc">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00700)</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10790e8a-2ff5-4ef2-b173-1243a06c5593"/>
    <dc:identifier>DB00700)</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/27a231d3-e557-4a1f-a466-c441ca8df61e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24652768</dc:provenance>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07732efb-f949-4c80-9392-edbb7694f9ca"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>http://www.malacards.org/card/hepatic_lipase_deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6296a05d-c370-469c-a87f-2226004938e9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low pancreatic zymogens</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613521">
        <rdfs:label>UROPORPHYRINOGEN DECARBOXYLASE; UROD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3900e827-1f82-466f-b8eb-a0b334883dff"/>
        <dc:identifier>https://www.omim.org/entry/613521</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/973c8776-ba0c-43fd-bb64-a7925e512885">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002574</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acute episodic abdominal pain</rdfs:label>
        <dc:identifier>HP:0002574</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/93b46512-5571-4d86-aa2f-9aabed0e00d8">
    <rdfs:label>Urea</rdfs:label>
    <dc:identifier>DB03904</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd62a22c-7c0e-4021-8693-3f5b2815ca2e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03904</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/396e3d6a-07ff-48b3-9d4c-d98035242f4e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb5d27f8-d092-48b7-abbc-61b77f74f234"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28958576</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/853a7a5a-00b4-4376-87bc-f404ddcfe175"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7196c84-160e-464c-8d4e-d387dd5e6536">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004371</ddiem:url>
        <dc:identifier>HP:0004371</dc:identifier>
        <rdfs:label>glycosaminoglycan accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e15cb9b8-7662-4b5e-a7d8-74ed9ed459de">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc25228f-6e42-4e53-89d3-39e013ef9a36"/>
    <dc:identifier>DB09154</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c83e41c4-d401-4e42-87ba-637166f8fe88"/>
    <rdfs:label>Sodium citrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09154</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/157640">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/00dace53-b78b-45e5-9b17-48727d09a210"/>
    <dc:identifier>https://www.omim.org/entry/157640</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/15594eed-fa23-4a0c-9be1-cbb1336c5ef3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a2d68f85-9ae2-488e-bc7c-3d07749ba41c">
        <rdfs:label>(r) AAV2/1-mediated calpain 3</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee421847-8bb8-4ac8-b48e-64c4e3d8b2bd"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91506b7a-08b6-4ef9-96c1-4c947fa92273">
    <rdfs:label>rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fccb7bb7-273d-407f-a354-59aa269bc420"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6a0ffffe-8025-49b4-817a-b89f206e03c4">
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1577f6c3-ac99-48b3-87a0-355cf11af13e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a9b1dcc-5da7-401e-b220-4c186b7374a8"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25092642</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f93b4c6e-1f3a-4acc-8009-158066ac0135">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c41f7267-e0f7-4ed4-8773-e48e748fc0c4"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c13556e-8a2e-4e65-9738-fd0a34c941ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14d20edc-032a-4808-93c8-23aba1c64fc9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d999685e-8068-4bd6-a05b-d1135b59859e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b3f4750-75ca-465c-95b6-8a086fe60dd2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97f28ae8-a9cd-4416-8587-1a872c76d68c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010975</ddiem:url>
        <dc:identifier>HP:0010975</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal number of b cells</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <rdfs:comment>Further data gathering is necessary to determine overall outcome of patients on long-term therapy "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617069">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/43932e7d-9a44-4650-9eeb-5c4db9354704"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/617069</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237400">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3b9dba3c-58af-4423-8bc2-8c9218b6e57d"/>
    <rdfs:label>HYPER-BETA-ALANINEMIA</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/161</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/237400</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>161</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c0d007e-6dd4-4a90-b09f-d075ec656ed8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/91254244-582a-4a66-811d-af1c5ec6bf82"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00494</ddiem:url>
    <dc:identifier>DB00494</dc:identifier>
    <rdfs:label>Entacapone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/71b60668-422a-410f-b760-c7f51160ddf0">
    <dc:identifier>DB00136</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6d2ec37f-b8e4-430d-8fbb-87a4a5ad8b95"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00136</ddiem:url>
    <rdfs:label>Calcitriol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f777c4a7-a5db-4c56-bf5c-8153c3997417">
    <dc:identifier>DB14778</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/92973068-fbcd-4a09-b6cd-addbe924bc3d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14778</ddiem:url>
    <rdfs:label>Setrusumab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607155">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dd67c847-a456-4ea9-8519-e2f6118413cb"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/607155</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8c9fba98-86ad-46fa-8274-bb1bc44d9ac8">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/feace97a-22c1-4fe3-8d87-777a5adbc8ad"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/128/22/2682</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17a15a02-0f1f-46af-a2df-58d531215023"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f21aa42-405f-4f79-9298-88572999b642"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b668883-956e-4b57-bb10-5792150a1818">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:label>Lipid accumulation( Abnorality in lipid meabolism)*</rdfs:label>
    <dc:identifier>HP:0003119*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d2cb7d42-e997-4b00-9e12-4262168185e2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef52a6ce-eb60-436a-a475-205ccbc7b8c7"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_113373</ddiem:url>
    <rdfs:label>sodium beta-hydroxybutyrate</rdfs:label>
    <dc:identifier>CHEBI_113373</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a1382e70-2f7d-4f98-9e1d-b8294918d196">
    <rdfs:label>iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59dfc651-c4a3-4d04-ad8c-3ba6cbd846f7"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/facb4505-9d7c-4447-acdc-6ec83bfd4c21">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>neutropenia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
    <dc:identifier>HP:0001875</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/93bd3ed6-b62a-4975-b88c-4c84e178d3f8">
    <dc:identifier>DB00994</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00994</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c49b166-1522-4727-afe6-89dc367b6596"/>
    <rdfs:label>Neomycin</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8008ff3b-fe6b-4268-841d-29e320dd48b6">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10222465</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c02dfb3c-a2ff-4480-af5f-2f7002b2203d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4055dde8-36f3-45db-81a6-c0fc8a5e2be4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/041310d8-8c07-48e6-8cc5-78ce40404c5d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <dc:identifier>HP:0001945*</dc:identifier>
        <rdfs:comment>The phenotype has been reported in association to treatment with baclofen as</rdfs:comment>
        <rdfs:label>hyperpyrexia in case of acute encephalopathic crises(Fever)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/98df1883-1660-4fb7-8d41-750ecee8cdef">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ca7a6ba3-a519-46b3-9158-ab828d39cc7f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5b69faee-0254-43cc-bd4a-7825b7273239"/>
    <dc:identifier>DB09270</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/087e8e36-fc43-45c7-9bb9-d859361963cd"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2db8abbe-2ac4-4d50-9739-3ac3689f8bf6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c65f0983-4c76-4afb-b322-cce3b2ab79d1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35a7dc2c-e274-4f32-b09b-7a0a1a08d9e1"/>
    <rdfs:label>Ubidecarenone</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9115973a-ea0b-4098-a9ed-194bab21ebfb">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d5167d7-2853-44c1-ae94-07dc7995f736"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/23eb7a2e-35b7-4d51-a4f7-daa5525c605a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ca376a1-39c5-421b-a730-af4ceaaa087a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d67980f-4051-438b-b284-f2d263e8efc4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f147acd7-c84c-49e6-bba6-dce6c278494c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac6b3afa-61cf-432a-a388-354b4d13e1c2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09270</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/926fef4f-4ec0-4116-a558-1a6540c7fa59"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64a179a5-6cb6-490f-a688-9f9e94af72f2">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000141</ddiem:url>
    <dc:identifier>HP:0000141</dc:identifier>
    <rdfs:label>Amenorrhea</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f862ef4-9376-4692-bf3d-81f45c8ae329">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low COX content and activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc592232-ce9b-4aa6-a506-8ff384e75c11">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
    <rdfs:label>DNA damage (Abnormality of DNA repair)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003254*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/633f06b5-affc-4bf6-a571-5b761c3d7a9c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <dc:identifier>HP:0002123</dc:identifier>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <rdfs:label>Myoclonic epilepsy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67c4cd09-a962-4479-a862-af65d014c933">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ce63eca6-1351-4233-bc1c-beea27331df5">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3be4f51b-47ad-482c-831b-07977a9d3143"/>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03519646</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91455ec6-84f4-4570-a300-659086401040"/>
        <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/870090f7-7fba-401a-bfc4-2ff27add7f00"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01685216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/facf414a-e223-4642-b7ef-470e626c6c0a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c968b70-5bbc-4983-930e-0119a1c5a8ea"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06720</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9cd394f2-3d0a-4c18-a102-d33682a25ef9"/>
    <dc:identifier>DB06720</dc:identifier>
    <rdfs:label>Velaglucerase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d6de6995-fbd7-4ecb-9a8b-9f5af75b3bc8">
    <rdfs:label>human recombinant acid ceramidase/human ACDase-encoding lentivector</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3ee60b5-77e3-48df-9380-9596654aed9c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/265de1af-7828-46f5-a598-ced8863b4449">
    <rdfs:label>Metabolism abnormality</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e99f380a-71f2-428d-a911-d3576b738869">
    <rdfs:label>linear growth velocity(Abnormality of body height)*</rdfs:label>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
    <dc:identifier>HP:0000002*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/faa7ed17-6027-4a08-a02a-1bd983ba14d6">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Abnormality in serotonin turnover (Abnormality of circulating hormone level)</rdfs:label>
    <dc:identifier>HP:0003117</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aefa60cd-2c4b-42c0-af1c-01d4e85c727c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08af73ce-7801-47e6-9387-f72674f5c7ec"/>
    <rdfs:label>rh-HMBS</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/249fc59f-b885-4626-9a50-a576a7cd2126">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27710244</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef7dcd2d-b04f-4a6c-be09-d95926e14705"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/33bc7e1a-c38a-4f6d-a1b6-1afe4d19c4a6"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95e03049-e330-4ef4-b3d7-7453c45d9f9e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29f58ace-9e5c-4cd5-a9d7-225d9afc2d2e"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c89bec3d-9005-47ca-a907-49522e3ae7c1"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT01379625</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d15deb6f-38b6-4e1f-9997-9701298b850f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42ca283f-e5db-4c34-a1c8-1106250455b1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb2efb58-06ee-477d-a58f-d1c91fd84600">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a5996189-49fc-4e66-bb10-4f9d8ef68090">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea0cb0c9-3385-46d0-bc16-2a66b0c53091"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1691971-0ed3-4f73-bd0e-bef7d49f58e3"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9cdeba2d-427a-4187-bbfd-ea073ffc31bf"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57c09e32-b11e-4b94-8721-f0cf0d565720">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005135</ddiem:url>
    <dc:identifier>HP:0005135</dc:identifier>
    <rdfs:label>T wave abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/668968ee-89cb-4547-8332-0a9f5f0a2087">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/52083313-db42-444d-802c-61f5af815215"/>
    <ddiem:failedToContributeToCondition>H65R</ddiem:failedToContributeToCondition>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a3ca57a8-98af-4628-ac76-4c39454a48c7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21275687-7a3b-4c7a-b1ce-ec0d42d2ce7f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20490928</dc:provenance>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <obo:RO_0003304>R266K</obo:RO_0003304>
    <obo:RO_0003304>R125Q</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e53c4b3-48e8-42b8-9c08-2b4d59c41411"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f359034-d240-4753-8a38-b3cc7e447802">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007479</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*</rdfs:label>
    <dc:identifier>HP:0007479*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8e43c76a-ab92-45bf-b112-b876e7150399">
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609458"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b8e07417-d590-4eb9-8e71-a759c75bdee1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b37a703-22bb-4910-b30d-77d3ee36bb2c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a03983e0-7352-4efa-9213-ffd618a6df18"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8ec5c7d2-50b6-43e2-a2cd-2f36a0a2129e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/23171ff7-86f7-4662-9991-cd71acb93ac9"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/76f38785-2411-41c0-a549-0db43c7ac2f0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09393</ddiem:url>
    <rdfs:label>Amino acids</rdfs:label>
    <dc:identifier>DB09393</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac416cd5-46e1-43c4-92d4-0cc11960e2ce"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1c895f2d-25f6-491f-8604-210077362172">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa0f8b6c-c1bd-442d-91ea-4f58857a9969"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00650</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/db4641c6-42f8-400f-ad68-1e773be34443"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3f45bc5-ec8d-4a3d-9e8e-9e530c053af0">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe28a519-d6a5-48b7-ad45-38b4f7ee5af7"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ba4b0ba7-0654-4cd1-a6df-644af85ccee6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/284c51a2-f422-45cc-9b01-7f46f25cea5c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59b54556-33c6-457d-a4d7-16bffeff71dd"/>
    <dc:identifier>DB00650</dc:identifier>
    <rdfs:label>Leucovorin</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c52c1cc3-fb8f-43da-88d2-c7fe1068f164">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22d10d8c-b82a-45a4-a036-cc7cfa067226">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2768f4c4-271d-4e64-a76e-2a3522bb075a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/223360">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/101</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/08f1703c-eae8-4070-9a2a-8884b114834a"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>101</ddiem:iembaseAccessionNumber>
        <rdfs:label>ORTHOSTATIC HYPOTENSION 1; ORTHYP1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/223360</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301647</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b14f691a-83a9-4bd3-94e0-ba1a7b4c3882">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001278</ddiem:url>
        <rdfs:label>orthostatic hypotension</rdfs:label>
        <dc:identifier>HP:0001278</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00889135</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/28b0dc99-e8fa-4a2a-9f6e-0e05bb2e0f3d">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b9e75a2-6dec-4521-8e62-6049e6a9734e"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8e59f97-08a1-44b0-aea7-79819394dde6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10947080</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/15c290ba-ca52-4db2-8f0e-e61f4e278029">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9fdc233c-8aea-4ee6-8472-3e92a051237d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7ffda5c-45fa-48e0-9d4b-419c68eabea4"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3132c7b7-eabc-4a57-b3b5-6e6f0b3b2b3d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26f3d96e-38a4-47f5-979a-95dd91f902bf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09081</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f8aa0272-49ff-4527-8b0a-9d60e3f26c07">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/572cc114-29e5-4baf-b43d-092d4f5154f4"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00887562</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26f3d96e-38a4-47f5-979a-95dd91f902bf"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Idebenone</rdfs:label>
    <dc:identifier>DB09081</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e928333b-209a-4d72-a049-12baa4fd3e51">
    <rdfs:label>Brexanolone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1ec35227-3931-412b-ab3a-3329464bb8d4"/>
    <dc:identifier>DB11859</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11859</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5a923e2-6a95-430f-b876-78c738353ef6">
    <dc:identifier>HP:0012465</dc:identifier>
    <rdfs:label>Increased liver iron level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012465</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca10883d-d6bf-43a1-afb8-53a1d0d74373">
    <rdfs:label>Clioquinol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb6e4275-647c-4d9d-b4e9-1d38d9ed7d73"/>
    <dc:identifier>DB04815</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04815</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/805b310e-457d-4b08-bc3b-7368a5b233dc">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bc9c7153-1bf5-4faf-8678-a1215acd8d24">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12373585</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/789e3967-4939-416c-bfec-83c98bc6fd87"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6277417b-895e-4621-a375-e9a19f697c4c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
        <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f03df27a-dab5-450b-8fbb-19dd5faf4b12"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00244</dc:identifier>
    <rdfs:label>Mesalazine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00244</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8c7060ed-662c-47b9-8a9e-211b2a348f73">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d32eb2e5-8968-4c34-90a6-d19725a9a46f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008373</ddiem:url>
        <dc:identifier>HP:0008373</dc:identifier>
        <rdfs:label>Puberty and gonadal disorders</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5993e6d8-a7b6-4d75-8604-cebb41ddf16d"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed705acd-bf64-4bea-b7ca-01a56d183d19">
    <rdfs:label>Hyperreflexia</rdfs:label>
    <dc:identifier>HP:0001347</dc:identifier>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/04a3bf9c-60dc-45ab-bea4-53f2077a8bd8">
    <dc:identifier>DB01041</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5c84e643-ea44-4206-b010-4bb950bbc74c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01041</ddiem:url>
    <rdfs:label>Thalidomide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76f2cd70-2954-4989-ad8f-1bcfe01e71d4"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5c60ce28-6cf1-456f-8d49-a14640207547">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aeed8480-af8d-4818-a221-af1bc77d0565"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e3863e53-2da2-44b5-9ac2-2a311a8f605a"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3cdfc36e-135c-4609-921d-278c9dc2968c"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2996cdeb-48a9-48b8-ade2-80fe7c05acbf">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd0777d6-e534-4ae3-8a6e-6ed6aa83369b"/>
        <rdfs:label>Tizanidine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00697</ddiem:url>
        <dc:identifier>DB00697</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/661b4198-289a-4668-8d69-cb00c611db56"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7c1aa3d1-05a1-4d6f-b299-916795533248">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f91d8138-3fb0-40ef-8590-3f2624203bea"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00052</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/858fa6a6-1558-4340-aeca-67ad17a10c80"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe9df77c-a788-4163-88e8-bc662ffcb6c1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ed68499-305c-4902-ac37-3b52963af006"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ec86aba-f75f-4c4c-9505-f47291916ecf"/>
    <rdfs:label>Somatotropin</rdfs:label>
    <dc:identifier>DB00052</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a55cff45-24db-4296-9a45-4cfdeae47268">
    <rdfs:label>proximal tubule salt losses (Proximal tubular defect)</rdfs:label>
    <dc:identifier>HP:0000114</dc:identifier>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/77df1127-8167-4dc0-aad4-633049044b5c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/53e6ef61-fd2a-4966-bd98-88361f7920f9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01329</ddiem:url>
    <rdfs:label>Cefoperazone</rdfs:label>
    <dc:identifier>DB01329</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e1a1a46d-b046-4bc7-8db7-39c4cbdc697d">
    <rdfs:label>Interferon Alfa-2a, Recombinant</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0dfafb8-2b69-448b-b8ef-f23e8a2a0553"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00034</ddiem:url>
    <dc:identifier>DB00034</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d0816d6-691b-47a0-9ff1-0a81ac0f7d2d">
    <dc:identifier>DB08883</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08883</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e2957043-f430-4cb2-9a76-e7b8eb907020"/>
    <rdfs:label>Perampanel</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a0a3c48-8d30-4959-b8a6-ebbaaa7eae9f">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0001013*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001013</ddiem:url>
    <rdfs:label>Tuberoeruptive xanthomas</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/35839c9c-6acd-4276-9de2-2b62a6b782b2">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/faa7ed17-6027-4a08-a02a-1bd983ba14d6"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dabf38d-e110-49a4-ba86-8152a8db464f"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/010abe84-4958-4559-9ba0-c5effa11b2e5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a272b3a9-92ee-4dad-91d0-20430457da9f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002243</ddiem:url>
    <rdfs:label>protein-losing enteropathy</rdfs:label>
    <dc:identifier>HP:0002243</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e3377d0e-77f3-4d17-8663-6be82deb2a36">
    <rdfs:label>Geneticin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04263</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b4958bde-45b3-498e-a7c4-e2d36c7c5e9e"/>
    <dc:identifier>DB04263</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f429dd25-c536-4de4-a55a-cb670fc08a3d">
    <rdfs:label>Poor traction response (Poor muscle tone)*</rdfs:label>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
    <dc:identifier>HP:0001290</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/97feaeee-513b-4072-8f60-33a110c05d8a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/457db156-13ed-4f0c-8f35-f915c97379c8"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70f9b211-d7a1-4b97-9f2d-3481c6a1a89e">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001959</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
    <rdfs:label>thirst</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee421847-8bb8-4ac8-b48e-64c4e3d8b2bd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9defa2e1-881b-41dc-887a-6ad47070e7a6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/15594eed-fa23-4a0c-9be1-cbb1336c5ef3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/80682c33-7a2d-4792-a76a-8a6a21d418cb">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/116bc0c8-a122-4627-a444-4a2077b781a0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e1ab158-f701-4a1d-9f42-c84a7de8d9a7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-013-9660-9</dc:provenance>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ae6cf2f5-0f58-40f8-b87d-2c698e715497">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed2effdc-eb3b-4773-b943-af50b488d58e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35839c9c-6acd-4276-9de2-2b62a6b782b2"/>
    <rdfs:label>Oxitriptan</rdfs:label>
    <dc:identifier>DB02959</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02959</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f4bcdf7b-ee40-4d83-abd3-672a72deccf3"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/080077be-b24a-428b-90d5-7524734b926c">
    <dc:identifier>HP:0000093</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
    <rdfs:label>Proteinuria</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55d16a8e-a807-43a3-b876-43a3875fc313">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1ec0d491-79dd-40ad-bee9-101a2e5e7e35"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f69c0b72-cf76-4666-86a9-daf4c9472ceb"/>
    <dc:identifier>DB03256</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03256</ddiem:url>
    <rdfs:label>(6R)-Folinic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7640647b-4339-4600-9fca-66643247efd7">
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <dc:identifier>HP:0030980</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
    <rdfs:label>Low brain glutamine concentration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607625">
    <ddiem:iembaseAccessionNumber>304</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/607625</dc:identifier>
    <rdfs:label>NIEMANN-PICK DISEASE, TYPE C2; NPC2</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d7df0109-8376-429c-88cc-149e0617e638"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/304</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad10cc7d-c4e0-4825-86a5-375ace181f71">
    <dc:identifier>DB09144</dc:identifier>
    <rdfs:label>Uridine triacetate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09144</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e6c9187-facb-40cc-b4d7-af4fd4b62c69"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/baa6814e-2896-4ba1-a20d-50117dd69c39">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3f05a32f-f489-46bb-909f-83f175b96a63"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f8b302ac-0869-48c5-b3ff-a93863b8a311">
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151216</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6faae395-7551-46ee-9d03-10e6e95134d6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c575efb8-1850-4586-b8c0-ae7fa939cb8e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/181bf6ea-7d67-4e81-9b82-b12a5195c957">
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:label>low HDL level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aeb89235-5ed0-438a-ba09-8396dcf286e0">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f0670b81-a688-43f6-8f4e-a5348037d5eb"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b882240-0913-4e11-8796-26c6b0fba53b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f2970c3b-0e99-4125-90e5-2af43fd55728">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f8c07b4-4e8a-43c8-a41c-80c979f4be6e"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee8dafe6-4dbb-4e9a-9a31-0e558eaa5ef3">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f531166-3666-4f59-bcbf-5d9bc1452dd5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e2787bb-2d69-4fe8-bfc8-7621bfa87b56"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25729805-decf-4817-a8bf-f150fe68813a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a48e2ea-b4b4-4935-8f9a-5f1940e8590e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/210c8447-f9a2-4d99-96bd-819cdfaa08c1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1894760</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e485633-bbc5-44a8-9e9b-e5cae77c2e87"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95b38d69-d382-4904-90dd-af785544d2f1"/>
    <dc:identifier>DB00627</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/102843f6-0376-43b9-9060-2c4ca3bc20ac"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/98f5a9a0-1ca3-4f81-8ce0-7ef6b51d6a26"/>
    <rdfs:label>Niacin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00627</ddiem:url>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000010">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:54+00:00</dc:date>
    <rdfs:label xml:lang="en">dietary supplementation</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with foodstuffs containing molecules closely related to the products or end processes of a genetically defective protein, which occur naturally in the diet. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/030cc812-aeb9-4238-bc0a-f749e3c6c6df">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/519ec94b-75f4-4b48-bc3a-c9d9fa4508e7"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0bcd47e8-6aaf-4970-beb7-6bb8bebc8fc6">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03269045</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93dc92e9-7f93-4c80-9038-55658b2e920f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6304e1e1-8f67-46c1-924c-e3bb8b175687"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7893271d-a01f-4f73-a5d2-55721471203e">
    <rdfs:label>Rofecoxib</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9545778-548b-432b-a207-76ae9b607196"/>
    <dc:identifier>DB00533</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00533</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbd057c1-87bb-431c-9f0d-a9728aa2e44d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000164</ddiem:url>
    <dc:identifier>HP:0000164</dc:identifier>
    <rdfs:label>Dental Defects</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f095d250-f471-402a-b16d-db8821fbe28e">
    <dc:identifier>HP:0000704</dc:identifier>
    <rdfs:label>Periodontitis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000704</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb725e7c-69f2-4bb5-a77a-bf92b5b519ba">
    <rdfs:label>High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*</rdfs:label>
    <dc:identifier>HP:0030390*</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030390</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/98172927-9a19-404a-aa16-35b954baa63d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26982753</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f94166b7-b97c-475c-969f-7b6ce635c74c">
        <rdfs:label>movement disorders</rdfs:label>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94f4ffc3-e26c-4817-8052-22ae5895e821">
        <rdfs:label>Nonepileptic paroxysmal abnormalities</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01993186</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6139de58-1e74-4b38-8265-123026d8ae8b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0100660</dc:identifier>
        <rdfs:label>Dyskinesia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d926ed0a-9b97-401c-b60f-57f31c0bd3a9">
        <dc:identifier>HP:0011197</dc:identifier>
        <rdfs:label>EEG with focal spike waves</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011197</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42ca283f-e5db-4c34-a1c8-1106250455b1"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02960217</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02036853</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/35f55e7d-9c0a-4a18-9bee-a36494e084a6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/081b18d7-436a-4d81-90b5-13d4392bf335"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00035</ddiem:url>
    <dc:identifier>DB00035</dc:identifier>
    <rdfs:label>Desmopressin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8206491a-abc8-46eb-ba7d-87ee9a3511b3"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/627ed782-013f-471f-821f-2c06ef4a9ca0">
    <rdfs:label>Developmental impairment</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
    <dc:identifier>HP:0001270</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0faeee0d-3152-4a1a-a565-260aa9773e6a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <rdfs:label>Low CSF glutamine level</rdfs:label>
    <dc:identifier>HP:0030980*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/572cc114-29e5-4baf-b43d-092d4f5154f4">
    <rdfs:label>Decreased activity of mitochondrial ATP synthase complex</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <dc:identifier>HP:0011925</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/14bd7029-0cbd-46ef-ba4b-9c7bea76000a">
    <dc:identifier>DB14872</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14872</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/83cc5294-624e-41a2-9b9e-a3262cdb783d"/>
    <rdfs:label>Lucerastat</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3453d0e-3e72-4b12-a506-e8a3ec31d7d8">
    <dc:identifier>HP:0003678*</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <rdfs:label>Progression of retinal degeneration ( Rapidly Progressive)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203700">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>411</ddiem:iembaseAccessionNumber>
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/203700</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/411</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/00dace53-b78b-45e5-9b17-48727d09a210"/>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4db3a7cf-6a89-4455-b365-b613010eea40">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/32876b67-ae8c-452a-a5a8-ce877744a0a1"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/570fc74b-c712-4d99-a41f-4740c60f3e5a">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003146</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003146</ddiem:url>
    <rdfs:label>hypocholesterolaemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250850">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1283</ddiem:iembaseUrl>
    <rdfs:comment>Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/250850</dc:identifier>
    <rdfs:label>METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ab4e16cf-cbe4-4f63-8f91-57a5abf7810a"/>
    <ddiem:iembaseAccessionNumber>1283</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64a0d3ac-0105-4369-ac97-5d15ce6a94b9">
    <rdfs:label>progression of neurodegeneration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002344</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8882d774-4255-4b71-9970-42d4abab5c5b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/30fe5507-ba0d-4df4-a73e-e0955b9cde74"/>
    <rdfs:label>Ad5/CMV/hUG-Br1</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9782606-532f-4ebe-88ad-610d2263d0fa">
    <ddiem:url>https://www.drugbank.ca/drugs/DB0084</ddiem:url>
    <dc:identifier>DB0084</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac05cff1-57dc-4556-9fc0-2ba1ed9719fd"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e334d56e-6aca-4427-871e-4ded0d7777ca">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1017b322-be22-4ef2-82d6-573ce5455c64"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18401027</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7fd0fecd-8a92-4bcb-af70-8e65c2c73b31"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b15e173-fb74-47f9-acb0-da57cae202c3">
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <rdfs:label>Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4d69e8d-711d-4ba6-ae2c-5cbc3806a96a">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Abnormal chondrocyte growth</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301835">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e0dbfb80-6c70-44e4-b7bf-086e8e3957bd"/>
    <rdfs:label>ARTS SYNDROME; ARTS</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/301835</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d46c6c61-c4ce-4d4e-a68d-0fab4a6c0d05">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/693313e6-ecc8-47b0-bc17-0ce88402721a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00480</ddiem:url>
    <rdfs:label>Lenalidomide</rdfs:label>
    <dc:identifier>DB00480</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/681cd7a6-e712-4de0-b921-86f969b67f91">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02329</ddiem:url>
    <rdfs:label>Carbenoxolone</rdfs:label>
    <dc:identifier>DB02329</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ceca1f5d-d80d-44ac-b3b5-c1233e3ba110"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5cf30840-dcfc-4587-a4f1-0d940ca92631">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45a74ebc-bca0-4b6a-9b6c-c7ce9bf33795"/>
    <rdfs:label>Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43a9ca12-493d-409b-a354-1d595d8d3c60">
    <rdfs:label>Elevated serum toxic intermediates in isoleucine pathway</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6d0f82c-deec-4db5-9711-51b1ac995c4f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low HDL-cholesterol</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <dc:identifier>HP:0003233</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a01a1b0-38d1-4ba8-8046-1d2db32453ed">
    <rdfs:label>Abnormal lecithin:cholesterol acyltransferase activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0011598</ddiem:url>
    <dc:identifier>MP:0011598</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/751f948e-e5f2-4a59-90e6-30a719e517ad">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/311fd0a1-67d6-464a-8796-fd753acfe59b"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-published-open-label-study-showing-brineura-cerliponase-alfa-reduced-the-rate-of-clinical-decline-of-children-with-cln2-disease-a-form-of-batten-disease-300635669.html</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/423e0df0-65c9-4f25-a417-578562324494">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/51a9301d-3e00-4d03-8cb2-b5e7df45869b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9591bce2-3647-4f7f-b29d-5a48597ee00d">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001638</dc:identifier>
    <rdfs:label>Cardiomyopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0b06ce02-68c2-44c4-9bb7-3236cab71c94">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/36938914-897f-48f3-b931-e9af05151cba"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/310a7f40-db1e-436a-8be8-aa92d97ae0b7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/175ae92f-fbb8-47ff-9365-b04374a3e4df">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:label>abnormal energy production in damaged mitochondria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03098797</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d15deb6f-38b6-4e1f-9997-9701298b850f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e2005a6-a28a-4b10-a81f-343eaca54174">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e2b1b895-4d3d-410e-873c-6694b528ec75"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63c24114-27a7-43f5-ac65-85d2766afeea"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4709e04-c3a4-4f00-a9fd-9f515c235ca8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95e03049-e330-4ef4-b3d7-7453c45d9f9e"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2f49c7f2-91f4-4a58-8252-85bdbdf213fd">
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11940-017-0473-2</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42ca283f-e5db-4c34-a1c8-1106250455b1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a48afd2-fb65-4a63-b681-3a1f1b25cf36"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02432768</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48e9e18a-5174-410f-b84e-02cf50288a89"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB11677</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11677</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/98172927-9a19-404a-aa16-35b954baa63d"/>
    <rdfs:label>Triheptanoin</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ea0ecde2-f8db-4262-a5f4-d00eea142fd1">
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/069dd1a7-45d1-4745-beaa-7a0df3f803ed">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011021</dc:identifier>
        <rdfs:label>Abnormality of circulating enzyme level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011021</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99587bf4-4994-4402-b63f-69378703d307"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ede27c3e-0424-48b9-b09f-21864d5df0af">
    <rdfs:label>Laronidase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/924d19d6-da2c-43c5-8ce7-ae39c0a5171d"/>
    <dc:identifier>DB00090</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/225b0779-2d61-4d88-b3d3-55e9fb8b5e06"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00090</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67cc6fe4-a599-4eb7-aed2-dacf0341e63e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040081</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal serum creatine kinase</rdfs:label>
    <dc:identifier>HP:0040081</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6857098-9cc7-4bbe-81ce-5e6019f8edb6">
    <dc:identifier>HP:0000114</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Proximal tubular dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e9f9e741-6079-4f68-bffd-5dfd564952c5">
    <dc:identifier>DB01026</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4dc4361-6536-4bcf-828e-8ccdb20374dc"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01026</ddiem:url>
    <rdfs:label>Ketoconazole</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ff6dcf59-0bae-483f-a8fa-eca18db9f4f8">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/58e532a9-b969-4391-9342-a38dc68fb0ab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dcb09c16-14c6-4653-9faa-e8a798e49698"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/715ad93b-f759-4536-b283-c054d44a2a30">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005978</ddiem:url>
        <dc:identifier>HP:0005978*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PCBD1-diabetes (Noninsulin-dependent diabetes)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24848070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3219ea8-29a0-405d-bf3b-3d7b2578b25e">
    <rdfs:label>Lysosomal enlargment (Abnormality of lysosomal metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <dc:identifier>HP:0004356*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02c99c1e-79f0-4e45-8daf-52faa5431fd9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00331</ddiem:url>
    <rdfs:label>Metformin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d6712a4-b75b-4b8f-bb9a-2d40e1e0177f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a880edae-89b3-4309-a7e4-4bca71ee6b72"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17994020</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd769ffd-f890-47dd-a883-ff28a825257a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00331</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1680417-9c34-49d8-8223-55d646b35318">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
    <rdfs:label>schizophrenia</rdfs:label>
    <dc:identifier>HP:0100753</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ce4ba43-97ca-4414-a98e-d8f17ff72e6a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45a50968-e979-4a3a-9a38-185f08671e04"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/20a513c1-2306-4a1f-b6b9-bb36b1f7fe2c"/>
    <rdfs:label>Cinacalcet</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01012</ddiem:url>
    <dc:identifier>DB01012</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c69e41a-7566-4e11-8751-bc39a8dea2df"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261000">
    <dc:identifier>https://www.omim.org/entry/261000</dc:identifier>
    <rdfs:label>INTRINSIC FACTOR DEFICIENCY; IFD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/80</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>80</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6acf3d17-a024-4398-8929-7fe2ed727e8e"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/490e2db1-0414-486d-8c66-0c4e129fe042">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>No result was accessible</rdfs:label>
    <dc:identifier>HP:0100851</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff065fb3-dc09-4879-853c-b129649d0f8f">
    <rdfs:label>PL-induced cytotoxicity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a1d3af4-e466-43c5-933d-0f733b2ce2ba">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/994905b2-8b95-4390-ac4e-5d2a11fdfecd"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bcd8aaf5-54aa-465d-bc9d-861fcc56f75a"/>
    <rdfs:label>Cholestyramine</rdfs:label>
    <dc:identifier>DB01432</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01432</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1145e28-21c7-47d3-a84d-8a1ab7d624e3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af015175-7786-4409-971b-6165b9b8f9df">
        <rdfs:label>Lamotrigine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e328d057-fff6-44c6-82d7-0da72e1eece3"/>
        <dc:identifier>DB00555</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00555</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee96c974-592a-400f-b348-701e34bb0cb7">
    <rdfs:label>high angiotensin- converting enzyme</rdfs:label>
    <dc:identifier>HP:0000841</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000841</ddiem:url>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c64ce725-322a-487d-8df8-e86d98123ade">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0aa01031-80d6-4058-8e11-cb1cdfdc541a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97993e48-8017-4ac0-9cbc-33bbf195b155"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/431819e7-bfcd-4207-9f7a-0f89e3881cbf">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No Studies were done on this drug.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27520363</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e5ffa037-5212-47a2-aa7c-741a14e321a4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3567b7de-43b0-4137-b32c-0afab0e5317d"/>
    <dc:identifier>DB00129</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00129</ddiem:url>
    <rdfs:label>Ornithine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eef6c8c4-8a46-4f62-bac1-2c8427e08aa6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased beta-galactosidase activity</rdfs:label>
    <dc:identifier>HP:0008166</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/db05e389-408f-43db-a44e-2d57f1922861">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02745</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c76b0e9-738e-4a23-92b7-0ce66ba4f9fa"/>
    <rdfs:label>Uridine</rdfs:label>
    <dc:identifier>DB02745</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c8aca26-d1c0-437a-a57a-7bddfc790f52">
    <dc:identifier>DB00028</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/228898fa-883d-4ff1-9035-113d9670722a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00028</ddiem:url>
    <rdfs:label>Immune Globulin Human</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75e6f57c-4625-4ef6-ae4b-2faab75f7b84"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c69b6fb-da21-486c-918f-2ac50c189397">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
    <rdfs:label>spasticity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001257</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/797f7b20-2a25-4334-bfda-481a1181921b">
    <dc:identifier>HP:0010979</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010979</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal lipoprotein profile</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c9d372d6-1ba7-4f49-8e0f-af85950130fb">
    <rdfs:label>Benserazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4335240a-369c-41eb-8b18-b96a8ac6a49d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12783</ddiem:url>
    <dc:identifier>DB12783</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71207d8a-5bda-4e5b-ba01-589867f54340">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Ataxia Progression(Rapid progression)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
    <dc:identifier>HP:0002719</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/29c5b4b8-21b3-4761-a894-74e857e66700">
    <dc:identifier>DB09422</dc:identifier>
    <rdfs:label>Soybean oil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09422</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cba92a08-d51f-4df4-bbb5-3082dc781462"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81a7c0ed-ff40-4103-9624-ce52e75cadee">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42cc703e-c02d-43ca-9e33-9b94536acae0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0a684fb-6346-497f-a7df-e081a03f3780">
    <rdfs:label>elevated intraneuronal cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7f8aad3b-02df-4fa5-ac14-75e0bf5c7e96">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6054b72-e2b6-4f54-b25f-d98832f77035"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12839</ddiem:url>
    <rdfs:label>Pegvaliase</rdfs:label>
    <dc:identifier>DB12839</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a2e0c5d1-3370-4e73-8949-0ec8797173cb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc764f60-b592-4ffe-bfdb-31fc4cb3890d"/>
    <dc:identifier>DB00688</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00688</ddiem:url>
    <rdfs:label>Mycophenolate mofetil</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b04ceaef-0651-4ed0-95d3-4267ed6e3845">
    <rdfs:label>secondary carnitine deficiency (Carnitine deficiency)*</rdfs:label>
    <dc:identifier>HP:0003234</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0a051edc-dfa8-47a9-a6a1-0cd854f1de69">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02234024</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a23e698f-a07c-4530-ade6-b6b596932254">
        <rdfs:label>Delayed Develoment</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0c751ad5-97bb-44c3-87a9-1c6ca7de7a5c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3d6454a9-5388-48bc-845c-2132464c8202"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0007121"/>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4e4f5fd2-5e4c-4208-902a-0191abcc3233">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14104</ddiem:url>
    <rdfs:label>Linoleic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a90c116e-7714-423c-904b-426bd90bb6f1"/>
    <dc:identifier>DB14104</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee72b01b-0d3a-42bd-9341-f10d7b3fe9ca">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/51004fec-5e13-4c0e-88b7-5d7dfe230564"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ae9df943-3a2c-408c-a10f-3e55ca622782"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b8682971-e50f-4a86-92af-c9db09824987"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1633296b-713a-49c6-bc24-da4ac4207a68">
        <dc:identifier>DB00683</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/830d7b46-0b96-4f45-a8c6-e793afb60af4"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00683</ddiem:url>
        <rdfs:label>Midazolam</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6266946-4ce6-47c6-aacd-95fe3be1cec5">
    <dc:identifier>MP:0002647</dc:identifier>
    <rdfs:label>decreased cholesterol absorption</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0002647</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da40f06d-8421-45e8-83e5-f5d96a1b7255">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>tissue damage</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b669816e-7179-45b2-8e72-00812caab757">
    <rdfs:label>lipid peroxidation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/82a9d000-5bdb-4926-b3ee-e895a1939ff6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00169</ddiem:url>
    <rdfs:label>Cholecalciferol</rdfs:label>
    <dc:identifier>DB00169</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8da0b819-a923-4cec-b173-2e9260fc503b"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fd93fdf1-f460-428a-8840-f5131a86b9a6">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-013-9660-9</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/082edd9e-0f8a-4e08-8ad6-58631299aa6c">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/823d9c1a-8b66-408b-b600-8b7aac54d32e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604290">
        <dc:identifier>https://www.omim.org/entry/604290</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/872</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ACERULOPLASMINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/32e4d2c8-b362-4d73-ad02-b69998945327"/>
        <ddiem:iembaseAccessionNumber>872</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a841ca76-7a18-4797-8a35-376117ca4d2b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f7066554-c56d-4ef8-a5e2-4b9adf0b1924"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5528424e-1ef1-4407-a1a5-9d1c3997c637"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/552c6b43-1ca7-4b4b-8833-aac9b1f9aee6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9678fc72-ca79-4e1e-b3eb-7bf4bb4bf6c1"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5569fe84-c12c-40aa-9191-4ec87d0d38cb">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4cbbc885-d9da-4a64-84e7-a69ea36ba2a4"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4f72b59-e0b9-48ef-a31c-bee9a2918b78"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02701</ddiem:url>
    <dc:identifier>DB02701</dc:identifier>
    <rdfs:label>Nicotinamide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c3c20a0-77e5-4d83-bc68-9717b29d1217"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/71a5b40d-0d67-434e-843e-67fe20afed36"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a513ba80-2018-41fc-aa58-5fa1f66a0d06">
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/797f7b20-2a25-4334-bfda-481a1181921b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20605907</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/105e31af-001e-4e3a-a3c0-dd4817910a6d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e67add11-86c8-45d1-959d-047cb9474ee4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/136120">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/528</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>528</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/39eb0793-945c-4ee2-ab80-6c11d4941eb9"/>
        <dc:identifier>https://www.omim.org/entry/136120</dc:identifier>
        <rdfs:label>FISH-EYE DISEASE; FED</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3d147d4-b8dd-4d48-80ed-13c14dbb52e6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5a8dd452-2929-46f9-9fdc-999c735b470b">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fcc4a72-027a-47fd-95df-23b27f5823a7">
        <dc:identifier>HP:0000725</dc:identifier>
        <rdfs:label>psychotic  disorder</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000725</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6234baa0-27b9-48e2-8cbd-36a6f8027183">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e40b87a3-485b-4cb3-b060-a4d624a2557f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417300086</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d806c492-9f9e-434c-b257-f5a88880e99a">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613153"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S152500161632250X</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4525ea4f-be11-4b37-a762-c7bdbe642b73"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/480660c9-10db-46ec-904f-eda478fbfd11">
        <rdfs:label>abnormal muscle function</rdfs:label>
        <dc:identifier>HP:0011804</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611105">
    <rdfs:label>LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL</rdfs:label>
    <ddiem:iembaseAccessionNumber>446</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/64f4eb4b-3b96-4524-a524-b1d75512b7e2"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/611105</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/446</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ffa61f77-9d83-4105-89e1-14d080f57115">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17cbff01-44df-4b92-8173-15b9f7d9e14a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ced1f50f-7a93-437a-bf10-f2e08a5b377f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/44a4e2fe-c3de-42b3-9906-d8e948b5af7c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46a6949d-3a76-4b77-bb20-d355e284ea9e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06819</ddiem:url>
    <rdfs:label>Phenylbutyric acid</rdfs:label>
    <dc:identifier>DB06819</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a57643e-2ed3-445b-8ec1-87af8404ca75">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f00c3f92-e3bd-4c20-ab77-5d28df319e61">
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb8b9429-5b0c-4d4c-9c5d-d5144668563c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/234a1a61-f558-4ae3-bc72-ed55c27c8d05"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e40308d-176f-49b6-9110-50a5f3d80c18"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26954033</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15728297</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28b419e5-4ed4-4305-9570-1bb54e9481fc"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83d03909-83f6-48b1-89ea-d70c3f7826a3"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00125</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1db7f17c-c5ec-447f-9317-03a6ee217cc4"/>
    <rdfs:label>L-Arginine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0fba050-9354-43a2-8988-5fb359be7456"/>
    <dc:identifier>DB00125</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/52c930ff-8b86-40ff-95ef-9a3530cf86d0"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3e4bb26-9003-4f6c-9053-4eb68c6a3da0">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8ec3f264-9c45-4c66-b46e-65ccec74394a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/230d7abd-32ac-4903-adad-acfd47ed3251"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88cf1e1b-908d-4b38-b0f0-325a006f3910"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03453918</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/de2d9b5c-0270-4f37-b52e-be363aaee057">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4068c445-fbad-4a74-b128-f8b4a51796f2"/>
    <dc:identifier>DB00808</dc:identifier>
    <rdfs:label>Indapamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00808</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36e061e1-98ed-403d-a8bf-f8f0cd6eb04f">
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <rdfs:label>GSD-associated enterocolitis(enterocolitis)</rdfs:label>
    <dc:identifier>HP:0004387</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004387</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/daeec9ef-d704-44a3-b4ed-4e585bd37563">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22202226</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f862ef4-9376-4692-bf3d-81f45c8ae329"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0003304>A354V</obo:RO_0003304>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/281e316f-cdc9-4f6c-8615-0cdb5d39deeb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/12a87a1f-c4b6-4890-a2be-052981285b8f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>A354V and C12775STOP</obo:RO_0003304>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0cb6e2b9-374a-4924-8797-7e08f7a78aa3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9b564889-401f-408b-a47b-62495db38fb3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4db0968-ef43-42b3-92f1-26b30a0129b5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04552</ddiem:url>
    <dc:identifier>DB04552</dc:identifier>
    <rdfs:label>Niflumic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e402c0c8-9dcb-4f2e-aa9e-5beb6cab9daa">
    <rdfs:label>neurotoxicity</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44352f17-ae4b-462a-a76c-e04c8c4a7b94">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025548</ddiem:url>
    <rdfs:label>High RBC's mean corpuscular volume</rdfs:label>
    <dc:identifier>HP:0025548</dc:identifier>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/55b0076e-b867-4c74-9b70-425b8c7ee411">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf121511-3775-4269-b8cb-ee60e6dec50e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7978d04-3eae-4af5-beac-8603fff76d00"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7705cf09-ef71-4d71-821f-02567e2be87f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29a675fb-fe97-4916-a2a3-4accf0ee1540">
    <dc:identifier>HP:0003119</dc:identifier>
    <rdfs:label>abnormal plasma lipids levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/284e04fc-22bd-42e5-97e4-a77d4cb6a878">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Eevated porphyrin precursors porphobilinogen</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
    <dc:identifier>HP:0012217</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/618098">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5</rdfs:label>
    <ddiem:iembaseAccessionNumber>1336</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/618098</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1336</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1ede508c-c8b5-4ebd-8003-ace4f229554a"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a46eb64e-3549-4415-9277-cde43a393917">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a83340ea-16dc-4202-828c-cd62edad118e">
        <rdfs:label>Large central visual field defect</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001129</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001129</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a936c969-5b8b-4677-b847-fddeed1408b4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff690c5e-5663-419f-824f-d36d41db3cd1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/857b3ebd-0a5a-4475-a42e-4acb808c2163">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9bd4d05-fe10-40b8-a2fd-0e275e0bee01"/>
    <rdfs:label>GNE gene lipoplex</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb23f011-4232-4540-b8ab-67ada0c1d20e">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699701381</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <ddiem:failedToContributeToCondition>Homozygotes of R252W ,Homozygotes of IVS4-1G→A ,Homozygotes of R413P</ddiem:failedToContributeToCondition>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95a3161d-8e66-44f7-8b86-1918985138bb"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01977820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20971365</dc:provenance>
    <obo:RO_0003304>P407S,A373T,R241C</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eaa749d3-0274-4866-b455-b38fc391bf84"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d92dd97c-d900-4617-82d7-f6c448684a34">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <dc:identifier>HP:0000127</dc:identifier>
    <rdfs:label>renal salt wasting</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e485633-bbc5-44a8-9e9b-e5cae77c2e87">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated LDL-C level</rdfs:label>
    <dc:identifier>HP:0003141</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4cc70fa-629a-43c6-8f50-8f103139579e">
    <dc:identifier>DB00026</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00026</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e511aab5-2354-416f-b713-ce1725c48bdf"/>
    <rdfs:label>Anakinra</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ada91d49-f682-4454-bf7a-9e6ea55c513c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/230d7abd-32ac-4903-adad-acfd47ed3251">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3e4bb26-9003-4f6c-9053-4eb68c6a3da0"/>
    <rdfs:label>flavanols</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4e0ec5d7-fa01-4fb5-9d26-20b106fc45d6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00178</ddiem:url>
    <rdfs:label>Ramipril</rdfs:label>
    <dc:identifier>DB00178</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/adb438aa-d2dd-4c9f-a447-f5da78dfb08e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00b63c8f-0a41-432c-8e93-7bd5590a11df">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Low IQ score</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <dc:identifier>HP:0001249</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47b97556-404b-4084-a8e9-94fe7e495808">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003260</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003260*</dc:identifier>
    <rdfs:label>High bone turnover markers</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8371b86a-b425-4088-bdb2-75ba10290bbd">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8923ab19-74dc-467c-adcc-383ef4ae393a">
        <rdfs:label>Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <dc:identifier>HP:0004356*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5794fd31-c739-481f-817d-169c451fd121">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4cbcb440-2d73-47de-b52a-969fa1f2864c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6ba69ef6-ba83-4ecf-81aa-bdbe9bcd0997">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69604a95-abd8-4c41-a97a-7b3c7fff0bfa"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd6c50dd-915a-4fd5-9ad4-e1a3ba0c0969">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/33402a6e-1a43-4505-800a-c6687ff36859"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d34f268-062f-4d53-b879-4e0b1bfff743">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc4bf23e-11ff-4e99-ac1d-abe999bce4fc"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01914</ddiem:url>
    <dc:identifier>DB01914</dc:identifier>
    <rdfs:label>D-glucose</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc467c63-570e-41ee-aa10-e774c4cf2dcb">
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/334b6661-4a81-48a6-8c93-fdb7f04c8f9a"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7fd0fecd-8a92-4bcb-af70-8e65c2c73b31"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e334d56e-6aca-4427-871e-4ded0d7777ca"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e18c6578-9392-4a38-a306-125fa1820046"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be0a6778-6e93-4ecb-b416-8bcb5605fdb0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/475243e9-000f-401b-8953-25948fa871fb"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9e9e804-cc3b-408e-ac7f-0c8674158489">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Growth Failure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <dc:identifier>HP:0002240</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/905c6bce-556d-4cfd-91d5-2f6b3258caf4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/81a7c0ed-ff40-4103-9624-ce52e75cadee"/>
    <rdfs:label>Carbamazepine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36b95f1a-df91-467c-a50b-c87ec779adf8"/>
    <dc:identifier>DB00564</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00564</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b0990825-ce94-4864-8aa0-4e72fec215af">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00083</ddiem:url>
    <dc:identifier>DB00083</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7bc11285-6f0f-4e3b-a695-a3062d9a0390"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7afa0ddc-bd89-4a6d-938f-28a1045420dd"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84a408d4-668a-4fbb-a3c1-59aee1603e7c"/>
    <rdfs:label>Botulinum toxin type A</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b49536bc-cddf-4f96-8880-5b10774394c1">
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/151be5f7-feb3-406a-b7c1-8a240a66e45d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a5059551-b6ab-414a-8de1-356fa39aa005">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e7c0acef-2abd-4252-a67d-00082517014b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19773212</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24579575-9738-45f9-82b6-ba9dd1c4b57c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a80053c8-8c30-455c-b5ab-522205c91a92"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc03bf3b-67c8-4c7d-b375-fa5674e751d2">
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ade771a-d313-411c-a7f1-4155b9998bc8">
        <rdfs:label>pathogenic exon trapping</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/nature10456</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f986987-9055-486a-b2b4-28c6f7a435f9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fdda8203-5e1c-4ef8-96ca-79b5c8d18cec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5c1c780-8905-4303-969d-da2c8c93c4b0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030098</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal fukutin mRNA expression</rdfs:label>
        <dc:identifier>HP:0030098</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5b5204d4-604b-4446-8451-2feaada6c5cf">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a57643e-2ed3-445b-8ec1-87af8404ca75"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1c2f6c03-54de-4c95-b3d1-1b81853eec57"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/301c1ff6-86ff-4cba-97f7-20d597ed093e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c5c83b3-1739-48af-bfe8-ee106e623527">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12319</ddiem:url>
    <dc:identifier>DB12319</dc:identifier>
    <rdfs:label>Benzbromarone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d7be776-85e9-4822-8d1e-74fb3e116c2c"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26c40c36-ac7f-43ac-b972-03359a71e9f3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f1820bc-016b-496c-a94c-cf94b12db1bb"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/201f602c-aa20-45f6-9b34-af41f441f76e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/226e1adc-7f31-42af-996b-2f807da94587"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21ca69f5-0d38-44d1-8a23-84534c54d966"/>
    <dc:identifier>DB14500</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14500</ddiem:url>
    <rdfs:label>Potassium</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d1485e2-3605-44f0-8f82-149371c09649">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2eb7f245-ae15-436a-84ac-d9afa5a22c79"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f0c805e-5f47-4d53-81c9-ca6f4015a607">
    <rdfs:label>Foot clouns</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011448</ddiem:url>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <dc:identifier>HP:0011448</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7f2f5cc-2401-4391-a007-ad0781d95b58">
    <rdfs:label>Modified Atkins diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dca892dc-ca47-46ff-8129-3daa7b2319d3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f3c2a85-b7ca-40dd-a048-8131e7d8fe30">
    <dc:identifier>A11EA</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01efe5ae-17c3-4f0b-9b33-46519bd97bc4"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EA</ddiem:url>
    <rdfs:label>Vitamin B-complex, plain</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c5c83a2c-b0e7-4b04-803d-99950ea0d752">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c620b734-6eb7-4cc8-8462-c031696e20fe"/>
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/829b9577-47f6-417c-baa3-7e1041d570b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17d9898d-46eb-4e5f-a8e3-0249de970794"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8a043c75-f97c-47a5-b296-89a00073bda3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac21e295-456a-4fcf-a700-38c8d334e9de"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11E</ddiem:url>
    <dc:identifier>A11E</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602360">
    <dc:identifier>https://www.omim.org/entry/602360</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4ff25e12-546a-4efc-85c8-2a95e0d9d5c6"/>
    <rdfs:label>L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6de31f14-2baa-485b-9da6-4fb11775d69a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <dc:identifier>HP:0012759</dc:identifier>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <rdfs:label>Neurodevelopmental abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f43dd3e-ced0-46c0-ae59-85c028feaef8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aeda1843-ddb1-41cb-b2f1-e7f39a2437f2"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e328d057-fff6-44c6-82d7-0da72e1eece3">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614462">
        <dc:identifier>https://www.omim.org/entry/614462</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/836</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>836</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f7f2fbd6-0215-4ef6-9eb2-cca1a8cbfd9a"/>
        <rdfs:label>HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/901ab7a1-3bc4-43d4-838d-57a26ee4df82"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1145e28-21c7-47d3-a84d-8a1ab7d624e3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74adec66-7c38-49a6-94c9-d8704231abaf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24777537</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/db89104a-9ece-4f76-8ab4-b9ede94b1baf">
    <rdfs:label>Green tea leaf</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14307</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2bc3fda1-2f35-4132-bc59-ed16673fb9ec"/>
    <dc:identifier>DB14307</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f5bf881-47ab-4931-8528-bf857e44e2f2">
    <rdfs:label>Erythropoietin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21e3945a-baec-42fe-90c2-dac64bf478c2">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/488b4f8a-bb56-4982-8364-aa8298c07ddb"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bf8619da-7c0a-4693-b916-6eea3d25a40c"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e13497f1-474c-4567-81a8-aef86d957d26"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/806eca2e-05f9-4bc0-98de-d01c7dc64b1a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00016</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00016</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d7991b6-8c52-4783-805b-998d9aee1aad"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000009">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:24+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is depleted in molecules closely related to the products or end processes of a genetically defective protein which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">dietary exclusion</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58c9f06f-ece8-4cbf-a31e-e28cb096b106">
    <rdfs:label>splenomegaly</rdfs:label>
    <dc:identifier>HP:0001744</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66f38b64-be28-49fd-a0e7-0e431ffbd22b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8829ad01-b171-4480-a4c7-c88738a41aeb"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c093448-0390-4e18-9ae3-d76ebe276929">
    <dc:identifier>HP:0031517</dc:identifier>
    <rdfs:label>verruciform xanthomas</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6f7142e-c9d8-4f85-ab9c-fe4d73c62c0a">
    <dc:identifier>HP:0040006*</dc:identifier>
    <rdfs:label>Low life span (Mortality)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f393f48-50e1-425e-a763-f2f167a7db0f">
    <dc:identifier>DB05481</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ce07ae9-7ba2-4cb1-94f0-06cb81c4fa2a"/>
    <rdfs:label>Recombinant alpha 1-antitrypsin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05481</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e67add11-86c8-45d1-959d-047cb9474ee4">
    <rdfs:label>r LCAT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a513ba80-2018-41fc-aa58-5fa1f66a0d06"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4771158-8243-48b3-86cc-12e8ad0e3ac5">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c7cdc935-3105-4645-b583-2ba8d1c5aad8">
        <ddiem:url>https://www.drugbank.ca/drugs/DB09539</ddiem:url>
        <rdfs:label>Omega-3-acid ethyl esters</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ea026115-6c1f-4698-800d-f73545862355"/>
        <dc:identifier>DB09539</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ea026115-6c1f-4698-800d-f73545862355">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d4771158-8243-48b3-86cc-12e8ad0e3ac5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16390715</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/38c6032f-eae4-4216-86ea-8833edb5e4dc">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7366945e-2b85-426d-8518-2c04e7de2d3c">
        <rdfs:label>Mild asymptomatic hypoglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0001943</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f1b2ab6-957d-4ae5-97ce-0a836aa5aa01"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/280544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42aab52a-c496-446b-bc78-3278c6faba65"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec5d63c9-461a-4e78-a642-091dd21f359e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2464ef8e-6401-4dc2-a288-040f84f55cd1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9ddc8301-39b6-495d-bd92-671bd769cc63">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2eb7f245-ae15-436a-84ac-d9afa5a22c79"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/092096ab-ad8e-4bc5-b65f-91b913051445">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7991dd77-d27c-4918-a27a-6f3d836350cb"/>
        <rdfs:label>Creatine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00148</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43559ff1-be86-4302-869e-0d2f6ac2075d"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f194769a-ca33-46bc-b41d-a2892ecfb1aa"/>
        <dc:identifier>DB00148</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d255ef3d-fa98-4ce3-b8c3-0bd44fa7590d"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a29c1da-0f5c-4a42-b02c-9828736b673e"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9ea98f7-5b19-414e-8f9e-37d618daf5c0">
    <rdfs:label>Hypoglycosylation of serum glycoproteins</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7d28311-a15d-46e4-a0a6-76f86ccfe373">
    <dc:identifier>HP:0003128</dc:identifier>
    <rdfs:label>lactic acidosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83cb08b0-212b-4bd6-9a6c-721135211b31">
    <dc:identifier>HP:0012238</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>High total plasma cholesterol leve</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d61b0a6b-7c0e-487c-9701-ad33b3efd371">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM."</rdfs:label>
    <dc:identifier>HP:0002156</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f614f9b-77cf-422a-9fad-1c28dccb6166">
    <rdfs:label>LJPC-401(Synthetic human hepcidin)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c7c8e2c-ba32-4ee3-b6ab-dc17a48b4f53"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/51a9301d-3e00-4d03-8cb2-b5e7df45869b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/751f948e-e5f2-4a59-90e6-30a719e517ad"/>
    <rdfs:label>recombinant human tripeptidyl peptidase-1 (rhTPP1)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4cba297-4f46-4ebd-9d1c-dda9d8328837">
    <dc:identifier>HP:0012378</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low physical capacity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b4b65d8-890d-477d-88f1-34256d2bf9f3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high intraneuronal GSL storage</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e7c0acef-2abd-4252-a67d-00082517014b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b49536bc-cddf-4f96-8880-5b10774394c1"/>
    <rdfs:label>Pamidronic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00282</ddiem:url>
    <dc:identifier>DB00282</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a5b8e795-d3f9-4106-a6d5-74fe3b07d7b5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54c1d61a-6285-4496-875b-d82db036f16b"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf121511-3775-4269-b8cb-ee60e6dec50e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1c6f6c66-7a1a-4b03-947b-0e8937d8bb02">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1051cb9-1c41-47d7-82ba-c9ec986e6218"/>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3900744-4943-49e9-8155-95730c2e2cf8"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <rdfs:comment>Due to its strong copper chelation capability, a copper salt should be added simultaneously</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f90f5d6-fc10-4aa8-a531-c859785bf9af">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <rdfs:label>Fine motor impairment</rdfs:label>
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f0ec199b-c9bc-44c3-9d20-8e11df73c851">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9591bce2-3647-4f7f-b29d-5a48597ee00d"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e8c45fa-68c2-48e8-b532-a25ea5a05528"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26067811</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/69247cb5-ee7c-47fa-a606-3e49e584e34a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6742e1f4-9c78-4174-8576-31a463a9b681"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c007aac0-f158-4798-8bc1-67e29bea54be">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <dc:identifier>HP:0004356</dc:identifier>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <rdfs:label>high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a67a25f0-5a18-4f17-b9d0-88ac40f7aa04">
    <rdfs:label>CoCarbs + HPro</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ea778b7-d326-4457-856a-90b1ad4716f5"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b28b7fa-91e0-4bc0-b3fe-71a5bf39da16">
    <rdfs:label>Speech and languague delay</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001270</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c392f4dc-3258-4309-acf8-044f0c34a52b">
    <dc:identifier>HP:0000407</dc:identifier>
    <rdfs:label>Sensorineural hearing impairment</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000407</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/824f0d26-2414-4b01-a187-0df1e093e912">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>Liver lysosomal storage abnormality</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9a6c49f-f4cc-4e18-aa1d-506d00f22ca1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe6641d1-1d10-4407-8fa5-becea5ae29c9"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/753ee70e-078f-46f0-8329-8d7bc9936cd6">
    <rdfs:label>Rituximab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/56095c63-b3c8-4119-a75a-02062841e258"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00073</ddiem:url>
    <dc:identifier>DB00073</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c201e71e-879a-4fdc-a150-4690eec5135d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000648</ddiem:url>
    <dc:identifier>HP:0000648</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Optic atrophy</rdfs:label>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000015">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:56+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that inhibits  a component of the pathway or network in which a genetically defective protein is found, compensating for alteration of activity of that protein.[PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">functional complementation of a defective protein by inhibition</rdfs:label>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f20d7ede-2eb2-4499-9093-693575fdb12e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11981</ddiem:url>
    <rdfs:label>Elamipretide</rdfs:label>
    <dc:identifier>DB11981</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b06ce02-68c2-44c4-9bb7-3236cab71c94"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8cfd1fa4-7589-4382-9a55-d2bde4c4f4b5"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1d01121d-b6f0-4acb-90e5-bac75683e06a">
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8be2a2df-66b0-4b5f-a9cc-3e1a00db082b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/708f741b-ddc4-4081-88d5-689bf538a07f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/055095de-8925-441f-9bf0-763a29c4f913"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/adf1ddd7-856a-436f-9fab-7a6f2af38d48"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3667276b-4bc5-4881-a32b-19855e732391">
    <rdfs:label>Mislocalization of R8L</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/796da9ca-6fd0-4d75-a76d-991a65249168">
    <dc:identifier>DB06281</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/307dd2e2-ec43-4adc-ab4e-7a3293ff5c63"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06281</ddiem:url>
    <rdfs:label>Torcetrapib</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cca4aa48-9081-4124-b3a6-8c0d98776e8b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09046</ddiem:url>
    <dc:identifier>DB09046</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a639fa8e-ab07-4780-ac55-65be5eff5a94"/>
    <rdfs:label>Metreleptin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/93611818-145d-424e-bd73-b74469a02618">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1cc5f1d-04dc-4739-9cdc-474889cb0fdc"/>
    <rdfs:label>Methylcobalamin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03614</ddiem:url>
    <dc:identifier>DB03614</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e80ec72-78d9-4cd7-adff-3f59f3e052d8">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>erythema</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
    <dc:identifier>HP:0010783</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/07400f16-4667-4233-872e-acc32860997a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/758e5331-1851-400d-aba8-0d52415d272e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/72e0106d-17fb-4b2a-9cd7-6657afcff582">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08834</ddiem:url>
    <rdfs:label>Tauroursodeoxycholic acid</rdfs:label>
    <dc:identifier>DB08834</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/283550da-1464-44fd-ba82-913e96b01916"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94cf7d76-41b4-4946-bcbe-3b2366300907">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1816edb7-bade-45dd-a0dd-f90d376cb1a5"/>
    <rdfs:label>GNT0003</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29174c89-bd31-439c-8a1d-f54ec4a94eeb">
    <rdfs:label>High urine phosphoethanolamine</rdfs:label>
    <dc:identifier>HP:0003239</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003239</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebc8ac9f-1335-4689-a0e7-1afc4fc2e16e">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Abnormal serum Methylfolate Level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/593cedbd-d0fc-4114-af12-4131ef718035">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec4bbe0a-0bed-4e78-9cc5-81897db520d9"/>
    <dc:identifier>DB03404</dc:identifier>
    <rdfs:label>Hemin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3cba925-497d-4b3d-a3bd-8233e6c04cf4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27a231d3-e557-4a1f-a466-c441ca8df61e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03404</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ba7ae92-79ab-44e0-b726-e231876cae23">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <rdfs:label>mitochondrial dysfunction</rdfs:label>
    <dc:identifier>HP:0003287</dc:identifier>
    <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d255ef3d-fa98-4ce3-b8c3-0bd44fa7590d">
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d6df4f3-6864-4a49-9cf2-b56ae9a6ac7f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80f416aa-06e5-4b0a-931a-bf2c370cf082"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60015586-1a87-4e55-9fed-0f0c77affbe6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/47890180-7047-4db8-9359-f3e1d85f75a0"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0631b78-62c9-423b-9bbe-9661ab8635b5">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
    <dc:identifier>HP:0002015</dc:identifier>
    <rdfs:label>Poor swallowing</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/72b9faa3-3472-4141-8e62-238b68e6387a">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B05BB01</ddiem:url>
    <dc:identifier>B05BB01</dc:identifier>
    <rdfs:label>electrolytes</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c7c192cd-7214-45d3-bf64-5663cf62986f"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e0db13d-237c-471a-8848-bdf4f0ef791c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a0179b63-47ff-4024-acbb-8b2cb3f924ae"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d96b39e4-978e-492f-a2aa-8c6a7ecb5d72">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35f94696-5960-469d-8da2-b6c54fc3ecec"/>
    <dc:identifier>DB01234</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28b0dc99-e8fa-4a2a-9f6e-0e05bb2e0f3d"/>
    <rdfs:label>Dexamethasone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01234</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2b3f65ca-a732-4358-a273-1f287d414f7e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd844373-1320-4740-b502-9b709d6bf178"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4227a61-405c-48d0-888b-90e2113570b5"/>
    <dc:identifier>DB00166</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00166</ddiem:url>
    <rdfs:label>Lipoic Acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1c6f6c66-7a1a-4b03-947b-0e8937d8bb02"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/88e98f11-5e1c-4654-8766-29e223aac649">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54ea38e9-9403-4197-90f4-85e815ff9921"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1d379a37-c79f-472a-935c-ec15a44e1466"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17164772</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8eb9fe5f-817a-4209-8cb0-5ab809d06605">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hyponatremia</rdfs:label>
    <dc:identifier>HP:0002902</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002902</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/396513ca-9008-4a43-ac8b-4126635e81ce">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_84293</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/96f33b6a-1233-46a0-946d-a29cd7cfd180"/>
    <rdfs:label>dimethyldithiocarbamic acid anion</rdfs:label>
    <dc:identifier>CHEBI_84293</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/232d961e-6226-4dc9-b7d7-492c8cb6ac15">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/96f33b6a-1233-46a0-946d-a29cd7cfd180"/>
    <rdfs:label>Thiram</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13245</ddiem:url>
    <dc:identifier>DB13245</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e1ab158-f701-4a1d-9f42-c84a7de8d9a7">
    <rdfs:label>Pyridoxine phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02209</ddiem:url>
    <dc:identifier>DB02209</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/80682c33-7a2d-4792-a76a-8a6a21d418cb"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97993e48-8017-4ac0-9cbc-33bbf195b155">
    <rdfs:label>Tocofersolan</rdfs:label>
    <dc:identifier>DB11635</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c64ce725-322a-487d-8df8-e86d98123ade"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11635</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/edf8fc13-bba5-4e0a-8fb1-34316117286f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/93b46512-5571-4d86-aa2f-9aabed0e00d8"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/789e3967-4939-416c-bfec-83c98bc6fd87">
    <rdfs:label>Neutropenia with IBD</rdfs:label>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <dc:identifier>HP:0001875+HP:0002037</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875+HP_0002037</ddiem:url>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000013">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:49+00:00</dc:date>
    <rdfs:label xml:lang="en">symptomatic treatment procedure</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure aimed at amelioration of one or more abnormal phenotypes generated as a consequence of a defective protein or process by a means unrelated to the immediate pathway or network environment of the defective protein. Generally working at the level of the tissue or overall organismal physiology. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db79c848-d699-4bdd-97de-6acc84788763">
    <rdfs:label>Liver injury</rdfs:label>
    <dc:identifier>HP:0001392</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001392</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dd800350-7a11-4d8a-93d8-06bee5bc4c6e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/925e129a-69f0-4cff-b92c-b63cf2c61533"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6742e1f4-9c78-4174-8576-31a463a9b681">
    <dc:identifier>C09</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0ec199b-c9bc-44c3-9d20-8e11df73c851"/>
    <rdfs:label>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d59d6ce-17ee-4cf7-97bc-f793a6a534da">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f3511ef5-9325-4d17-b81d-21e4b828d382"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4d4fec2-5395-47fd-bb9d-7376dcff5112">
    <rdfs:label>N-acetylmannosamine</rdfs:label>
    <dc:identifier>DB12536</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/de895648-6d1b-4307-9ac7-2a728f03cc91"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12536</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74659699-4ff3-442c-bf93-012989318adc">
    <rdfs:label>Protoporphyrin</rdfs:label>
    <dc:identifier>DB02285</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d3a611fc-9faa-4df8-813b-048135d098b3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02285</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1e4016c9-e3ef-4494-8b84-dbe04ff1c12a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a4219ff-a57d-4fbc-b44a-801459eb732d"/>
    <dc:identifier>DB01132</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01132</ddiem:url>
    <rdfs:label>Pioglitazone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64e22111-d47e-4d09-820d-b2c69c905f09">
    <rdfs:label>Progesterone</rdfs:label>
    <dc:identifier>DB00396</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00396</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e2e0922-3ea1-4f29-85af-4bd6c6b8730a"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/011b2dd9-860b-4b03-a2a2-46197f724c5a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03485</ddiem:url>
    <dc:identifier>DB03485</dc:identifier>
    <rdfs:label>Alpha-D-Fucose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a4999ac-2701-4ac6-a25d-8ff2aad62413"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/018a9910-dcdd-4448-aea3-c90ee09687bd">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal reflexes</rdfs:label>
    <dc:identifier>HP:0001347</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e176db95-096a-4f1d-96bb-e5de2b06c68e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd85b471-bc6c-48f8-b254-a5ee254e4cdf"/>
    <rdfs:label>Copper Histidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7df696fa-e2dd-44c9-bbfb-3dad4457a11b">
    <rdfs:label>abnormality of proteoglycan metabolism</rdfs:label>
    <dc:identifier>HP:0004355</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004355</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8df1d097-3ecf-4e50-8c0c-7632bb1f1971">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>elicited hyperactivity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000752</ddiem:url>
    <dc:identifier>HP:0000752</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25729805-decf-4817-a8bf-f150fe68813a">
    <rdfs:label>Low HDL-C</rdfs:label>
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/41e30bba-60cd-4e49-b848-e2a13f7a6a36">
    <dc:identifier>DB01233</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60e078ca-49b9-43de-88c8-417a5cf7dad2"/>
    <rdfs:label>Metoclopramide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01233</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9fcafd6e-bedc-49ed-91bf-a11be8554495">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cbe9012b-f1e3-448b-bf71-15ba99ccb085"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04729</ddiem:url>
    <dc:identifier>DB04729</dc:identifier>
    <rdfs:label>Gentamicin C1a</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27286958-5551-4ec5-a702-e1448996dd38">
    <dc:identifier>HP:0001635</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cardiac dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000002">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a treatment directly or indirectly compensates for the loss or gain of activity of a genetically defective protein within the network or pathway of which that protein is a member. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <rdfs:label xml:lang="en">complementation therapy</rdfs:label>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c6e574d2-25b9-4674-a7b7-5e839f9b45b1">
    <rdfs:label>Activated charcoal</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09278</ddiem:url>
    <dc:identifier>DB09278</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2278b6d1-9cbd-4467-8d51-87c83cff9a16"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2aee4353-721c-43ef-8f64-a4e9a42bc31a">
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <rdfs:label>high plasma ferritin</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9b68aa05-0eed-4129-acbd-10ed44da11da">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc821605-f48b-4aee-8266-64851a34d193">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8fa9c06-7894-4ec4-ac4a-8fa0a32a832e"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46f21f88-d4a4-4c5a-9795-fe8c92d0a58e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>hydroxypropyl-β-cyclodextrin (HPBCD)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/954510a3-bec9-40b4-b2ff-9938d47e4332">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17c97d6b-838b-4736-9501-6249a54ee112"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c126bc6c-42f1-44fc-8bd0-ffc45b29275e">
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a22c6df3-d7d7-4891-b994-58e908697c6e">
    <rdfs:label>Low cerebral creatine content</rdfs:label>
    <dc:identifier>HP:0012113*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9ec915a-c5a3-4145-ba20-a391884e0e7b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7b809b6-2a67-4fb7-998f-9fd6e8a7b8c6"/>
    <rdfs:label>AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/57ac0e4c-3bd9-4367-8b96-e6509c4cfdbf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3951351d-7944-447f-aa46-6845ce89e9d6"/>
    <dc:identifier>DB08809</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08809</ddiem:url>
    <rdfs:label>Dichloroacetic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/026d0f9c-5d64-4d55-bb60-180c855bb8e4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00143</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4bad7605-4336-457e-ab25-cc6b4143163b"/>
    <dc:identifier>DB00143</dc:identifier>
    <rdfs:label>Glutathione</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/249900">
    <rdfs:label>METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>293</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/249900</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4ec8fccb-2a3c-4155-bec9-ff4f9a186750"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/293</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a64e1c1-47a5-4d55-89bd-9d50bec66fcf">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b1717d9-350f-4804-8414-0fc839d29dba"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eef6c8c4-8a46-4f62-bac1-2c8427e08aa6"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef880a2d-b78d-4152-aeeb-59c149620929">
    <dc:identifier>DB11133</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/249fc59f-b885-4626-9a50-a576a7cd2126"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89322347-9e0e-4b12-b58b-1ea908badbf0"/>
    <rdfs:label>Omega-3 fatty acids</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11133</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240800">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d349738a-8804-4023-be1c-8909f9497c33"/>
    <dc:identifier>https://www.omim.org/entry/240800</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPOGLYCEMIA, LEUCINE-INDUCED; LIH</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b4d2f32-01dc-4433-8b4c-e07c0f9595ac">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/74f6d862-c934-4c90-a0b0-21ae6aa5a6d6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00742</ddiem:url>
    <dc:identifier>DB00742</dc:identifier>
    <rdfs:label>Mannitol</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/180de5d1-58b7-4a06-a5e4-f61f378b1402">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ab2264e1-4cee-4a87-83ec-e69558954d9e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f10c1d58-35e4-46d6-8212-91366c0068e5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB15066</ddiem:url>
    <dc:identifier>DB15066</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5df87cb2-8302-4ae3-94f7-4196a92aade4"/>
    <rdfs:label>Givosiran</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5e97b65-cd44-46ea-9722-a9d72653f1b5">
    <rdfs:label>Abnormal pulmonary ceramide level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/900001f7-3034-4510-9109-22c9ab8b116a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e26f6fd-01ac-48e6-977e-3eebbfa0dbed"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf56a36b-aafb-4ca4-947c-c786d81b6184"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00188</ddiem:url>
    <dc:identifier>DB00188</dc:identifier>
    <rdfs:label>Bortezomib</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef73d6ce-55d3-47e1-9c86-360aeaa4e173">
    <rdfs:label>Polythiazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/923cbeac-b004-4544-8323-604721f9f503"/>
    <dc:identifier>DB01324</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/885f27fb-1ccf-4001-b446-dfccdf1e3d8a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01324</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3ebfe97-d39f-4162-ab36-1786a8245720">
    <dc:identifier>DB00620</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/359d6017-769f-408c-adcf-1ac913682a01"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00620</ddiem:url>
    <rdfs:label>Triamcinolone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c06adc2b-d949-4f95-ab58-129a404418d3">
    <rdfs:label>Captopril</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2861f911-6f20-4f98-add4-9e8cde25d325"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01197</ddiem:url>
    <dc:identifier>DB01197</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dce4b37f-89ca-41a2-ac03-a7a631001c48">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baa5bc29-097a-4f7f-9bd7-b4056e03d8d4"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c634e67b-d154-4908-897f-d34870f377c1"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
        <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e2f3a6c-7ae4-402a-a9b4-17e8dfe7a43e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low growth rate (Abnormal growth)*</rdfs:label>
    <dc:identifier>HP:0001507*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36ff058d-38f6-4582-8989-7a116fe2e155">
    <dc:identifier>HP:0002353</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <rdfs:label>Abnormal EEG results</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bcbe2b99-136c-4d8c-bebc-8849697ed432">
    <rdfs:label>Acitretin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/913fca9a-2e33-4493-9022-9d6f2503804c"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d37a1658-35ca-44f5-9734-07798de22bb2">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ec2c82f-ce75-410d-93d5-3883dd1f9d45"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f095d250-f471-402a-b16d-db8821fbe28e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00459</ddiem:url>
    <dc:identifier>DB00459</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9806fd37-4b2c-4760-b1ba-219e83d03d0c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9511275c-2da8-4476-aef1-14e317a09ae2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002474</ddiem:url>
    <dc:identifier>HP:0002474*</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>communicative skills abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7034fe03-18c5-4a66-8457-5d3e651862b5">
    <rdfs:label>Norleucine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/162ccdcc-7d88-4f0f-88a2-ad7a1ef16dce"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/087fd8a8-711c-4ff0-b94c-2577485a933c">
    <rdfs:label>defected  L-2-HGDH enzyme activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f283c262-90b2-49ed-ae3c-d72526c85e12">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
    <rdfs:label>defect in skeletal mineralization</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0006462</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f0ca86c-94e9-4abb-abfc-c821e53a3a05">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997711</dc:provenance>
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient .</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76423b6c-3826-4bea-b73c-8c3f9b88f225">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80f3d07e-2e5e-4024-a26f-56cae1238b60"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/13d867a8-6eb8-4a32-a3e1-92cb0e1c5c7f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fb4db80b-8a2c-48a7-a1ba-1cc78bdf1dfd">
    <dc:identifier>DB14644</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14644</ddiem:url>
    <rdfs:label>Methylprednisolone hemisuccinate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b9e457a6-f04a-4c79-8dc6-8ee42b28ee7e">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31e70ea5-9230-4178-aaab-2decfbfbef3e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/56513bf6-6130-4ae0-b5e5-7a470380f7c8"/>
        <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e802fb62-f7fd-45df-a650-f4637a0b7653"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b199ad0d-4236-4729-8794-3740e0536d68">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c4c6fb84-745a-4305-96ec-bcd8db0eb68e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <rdfs:comment>THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea19348f-53d3-4cda-a08a-4929542080c3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000093</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
        <rdfs:label>proteinuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7e9d8af6-af5a-4be9-b879-8e7309a32672">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bff6097a-4fc6-4e42-bbe2-85c7476e42f4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42205bfc-54c7-4a8b-a3dc-1b1f530d2471"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d3ecf923-0d3d-453f-ab43-164f152179e4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/49f729cc-0749-420b-a741-e1c45021f106"/>
    <rdfs:label>Albiglutide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09043</ddiem:url>
    <dc:identifier>DB09043</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f7066554-c56d-4ef8-a5e2-4b9adf0b1924">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/082edd9e-0f8a-4e08-8ad6-58631299aa6c"/>
    <dc:identifier>DB01609</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01609</ddiem:url>
    <rdfs:label>Deferasirox</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f9c81d97-653b-46d4-9a29-9a05dc136bdb">
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <dc:identifier>B01A</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/326c9991-2a34-4e4b-ad88-d99056551405"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01A</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cdd1ed46-f8ec-4962-a35b-d4e37d5530c2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9fceb068-ba0f-432f-a660-15b5fe71d437"/>
    <rdfs:label>FIV-hAAT-G6Pase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c27a337c-1558-424f-8c07-42b25a54269d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f939721f-e88c-4b01-b45f-92b2a88e415b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09449</ddiem:url>
    <dc:identifier>DB09449</dc:identifier>
    <rdfs:label>Sodium phosphate, monobasic</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d458930-9fd1-4d3d-8e6b-e6db8651fec3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7a19f96d-d21e-4518-af9e-7954d55aaf4f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c909a90d-a6cd-4c29-b301-cb8e2bbdad1e"/>
    <dc:identifier>DB00877</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00877</ddiem:url>
    <rdfs:label>Sirolimus</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e51f9b7f-51d0-4e1f-92d4-3eeded20bb87">
    <rdfs:label>failure-to-thrive</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001508</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2a065c8-2888-4a44-b31f-c0053113d5a3">
    <rdfs:label>low HDL-C level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <dc:identifier>HP:0003233</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ccb38efc-f62d-4bff-b892-6e0c4425d9b2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/326c9991-2a34-4e4b-ad88-d99056551405"/>
    <rdfs:label>PERIPHERAL VASODILATORS</rdfs:label>
    <dc:identifier>C04</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C04</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8cf172e8-83ac-4396-ae42-7ab5fff51e9e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/42b8adb7-ade4-493f-b07f-1129effa361e"/>
    <rdfs:label>ARC-AAT</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e802fb62-f7fd-45df-a650-f4637a0b7653">
    <rdfs:label>Autoimmune encephalopathy(Encephalopathy)*,(Autoimmune disorder)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298,HP_0002960</ddiem:url>
    <dc:identifier>HP:0001298*,HP:0002960*</dc:identifier>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ab0b594-0336-49bd-92cf-df1cea291a8c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/326c9991-2a34-4e4b-ad88-d99056551405"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0fd09e75-b756-4bba-b4e4-3408e2f1d2d2"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09CA</ddiem:url>
    <dc:identifier>C09CA</dc:identifier>
    <rdfs:label>Angiotensin II receptor blockers (ARBs), plain</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8c451e6c-9bc6-402b-a77b-d8e87b2c622a">
    <dc:identifier>CHEBI_28384</dc:identifier>
    <rdfs:label>vitamine K</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_28384</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac60b341-3759-4b43-a0d2-a30aa2a5b93f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ca5120a-be3e-4ea1-a73f-3cefa06b2cdc">
    <dc:identifier>HP:0001738</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001738</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>pancreatic dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a880edae-89b3-4309-a7e4-4bca71ee6b72">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02c99c1e-79f0-4e45-8daf-52faa5431fd9"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ddc0cd1e-e1c2-4f64-991a-7053195921b0">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e53c4b3-48e8-42b8-9c08-2b4d59c41411"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29119254</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0003304>"P49L, A114V, I278T, R266K, or R336H"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <ddiem:failedToContributeToCondition>"R125Q, E176K, T191M, T262M, or G307S"</ddiem:failedToContributeToCondition>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2fa75935-c72e-481f-a430-1bb088b2fc2e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b04751a-7afa-4333-b972-e2b7a2e5585b"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8fa90139-889a-4b47-a02e-e925f8f87048">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01151</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/56e0c6b7-8506-4f51-b410-11d7cbc22d97"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0e566ad3-7527-4183-9ab9-21ccd32a521f"/>
    <dc:identifier>DB01151</dc:identifier>
    <rdfs:label>Desipramine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea489b4e-c464-4c5e-b2ea-85999ff6106a">
    <rdfs:label>Spironolactone</rdfs:label>
    <dc:identifier>DB00421</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00421</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/226e1adc-7f31-42af-996b-2f807da94587"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42c04718-12ea-449a-abeb-50a20cc0b7e9">
    <rdfs:label>recombinant canine α-l-fucosidase enzyme</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/74c351c6-099e-4925-b48e-d2eacbedfca1"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4dcb6f7f-1c50-4d0b-b995-42e17bdcd8c7">
    <dc:identifier>HP:0002173</dc:identifier>
    <rdfs:label>hypoglycemic seizures</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002173</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bff6097a-4fc6-4e42-bbe2-85c7476e42f4">
    <rdfs:label>Benazepril</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00542</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b199ad0d-4236-4729-8794-3740e0536d68"/>
    <dc:identifier>DB00542</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc063306-975b-4cc6-a293-9f512fe43e85">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
    <dc:identifier>HP:0012535</dc:identifier>
    <rdfs:label>Defected neurotransmitter homeostasis in the CNS</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e776d7d-566a-40fe-84fa-b566a673404c">
    <rdfs:label>Decreased activity of mitochondrial complex I</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011923</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011923</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dcb09c16-14c6-4653-9faa-e8a798e49698">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01124</ddiem:url>
    <dc:identifier>DB01124</dc:identifier>
    <rdfs:label>Tolbutamide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff6dcf59-0bae-483f-a8fa-eca18db9f4f8"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b1d19a9-6e8e-4f30-8592-a75f666ef295">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:label>acute congestive heart failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0671d13b-592d-4795-92b0-dd66de06f330">
    <rdfs:label>Nicotinamide Mononucleotide</rdfs:label>
    <dc:identifier>DB03227</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03227</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd3ab056-38f2-482a-9e04-54bf48789c5b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78560ee8-6f2a-4abe-8a08-e27d871129a4">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <dc:identifier>HP:0025464</dc:identifier>
    <rdfs:label>Increased ROS formation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebee71bb-713f-462e-b178-92329624d5a0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
    <rdfs:label>High level of very low-density lipoprotein</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003362</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24d1a065-8bf4-4775-99bd-9cc67f68e16d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased serum iron</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
    <dc:identifier>HP:0003452</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/43e592ef-1c4f-49f9-882e-95dae9884a62">
    <rdfs:label>Interferon beta-1a</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00060</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76f2cd70-2954-4989-ad8f-1bcfe01e71d4"/>
    <dc:identifier>DB00060</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e48c0ef-ef8d-4458-89a1-072b3d07abe4">
    <dc:identifier>HP:0001332</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:label>Limb dystonia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c229c5a2-4af7-4983-99a8-9d44a982820c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
    <dc:identifier>HP:0000982</dc:identifier>
    <rdfs:label>Palmoplantar keratoderma</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/11c49b2d-4931-4289-991b-74f7055da944">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/956742ee-5f4d-49a2-8883-e3f8b11d25ae"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00186</ddiem:url>
    <dc:identifier>DB00186</dc:identifier>
    <rdfs:label>Lorazepam</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcf74aa4-1530-436c-ab50-a8a6e53e73a8">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0012103</dc:identifier>
    <rdfs:label>mitochondrial toxicity*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2250d47e-f993-419a-b0da-31818b524446">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ba130a5-d332-4bbf-a316-0228dba20d0c"/>
    <rdfs:label>NA</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4d804f3-35db-4b08-96a9-4e3095bfe98c">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0002463</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002463</ddiem:url>
    <rdfs:label>language impairment</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eaeed061-6d87-4061-a06d-8ae6afd2a012">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low serum HDL-cholesterol</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc831033-aae4-4699-89c5-403ecdce600c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00360</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e189ad2-b151-4792-9c68-c134c779cd37"/>
    <dc:identifier>DB00360</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb23f011-4232-4540-b8ab-67ada0c1d20e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2e9d1253-88be-4142-89d9-5516fe4a3979"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/484bd694-80c4-4f12-a0fa-02a0c6e0d67d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be25ed7f-9f1c-4b1d-8c23-79d30d1a1da4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6fb57652-d719-400b-9099-21e4cdbe02b4"/>
    <rdfs:label>Sapropterin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a3008a5-2879-4912-9f35-995088468c72">
    <dc:identifier>done</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
    <rdfs:label>"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level."</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/568e03ef-48b2-4c45-a292-816c693e1fee">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/36644a18-a833-4c17-b451-0c3f4eeb3576"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/351b5169-032e-4329-92ea-1af53b0c997f">
    <dc:identifier>HP:0025463</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>oxidative injury*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025463</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/52eaa10b-186a-41bb-965b-f01a032625b6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19ebbb66-bf73-4a3e-b7fe-6318dbae4828"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/38c6032f-eae4-4216-86ea-8833edb5e4dc"/>
    <rdfs:label>Dextrothyroxine</rdfs:label>
    <dc:identifier>DB00509</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00509</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe28a519-d6a5-48b7-ad45-38b4f7ee5af7">
    <dc:identifier>HP:0012446</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>cerebral folate depletion</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5db27d7f-2f60-424a-9a83-c5892844fdcc">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4cf97478-4eba-4eae-8e7e-fd274d053a6c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fdda8203-5e1c-4ef8-96ca-79b5c8d18cec">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc03bf3b-67c8-4c7d-b375-fa5674e751d2"/>
    <rdfs:label>antisense oligonucleotide (VMO AED cocktail)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cc68a88-19c2-498c-a5d4-ea28e1d6610c">
    <rdfs:label>ER-associated degradation of R8L</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/769b75e8-60ec-48a0-af5e-f9f921887fbf">
    <dc:identifier>DB00695</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2861f911-6f20-4f98-add4-9e8cde25d325"/>
    <rdfs:label>Furosemide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00695</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb6d5cd9-2ee2-4d22-b46f-7231d752f071">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e58916ee-5c61-4857-b6ba-73491be6c342"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4347dfb2-343a-41cd-9f92-8179c4f46690">
    <dc:identifier>DB14751</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ebf05964-087a-4d93-9627-033360157f48"/>
    <rdfs:label>Mecasermin rinfabate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14751</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/521b7aac-bdbc-411f-a960-1bd4fd48475b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04d81839-a7d2-4559-bb2f-39b1dacbc8cd"/>
    <rdfs:label>RT001 (11,11-di-deutero-linoleic acid ethyl ester)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0bdc290e-7ffe-4a6c-b765-8625b875414d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/158c4dd4-ef2b-48da-9b13-37fcc8648d56"/>
    <rdfs:label>Retrovirus</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9be4c9ce-ce35-46c6-8f6a-0c7417662b3b">
    <rdfs:label>Increased total cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <dc:identifier>HP:0003124</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c6fd51ea-b017-4fe3-8709-003190066f63">
    <rdfs:label>AAVrh.10CUhCLN2</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/61be833f-7252-4c1c-ba42-e7e5476a8623"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/27cc3d3c-6a8b-4e3c-bb8a-893c01e503bd">
    <dc:identifier>DB04075</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13ae8755-99f6-4c92-9758-82f2b0347325"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04075</ddiem:url>
    <rdfs:label>N-Acetyl-L-Glutamate</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c4c3d475-c4f0-460d-b27c-aec71157a44e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b4c0327-aeba-49fb-9824-3b21421478c2"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8ef57078-492d-4e59-88b4-e1f111e8cf3b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/086c0f1a-77fe-4054-b80f-861251ffadeb"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a27ff32e-347f-4abb-b5ff-ceeab02faa6a"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac219734-d3b7-4fd3-b12a-ae6e8cb9cfa0"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10f49877-1012-4b56-b226-81e3a5eaa8de">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09A</ddiem:url>
    <rdfs:label>ACE INHIBITORS, PLAIN</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0fd09e75-b756-4bba-b4e4-3408e2f1d2d2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/326c9991-2a34-4e4b-ad88-d99056551405"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/226e1adc-7f31-42af-996b-2f807da94587"/>
    <dc:identifier>C09A</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54d8c709-e629-4030-bcca-29554433cbd4">
    <rdfs:label>High urinary malonic acid</rdfs:label>
    <dc:identifier>HP:0012120</dc:identifier>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cc67426f-4fc5-42fd-b403-387b7bcc658b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01001</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48ebff14-4388-4607-8598-c0a0bd142e37"/>
    <rdfs:label>Salbutamol</rdfs:label>
    <dc:identifier>DB01001</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/19aa756d-5b56-432f-8256-6811b5817130">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67c3f3aa-2f10-4535-aac2-02a668265042">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00440</ddiem:url>
        <dc:identifier>(DB00440</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41501593-2696-4c57-ac5e-f7a8c80c44a3"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/adfdf709-a3c7-46a9-8391-c287d9fab1ab">
    <rdfs:label>Pyridoxal</rdfs:label>
    <dc:identifier>DB00147</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00147</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79b4889e-9eda-47c3-a911-320213d21f37"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1255fa44-293d-4af9-88e7-f8315de302a7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00594</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10790e8a-2ff5-4ef2-b173-1243a06c5593"/>
    <rdfs:label>Amiloride</rdfs:label>
    <dc:identifier>DB00594</dc:identifier>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy">
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:label xml:lang="en">direct complementation of a genetically defective protein by gene therapy</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <obo:IAO_0000115 xml:lang="en">Insertion of one or more normal copies of a genetically defective gene into the genome of affected cells.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9c0abdc8-54a2-4c9c-a2f2-6bca4546ab77">
    <rdfs:label>Resolaris (ATYR1940)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e70f994-27c9-4e4d-a986-2bd0beab0cb0"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5be9c2ee-bb44-4972-b74f-1ea403bdb267">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1419693a-b4d5-4cf4-a559-f001d3930e38"/>
    <rdfs:label>mitochonic acid 5</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/35b45750-2ed4-4c8a-9e39-5e485588603c">
    <rdfs:label>Prokinetic agents</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0658f2a0-b589-4152-a4fb-5c35c71429fc"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a896a7f9-17a8-4ded-9da9-862737b9134f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b491465-a240-4154-b969-08683aeb5e4d"/>
    <rdfs:label>rAAV-PPCR</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3d6454a9-5388-48bc-845c-2132464c8202">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12351</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0a051edc-dfa8-47a9-a6a1-0cd854f1de69"/>
    <rdfs:label>Siagoside</rdfs:label>
    <dc:identifier>DB12351</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48e4f774-10d2-4006-8e7f-39e13770fa32">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal muscle physiology</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <dc:identifier>HP:0011804</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4b11a87-9be8-4fa8-ae7d-d003d4cfc7b8">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
    <dc:identifier>HP:0001954</dc:identifier>
    <rdfs:label>Periodic fever</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4055dde8-36f3-45db-81a6-c0fc8a5e2be4">
    <rdfs:label>Chlorpromazine</rdfs:label>
    <dc:identifier>DB00477</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8008ff3b-fe6b-4268-841d-29e320dd48b6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00477</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/92c14f1b-1165-4cdf-b13e-1e3145abfc97">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a183fc96-1469-4ac2-9583-93a18069dae8"/>
    <rdfs:label>AAV2/1-MCK-Sgca</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a45a089b-db29-4167-aa94-922114e913b4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/691fbe9d-ccf5-45d2-bb04-9bac8ab7404d"/>
    <dc:provenance>https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/107/7/2952.abstract</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a5ac47d4-f42d-4f4b-a1bd-a312b56f9941"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93564753-bc66-4d8a-9d13-5059b03b8ce1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:label>elevated serum toxic intermediates (</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/32d5182e-6374-4a42-9661-4ef7f999b92e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2e79e5e8-54e3-4dc6-b01b-bc314517e168"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06cf7c79-9c5a-49e7-bb18-983cc32c859c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001410</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Liver dysfunction</rdfs:label>
    <dc:identifier>HP:0001410</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e40b87a3-485b-4cb3-b060-a4d624a2557f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a8dd452-2929-46f9-9fdc-999c735b470b"/>
    <rdfs:label>Lithium citrate</rdfs:label>
    <dc:identifier>DB14507</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14507</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/568fdcad-42b8-4de3-b784-f8ee2e8009bd">
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
    <rdfs:label>generalized tonic-clonic seizure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <dc:identifier>HP:0002069</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/43e9faa6-6a84-4594-9375-87e1e76a42aa">
    <dc:identifier>DB11672</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11672</ddiem:url>
    <rdfs:label>Curcumin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5eb6b191-461c-49a6-b9e9-e8865b5c61cb"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1da0a842-bc3d-4264-803a-965c15d686d5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3b7eda4-e7a3-486c-b45b-87bc92c0f78f"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e40308d-176f-49b6-9110-50a5f3d80c18">
    <dc:identifier>HP:0001635</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:label>Congestive heart failure</rdfs:label>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9182c1e-c767-4ad1-8abd-89b4f39324f7">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Low expression of AGA enzyme</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d125f137-5da6-4b64-ab27-e58c3b8be92a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00999</ddiem:url>
    <dc:identifier>DB00999</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/171dd1a7-1e38-46cf-afb2-6b6df6df20fb"/>
    <rdfs:label>Hydrochlorothiazide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b1940db-437f-4e27-a679-0c2ebeaccb74">
    <dc:identifier>HP:0001892</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
    <rdfs:label>Vitamin K insufficiency</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf40369c-f4df-42b2-abe4-038fc0d19f81">
    <dc:identifier>DB08875</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e21f5579-2510-4739-9cd8-9846b53bb1fc"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08875</ddiem:url>
    <rdfs:label>Cabozantinib</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/90befcde-a2db-43ea-9565-cbe62068e277">
    <dc:identifier>DB01323</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01323</ddiem:url>
    <rdfs:label>St. John&amp;apos;s Wort</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d605c45e-f53c-405a-9d81-fb52029a509b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9d9d8730-f5db-44c6-be4f-0f05f4afcbb0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ccf5bb9-081f-4ec5-b11b-63bb61b92af3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4070867-aab0-4588-8643-aa29080652aa"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2c0d925-42d7-44c1-b1df-921cc8ebed69"/>
    <dc:identifier>DB00119</dc:identifier>
    <rdfs:label>Pyruvic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00119</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5403eb4-ac6f-4285-9158-2e17cb90aef7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8c7060ed-662c-47b9-8a9e-211b2a348f73"/>
    <rdfs:label>Estradiol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df21a0d0-67be-4a0e-bafb-99205d815dbf"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00783</ddiem:url>
    <dc:identifier>DB00783</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55aaa97c-b997-4ed9-b454-5ccd8f3aeaef">
    <rdfs:label>low levels of purines</rdfs:label>
    <dc:identifier>HP:0004369</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004369</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd609f51-5db7-45bb-8398-edb18a190327">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1d6ae3a2-74ca-4b53-9a9b-81f5af923800"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be1c7b8b-6327-4acb-8d03-60db7ff3521a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4a2072c-f74b-47a9-97b1-5705142e0af3"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600721">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/600721</dc:identifier>
    <rdfs:label>D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1</rdfs:label>
    <ddiem:iembaseAccessionNumber>166</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/166</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8e73758c-2d95-469d-8b0b-c36fd2dd6e4d"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b37a703-22bb-4910-b30d-77d3ee36bb2c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8e43c76a-ab92-45bf-b112-b876e7150399"/>
    <rdfs:label>AAV1vector expressing α-Mannosidase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8278ac64-df9a-495f-b076-78bb1de0e6e0">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>behavior al abnormalities</rdfs:label>
    <dc:identifier>HP:0000708</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23eb7a2e-35b7-4d51-a4f7-daa5525c605a">
    <rdfs:label>Corneal Oedema</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012040</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012040</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74d76b39-af12-4f6e-8e59-f3ab1d2d4d3f">
    <dc:identifier>DB00679</dc:identifier>
    <rdfs:label>Thioridazine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00679</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed6a7b13-172f-42b1-b3be-7f656c743c5e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1dde6c80-7a90-4241-b9ed-4c28c6b08fa0">
    <dc:identifier>DB08876</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef2ce195-7d13-4a57-84ec-e5c4edf44b0c"/>
    <rdfs:label>Taliglucerase alfa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08876</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7c3e0f7-9859-4f87-a250-9105b223035c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <rdfs:label>Increased serum ferritin</rdfs:label>
    <dc:identifier>HP:0003281</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0f02fb9-f385-4ea4-b9a0-2d7139fbfdf1">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003158</dc:identifier>
    <rdfs:label>Hyposthenuria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/225523a7-a77f-45e0-a02b-e8a3efd83a55">
    <rdfs:label>Insulin Human</rdfs:label>
    <dc:identifier>DB00030</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00030</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c49889f2-0bcb-4434-acbe-dd72818e60b5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c81e6bf-0551-40b5-838d-16378adb2b19"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a0ffffe-8025-49b4-817a-b89f206e03c4"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/73a32f2b-8fe7-46c5-bb22-713f58ab73ba">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00672</ddiem:url>
    <dc:identifier>DB00672</dc:identifier>
    <rdfs:label>Chlorpropamide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f07ce68b-d27a-4397-b241-14186ca5c426"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9cd74f4c-cd2d-4757-9989-a0fdf6ea739a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/de272b2f-b711-4044-9b43-3687787e84f4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21c503c7-1815-4367-9962-5dbe89bc0ef5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3bdfa5fc-a54a-4a96-9372-1b62cc2f726b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7a137e3-8976-4fc4-a52d-b2b7755f6d9b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18f0720c-357a-4aab-8436-2fc53ccc4607"/>
    <dc:identifier>DB06151</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/681164d5-c0e2-4016-a99b-19c9c42823db"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06151</ddiem:url>
    <rdfs:label>Acetylcysteine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/038e9d9e-c878-4757-b572-43bb5ec82ba3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/65245101-ad1b-44b9-b076-00a1404fcb02">
    <rdfs:label>Biotin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00121</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0bcd47e8-6aaf-4970-beb7-6bb8bebc8fc6"/>
    <dc:identifier>DB00121</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b25fbfaa-c6ba-4944-9d4f-74e1513acb25"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e87169b7-2ac0-4036-957e-b83f15323a3c"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91f5db3e-09a5-4627-8f16-98cf1a0cfd0c">
    <rdfs:label>Brain lysosomal storage disease</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80f3d07e-2e5e-4024-a26f-56cae1238b60">
    <rdfs:label>enanthate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6f0ca86c-94e9-4abb-abfc-c821e53a3a05"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32362</ddiem:url>
    <dc:identifier>CHEBI_32362</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f6d4cc6-b3b3-4064-844d-8058cf522e5e">
    <rdfs:label>leucine-restricted diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/33daa5b8-c7ee-4b61-8008-7727bec44c93"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/beb18e6e-00e8-4446-aa55-4456deced9a0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02479a32-fdaf-45f8-8c41-28a999fca6c3"/>
    <rdfs:label>scAVV9.CB.CLN6</rdfs:label>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000007">
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <rdfs:label xml:lang="en">functional complementation of a genetically defective protein</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the composition or metabolic activity of the pathway or network in which the defective protein is found is modified, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:22+00:00</dc:date>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/849f8577-045f-4843-bf30-8613a3ebd056">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>Abnormal movement</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af2917b4-6861-4d20-9395-9c32ee501360">
    <dc:identifier>HP:0001945</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
    <rdfs:label>Fever</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c2db1c3-de24-41e0-9113-6d9938f02d12">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0001954</dc:identifier>
    <rdfs:label>periodic fever</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a5c7949-5cbd-4ff1-be82-0a2535b58d13">
    <rdfs:label>Abnormal reticulocyte count</rdfs:label>
    <dc:identifier>HP:0004312</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004312</ddiem:url>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7066d890-559e-4241-a9e8-5af0f67e1ab7">
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <rdfs:label>Behavioural abnormalities</rdfs:label>
    <dc:identifier>HP:0000708</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48e9e18a-5174-410f-b84e-02cf50288a89">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011013</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>abnormal carbohydrate metabolism*</rdfs:label>
    <dc:identifier>HP:0011013</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7658b3b9-637e-4712-bb31-58657ff0295d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low β2 microglobulin,creatinine ratio</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52c143c1-5b06-4377-b6c3-981d6867a5cc">
    <dc:identifier>HP:0012758</dc:identifier>
    <rdfs:label>neurodevelopmental delay</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012758</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8ce58f0-07ca-4fb5-a1fb-730941ed58e4">
    <rdfs:label>N-octyl-4-epi-β-valienamine (NOEV)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f26406be-b3fa-4624-9194-b5bd22d74e43"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a59813ef-20e6-4123-800a-d4470024d8bc">
    <dc:identifier>DB14476</dc:identifier>
    <rdfs:label>DL-alpha-Tocopherol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14476</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/216df2c3-a4bb-4aba-a932-70361dccd770"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c33f7162-f403-4efa-b160-9e2c06db2e1a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5addf18-ba54-4593-978f-473ec4db7b56"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cad854a7-6fe4-48f4-b0f0-240d23f51a98"/>
    <rdfs:label>Agalsidase beta</rdfs:label>
    <dc:identifier>DB00103</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00103</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a540f2a5-701c-4a71-80de-5623081cc8b3">
    <dc:identifier>HP:0020062</dc:identifier>
    <rdfs:label>Low Hemoglobin concentration</rdfs:label>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0020062</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8ed148c7-0062-4530-86a4-2e5bc3923f75">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/354665e3-ec16-4be4-884e-4a5accf9eefc"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1884cefc-b8a3-4fe9-bd4e-309271691755">
    <rdfs:label>Citric acid</rdfs:label>
    <dc:identifier>DB04272</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04272</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/23d32d63-6727-4901-be7d-fd703e4ad64b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f12ff78-af04-47cf-97b1-316522858f96">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00099</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c557f90-3e7a-4a4d-bd3f-540a7ac388fc"/>
    <rdfs:label>Filgrastim</rdfs:label>
    <dc:identifier>DB00099</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3eba4a39-7cf3-408f-ab8c-5bd0d8713ada">
    <rdfs:label>Increased muscle lipid droplets</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012240</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012240</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d02ee231-7521-4727-a574-2ed0b6537466">
    <rdfs:label>Calcium</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01373</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/33b39528-b2d9-4958-8602-e1d68f64e626"/>
    <dc:identifier>DB01373</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17f84492-8f3b-48d6-a669-b5ddb511f67c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0003119*</dc:identifier>
    <rdfs:label>Atherogenic dyslipidemia(Dyslipidemia)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41194c80-fe94-45f8-bdeb-bb36fbf35934">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high EMA levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003219</ddiem:url>
    <dc:identifier>HP:0003219</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a3ce599-ebd7-4907-a98c-53055e1abcd8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00162</ddiem:url>
    <dc:identifier>DB00162</dc:identifier>
    <rdfs:label>Vitamin A</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ef2b483-08ef-4576-8923-ec345b32f2bb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/66569eaf-23d9-46be-8ce1-f874aa17e5fd"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d0bb9bf-a8e7-48c8-9a8d-c964f727c0ea">
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <dc:identifier>HP:0003679</dc:identifier>
    <rdfs:label>Cardiomyopathy progrssion</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003679</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/047567d0-5bda-44c4-adff-efe264d274b4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f49a3a1a-3b53-4777-a0c7-bdb9707949f3"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/162534b3-0dce-4b85-946b-d7ebda67d0d0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bfd6ac61-d061-404e-9305-58274ad9cc60"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5b0d282-b71b-47fd-a382-b7a552793f1d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06667</ddiem:url>
    <dc:identifier>DB06667</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e052f281-ed0b-4396-8cd6-fd0ab5139ced">
    <rdfs:label>scaling</rdfs:label>
    <dc:identifier>HP:0040189</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f66f9506-4df1-43a6-81a2-f8f56310b7b7">
    <rdfs:label>rAAV8-mediated gene therapy expressing murine HMB-synthase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/195abc35-1261-41f7-9dcd-2c5bac1bb947"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99c34140-404b-4958-aa67-518946d40205">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05294</ddiem:url>
    <rdfs:label>Vandetanib</rdfs:label>
    <dc:identifier>DB05294</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f8ff6c6-0ad3-4dcf-9c7a-7df1f8021f77"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a4657ea-92ad-4b4a-ad07-c7f946d2ba84">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
    <dc:identifier>HP:0001878</dc:identifier>
    <rdfs:label>hemolytic anemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c771145d-0314-4329-b292-a1ac5b74a960">
    <rdfs:label>keto-analogues of essential amino acids</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dea65027-682e-4c3d-b82b-bc00aaf17fc6"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4639114-18ba-4d55-9b88-40477ce44812">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00951</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/06d21628-d4fd-4d93-be7a-435600733ad4"/>
    <dc:identifier>DB00951</dc:identifier>
    <rdfs:label>Isoniazid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dc5333b-258a-4ca1-8f24-08dbbb0d4e69">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:label>neurological damage</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee576832-b743-4ee2-b4b4-42f50609adbf">
    <dc:identifier>HP:0004359*</dc:identifier>
    <rdfs:label>Abnormal Fatty acid oxidation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17d9898d-46eb-4e5f-a8e3-0249de970794">
    <dc:identifier>DB01626</dc:identifier>
    <rdfs:label>Pargyline</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01626</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5c83a2c-b0e7-4b04-803d-99950ea0d752"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607483">
    <rdfs:label>THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/607483</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/83096072-0304-4c9f-9bd1-365dd07bf7de"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bb443dc-c9a1-4a47-9858-b8d6f176b41a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025280</ddiem:url>
    <rdfs:label>Pain in the skin</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025280*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4605bd1-99dd-448c-9929-cded69d2d93d">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0003193</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0003193</dc:identifier>
    <rdfs:label>Abnormal cholesterol efflux from cells</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/07aea259-f1c5-4323-92d5-ab1d7cc85170">
    <dc:identifier>DB00741</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e82a950e-b391-4ae1-9645-b5783a55cade"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00741</ddiem:url>
    <rdfs:label>Hydrocortisone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/741d9133-34f4-4e1b-81fe-b50297fa2781">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001638</dc:identifier>
    <rdfs:label>Low myocardial function</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7160758e-4dfc-4338-a6ec-24de3c0f9e23">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/56a6fcb4-d820-482d-8b02-fbdd68771725"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad0daecf-dea0-4e1f-8dab-370549fbbc56">
    <rdfs:label>Haloperidol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00502</ddiem:url>
    <dc:identifier>DB00502</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eaeb86a5-34df-4780-8ac6-257c2f996622"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000006">
    <rdfs:label xml:lang="en">compensatory complementation of a genetically defective protein</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the normal product of a defective enzyme or protein is provided to alter its concentration or availability by delivery, stabilisation or modulation of turnover. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:02:30+00:00</dc:date>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b7d156fa-a206-4de1-ba6f-e3343317baa9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>fiber necrosis</rdfs:label>
    <dc:identifier>HP:0003713</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea0cb0c9-3385-46d0-bc16-2a66b0c53091">
    <dc:identifier>DB04844</dc:identifier>
    <rdfs:label>Tetrabenazine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04844</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb2efb58-06ee-477d-a58f-d1c91fd84600"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43e10118-658b-4eb5-b207-402fdb370811">
    <dc:identifier>HP:0100660*</dc:identifier>
    <rdfs:label>levodopa‐induced choreic dyskinesia(Dyskinesia)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0bb144f-274b-445e-981d-b02e31a48ffb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003077</dc:identifier>
    <rdfs:label>Hyperlipidemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0414292-5aa7-4e8c-be32-bf47664d40db">
    <rdfs:label>Generalized muscular hypotonia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
    <dc:identifier>HP:0001290</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ade4700-97b1-498d-a7d4-681e2e1dc14d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/259c7d8d-08dc-470b-a873-ed81004c39c3"/>
    <rdfs:label>Gene therapy *</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/efe0f2aa-bd21-44e1-9651-252ba4aebe3b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ace9b493-14b8-4a7f-95fa-fe40c5f53168"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73cadc5b-000f-442e-9b49-eab527552436">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/459928b6-fc70-4b49-8e96-831e3148ce32"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4d7dec9c-337a-49a0-90d5-5a6868d32bfe">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1411e574-7daa-4af3-adb9-1d26e9e42459"/>
    <rdfs:label>Pyridoxal phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00114</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6151fe98-6dde-441c-a590-fa9e3a7db20e"/>
    <dc:identifier>DB00114</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a26b6774-041f-4886-b801-26108936435c">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01BC</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12eec389-bb30-4a74-88b5-f8d71c41c2c1"/>
    <rdfs:label>Antiinflammatory agents, non-steroids</rdfs:label>
    <dc:identifier>S01BC</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f09c3fe-38e3-4f38-a480-f42c024f7f5d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
    <rdfs:label>low visual acuity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007663</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee69fbef-4f21-47b9-87c5-043d0af63a4e">
    <rdfs:label>Folic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21e3945a-baec-42fe-90c2-dac64bf478c2"/>
    <dc:identifier>DB00158</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00158</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9ae05e9f-c8ab-461e-9089-6e60a3852c20">
    <rdfs:label>CER 001, a recombinant high-density lipoprotein (HDL)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e6f976d3-acd0-4edd-8889-ccbd7e1d2c7a"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5b89d953-8b65-4815-931f-14ea2bf987d1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b9840834-9053-49e8-83be-61097fb2f5ea"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e8bed6d-805d-40be-a6c5-4b444152e011">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/045201af-3f3e-4f15-bf61-446f086f209e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3fc74b16-9757-4b3d-b4fe-3f02bf113f35">
    <rdfs:label>hepcidin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a45a089b-db29-4167-aa94-922114e913b4"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a024037e-99c1-4a13-b24e-43d1ce01b8d1">
    <rdfs:label>Enlarged size of the liver</rdfs:label>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <dc:identifier>HP:0002240</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a25247fe-6049-4239-8414-e22c55252f57">
    <dc:identifier>HP:0001945</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
    <rdfs:label>Oral ulceration</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/12a87a1f-c4b6-4890-a2be-052981285b8f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09241</ddiem:url>
    <rdfs:label>Methylene blue</rdfs:label>
    <dc:identifier>DB09241</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/daeec9ef-d704-44a3-b4ed-4e585bd37563"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/708f741b-ddc4-4081-88d5-689bf538a07f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d01121d-b6f0-4acb-90e5-bac75683e06a"/>
    <rdfs:label>AAV2 /1-mSeAP-propmyoD76A</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c575efb8-1850-4586-b8c0-ae7fa939cb8e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f8b302ac-0869-48c5-b3ff-a93863b8a311"/>
    <rdfs:label>AAV2CUhCLN2</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d511275e-4a4a-4d83-947f-5164e1de4f4d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
    <dc:identifier>HP:0001987</dc:identifier>
    <rdfs:label>hypolysinemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219750">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ebb0f727-b587-481a-a075-d124564c9831"/>
    <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/219750</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
    <rdfs:label>CYSTINOSIS, ADULT NONNEPHROPATHIC</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/222da882-988e-43a8-8ef9-fc51b4693900">
    <dc:identifier>DB02772</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f573d87b-f907-4ddb-bf62-c0cfa09c2c7b"/>
    <rdfs:label>Sucrose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02772</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b5cace4-cf31-4894-b705-91b62109460f">
    <rdfs:label>Nummular eczema (Eczema)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000964</ddiem:url>
    <dc:identifier>HP:0000964*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c798d8a-cdae-4a31-8e45-d0608a9544cd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e795b9f9-a76f-43f3-b499-1ded96d003eb"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2530e119-fe78-4979-aead-8652940cb4c4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af9a38c1-7a86-4eab-88dc-e84307714ce5"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f2227517-183a-440f-9c2d-1835ccb1051c">
    <rdfs:label>OTZ (L-2-oxothiazoline-4-carboxylic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f2ecdfe-01a5-46ad-891f-f941a12c3d7d"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97549989-1e80-47f0-a3ac-cdcbcbac0875">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14933</ddiem:url>
    <rdfs:label>Nicotinamide riboside</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/72448ed1-f134-441e-aa2d-fc6857fcc36b"/>
    <dc:identifier>DB14933</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe4c0af5-1395-42c8-b2f5-755f8a766920">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
    <dc:identifier>HP:0002353</dc:identifier>
    <rdfs:label>Abnormal Awake EEG</rdfs:label>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/111301c0-4648-481f-aceb-e99a90077dfb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002872</ddiem:url>
    <dc:identifier>HP:0002872*</dc:identifier>
    <rdfs:label>"Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)"</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dd76222e-2c01-484c-92ae-8c82bb8ed359">
    <rdfs:label>nitrilotriacetate</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_25548</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/38c55386-8c65-4df2-9267-d3cef8f1da65"/>
    <dc:identifier>CHEBI_25548</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277410">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>316</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/316</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/277410</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7a7c96dd-d2cf-44ad-819c-ca0c50844862"/>
    <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb8b9429-5b0c-4d4c-9c5d-d5144668563c">
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
    <rdfs:label>Painful neuropathy(neuropathy)*</rdfs:label>
    <dc:identifier>HP:0009830*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4f72b59-e0b9-48ef-a31c-bee9a2918b78">
    <dc:identifier>HP:0003107*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <rdfs:label>High desmosterol,cholesterol ratio (Abnormality of cholesterol metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a6289472-e6b7-426d-9fd1-2ee17a2716a4">
    <rdfs:label>Recombinant human Aspartylglucosamidase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5218987a-ebf4-4538-978b-86ba27c2a540"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6d8b558-148e-4b74-b5b9-5b3c0fcce6fe">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aae49135-1dc5-487e-8ed4-a68994200325"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/87581fac-db17-4ef5-bfe2-26b940cd6d20">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80d72dbc-8013-4960-82cd-d0ac7a366c59"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9cc8bb54-05f8-4463-8b56-888ca8e531a7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/36add6ef-408c-49a7-b8d0-7e3b9a1708d3"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/27d19c48-cdc1-412f-98d2-433fd42acef9">
    <dc:identifier>DB08830</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/90e18917-a693-42a4-90d3-53de6a4e0315"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08830</ddiem:url>
    <rdfs:label>Dehydroascorbic acid</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f4d54750-8763-41bc-9f10-bac1fae584c0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9fa19499-5b5e-4f1b-a85e-c0bc7911cfa0"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7997f088-3492-45e6-bc3c-66b9cdd70ece">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/74f0b6c4-c58b-4abe-bb18-e433d5aa4c71"/>
    <rdfs:label>6S-NBI-DGJ</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe2d0428-e06c-4c37-8f86-7fe4a1692996">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a583c728-3399-47d6-b191-001b2709f96e"/>
    <dc:identifier>DB12528</dc:identifier>
    <rdfs:label>Glyceryl Trierucate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12528</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8be4c40-288e-495d-889f-cde233a55219">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a8468dc9-bed3-420d-a968-818e1b76639c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/68271fdc-9335-4b6c-90c6-652c1f26193c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76c9b06d-09c2-4a52-8ccd-8cb811e329d4"/>
    <dc:identifier>DB00112</dc:identifier>
    <rdfs:label>Bevacizumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00112</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71ff8195-9337-43b2-ad2d-be73e8b092f5">
    <rdfs:label>Failurre to thrive</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
    <dc:identifier>HP:0001508</dc:identifier>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a73e4ae-cc6e-4489-901c-887f58290999">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/00dead0e-58e7-44ec-93b7-fbc81dab0bb0"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4315d0c-f106-40ac-8729-bf690f45a060">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0e4df528-7461-4972-9c75-1c5ab7a71feb"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44ae1496-faa8-4323-9e1a-d63575b8e421">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
    <dc:identifier>HP:0010978</dc:identifier>
    <rdfs:label>Abnormality of immune system physiology</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56699ab9-9e45-4ecc-85fe-bf53ab332f6b">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000867</dc:identifier>
    <rdfs:label>secondary hyperparathyrodism</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b58a00e0-7502-4b2d-95c9-2688df47a7da">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/effa89f1-3530-4a76-b82e-8e6fd4874845"/>
    <dc:identifier>N06AB</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N06AB</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ff27b74-1aaa-43ba-9d0e-dfae23834546">
    <rdfs:label>Glycosade</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e4965650-0784-4713-952a-141088dd720a"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e8ed0193-d5f2-41f5-9677-835fbf20ed50">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa2db852-321c-42d7-81cc-5aa0ba48fbe6"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/854ad32c-ab91-4cfd-af73-3a3249484d4c">
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <rdfs:label>Low levels of serum vitamin B12</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100502</ddiem:url>
    <dc:identifier>HP:0100502</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/32bcc737-44fd-4297-9554-cde531ebec14">
    <dc:identifier>N05A</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N05A</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa785027-3063-4132-a0d6-87b8d0a3a21d"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/120e1c32-5887-4a29-a3f6-9bfbdea97272">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b8dae78a-3c37-4093-a22e-4dbf7c3662c6"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/180a9576-bb7e-41b4-9f7a-00618d1aaef6">
    <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005346</ddiem:url>
    <dc:identifier>HP:0005346</dc:identifier>
    <rdfs:label>Abnormal facial expression</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc8d0c48-cdee-486a-81cc-fd0089f5063d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03793</ddiem:url>
    <dc:identifier>DB03793</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b910b8c8-281b-4f62-8f85-5d3de5366b9e"/>
    <rdfs:label>Benzoic Acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe3970d4-ca2e-49df-bf20-da83bac44bee"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/31b156db-b03d-45df-9be0-60e78e9b0953"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9dc45c02-4cc8-47d9-b681-4defcba780f3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5eaf7e8b-cdb3-4852-95b2-a6f197efb99f">
    <dc:identifier>DB12374</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a78425e9-6824-49aa-9952-78a5ab0908b4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12374</ddiem:url>
    <rdfs:label>Velmanase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7c9ab69-8fb3-4fe3-954b-f934928f6d6e">
    <rdfs:label>decreased male libido</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040306</ddiem:url>
    <dc:identifier>HP:0040306</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a92c0a0-cb06-4931-968e-ea1f63402bf3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1c2f6c03-54de-4c95-b3d1-1b81853eec57"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a8b4fb9-17de-4ba0-9370-b9c2ae71964c">
    <rdfs:label>AAV9-TAZ</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c31f8455-cccf-4655-9816-8540d65e4807"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5f8c393-5ab9-47bd-8041-42ff65df3a70">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <dc:identifier>HP:0040006*</dc:identifier>
    <rdfs:label>Reduced life span (Mortality)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd9c9eff-8cf7-437d-8e56-d8b24afab5d8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eacaf8f7-5e99-4a8f-a532-4f50aaeb3514"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/84b7a55d-b7d1-4a68-a515-f9f6407dff6d">
    <rdfs:label>POTASSIUM-SPARING AGENTS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7cca3e14-d87f-426e-aa10-42621e7b046b"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03D</ddiem:url>
    <dc:identifier>C03D</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21275687-7a3b-4c7a-b1ce-ec0d42d2ce7f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00855</ddiem:url>
    <dc:identifier>DB00855</dc:identifier>
    <rdfs:label>Aminolevulinic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/668968ee-89cb-4547-8332-0a9f5f0a2087"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ae07acec-0680-4ae4-a392-bf193638d4b0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a672cced-80dc-452a-919b-53e1fc886c6f"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9c3a1f1b-21fc-4f63-865f-a52b3733ad84">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c2c8bd01-cbd2-482b-a019-4083d177bca8"/>
    <rdfs:label>AAV2/5-PBGD</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8d157187-611f-4162-9ed1-548d7d7f0f6e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69b174a2-5d94-46a3-8f7a-bb8fb4d48253"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffce60b8-9af4-45c8-b2f9-5ceedaaae774">
    <rdfs:label>hyperproteinemia</rdfs:label>
    <dc:identifier>HP:0002152</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002152</ddiem:url>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6ae459dd-202b-4a99-bb34-f754d08ea8eb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3fd77688-a589-4344-91c9-d72ffa6133c7"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0d927831-73d5-4ecb-a2d8-8d0e912e9a19">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b36bf83-d101-48fe-b3a8-64e6e7ddea76"/>
    <rdfs:label>volanesorsen (IONIS-APOCIIIRx)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5bd91e87-0822-43fc-8bc6-731636b73e27">
    <rdfs:label>Poor traction response</rdfs:label>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e7bc15d7-8aff-4676-a90e-0185972449a8">
    <dc:identifier>DB00829</dc:identifier>
    <rdfs:label>Diazepam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00829</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8d3cda4e-4c72-407d-9df9-b73b287f9b11"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97f774fc-23d3-4497-bda6-18bc870cbffe">
    <rdfs:label>Enlarged kidney</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000105</ddiem:url>
    <dc:identifier>HP:0000105</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0e94f7e8-88d7-478d-b97c-aafb86c235df">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91901072-3df5-476e-bf87-37f88814d7d4"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b7e484e-749c-4b01-9395-62dc3548331f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/45e955eb-1792-4af9-9f30-02ee490c6151"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5db1a34-1a50-4510-9ef8-c7e2ba649228">
    <rdfs:label>pseudoexon activation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d06d20e-3f02-426a-a18b-91a8a6faa6fe">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/66738762-4e03-4fe5-b2fd-93b46c5fb025"/>
    <rdfs:label>rAAV-GPE-G6PT</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac688a8f-9320-4667-8582-60fd2acec57a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eae0b3b6-3e42-4a65-96c7-61f01015946c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0396e121-157c-4b53-a8be-e8b72a002a8f">
    <dc:identifier>CHEBI_26537</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4dd82091-918d-4f25-9eab-c6e3df0c6a7e"/>
    <rdfs:label>retinoid</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_26537</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5a076fae-88db-4c0c-a4d0-9f9ddd4d74ab">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f58140ca-e45f-477c-b321-d3ec313489c6"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/121270">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/121270</dc:identifier>
    <rdfs:label>COPPER DEFICIENCY, FAMILIAL BENIGN</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/70e21725-088a-4672-9be2-2850fe9ac9fb"/>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29def92e-5516-4bb6-b5a0-0d593dd76c72">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c7c8f344-6019-4010-8ed2-c7e422fbedc0"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9c84e39-6fa8-412d-bb42-cc8e5c60dbd2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ae00dede-294d-4cc1-94df-e4a33c2d254e"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1f47100-dece-4525-a9cb-2e8d21403482">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ceea5acf-6fef-4179-8434-f327d14d8802"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dd00ea0-654b-478d-a23e-13edaf479f8a">
    <rdfs:label>Low dopamine level</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0012656</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/287077a0-645c-4c1e-804c-ed361a97a4d2">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Myositis</rdfs:label>
    <dc:identifier>HP:0100614</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59574948-7c0e-4964-8127-3a0ccf3dd0b6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6acd19f6-8073-4c78-a86b-2b9a4b7b8bd1"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/793c2145-5f36-469f-9939-fdd4bbca8011">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48d78a37-187f-48e7-aa66-927264aab24c"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e9aa4ae-926b-4967-afe9-9da29800e24a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a7dc0fe-1bfa-47c4-b00a-9ccae5a808ea"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/41886e1a-866e-44bb-a942-c1f5dbca051c">
    <rdfs:label>Pitressin tannate in oil</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f933877-4287-4f5f-838e-94afbc813f28"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f03df27a-dab5-450b-8fbb-19dd5faf4b12">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/805b310e-457d-4b08-bc3b-7368a5b233dc"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/35639fb0-84b4-46b2-a200-181ecfb9b50b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e2b5f0a8-7c5e-4b2c-92ac-7083bf8882aa"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09fe99c8-adf4-49c9-924f-67c404fb40e2">
    <rdfs:label>METABOLIC ENCEPHALOMYOPATHY</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a90ac572-25ca-48f0-b799-3dbb05f8d201">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9782606-532f-4ebe-88ad-610d2263d0fa"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7adcd04-0cc3-4eff-8d8b-b21a7fbdffe1">
    <rdfs:label>low quality of life(Constitutional symptom )*</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e731f8b0-b078-4018-9508-323979ae89fa">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e58916ee-5c61-4857-b6ba-73491be6c342"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/77c8a7bc-fe4c-41ab-889c-5dac9e884e0b"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2fb38993-0aa6-49f4-880b-5c571cfc4b6b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1b77eeb9-0e4e-4e1c-87c4-a6d815a0140a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/958fa7b7-e627-4c36-8dfd-bfe2386747b4">
    <rdfs:label>AAV2-hAADC ( Gene therapy)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/51b6a003-5934-40b8-8534-86d4be24e61c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2768f4c4-271d-4e64-a76e-2a3522bb075a">
    <rdfs:label>Droxidopa</rdfs:label>
    <dc:identifier>DB06262</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06262</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c52c1cc3-fb8f-43da-88d2-c7fe1068f164"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/203f3123-efdb-4211-9981-cdb8be77acd3">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>High serum amyloid A protein</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f7cd3f95-7ef2-405a-8e7c-73c5b7cdffc6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b3c4893c-911f-4aeb-a43c-03226f343d90"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a4b044f-a8d1-4efd-8e5c-fb0cce150840">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
    <rdfs:label>hypoglycaemia</rdfs:label>
    <dc:identifier>HP:0001943</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9c3123a7-9627-47d5-a9f2-c1743b0f3ac8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d66c5f1-0aec-4b66-ba71-f4da66f27f48"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/31e70ea5-9230-4178-aaab-2decfbfbef3e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fb4db80b-8a2c-48a7-a1ba-1cc78bdf1dfd"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4cbcb440-2d73-47de-b52a-969fa1f2864c">
    <rdfs:label>Recombinant human palmitoyl-protein thioesterase 1 ( PPT1)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8371b86a-b425-4088-bdb2-75ba10290bbd"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e98df495-1c68-4258-98b9-163f4bea9b80">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f3a46543-1626-4a13-a9a3-25f51f02cd03"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d7d7946c-789d-48b2-923f-28e89d796e1a">
    <rdfs:label>AAV-mediated gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c34fed74-6831-4a40-9bdf-a295fac03ac5"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fb23a033-3822-4336-a31a-12fd0178a6e5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74d76b39-af12-4f6e-8e59-f3ab1d2d4d3f"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dcfb37cb-d346-46da-a4ec-ee32dd1bdf2e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab22f209-2c7d-4ca2-b877-8f18119c110b"/>
    <rdfs:label>ISIS 703802 (AKCEA-ANGPTL3-LRx)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb396713-e9a9-4fd6-9300-97ef2f66d5e5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ab9fdea2-592d-43ed-b52f-825528b943ae"/>
  </rdf:Alt>
</rdf:RDF>
